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Chronic obstructive pulmonary disease (COPD) has emerged as a major policy focus for 
health systems throughout Western Europe. This reflects the increased prevalence, 
associated healthcare utilisation and costs of COPD, and the potential to substantially 
improve outcomes through achieving reductions in smoking. The aim of this PhD was to 
develop projections for the prevalence, healthcare osts and number of deaths in people with 
COPD in England and Scotland over a 20-year horizon (i.e. from 2011 to 2030). 
Methods 
I undertook a phased programme of work, which began with a systematic review of the 
published and unpublished literature to identify models that were suitable for estimating 
and/or projecting the prevalence and disease and economic burden from COPD. This 
involved searching Medline, Embase, CAB Abstracts, World Health Organization (WHO) 
Library and Information Services and WHO Regional Idexes, and Google over the time 
period 1980-2013. The models were then critically appr ised for their quality of reporting. 
From these, I selected the Dutch Model developed by Erasmus University for generating 
projections. Suitable data sources from both England and Scotland were identified, sourced 
and carefully processed in order to run the modelling exercises. Rates of incidence and 
prevalence were calculated using English and Scottish healthcare datasets and population 
data were obtained from the Office for National Statis ics (ONS) and the General Register 
Office for Scotland (GROS). Relative risks for all-cause mortality among people with COPD 
were calculated from the Clinical Practice Research Datalink and mortality data were 
obtained from the ONS and GROS. The Model was thus adjusted to apply to England and 
Scotland. I then travelled to the Netherlands to work with the developers of the Dutch Model 
and ran a baseline model and an array of sensitivity analyses with modified inputs to the 
Model. Finally, my Rotterdam colleagues calculated uncertainty intervals for some of the 
estimates using probabilistic analysis. 
Results 
Using the probabilistic means and uncertainty intervals, in England, the modelled prevalence 
of diagnosed COPD among males of all ages in 2011 was 1.8% (95% uncertainty interval 
1.8-1.9) increasing to 2.0% (1.7-2.1) by 2030. In females, in England, the baseline estimate 
was 1.8% (1.7-1.8) in 2011 increasing to 2.4% (2.0-2.6) in 2030. In Scotland, the modelled 
prevalence among males was 1.9% (1.8-1.9) in 2011 and this was projected to stay the same 
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at 1.9% (1.7-2.2) by 2030. In females in Scotland, the estimated prevalence was 2.2% (2.1-
2.3) in 2011 and was projected to increase to 2.5% (2.1-2.7) in 2030.Using the Model I 
estimated that overall in 2011 there were a total of 952,000 (941,000-966,000) people with 
diagnosed COPD in England and 106,000 (103,000-110,000) in Scotland and that these 
numbers would increase to 1,325,000 (1,117,000-1,408,00 ) in England in 2030 and 125,000 
(113,000-136,000) in Scotland in 2030, respectively. The greatest increase in COPD was 
projected to be in females over 65 years of age in both countries.  
The total annual direct healthcare costs of COPD in England were projected to increase from 
£1.60 (95% uncertainty interval 1.18-2.5) billion in 2011 to £2.35 (1.85-3.08) billion in 
2030. In Scotland, costs were projected to increase from £170 (128-268) million in 2011 to 
£210 (165-274) million in 2030. These costs were calcul ted in terms of 2011 costs without 
the application of any economic trends (i.e. no annu l increase applied for inflation).  
The number of deaths among people with COPD in England was estimated to be 99,000 
(93,000-129,000) in 2011, increasing to 129,000 (126,000-133,000) in 2030. In Scotland 
there were estimated to be 10,000 (9,000-12,000) deaths in 2011, increasing to 14,000 
(13,000-15,000) in 2030. 
The Dutch Model demonstrated a 39% increase in the umber of people with COPD in 
England and a 17% increase in Scotland between 2011 and 2030. It provided an estimate of a 
30% increase in deaths among people with COPD in England and of a 43% increase in 
Scotland. Overall, there was a projected 46% increase in the direct healthcare costs required 
to care for people with COPD in England and a 23% increase in Scotland between 2011 and 
2030. The reasons for these differences are largely due to higher COPD-related excess 
mortality in Scotland and to differences in the data used for populating the model in both 
countries. 
Conclusions 
There are likely to be substantial increases in the number of people with COPD, associated 
morbidity, direct healthcare costs and mortality in both England and Scotland over the next 
two decades. These increases in numbers will predominantly occur in females over 65 years 
of age and are likely to have substantial societal mpact in terms of organising the health and 
social care for this frail population.   
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I describe the rationale for this study in Chapter 1. Firstly, I describe the background, then 
the rationale for the choice of chronic obstructive pulmonary disease (COPD) as the 
condition under study and the selection of England  Scotland as the setting for the study. 
Then, in Chapter 1, I consider the selection of the Dutch Model and the timeframe for 
projections. The overall aim of the PhD was to select an epidemiological model to make 
projections for the prevalence and burden of COPD in England and Scotland from 2011 to 
2030 using routinely collected healthcare data. I conclude Chapter 1 with a breakdown of the 
two phases of the PhD: Phase 1 – systematic review and Phase 2 – modelling study. 
In Chapter 2, I introduce COPD as the condition under study. In it, I consider the history and 
definition of COPD and how this relates to its diagnosis. Then there is discussion of different 
definitions of COPD for research. This is followed by a section on the risk factors and 
epidemiology of COPD. The chapter continues with sections on the clinical features, 
prognosis and management of COPD. 
In Chapter 3, I discuss the collection of healthcare data in England and Scotland with an 
overview of how these data may be reused for research purposes. I concentrate on particular 
issues: the current state of data gathering in England and Scotland; the validity of the data 
that are recorded, how these can be used; and the regulatory framework that is in place to 
secure patient privacy. I also consider the validity of the routine data that were selected for 
use with models to provide projections in this PhD. 
In Chapter 4, I introduce different methods of modelling including Markov modelling, 
demographic modelling, risk factor modelling and time trend modelling. This is followed by 
an introduction to quality adjusted life years (QALYs) and disability adjusted life years 
(DALYs). This chapter introduces these models before the systematic review in Chapter 5 
which identifies examples of these different types of models. In Chapter 4, I concentrate on 
Markov modelling because this is the type of model most often used in the studies found in 
the systematic review. 
In Chapter 5, I present a systematic literature review of models for calculating the prevalence 
and burden of COPD. This was firstly undertaken in 2011 when the PhD was begun and 
updated in 2013. The aim was to identify all models for calculating the prevalence and 
burden of COPD, then to assess the quality of these models with a view to selecting one to 
use to provide projections of prevalence and burden of COPD in England and Scotland. As a 
first step to assessing the quality of the models a quality of reporting framework was 
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designed and subsequently published. The model that scored highest in relation to the quality 
of reporting framework was the Dutch Model at that time (2011), and so I decided to 
approach the Rotterdam team with a request for collab ration in order to use their model 
with English and Scottish Data to produce projections for England and Scotland. Chapter 5 
presents 22 models for calculating the prevalence ad burden of COPD in different contexts 
and settings. I include an appraisal of the overall quality of the models for the seven models 
which scored most highly on the quality of reporting framework assessment. The reason for 
this is that the overall quality of the model can only be appraised where the reporting is 
sufficiently detailed. From the 22 models, I selected the Dutch Model to proceed with 
estimating projections for the COPD population in England and Scotland.  
In Chapter 6, I begin by describing the working of the Dutch Model then I give an overview 
of the data required by the Model and appropriate da sources. Then, I give detailed 
consideration to the sourcing of each of the appropriate data inputs and the permissions that 
were required to obtain each dataset. Finally, I discuss the strengths and limitations of these 
datasets. 
In Chapter 7, I include a description of the computer programme used to run the Dutch 
Model followed by a list of the sensitivity analyses run on the programme following the base 
case. I present the results of the base case modelling fo lowed by tornado diagrams detailing 
the sensitivity analyses. Then I present the uncertainty intervals. I then discuss the meaning 
of these findings. 
In Chapter 8, I summarise the principal findings, followed by the strengths and weaknesses 
of the work presented in this thesis. I then discus the meaning of the study in the context of 
other work, including work on the smoking epidemic and the Global Burden of Disease 
Study. This is followed by my discussion of the implications of the work for policy and 
practice and finally consideration as to what question  remain to be answered by further 
research. I end this thesis by summarising my main conclusions from this body of work. 
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Chapter 1 Background, rationale and aims 
1.1 Background 
Policymakers and governments must decide their healthcare priorities on the best 
information available to them. This PhD was begun in 2011 and, at that time, elements 
influencing healthcare were coming together to create an especially challenging environment 
for decision makers. These elements included demographic trends and an economic 
downturn. 
The demographic trend is for populations globally to live longer lives with the result that 
they require substantial health and social care when t y are frail and elderly. Globally, there 
has been a shift in the distribution of deaths from younger to older ages and from 
communicable, maternal, perinatal and nutritional causes to non-communicable 
disease.(Mathers and Loncar 2006) This is combined with a drop in the birthrate (see 
Glossary) so that there are fewer younger, economically active individuals in the population 
to provide and fund this care. In addition, these eld rly populations often suffer from 
multiple long-term conditions.(Barnett, Mercer et al. 2012) This has implications for the 
complexity of care required.  
2011 was characterised by a substantial economic downturn. Health expenditure across 
Organisation for Economic Co-operation and Development countries (OECD) did not 
increase in 2010 and 2011 as a result of the global economic slowdown.(OECD 2013)  
1.2 Rationale for a PhD in modelling 
In 2011, I wondered what the best and cheapest methods were to help governments focus 
their healthcare resources according to the greatest source of need. To me, it seemed 
important that policymakers and governments should have accurate information as to how to 
prioritise healthcare needs among their population. I had heard of the Global Burden of 
Disease (GBD) Study and at that time (2011) there were projections of the GBD until 
2030.(Mathers and Loncar 2006) This study introduce m  to the concept of modelling non-
communicable diseases to predict future burden of disease. 
I turned to Merriam-Webster’s dictionary to find the definition of a “model” as “a system of 
postulates, data and inferences presented as a mathe atical description of an entity or state 
of affairs.”(Merriam-Webster 2013) 
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As a non-mathematician, I realised that there would be a limit as to the level at which I could 
engage with any particular model. However, modelling clearly has an important role in 
predicting future population disease burden, and so I decided to pursue this track. 
1.3 Rationale for a PhD in COPD 
I have always been interested in respiratory disease, especially smoking-related disease as it 
is so potentially preventable. As a General Practitioner, I am always encouraging patients to 
stop smoking and I wanted to look at a condition which was relevant to my everyday 
practice in Lothian, Scotland. I was interested to see that in the Mathers and Loncar 
projections COPD was ranked as the fifth leading cause of death in 2002 and was modelled 
to rise to the fourth leading cause of death globaly by 2030, see Table 1.1.(Mathers and 
Loncar 2006) This ranking is based upon modelling using World Health Organization 
(WHO) estimates for global tobacco-caused deaths in 2000.(Ezzati and Lopez 2003) COPD 
is, therefore, important in the context of the increasing prevalence of non-communicable 
diseases; and so I decided to focus upon COPD.  
Table 1.1 Global ranking of causes of death (Mathers and Loncar 2006) 
Condition Rank in 2002 Projected rank in 2030 
Ischaemic heart disease 1 1 
Cerebrovascular disease 2 2 
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1.4 Rationale for modelling in England and Scotland , 2011 to 
2030 
The Mathers and Loncar projections were global; however, I was unable to find projections 
specifically for Scotland for COPD prevalence and burden which would be most relevant to 
my own clinical practice. I therefore decided to aim to model projections for Scotland. I 
realised that this work would have much more research impact if I could compare Scotland 
with its neighbour, England, therefore I decided to additionally model projections for 
England. The period of projection from 2011 to 2030 was taken to be comparable with the 
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Mathers and Loncar time period.(Mathers and Loncar 2006). I also hoped that I would be 
able to use a more up to date source for my projecti ns han the WHO 2000 estimates. 
1.5 Aim 
The general aim of the PhD was to model the prevalence and burden of COPD. In order to 
fulfil this aim I undertook two phases of work as described in Sections 1.6 and 1.7. This then 
led to the specific aim of producing projections for the prevalence and burden of COPD in 
England and Scotland from 2011 to 2030 using an appropriate model. 
1.6 Phase one – systematic review 
The above rationale laid the foundations for phase one of my PhD. It was necessary to firstly 
investigate models for calculating the prevalence and burden of COPD. I decided to do this 
using a systematic review and defined the disease burden of COPD as being seen broadly 
from the perspective of the healthcare system. Therefore, the disease burden constitutes the 
numbers of people with COPD, numbers of COPD exacerb tions in the population, the direct 
healthcare costs of these and also the numbers of COPD deaths. 
I carried out the searches for the systematic review in 2011 and updated them in November 
2013. There was no published scoring system for chronic disease models and so I 
constructed a quality of reporting framework for COPD models in discussion with Professor 
Simon Capewell of Liverpool University. At the time of the original searches the model 
which scored most highly on the quality of reporting framework was one (Hoogendoorn, 
Rutten-van Molken et al. 2005) of the three included models developed by a research team at 
Erasmus University, Rotterdam.(Feenstra, van Genugt et al. 2001; Hoogendoorn, Rutten-
van Molken et al. 2005; Hoogendoorn, Rutten-van Molken et al. 2011). I then updated the 
systematic review searches in 2013 as I was writing up my thesis and found a study (Pichon-
Riviere, Augustovski et al. 2011) which scored slightly higher on the quality of reporting 
framework; however, the Dutch Model remains the focus for phase two as a result of the 
work done in 2012 and 2013 towards using it for modelling. 
1.7 Phase two – modelling study 
The aim was to produce projections for the prevalence and burden of COPD in England and 
Scotland from 2011 to 2030 using an appropriate model. Following on from the systematic 
review, I contacted Erasmus University as the literature I had found suggested that their team 
had the most expertise in modelling in this area and suggested collaboration. They agreed 
that I could use the most up to date version of their Dutch COPD model with data from 
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England and Scotland to make projections of the prevalence and burden of COPD in these 
countries from 2011 to 2030. This would be the first time such projections had been made as 
previous models had either had global scope or, for English models, only modelled current 
prevalence instead of including future projections. I  addition, none of the English models 
identified included detailed projections of COPD exacerbations or costs, which was 
something that the Dutch Model would be able to provide. 
The inputs to the model would consist of a selection of routinely collected data. I had to 
consider what were the best available options for these inputs and which were the most valid. 
The inputs would then be modified and the model re-run to provide sensitivity analyses as is 
often done in modelling studies. This demonstrates th  sensitivity of the output of the model 
to fluctuations in each of the different inputs separately and gives an indication as to whether 
the intrinsic assumptions that went into the model w re accurate and stable. 
1.8 Conclusion to Chapter 1 
In this chapter I have outlined the context in which I began my PhD in 2011 in terms of an 
economic downturn and increasing demographic challenges. I then explained my rationale 
for choosing a PhD in modelling the prevalence and bur en COPD. I also explained the 
setting of my studies in my local populations of Engla d and Scotland. I then summarised 




Chapter 2: Basic concepts in COPD 
2.1 Introduction 
COPD is an important chronic disease in the context of an ageing population. This chapter 
sets out to present an overview of the medical aspect  of COPD. I begin by reviewing 
definitions of COPD followed by a discussion of its diagnosis. Then there is a section on the 
challenges of measuring the epidemiology of COPD. Then a summary of the aetiology of 
COPD leads into a discussion of its pathophysiology. I discuss the chief clinical features of 
COPD and its prognosis and management. I finish wita summary of patient perspectives in 
COPD and conclude this chapter. 
2.2 Definitions of COPD 
In any epidemiological study, it is important to review the definition of the index condition 
as incidence and prevalence will fluctuate widely depending on how many patients are 
determined as “having the condition” or “not having the condition”.  
2.2.1 Historical context of COPD definitions 
Since the beginning of the 20th Century, a relationship has been recognised between thr e 
overlapping conditions: emphysema, chronic bronchitis and asthma. In the 1950s, the 
London smog resulted in an increased number of deaths from respiratory causes clearly 
related to air pollution.(Fletcher 1978) Interest in defining this condition continued to 
increase and it emerged that Americans were labelling it “emphysema” while the British 
favoured the term “chronic bronchitis”.(Calverley and Wedzicha 2007). This group of 
conditions principally referred to three types of disorder: 1) chronic or recurrent excessive 
secretion of bronchial mucus; 2) intermittent obstruction to bronchial flow (asthma); and 3) 
persistent obstruction to bronchial airflow due eith r to emphysema – defined pathologically 
as the enlargement of the size of air spaces in the lung peripheral to terminal bronchioles – or 
to an obstructive form of bronchitis for which the underlying anatomical basis was not yet 
appreciated.(Fletcher 1978) 
In 1960 the Medical Research council’s committee on the aetiology of chronic bronchitis 
concerned itself with the question of how smoking ad other factors cause airflow 
obstruction. This led to Fletcher and Peto’s seminal work in which they followed 
prospectively, approximately 1000 working men in Lond n, studying respiratory symptoms 
and changes in lung function over a period of 8 years.(Fletcher and Peto 1977) The men 
were aged 30-59 and few had any clinical disease. Th y were seen every 6 months and 
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questions and measurements were made to assess mucu hypersecretion and bronchial 
infections. Six monthly FEV1 readings were made, allowing estimates to be made of the 
average rate of decline of FEV1 for each man during the study. Only 103 of the men were 
non-smokers, none of these non-smokers had any evidence of even moderate airway 
obstruction. 
Fletcher and Peto drew the following conclusions from their prospective study. Firstly, that 
FEV1 declines continuously and smoothly over an indiv dual’s life with a slight acceleration 
of rate of loss with ageing. Secondly, they identified that non-smokers lost FEV1 slowly and 
almost never developed clinically significant airflow obstruction. Thirdly, they found that 
some smokers were more or less susceptible to the effects of smoking on their FEV1 decline. 
Fourthly, they found that susceptible smokers who stopped smoking would not recover lost 
FEV1, but that the rate of decline in FEV1 would revert to being parallel with the non-
smoking curve. This could result in a substantial delay to disability and death if smokers 
stopped before severe damage was done. These findings are illustrated diagrammatically in 
figure 2.1. 
Figure 2.1 The natural history of FEV1 with age and smoking and the thresholds of 
disability and death. Reproduced with permission (Peto and Fletcher 1977)
 
Additionally, they found that after adjusting for FEV1, smoking, age and height there was no 
independent correlation between FEV1 slope and indices of either mucus hypersecretion or 
bronchial infections. They were surprised at this finding and so confirmed it by relating 
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changes in FEV1 level to changes in expectoration and to episodes of bronchial infection in 
individual men and found no consistent or significant effects: the loss of FEV1 that an 
individual man suffered from one six monthly survey to the next was on average the same if 
a chest cold chest illness or attack of sputum purulence intervened as if it did not.(Fletcher 
and Peto 1977) 
This somewhat surprising finding laid the ground for further work that characterised airflow 
obstruction and mucus hypersecretion as two quite diff rent diseases. Another study 
obtained follow up data over 20 years for 2718 British men with details of airflow 
obstruction and mucus hypersecretion and causes of death. (Peto, Speizer et al. 1983)The 
aim was to relate initial mucus hypersecretion and irflow obstruction to subsequent cause-
specific mortality. They found that when the 108 men whose airflow obstruction values were 
more than two standard deviations below average for thei  age and area of residence were 
compared with the larger group of 1464 men whose airflow obstruction values were better 
than this average, 27% of the former were certified as ying of COPD and only 1% of the 
latter were so certified. The COPD death rate among the 108 was more than 50 times that 
among the 1464, since the former were at risk for fewer years because of an excess among 
them of premature deaths both from COPD and other causes. However, when comparing 
men who reported producing phlegm both in the morning and during the day with men who 
did not produce phlegm a relative risk of only 4.4 was seen for COPD mortality, which 
reduced to 1.4 with adjustment for airflow obstruction. Therefore the presence or absence of 
mucus hypersecretion is not predictive of subsequent mortality from COPD. The authors 
concluded that the type of mucus hypersecretion that leads to noticeable phlegm production 
is not a link in any important causal chain that accelerates the development of airflow 
obstruction. Mucus hypersecretion and airflow obstruction are therefore two distinct morbid 
processes. The authors then recommended that the term “chronic bronchitis” should not be 
used to indicate airflow obstruction.(Peto, Speizer et al. 1983) 
Further studies have added to the evidence that it is he airflow obstruction and not mucous 
hypersecretion that has the relationship with mortality.(Calverley and Wedzicha 2007)  
Airflow obstruction data is also available in evidenc  in the Framingham study which 
collected information on cigarette consumption, self-reported chronic cough, FEV1 and 
FVC.(Freund, Belanger et al. 1993) Heavy smokers, both men and women across all age 
groups, sustained diminished FEV1 in a dose-related f shion, data for FVC showed an 
equivalent trend. Cigarette smoking was an independent risk factor for chronic cough, 
reduction in FEV1 and FVC. The Framingham study did not consistently record the 
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incidence of COPD because of difficulties in definition and determination of onset, however 
a highly significant relationship between the rate of cigarette smoking and mortality was 
thought to represent the comorbid effect of the development of obstructive lung disease in 
smokers.(Freund, Belanger et al. 1993)  
Further evidence from the Framingham study demonstrated that poorer lung function after 
14 years of follow up was related to baseline lung function and cigarette smoking. (Sorlie, 
Lakatos et al. 1987)Follow up FEV1 was lower in smokers than non-smokers. Poorer lung 
function in smokers at follow up was also demonstrated following adjustment for initial lung 
function impairment, respiratory symptoms and stature. This study also showed that those 
who quit smoking have better lung function on follow up than those who continue to smoke. 
In this way the Framingham study helps to re-inforce the Fletcher-Peto evidence as to the 
significance of airflow obstruction from cigarette smoking and its association with mortality 
and morbidity. 
An analysis of the Framingham Offspring Cohort, published in 2009, looked at spirometry 
measurements of 4391 males and females with an age ran of 13-71 at baseline.(Kohansal, 
Martinez-Camblor et al. 2009) In order to revisit the natural history of COPD, this work 
recreated the Fletcher and Peto lung function curves but with the advantages that they 
included females, it was a larger cohort with a larger age range, participants were followed 
up regularly for up to 26 years and the spirometric measurements were standardized. 
Participants were considered to be “healthy” if they r ported “no” to all questions concerning 
dyspnoea on exertion, increased dyspnoea, nocturnal dyspnoea, nocturnal cough or wheezing 
at exam 1 and were never reported by an examiner to have a clinical diagnostic impression 
of asthma, COPD, chronic bronchitis or emphysema during follow up examinations. By 
contrast if any of these criteria were fulfilled they were considered as “unhealthy”. 
Figure 2.2 demonstrates the chief findings from this study. Firstly they found that health 
never smoker females achieved lung growth earlier than males and their rate of decline with 
age is slightly, but not significantly lower. Secondly, they clearly showed that smoking 
increased the rate of decline of FEV1 in both males nd females. Thirdly they demonstrated 
a range of susceptibility to the negative effects of moking on lung function and, in contrast 
to the Fletcher-Peto cohort, found that the presence of respiratory symptoms at baseline or 
follow up identified individuals who were more susceptible to the effects of smoking. This is 
an observation that may prove clinically useful. And fourthly, they confirmed that smoking 
cessation has a beneficial effect on lung function decline with age, especially in those who 
quit at younger ages. 
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Figure 2.2 Mean FEV1 values (expressed as percent of its value at the age of 25) by 
age in smokers who quit smoking before the age of 30 (Q<30), between 30 and 40 
years of age (Q30-40) and after the age of 40 (Q40+). Curves from health never 
smokers (NS) and continuous smokers (CS) are included for comparison. A males, 
B females.  
Reprinted with permission of the American Thoracic Society. Copyright © 2015 American 
Thoracic Society. (Kohansal, Martinez-Camblor et al. 2009)The American Journal of 
Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
 
In the Framingham Offspring Cohort, males started smoking at a mean age of 17.5 years, 
before the lung was fully mature, in contrast to females who started at a mean age of 18.8 
years. In subsequent years teens have begun to start smoking at much younger ages which 
could cause more deleterious effects on lung growth. The small FEV1 increase in males in 
the oldest categories could be due to survivor bias or smaller sample size as this trend is not 
seen in women. The percentage of male and female continu us smokers developing airflow 
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obstruction was similar, thus suggesting that males nd females are equally susceptible to 
tobacco smoke. It was also observed that smoking appeared to reduce the FEV1 peak in 
males. No such peak was identified in females. However, for males, at least the results are 
consistent with the hypothesis that smoking during adolescence reduces lung growth. 
In contrast to the model proposed by Fletcher-Peto, in which it was proposed that those who 
quit smoking would find their lung function decline r vert to parallel with non-smokers, the 
Framingham Offspring Cohort produced data which demonstrated different, steeper, slopes 
for quitters at older ages in both males and females. These data highlight the importance of 
early quitting.(Kohansal, Martinez-Camblor et al. 2009) 
These studies comprise the key evidence from which our understanding of the condition 
known as COPD is drawn. Other terms used included “chronic obstructive airways disease” 
(COAD) and “chronic obstructive lung disease” (COLD). “Chronic non-specific lung 
disease” and “chronic airflow limitation” persist in the literature but are less often used since 
the advent of formal agreed UK and international definitions such as the National Institute 
for Health and Care Excellence (NICE) definition and the Global organisation for 
Obstructive Lung Disease (GOLD) definition. These ar  reviewed below. 
2.2.2 Definition from the 2010 National Institute f or Health and Care 
Excellence (NICE) guideline for COPD 
The following definition is from the 2010 update of the 2004 NICE / British Thoracic 
Society (BTS) guidelines on COPD:(NICE 2010) 
“Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction. 
The airflow obstruction is usually progressive, notfully reversible and does not change 
markedly over several months. The disease is predominantly caused by smoking.” 
The guidelines then go on to clarify that airflow obstruction is defined as a reduced post-
bronchodilator FEV1/FVC ratio < 0.7 (FVC = Forced Vital Capacity) when FEV1 is less 
than or equal to 80% of the predicted normal. A diagnosis of COPD should only be made in 
the presence of breathlessness and/or cough. 
The guidelines state that COPD is now the preferred term for the conditions in patients with 
airflow obstruction who were previously diagnosed as h ving chronic bronchitis or 
emphysema. This preference for the term COPD is as a re ult of the importance of airflow 
obstruction in relation to mortality.  
33 
 
2.2.3 Definition from the 2013 updated Global Initi ative for Chronic 
Obstructive Lung Disease (GOLD) guidelines 
The updated 2013 GOLD guideline (GOLD 2013) gives the following definition for COPD: 
“COPD, a common preventable and treatable disease, is characterised by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic inflammatory 
response in the airways and the lung to noxious particles or gases. Exacerbations and 
comorbidities contribute to the overall severity in individual patients.”(GOLD 2013) 
The authors go on to stress that the definition does not use the terms chronic bronchitis and 
emphysema and excludes asthma. The symptoms of COPD include dyspnoea, chronic cough 
and chronic sputum production, and episodes of acute worsening of these symptoms 
(exacerbations) often occur. The same post-bronchodilat r spirometry threshold of 
FEV1/FVC<0.7 is given for persistent airflow limitation and thus COPD as in the NICE 
guideline above. 
“Chronic bronchitis” overlaps with COPD, and its definition is clinical. It is defined as 
“cough with excessive production of sputum present for at least three months in each of two 
consecutive years.”(GOLD 2010) 
2.2.4 How the definitions of COPD relate to diagnos is 
The GOLD criteria describe “usually progressive airflow limitation which is not fully 
reversible” as the hallmark of COPD. GOLD recommends that this airflow obstruction is 
confirmed by a FEV1/FVC ratio <0.7. GOLD criteria use this as a fixed threshold for the 
measurement of obstruction. The severity of the COPD may then be assessed by the FEV1 in 
the context of its percent of predicted normal values according to age, sex and height.(GOLD 
2010) 
GOLD guidelines recommend consideration of the diagnosis of COPD in any patient over 40 
years of age who has persistent dyspnoea, a chronic c ugh with or without sputum 
production and a history of exposure to risk factors such as tobacco smoke, occupational 
dusts and chemicals or smoke from home cooking or heating fuel.(GOLD 2010) The 








In order to exclude reversible obstruction, as may be present in asthma, the spirometry 
should be performed 15 minutes after administration of a bronchodilator.(GOLD 2010) 
Both FEV1 and the ratio decrease in COPD. A reduction in the FVC alerts the physician to 
the presence of a possible restrictive defect. 
The obstructive pattern of spirometry is most easily understood with reference to the 
volume-time graph in Figure 2.2. The dashed line shows an exhalation from 0 to a FVC of 
3.5 litres with an FEV1 of 3.0 litres. FEV1/FVC ratio is 3.0/3.5 = 86%, within the normal 
range. The obstructive (solid) line shows an exhalation from 0 to an FVC of 3.5 litres with an 
FEV1 of 1.8 litres. FEV1/FVC is 1.8/3.5 = 51%, this is less than 70%, therefore it is an 
obstructive picture.  
Figure 2.3 Time-volume graph showing obstructive pattern. Reproduced under 
Creative Commons licence (Cheek 2014) 
 
The reason the clinical definition of COPD is based on spirometry is because of the 
relationship between airflow obstruction and mortality. Clinical patterns alone are too 
inconsistent to diagnose COPD. This was demonstrated by a study (Mannino, Etzel et al. 
1993) of 4461 middle-aged Vietnam war veterans, which investigated whether the presence 
of clinical indications for spirometry would identify those with lung obstruction on 
spirometry.(Mannino, Etzel et al. 1993) All participants had both clinical and spirometric 
parameters assessed. Among those without a clinical dicator of COPD, 6% of the never 
smokers, 6% of the former smokers and 14% of the current smokers had lower than normal 
FEV1. This study demonstrates that using clinical indicators as a basis for pulmonary 
function in middle aged men misses many with low lung function and airways obstruction, 
especially in current smokers.(Mannino, Etzel et al. 1993) Clinical features alone are 
therefore a poor predictor of airways obstruction and thus mortality.  
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2.2.5 Diagnosis of COPD in elderly patients 
It is important to be aware that both FEV1 and FVC decline proportionately with age and so 
although, graded as “moderate COPD” many older patients may often have had a “normal” 
FEV1 for their age. Therefore, reporting the FEV1 alone should be regarded as an unreliable 
marker of obstruction unless considered in the context of FEV1:FVC.(Editorial 2011)  
It is now a well-established disadvantage of using the fixed 0.7 threshold that this can lead to 
a diagnosis of COPD in even the non-smoking elderly because of the age-related decline in 
FEV1.(Mohamed Hoesein, Zanen et al. ; Mannino, Sonia Buist et al. 2007) An alternative 
which has been suggested is to use the population’s lower limit of normal – the bottom 5% 
of the normal population distribution for FEV1/FVC ratio, although a consensus on the 
“representative population” has not yet been reached.(Price, Yawn et al. 2010) The most 
commonly used representative population for decisions regarding the percent of predicted 
FEV1 is the European Community for Coal and Steel Cohort (ECCS) and is over 20 years 
old, based only on a working white European population.(Quanjer PH, Tammeling GJ et al. 
1993) 
2.2.6 Co-existing asthma in COPD 
An additional complication to the diagnosis of COPD is whether concomitant asthma may be 
present. Using two large cross-sectional population studies, Soriano et al., (Soriano, Davis et 
al. 2003) quantified the overlap between various obstructive lung diseases as diagnosed by 
either the patient’s GP or self-reported. They found that 17% of the United States (US) and 
19% of the United Kingdom (UK) populations had been diagnosed with more than one 
obstructive airway disease. They also found that the prevalence of asthma-COPD overlap 
increased with age for both men and women.(Soriano, Davis et al. 2003)  
How best to manage these older patients with concomitant asthma and COPD is uncertain as 
they are a group of patients who are often neglected by guidelines because they are often 
excluded due to co-morbidities and age from the trials that provide the evidence 
base.(McDonald, Higgins et al. 2013) In addition, there is confusion among clinicians about 
whether and how they should differentiate asthma from COPD. There is pervading 
uncertainty among clinicians as to the use of diagnostic labels for obstructive diseases and 
non-systematic use of terms.(Gibson and Simpson 2009) 
The value of diagnosing asthma and COPD overlap syndrome (ACOS) is increasingly being 
recognised. The two conditions share important risk factors including increasing age, 
smoking, bronchial hyper-responsiveness and exacerbtions. By understanding these risk 
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factors there may be increased scope for preventing the accelerated loss of lung function that 
leads to COPD.(Gibson and Simpson 2009) 
One study found that subjects with the overlap syndrome had a statistically higher frequency 
of respiratory symptoms, functional limitation and hospitalisation with respect to subjects 
with the diagnosis of asthma or COPD alone.(de Marco, Pesce et al. 2013) These findings 
were echoed in another study that found that ACOS was associated with a lower health 
related quality of life.(Kauppi, Kupiainen et al. 2011) 
  
2.2.7 Defining COPD for the purpose of this thesis 
The definitions given above are primarily based on spirometry. These definitions have been 
used in a large number of population surveys in order to establish the epidemiology of 
COPD. In the Obstructive Lung Disease in Northern Sweden Studies, the prevalence of 
COPD among the over 45s was 14% according to the GOLD spirometry criteria. However, 
only 18% of 1500 patients invited to the survey for spirometry had previously been 
diagnosed as having either chronic bronchitis, emphysema or COPD (Lundback, Lindberg et 
al. 2003). There is, therefore, a major difference between the prevalence of spirometrically 
defined COPD and physician diagnosed and recorded COPD. 
This under-ascertainment of COPD is because many people who have breathlessness or 
excess sputum production simply dismiss these sympto s as part of older age or “a smoker’s 
cough” and consider them to be normal: such people nev r seek medical attention for these 
symptoms. Following on from this, there have been studies of case-finding of COPD by 
performing spirometry in smokers (Tinkelman, Price et al. 2007). The yield for case-finding 
of undiagnosed COPD by spirometry has been shown to be 10-20% of smokers over 40 
years of age in one study based in England and Colorado (Tinkelman, Price et al. 2007), and 
20.7% (95% CI 18.3-23.4) in another, based in Toront .(Hill, Goldstein et al. 2010) 
For the purposes of this thesis, it is important to keep in mind how COPD has been defined, 
especially when a prevalence estimate has been provided. The prevalence based on 
spirometric survey, is the total prevalence of COPD including undiagnosed COPD, and is 
much higher than the prevalences based on healthcare records or prevalence of “physician 
diagnosed COPD”. The prevalences are also markedly different depending on the age group 
in which the prevalence was measured. 
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For the modelling phase of this thesis, the prevalence of COPD was based on a health 
services definition of COPD. As described in Chapter 6, a primary care dataset was used to 
establish the prevalence of physician diagnosed COPD based on a Read Code entry into the 
medical notes. 
The rationale for concentrating on physician diagnosed COPD as opposed to spirometrically 
defined COPD is that there have been many spirometry-based surveys estimating the 
prevalence of COPD and several models based on them as can be seen in Section 2.3. 
However, only physician diagnosed COPD will contribute costs which can be identified as 
due to COPD. Therefore this is the most useful measur  for determining the active burden of 
COPD on healthcare services. Unless medical practices change to result in greater rates of 
ascertainment, the burden of COPD on healthcare services in terms of costs and hospital 
admissions will be dependent on the rate of diagnosed COPD, therefore I have chosen to 
focus on physician diagnosed COPD. This also enables the use of the Dutch Model with 
routinely gathered healthcare data as I will expand upon in Chapter 6. 
2.3 Epidemiology of COPD 
2.3.1 Global epidemiology of COPD 
The global epidemiology of COPD has been described in a series of spirometry survey 
studies under the banner of the Burden of Obstructive Lung Disease or BOLD 
study.(Chapmann, Mannino et al. ; Buist, McBurnie et al. 2007) These studies covered North 
America, Europe and Asia and were then extended into South America by the PLATINO 
studies.(Menezes, Perez-Padilla et al. 2008) These studies were dominated by cross-sectional 
surveys of prevalence. The aim of the BOLD studies wa to standardise these surveys in 
terms of the use of methods including spirometry.  
A recent systematic review summarised what is known about the prevalence of COPD in 
Europe.(Atsou, Chouaid et al. 2011) It grouped the prevalence estimates according to the 
criteria used to classify the disease; these estimates are shown in Table 2.1 below. There 
were three studies that had used questionnaires about symptoms of chronic bronchitis to 
judge prevalence (Cerveri, Accordini et al. 2001; Huchon, Vergnenegre et al. 2002; Cerveri, 
Accordini et al. 2003). There were six studies thatjudged prevalence based on physician 
reports (Lundback, Nystrom et al. 1991; Montnemery, Adelroth et al. 1998; Hedman, Kaprio 
et al. 1999; Montnemery, Nihlen et al. 2006; Schirnofer, Lamprecht et al. 2007; Cazzola, 
Puxeddu et al. 2011) and 20 studies that used spiromet y (Bakke, Baste et al. 1991; Brotons, 
Perez et al. 1994; Renwick and Connolly 1996; Marco Jordan, Martin Berra et al. 1998; 
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Dickinson, Meaker et al. 1999; Jaen, Ferrer et al. 1999; Pena, Miravitlles et al. 2000; Viegi, 
Pedreschi et al. 2000; Hasselgren, Arne et al. 2001; Tzanakis, Anagnostopoulou et al. 2004; 
Murtagh, Heaney et al. 2005; Sichletidis, Tsiotsios et al. 2005; Shahab, Jarvis et al. 2006; 
Stavem, Sandvik et al. 2006; Buist, McBurnie et al. 2007; Bednarek, Maciejewski et al. 
2008; Hansen, Pedersen et al. 2008; Roche, Dalmay et al. 2008; Miravitlles, Soriano et al. 
2009; van Durme, Verhamme et al. 2009). There were also three studies that had estimated 
the prevalence using modelling (Stang, Lydick et al. 2000; Feenstra, van Genugten et al. 
2001; Peabody, Schau et al. 2005). In addition to the different definitions, the studies were of 
different sizes and covered different age groups in different countries. This resulted in very 
variable estimates of the prevalence of COPD. In Europe, the prevalence of COPD varied 
from 2.1% to 26.0% depending on age group and methods used.(Atsou, Chouaid et al. 2011) 
Table 2.1 European prevalence of COPD from Atsou. Reproduced from BMC 




Study Country Sample 
size 
Age (yr) Prevalence 
(%)* 
Symptoms Cerveri 2003 Italy 18645 20-44 9.5 
 Huchon 2002 France 14076 ≥25 4.1 
 Cerveri 2001 16 Countries 14819 20-44 2.6 
Physician 
reports 
Cazzola 2009 Italy 15229 NS 2.5 
 Schirnhofer 2007 Austria 1250 ≥40 5.6 
 Montnemery 2006 Sweden 3692 20-59 3.6 
 Hedman 1999 Finland 3102 18-65 3.7 
 Montnemery 1998 Sweden 8469 20-59 4.6 




Miravitles 2009 Spain  4274 56.6(10.7) 10.2 
 van Durme  2009 Netherlands 7983 ≥55 11.6 
 Hansen 2008 Denmark 4757 45-84 12.0 
 Bednarek 2008 Poland 1960 56.7(11.6) 9.3 
 Roche 2008 France 4764 59.9(10.1) 2.6 
 Buist 2007 Austria 1258 ≥40 26.1 
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  Germany 683 ≥40 13.3 
  Poland 526 ≥40 22.1 
  Norway 638 ≥40 18.8 
 Shahab 2006 United 
Kingdom 
8215 55.5(13.5) 13.3 
 Sichletidis 2005 Greece  6112 21-80 16.4 
 Murtagh 2005 Ireland 2484 53.3(8.6) 6.3 
 Tzanakis 2004 Greece  888 ≥35 8.4 
 Hasselgren 2001 Sweden 4814 43(14.8) 2.1 
 Peña 2000 Spain  3978 40-69 9.1 
 Viegi 2000 Italy 1727 ≥25 11.0 or 
18.3 
 Jaen 1999 Spain  497 20-70 7.2 
 Dickinson 1999 United 
Kingdom 
353 68.25 9.9 
 Marco Jordán 1998 Spain  460 40-60 6.8 




783 66.1 9.0 
 Brotons 1994 Spain 642 35-65 6.4 
 Bakke 1991 Norway  1275 42(16.1) 4.5 
Models ** Peabody 2005  Spain NA ≥30 6.2 
  Norway NA ≥30 6.3 
  Poland NA ≥30 6.7 
 Feenstra 2001 Netherlands NA ≥20 1.5 
 Stang 2000 Spain  NA ≥45 10.3 
  Italy NA ≥45 11.1 
  France NA  ≥45 10.4 
  United 
Kingdom 
NA  ≥45 15.0 
Notes: Symptoms reported were of chronic bronchitis. Age was reported in various ways, 
either as a range or mean (SD) is given. Functional respiratory test definitions: FEV1/FVC 
ratio <70%, FEV1<80% of predicted, FEV1/FVC ratio <65%, FEV1/FVC ratio 70% or 
FEV1/FVC ratio <88%(male)/89%(female). NS =not specifi d(Atsou, Chouaid et al. 2011)  
*95% Confidence intervals were not available for these values. 
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**These models used a variety of different techniques and definitions to generate their 
prevalence estimates. They are all reviewed in Chapter 5. 
From the BOLD study, there are estimates available for the prevalence of COPD in other 
sites around the world, these estimates are shown in Table 2.2. This study used survey 
techniques to obtain a broadly representative sample of adults over 40 in each region. The 
study also had strict criteria, using only post-bronchodilator spirometry with a 0.7 
FEV1/FVC ratio as definition.(Buist, McBurnie et al. 2007) 
Table 2.2 Results from the BOLD study, adults over 40 years (Buist, McBurnie et al. 
2007) 






Guangzhou, China 473 11.3% 
Adana, Turkey 806 19.1% 
Cape Town, South Africa 847 23.8% 
Reykjavik, Iceland 755 17.9% 
Vancouver, Canada 827 19.3% 
Lexington, USA 508 19.6% 
Manilla, Philippines 893 13.8% 
Sydney, Australia 541 19.2% 
*Confidence intervals were not published for these values 
The authors of the BOLD study commented that their estimates were generally higher than 
had previously been found. They reflected that this may be a result of prevalence based on 
symptoms or physician reports leading to under-ascertainment of the prevalence of COPD, in 
comparison to that based on spirometry.  
The PLATINO study added five Latin American cities using the BOLD methodology in 




Table 2.3 PLATINO results, adults over 40 years (Menezes, Lopez et al. 2009) 





São Paulo, Brazil 1000 15.8% 
Santiago, Chile 1208 16.9% 
Mexico City, Mexico 1063 7.8% 
Montevideo, Uruguay 943 19.7% 
Caracas, Venuzuela 1357 12.1% 
*95% Confidence intervals were not published for these values 
The Global Burden of Disease (GBD) initiative by the World Health Organization (WHO) 
has included COPD in its list of conditions since its first estimates in 1994.(Murray 1994; 
Murray and Lopez 1994; Shibuya, Mathers et al. 2001; Lopez, Shibuya et al. 2006; Mathers 
and Loncar 2006) It uses data available from countries and modelling to calculate disability 
adjusted life years (DALYs) and life lost to disability or to premature mortality from COPD. 
They also collate statistics on COPD mortality. In 2001, they produced their estimates that 
COPD was the fourth most common cause of death in the world. This estimate was updated 
on the basis of figures from 2010 to the third most common cause of 
death.(GlobalBurdenofDisease 2012) The methods of the GBD Study differ from the 
methods used for most of the models explored in this dissertation and are discussed further in 
the systematic review, Chapter 5. 
COPD is clearly a significant problem in the global context. Results from the BOLD study 
put the prevalence among the over 40 years age group m st commonly at around 20%. And 
the GBD study puts COPD as the third most common cause of death in 2010. Now to 
explore the importance of COPD in the context of Engla d and Scotland. 
2.3.2 Epidemiology of COPD in England 
The East of England Public Health Observatory has produced a modelled prevalence 
estimate of COPD from the 2001 Health Survey of Engla d spirometry data, updated with 
2009 demographic data and 2011 smoking rates, see Tabl 2.4.(ERPHO, Walford et al. 
2011) This, therefore, uses a definition of COPD based on spirometry thresholds. This is an 
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estimate of undiagnosed prevalence and was calculated using Nacul’s method.(Nacul, Soljak 
et al. 2007) This study is reviewed as part of the systematic review in Chapter 5.  
Table 2.4 Prevalence of COPD in England from East of England Public Health 
Observatory 
East of England Public Health 
Observatory(ERPHO, Walford et al. 2011) 
Prevalence (%) 
Males 16+ 4.49 
Females 16+ 2.28 
All persons 3.64 
 
The second part of this thesis which uses the Dutch Model to project the prevalence of 
COPD in England involved obtaining data from the Clinical Practice Research Datalink 
(CPRD), limited to its English population. This large database includes over 6% of English 
general practices. In this case, COPD was determined according to how patients had been 
coded in their electronic GP records. Therefore this definition only included physician-
diagnosed cases, see Table 2.6.  
Table 2.5 Incidence and prevalence of COPD in England from Clinical Practice 
Research Datalink (CPRD) 
Clinical Practice Research Datalink 2011 Incidence per 
person year 
All English patients over age 35* 0.00385 
Clinical Practice Research Datalink Prevalence (%) 
 
All English patients over age 35 3.35 
*Age over 35 was used because consensus is that COPD cannot reliably be diagnosed in 
younger age groups. 
For the purposes of this thesis, I used the CPRD prevalence of COPD based on physician 
diagnosed cases. A prevalence of 3.35% among those aged over 35 in England is therefore 
the baseline prevalence. 
2.3.3 Epidemiology of COPD in Scotland 
There are two main Scottish sources of primary cared ta for the diagnosed prevalence of 
COPD in Scotland both shown in Table 2.6. The firstis the Practice Team Information 
Programme (PTI), which uploads data from 6% of the General Practice (GP) practices in 
Scotland from the whole practice team including nursing entries. The PTI defines COPD 
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prevalence as patients who have consulted a GP or practice nurse at least once during the 
year and coded with a COPD Read Code.(SPHO-PTI 2012) Detailed data of how the PTI 
prevalence changes with age was sought as part of the modelling phase of this thesis. 
A second Scottish source of primary care diagnosed COPD prevalence is the Quality and 
Outcomes Framework (QOF), which records data from all Scottish practices which are on 
the New General Medical Services Contract (nGMS) introduced in 2004 who have chosen to 
submit data for scrutiny and for the award of financi l incentives if the data reflect high 
enough quality practice.(GMC 2003) The COPD prevalence rate from QOF is the proportion 
of patients who are included on the COPD register across all practices. It is a crude 
unadjusted rate: practices with more elderly people r greater socioeconomic deprivation are 
likely to have a higher prevalence of COPD. In 2010/1 , there were 857 Scottish practices 
with patients on the COPD register out of a total of 876 nGMS Scottish practices and 1002 
Scottish practices in total.(SPHO 2012)   
Table 2.6 Physician diagnosed prevalence of COPD in Scotland (SPHO 2012) 
Practice Team Information 2010/11 Prevalence (%) 
Males all ages 1.49 
Females all ages 1.76 
Quality and Outcomes Framework 
2010/11 
 
Males and females, all ages, crude rate 2.04 
 
Incidence data on COPD in Scotland were harder to source. The main source used by 
government statistics is the Scottish Morbidity Record 01 (SMR01). However, this uses 
admission to hospital with a COPD episode as a proxy f r incidence and so is not a true 
incidence figure. Better estimates of incidence as number of new diagnoses of COPD were 
obtained from the Lothian COPD Cohort database. The Lothian COPD Cohort database was 
constructed from extracts of primary care data from practices in Lothian and is fully 
described in Chapter 6. The age related COPD incidee rates in the Lothian COPD cohort 
database was calculated as the number of new diagnoses per time period in the database. The 
formula for this is presented in Chapter 6. 
2.3.4 Conclusions to epidemiology section 
Depending on the ages included in the prevalence estimate and whether the estimate is based 
on a spirometry survey or physician-diagnosed COPD, there is variation in the published 
prevalences of COPD from 1.5% to 26.1% across the world. There is, thus, a pressing need 
for standardisation. In those aged over 40, most prevalence estimates are around 20% in 
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spirometry surveys. The BOLD study in London, UK found a prevalence of 18.9% among 
men aged over 40 and 16.0% among women aged over 40.(Hooper, Burney et al. 2012) 
Among the physician-diagnosed population in Scotland estimates are around 2% (all ages) 
and in England around 3% (age over 35). This demonstrate  that there is likely to be 
substantial under-diagnosis of COPD. However, the physician-diagnosed population are 
likely to be those whose symptoms affect them enough to engage in healthcare seeking 
behaviour. This diagnosed section of the COPD population is thus the section that will 
consume the most healthcare resources. Therefore, I focused on the physician-diagnosed 
population for the modelling phase of the PhD to all w projections of healthcare resources to 
be made according to where they are most likely to be used. Unless COPD screening is 
introduced or there are much greater resources spent on healthcare it is likely that the rate of 
COPD ascertainment will remain fairly constant. Alternatively, it can be taken that the 
projections for COPD prevalence in England and Scotland made by this thesis are very 
conservative estimates. 
In order to perform the modelling undertaken in the lat r stages of this PhD, it was necessary 
to have sources for physician diagnosed incidence ad prevalence data in England and 
Scotland. The following sources were therefore select d: English prevalence and incidence 
data both came from a large sample COPD case-control study extract from the CPRD (see 
Appendix 1.1). The denominators were from the whole p pulation of CPRD patients. The 
CPRD population has been shown to be representative of th  whole UK population; this is 
discussed further in Chapter 3. (Campbell, Dedman et l. 2013) Scottish incidence came 
from the Lothian COPD Cohort Database as using physician recorded primary care Read 
Codes was felt to be more accurate to provide true new diagnoses rather than the option of 
SMR01 hospital codes for admissions to provide the incidence rate. Not all cases of COPD 
require hospital admission and so the hospital coded rate may substantially underestimate the 
prevalence of COPD. Scottish prevalence came from the PTI Database as discussed with 
Information Services Division and they recommended this source as more representative 
than the QOF crude estimates. Further details of all these sources are given in Chapter 6. 
2.4 Morbidity, mortality and costs of COPD 
2.4.1 Morbidity from COPD 
It is estimated that diagnosed COPD is responsible for 1.4 million GP consultations per year 




COPD is the second largest cause of emergency admission in the UK, one in eight (130,000) 
emergency admissions to hospital is for COPD.(BLF 2007) Overall, respiratory disease is 
estimated to account for 5.2 million bed days, COPD itself accounts for more than one 
million bed days each year in hospitals in the UK.(BTS 2006) 
About 30% of patients admitted with COPD for the first time will be readmitted within three 
months.(BTS 2006) Admission patterns vary by up to five times in different parts of 
England; this reflecting differences in the underlying prevalence of COPD and wide 
variations in the quality of care that is provided in the community.(HealthcareCommission 
2006) 
2.4.2 Mortality from COPD 
It is estimated that over 30,000 people die from COPD every year in the 
UK.(HealthcareCommission 2006) There is some controversy over the official figures for 
mortality from COPD as many patients die with the disease rather than of the disease, as 
discussed below.  
There follows data for England and Wales, these figures are coded in International 
Classification of Diseases 10 (ICD-10) codes from the death certificate.(WHO 2010) Codes 
J40 to J47 are the chronic lower respiratory diseases to which COPD is the major 
contributor. If COPD is recorded as the underlying cause of death on the death certificate 
then the death will be registered as a chronic lower respiratory disease death. In England and 
Wales it appears that there are more deaths among males, and that deaths are increasing 
overall among both sexes, see Figure 2.3. 
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Figure 2.4 Number of deaths identified from death certificates with codes of J40 to 
J47 identified as underlying cause of death in England and Wales 2006-2012 by sex 
 
The General Register Office for Scotland (GROS) has released the following figures for 
mortality from COPD in Scotland, see Figure 2.4.(GROS 2012)  
Figure 2.5 Number of deaths from GROS with codes of J40 to J47 identified as 
underlying cause of death in Scotland 2000-2012 by sex 
 
Here it can be seen that deaths from COPD are slightly higher among females than males, in 
Scotland, and that deaths are perhaps continuing to increase for females while remaining 




























However, overall these mortality figures present a misleading picture of the burden of 
mortality among COPD patients because so many patients with COPD have significant 
smoking-related co-morbidities and, therefore, die with COPD rather than of COPD 
(Hansell, Walk et al. 2003). It has been shown that 8.0% or 312,664 deaths in England and 
Wales over a six year period had obstructive lung disease (including asthma) mentioned on 
the death certificate. Of these, 59.8% had obstructive lung disease comprising the underlying 
cause of death. In the remainder of deaths the leading causes were acute myocardial 
infarction, other ischaemic heart disease, lung cancer and bronchopneumonia.(Hansell, Walk 
et al. 2003) It can be concluded from this study that information on COPD from death 
certificates significantly underestimates the burden of the disease.(BLF 2007) 
2.4.3 Costs of COPD 
The direct cost of COPD to the UK healthcare system was previously estimated to be 
between £810-£930 million a year.(HealthcareCommission 2006) Direct costs are the cost of 
medical care for routine and emergency management of COPD. More than half these costs 
relate to the provision of care in hospital. COPD is among the most expensive conditions 
treated by the National Health Service (NHS) in the UK.(BTS 2006; NICE 2010)  
The indirect costs of COPD are substantial, however, th y are difficult to quantify. Indirect 
costs include the “social and economic costs” of lost days from work through ill health and 
informal caring for relatives with the disease. One estimate of the impact of annual 
productivity is 24 million lost working days per annum.(HealthcareCommission 2006; NICE 
2010) 
One important outcome from this PhD is an estimate of he direct cost of caring for COPD 
patients in hospitals and primary care for Scotland  England in 2011 and projections 
without inflation to 2030.  
2.5 Aetiology of COPD 
2.5.1 Prenatal and postnatal lung growth 
Adult COPD results from an accelerated decline in lung function as proposed by Peto.(Peto 
and Fletcher 1977) However, failure to attain maximal airway growth also has a role. 
Prenatal lung growth is relevant; lung function is reduced among children of low birthweight 
whether as a result of prematurity or intra-uterine growth retardation. (Rona, Gulliford et al. 
1993) In addition, lung function is reduced among children whose mothers smoked during 
pregnancy, and there is also an effect of childhood exposure to second-hand smoke on lung 
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function. (Cook, Strachan et al. 1998). Thus, both prenatal and postnatal airway growth 
affect the maximal lung growth reached in early adulthood and, therefore, the baseline from 
which lung function decline begins. 
2.5.2 Bronchial hyper-responsiveness 
The role of reversible airways narrowing related to asthma in the generation of COPD 
remains controversial. Bronchial hyper-responsiveness describes an inflammatory process in 
the airways initiated in atopic persons by allergen exposure. If this inflammation continues it 
is thought to promote remodelling of the airways, which leads to irreversible airflow 
obstruction, such as is found in COPD. In this way, people who do not smoke may develop 
COPD (or overlap syndrome as previously discussed in Section 2.2.6) as a result of 
remodelled asthma. However, in people who do smoke bronchial hyper-responsiveness may 
be a feature of the immune response to smoking.(Strachan and Sheikh 2004) 
2.5.3 Effects of childhood respiratory tract illnes s 
Barker’s study found that bronchitis, pneumonia andwhooping cough before the age of five 
years were associated with a reduced FEV1 in adulthood.(Barker, Godfrey et al. 1991) 
Another study found that a medical history of bronchitis, pneumonia or asthma in early life 
was associated with a more than twofold increase in COPD mortality (adjusted hazard ratio 
2.37, 95% CI 1.16-4.83)(Galobardes, McCarron et al. 2008) Such findings could reflect lung 
damage due to early episodes of chest infection, a longstanding susceptibility to all forms of 
lung disease, continued environmental exposure or socioeconomic disadvantage.(Strachan 
and Sheikh 2004) Of these suggested mechanisms, longstanding susceptibility or continuing 
environmental exposure are favoured. This is as a result of some research that scrutinised the 
impact of childhood infections with respect to season of birth. Babies born in the autumn are 
at substantially greater risk of viral bronchiolitis, bronchitis and pneumonia as a result of 
seasonal fluctuations in environmental viruses. If uch early infections have a direct impact 
on adult lung function or increased respiratory symptoms then these outcomes should be 
more frequently observed among autumn births. However, such an association was not found 
in several large datasets. (Strachan, Seagroatt et l. 1994)  
2.5.4 Smoking and COPD  
The definition of COPD characterises it as arising from enhanced chronic inflammatory 
response in the airways and the lung to noxious particles or gases(GOLD 2013). 
In the UK and most other economically-developed natio s, cigarette smoke is 
overwhelmingly the most common risk factor. The epid mic of COPD in the Western world 
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has followed the epidemic of smoking. The classic Doll et al. study of smoking doctors in 
the 1950s demonstrated a dose-response relationship between severity of lung disease and 
number of cigarettes smoked.(Doll, Peto et al. 2004)  
Other exposure factors may have a role in specific populations where rates of cigarette 
smoking are insignificant or absent, for example in China, South East Asia and parts of 
Africa exposure to biomass cooking fuel smoke in poorly ventilated indoor settings results in 
COPD.(Norman, Barnes et al. 2007) This is particularly manifest in non-smoking women. 
Outdoor air pollution from factories and traffic may lso have a role.  
In addition “noxious particles or gases” may come from industry and occupational dusts. The 
lines of definition and diagnosis are not clear between COPD due to smoking and fixed lung 
obstruction as a result of occupational exposure to dusts and particles; however, diseases 
such as silicosis, pneumoconiosis, asbestosis and psitticosis are generally considered to be 
distinct from COPD. For the purposes of this PhD, COPD is defined as overwhelmingly 
caused by smoking; exposure to other dusts are not taken into account. 
2.5.5 Phenotypic variation 
One of the great mysteries of COPD is to explain why there are some people who may 
smoke all their lives and yet be only mildly, if at all, affected by COPD. FEV1 decline is 
present in 20-50% of smokers.(Lundback, Lindberg et al. 2003) It needs to be explained why 
50-80% of smokers do not suffer a demonstrable decline in FEV1. Recent genetic and 
immunology studies (see Sections 2.5.6 and 2.5.7) are only just beginning to shed light on 
the mechanisms by which some people succumb to COPD whereas others remain well, 
despite a lifetime of smoking.(Lundback, Lindberg et al. 2003) 
2.5.6 Smoking and genetics 
Much work has been going on over the past few years to try and discover the genetic 
associations of COPD. It has been known for some tihat the genetically determined 
absence of alpha-1-anti trypsin is associated with accelerated lung function decline and 
premature death, especially in smokers. However, moe recently, the sequencing of the 
human genome enables Genome Wide Association Studies (GWAS). This methodology 
enables candidate single nucleotide polymorphisms (SNPs) to be mapped from the genome 




For example, the first GWAS study for COPD found two candidate polymorphisms on 
chromosome 15 at a locus which has been previously described as formally associated with 
smoking behaviour and lung cancer.(Pillai, Ge et al. 2009) The so-called AGPHD1/ 
cholinergic receptor nicotinic alpha 3 (CHRNA3) on chromosome 15q25 was thought to be a 
genetic determinant of smoking intensity. It has recently been confirmed using statistical 
mediation studies (see glossary) with a large cohort of genetically profiled COPD smokers 
that CHRNA3 affects COPD via pathways affecting smoking intensity as measured by pack-
years. In other words, this gene mediates nicotine addiction and has been shown to have a 
relationship with COPD. (Siedlinski, Tingley et al.2013) Other identified gene variants 
FAM13A (family with sequence similarity 13 member A) and HHIP (Hedgehog interacting 
protein) SNPs have been shown not to act through these pathways although they are still 
postulated to be COPD susceptibility genes.(Siedlinski, Tingley et al. 2013) 
Also under investigation is how different genes contr l different people’s level of 
inflammatory response to an inflammatory stimulus sch as cigarette smoke or an infection. 
Some cell studies have shown that cells from those with COPD are prone to an exaggerated 
and potentially more locally harmful immune response to a common infectious agent such as 
rhinovirus.(Baines, Hsu et al. 2013) 
2.5.7 Smoking and the immune response 
Inhalation of smoke deposits carbon, oxygen free radicals and other particles in the lung; to 
which there is an immune reaction. The body increases the production of mucous and the 
number of goblet cells in an attempt by the mucocillary ladder to clean the lung of noxious 
and foreign particles.(Ganesan, Comstock et al. 2013) As smoking continues there will be 
release of pro-inflammatory cytokines by airway epithelial cells which will recruit innate 
immune cells to the lungs(John, Kohse et al. 2014). These neutrophils and macrophages then 
release oxygen radicals and proteolytic enzymes such as neutrophil elastase and matrix 
metalloproteinases. The adaptive immune system also h  a role: CD8+ T cells and natural 
killer cells also destroy lung parenchyma by releasing perforin and granzyme B. There also 
begins a process of chronic inflammation with lymphoid neogenesis: the iBALT – inducible 
Bronchus Associated Lymphoid Tissue which organises adaptive immune cells into 
lymphoid follicles around the small airways. In these follicles antigen retention, 
immunoglobulin class switching and affinity maturation occur.(Brusselle, Joos et al. 2011) 
The chronic inflammation spurs airways remodelling with increased deposition of fibrin 
which also reduces the lung’s elastic recoil (known as compliance, see 2.6) and eventually 
there is squamous metaplasia and consequent loss of gas exchange surface (Herfs, Hubert et 
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al. 2012). There is increasing evidence that these changes represent a type of accelerated 
ageing in COPD.(MacNee 2009; MacNee and Tuder 2009)  
Recently, scientific consensus has grown that the lungs in COPD are colonised by bacteria 
and viruses even when the disease is stable. Techniques such as quantitative polymerase 
chain reaction (PCR) have enabled the bacteria H influenzae, S pneumonia,  and Moraxella 
catarrhalis to be detected in about 25% of patients with stable COPD and in more than 50% 
of patients during exacerbations.(Garcha, Thurston e  al. 2012) Macrophages from patients 
with COPD have demonstrated impaired phagocytic respon es to bacteria compared with 
non-smokers and smokers who do not have COPD. So it seems that those who develop 
COPD have an abnormal immune response.(MacNee 2009;Garcha, Thurston et al. 2012) 
The role of the abnormal or exaggerated immune response is also being investigated in 
exacerbations. It has been discovered that during exacerbations there is an increase in the 
concentration of bacteria that colonise the lower airways and that colonisation with a new 
bacterial strain is also often a key element in the development of an exacerbation.(Brusselle, 
Joos et al. 2011) Viruses can be detected in 10-15% of sputum samples in patients with 
stable COPD and 30-60% of those with COPD exacerbations. Rhinovirus and influenza virus 
are most commonly associated with viral exacerbations. Sputum eosinophils are increased 
during viral exacerbations.(Brusselle, Joos et al. 2011) Exacerbations are an important 
feature of COPD and an important contributor to the ov rall disability from COPD. 
2.6 Pathophysiology of COPD 
In terms of the pathophysiology of COPD the key feature is airways resistance, also termed 
airways obstruction. The destruction of the lung parenchyma and, in particular, the loss of 
elastin reduces a property of the lung known as “compliance”. The compliance of the lung is 
the elastic recoil that returns the lung to its resting volume following normal inspiration. 
Firstly, during inspiration, the diaphragm descends and the rib cage expands resulting in a 
low pressure in the lung cavity. Air is drawn down the trachea, along the bronchi, the 
bronchioles and into the lung parenchyma. As the air pressure inside the chest cavity 
equalises to that outside the chest cavity and the rib cage and diaphragm are no longer 
moving dynamically, the expiration phase begins. In co trast to inspiration, expiration is 
passive. The diaphragm and intercostal muscles relax and the only force acting is the elastic 
recoil of the lungs, (i.e. their compliance). The compliance of the lung tissue holds open the 
lung air sacs and bronchioles by what is known as the “guy rope effect”, (as in the way of 
guy ropes on a tent) as the lung inflates and deflates thereby maximising the time for gas 
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exchange to take place. Since the resistance to airfl w s inversely and exponentially related 
to the diameter of the airway, small decreases in airway diameter lead to large increases in 
resistance.(Holleman and Simel 1995) Thus, in COPD, the “guy rope effect” is reduced as a 
result of the reduction of elastin in the lung and so the distal airways narrow, causing airway 
resistance and obstruction. The airways may even collapse trapping deoxygenated air in the 
terminal bronchioles and air sacs, thereby inhibiting efficient gas exchange.  
2.7 Clinical features 
Traditionally patients with COPD have been described as “pink puffers” or “blue bloaters”. 
The “pink puffers” are affected by air trapping in bullae which results in the high residual 
volumes which manifest clinically as a barrel shaped chest and palpable heart apex.(Lemyze 
and Bart 2011) Patients cope naturally with the air tr pping by pursing their lips on 
expiration, thus maximising the pressure inside the chest cavity for as long as possible to 
prevent the collapse of the distal air spaces. Patients remain pink because their PaO2 (partial 
pressure of oxygen) is normal enough for their haemoglobin to be saturated with oxygen and 
they are described as puffers because in later stages of the disease they have to work hard 
with pursed lip breathing and an increased respiratory rate to maintain this PaO2. They also 
use their accessory muscles to help with this increased work of breathing. Hoover’s sign is 
common; this is the paradoxical inward movement of the lateral diameter of lower part of the 
rib cage with inspiration and is a sign of airflow bstruction.(Bruyneel, Jacob et al. 2011) 
“Blue bloaters” have blue lips due to deoxygenated haemoglobin circulating as they are 
unable to maintain blood oxygen saturation and their PaO2 falls centrally. They often suffer 
with co-existent right heart failure leading to fluid retention, peripheral oedema and ascites: 
hence the appearance of bloating. The presence of central cyanosis is an important clinical 
finding as it indicates that the brain is likely to have switched from a hypercapnic respiratory 
drive for respiration to a hypoxic drive. In this setting the provision of supplemental oxygen, 
if not carefully titrated, may improve the oxygen saturation to a level that the hypoxic drive 
in the brainstem switches off and the patient stops breathing. This may have the unintended 
consequence of potentially fatal acidosis. 
Emphysema (pink puffer) and chronic bronchitis (blue bloater) is the traditional clinical 
dichotomy but it is unsatisfactory for many reasons. The pathologies of emphysema and 
mucous hypersecretion co-exist in the majority of smokers and whether the pink puffer or 
blue bloater clinical features are in evidence is often to do with the length of time the patient 
has been smoking. A pink puffer is at an earlier stage of the disease as their hypercapnic 
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drive is still functioning in their brainstem and they consequently raise their respiratory rate 
to compensate. The blue bloater has lost sensitivity o high CO2 and so their blood pH is 
likely to be slightly acidotic as this gas accumulates. 
2.7.1 Frequent exacerbator phenotype 
COPD exacerbations are an important cause of COPD morbidity and hospital admissions. 
The frequent exacerbator phenotype is a more useful clinical identity than either pink puffer 
or blue bloater. COPD exacerbations affect FEV1 declin  independently of cigarette 
smoking. Exacerbations are associated with increased irway inflammation, lung function 
decline and increased bacterial colonisation. Following an exacerbation there is increased 
susceptibility to further exacerbations. Exacerbations have been observed to cluster together 
in time in patients.(Wedzicha and Donaldson 2012) 
It emerged from the ECLIPSE study that one relatively consistent group of patients were 
particularly prone to frequent exacerbations.(Vestbo, Agusti et al. 2014) The frequent 
exacerbators were identified by a history of two or more exacerbations in the past year. They 
were found to represent a stable phenotype and also exhibited decreasing FEV1, reflux 
heartburn and a high white cell count. Conversely, patients who had had no exacerbations in 
year one or two of the study had a 75% chance of no exacerbations in the third year.(Vestbo, 
Agusti et al. 2014) In the future it may prove possible to trial new therapies and intensive 
therapies specifically targeted to help this group (i.e. using a personalised medicines 
approach). 
2.8 Prognosis 
Recent research has provided a basis for the following statements regarding the prognosis of 
COPD and has updated the Fletcher-Peto trajectory.(Vestbo, Agusti et al. 2014) COPD is a 
very heterogeneous disease with a very variable course over time. COPD is now regarded as 
a syndrome-type disease in which symptoms, health sta us and exercise capacity fluctuate 
over time, but may be poorly related to the FEV1.(Editorial 2007) The problem is that the 
longitudinal FEV1 does not correlate very highly with patient-reported outcomes as assessed 
by a health status tool (for example the St George’s R spiratory Questionnaire). Change in 
FEV1 is only weakly correlated with symptom scores over time.(Kesten, Celli et al. 2011) 
This suggests that the declining FEV1 does not necessarily capture how the patient feels “in 
themselves” as reflected in their level of coughing, breathlessness and exercise capacity 
therefore, spirometry alone provides a very incomplete picture of COPD. (Westwood, 
Bourbeau et al. 2011) There is increasingly recognition that COPD is a multi-system 
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disorder and that factors such as Body Mass Index (BMI) and cardio-respiratory exercise 
reserve indicate prognosis more accurately than FEV1 alone because they consider COPD in 
the context of its common and important co-morbidities.(Editorial 2007; Wood 2011) 
Similarly, improvements in clinical symptoms do not ecessarily correlate with slowing of 
FEV1 decline as assessed by spirometry.(Qaseem, Wilt et al. 2011) Such considerations have 
led to the development of new ways of assessing pronosis. In this context, there is a 
reframing of the importance of FEV1 decline and other physiological measurements 
including CT-measured lung density as a quantificaton of emphysema, bronchodilator 
reversibility, systemic inflammatory markers and exercise capacity. These will be discussed 
below. 
2.8.1 FEV1 decline 
The original Fletcher-Peto trajectory assumed a smooth l ngitudinal progressive decline in 
lung function. In this context, the airflow obstruction as determined by the % of predicted 
FEV1 was used as a guide to the severity of the COPD, classifying a patient as “mild, 
moderate, severe or very severe” as below. Spirometry is performed in patients in their stable 
non-exacerbated state to guide the classification. The latest NICE guidelines harmonised the 
definitions of each stage of airflow obstruction with the GOLD/ATS/ERS 
guidelines(Qaseem, Wilt et al. 2011). The thresholds f airways obstruction used in the 
NICE and GOLD/ATS/ERS guidelines are shown in Table 2.7.(GOLD 2010; Qaseem, Wilt 




Table 2.7 Thresholds of airways obstruction used to define severity categories in 
COPD 
































Severity of airflow obstruction 




50-79% Mild Moderate Stage 2 – 
Moderate 
Stage 2 – 
Moderate 










* symptoms should be present to diagnose COPD in people with NICE 2011 mild airflow 
obstruction.  
**or FEV1<50% with respiratory failure 
However, there have been few longitudinal studies to confirm the Fletcher-Peto trajectory 
and the latest evidence shows that the FEV1 decline with time may be less and more variable 
than was stated in their original paper. The ECLIPSE study was a longitudinal prospective 
observational study of moderate, severe and very severe COPD patients which showed a 
mean rate of change (+/- SD) in FEV1 as a decline of 33(+/-2) ml with significant variation 
56 
 
across the study.(Vestbo, Edwards et al. 2011) Overthe three year study period 38% of 
patients had a decline in FEV1 of more than 40ml per year, 31% had a decline of 21ml to 
40ml, 23% had a change between a decline of 20ml per year and an increase of 20ml per 
year, and 8% had an increase of more than 20ml per year. The mean rate of decline was 
21(+/-4) ml greater in current smokers than current non-smokers, 13ml (+/-4) greater among 
patients with emphysema on Computer Tomography (CT)Scan and 17(+/-4)ml per year 
greater in those with bronchodilator reversibility than in those without bronchodilator 
reversibility. An association with lung function decline of low levels of club cell secretory 
protein was also found, confirming findings from the Lung Health Study.(Park, Churg et al. 
2013) In the ECLIPSE study, all patients were receiving treatment for their COPD from their 
doctors (Vestbo, Edwards et al. 2011). It would seem that some of the variable decrease in 
lung function demonstrated may be accounted for by a treatment effect in conjunction with 
different underlying susceptibilities. And it might also be expected that the FEV1 decline 
might be larger in untreated patients. 
2.8.2 Computer Tomography (CT) defined lung density  over time in 
COPD 
It is now known that lung density changes over time n COPD are dependent on smoking 
status and gender. Smokers and women lose lung density more rapidly; however, variability 
between patients is significant. Change can be assessed using CT and sRAGE (soluble 
Receptor for Advanced Glycation Endproducts) may potentially be a biomarker for 
assessment of emphysema development in the future.(Vestbo, Agusti et al. 2014) 
2.8.3 Bronchodilator reversibility 
The latest evidence is that this is very variable among COPD patients. It is also unstable 
within individual patients and therefore difficult to use clinically. At present it is not thought 
that bronchodilator reversibility will be useful in defining subtypes of COPD.(Vestbo, Agusti 
et al. 2014) 
2.8.4 Systemic inflammation 
The ECLIPSE study confirmed that not all COPD patients have elevated biomarkers of 
systemic inflammation, one-third of participants had no evidence of elevated biomarkers of 
systemic inflammation for the three year follow-up. It appears the IL-8 and TNF Alpha are 
markers of smoking rather than markers of systemic inflammation. However, there was a 
small group (16%) of COPD patients in the ECLIPSE study who had persistent systemic 
inflammation and this was associated with a six-fold increase in all-cause mortality at three 
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years of follow-up. This finding makes way for using systemic inflammatory markers to 
improve prediction of mortality.(Vestbo, Agusti et al. 2014) 
2.8.5 Exercise capacity and the BODE index 
Limb muscle dysfunction is a major component of reduced exercise tolerance and also 
affects quality of life and mortality.(Maltais, Decramer et al. 2014) COPD results in 
metabolic and structural changes in the muscle. Physical inactivity contributes to muscle 
dysfunction but inflammation, oxidative stress, nutritional imbalance and hypoxaemia also 
have a role. Muscles are also compromised during COPD exacerbations.  
Exercise capacity is of prognostic value in COPD. B -BMI, O-airflow Obstruction as 
measured by FEV1, D-Dyspnoea as gauged by the Medical Research Council’s (MRC) 
dyspnoea scale, and E-Exercise capacity by way of the six-minute walk test, form the BODE 
index prognostic tool. (Puhan, Garcia-Aymerich et al. 2009) The BODE index has been 
evaluated recently for prognostic prediction and found to compare favourably with the 
GOLD 2011 rubric for combining predictive elements (see section 2.8.8)(de Torres, 
Casanova et al. 2014) 
2.8.6 Co-morbidities 
There is increasing recognition of the value of co-m rbidities in predicting prognosis in 
COPD. The 2013 GOLD guidelines have been adapted to include consideration of 
comorbidities when assigning a severity class to a COPD patient. COPD patients have a 
higher prevalence of osteoporosis, anxiety and panic ttacks, ischaemic heart disease and 
heart failure.(GOLD 2013)  
2.8.7 The DOSE Index 
Another important assessment tool is the DOSE index.(Jones, Donaldson et al. 2009) This is 
D-Dyspnoea (MRC dyspnoea scale), O-airflow Obstruction, S-Smoking status and E-
Exacerbations. This is a pragmatic test designed to be used in clinical settings as a 
multicomponent prognostic tool. According to multiple regression analysis, the four DOSE 
variables explain 48% of the variance in health statu . There is no need for the six minute 
walk test which limits the applicability of the BODE index in routine clinical settings where 
space, staffing and time are limited. The DOSE index is not only a measure of COPD 
severity but a guide to management. If the patient is suffering from dyspnoea they should be 
referred for pulmonary rehabilitation. If they have a certain level of obstruction they should 
be offered steroid inhalers, if they suffer recurrent xacerbations then long-acting 
bronchodilators would be more appropriate and if they are still smoking they should be given 
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smoking-cessation help. The DOSE index has been validated against other markers, for 
example, against healthcare utilisation in large datab ses, and has been shown to be useful 
for predicting future events such as hospital admissions and exacerbations.(Jones, Donaldson 
et al. 2009)  
2.8.8 Assessment of COPD severity as per GOLD guide lines 
The above considerations resulted in the latest update of the GOLD guidelines 
recommending that the following four components be assessed separately in order to 
categorise a patient’s severity of COPD: degree of airflow limitation using spirometry (as 
above), symptoms, risk of exacerbations and comorbidities according to a rubric in the latest 
GOLD guidance.(GOLD 2013) 
Symptoms are assessed with a validated questionnaire such as the COPD Assessment Test 
(CAT), the Modified British Medical Research Council (MRC) breathlessness scale or the 
clinical COPD Questionnaire (CCQ). A history of frequent exacerbations and comorbidities 
are also taken into account.  
Although there is evidence that all the components identified by the GOLD algorithm 
influence prognosis, the level of effect is usually not exactly known. How the factors interact 
and their combined prognosis is only crudely predict  by the rubric and further research is 
needed in this area to refine predictions. 
2.8.9 Life expectancy in COPD 
A recent Swedish study(Stallberg, Janson et al. 2013) of retrospective linked electronic 
medical record data from COPD patients has confirmed that people with COPD have a 
markedly reduced life expectancy. Overall life expectancy (standard deviation) for the 
COPD population was 8.3 (6.8) years lower than in the average Swedish population; 9.4 
years lower for women and 7.4 years lower for men. All-cause mortality was 3.5 times 
higher in the study population (age-standardised) compared with the death rate in the 
Swedish population.(Stallberg, Janson et al. 2013) 
Life expectancy for COPD has not so far been described for Scotland and England. 
2.9 Management of stable COPD 
The 2011 Clinical Practice update from the European Respiratory Society, American College 
of Physicians, American College of Chest Physicians and American Thoracic Society 
emphasises the wide variation between individuals with COPD.(Qaseem, Wilt et al. 2011) 
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They state that spirometric decline cannot be used to measure individual long term response 
to treatment. Instead, the goals of COPD treatment are described as follows: 
1. Reduce lung function decline 
2. Prevent and treat exacerbations 
3. Reduce hospitalisations and mortality 
4. Relieve disabling dyspnoea 
5. Improve exercise tolerance and health related quality of life. 
 
2.9.1 Smoking cessation 
Smoking cessation is the most important strategy for preventing and improving COPD. 
(NICE 2010) A Cochrane review (van der Meer, Wagena t l. 2003) found that 
psychosocial therapies in combination with pharmacological therapies were more effective 
than psychosocial therapies alone among COPD patients at five years (risk difference = 0.17, 
95% CI 0.14 to 0.19, relative risk 4.19, 95% CI 3.41 to 5.15). However, the review identified 
a need for further research to test the effectiveness of psychosocial therapies alone and to 
determine the most effective psychosocial intervention. 
2.9.2 Inhaled therapies 
The mainstay of COPD treatment (apart from smoking cessation) is inhaled therapies. There 
is a consensus that long-acting bronchodilators, inhaled corticosteroids or combination 
therapies reduce the annual rate of decline of FEV1 more than placebo. (Qaseem, Wilt et al. 
2011) A Cochrane review of 23 studies found evidence for a significant change in FEV1 
with salmeterol 50 mcg twice daily of 51 mls (95% CI 32 to 70).(Appleton, Poole et al. 
2006) A Cochrane network meta-analysis put inhaled tr atments in the following order of 
efficacy according to their effects on the St Georg’s Respiratory Questionnaire and trough 
FEV1: 1) inhaled corticosteriod/long acting beta agonist combination, 2) long acting 
muscarinic antagonist, 3) long acting beta-agonist and 4) inhaled corticosteroid. However, 
the seeming advantage of combination inhalers is tempered by their expense and their 
capacity for adverse events including pneumonia.(Kew, Dias et al. 2014; Kew and 
Seniukovich 2014) 
In terms of exacerbations, treatment with salmeterol combined with fluticasone, tiotropium, 
other long acting beta-agonists and other inhaled corticosteroids reduced annual rates of 
exacerbations.(Wilt, Niewoehner et al. 2007). Tiotropium also reduced the number of 
hospitalisations compared with placebo.(Niewoehner, Rice et al. 2005)  
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However, in terms of mortality the TORCH trial (TOwards a Revolution in COPD Health) 
showed no difference in pulmonary cause mortality wh salmeterol or fluticasone or 
combined therapy versus placebo.(Calverley, Anderson et al. 2007) One meta-analysis has 
found an increase in pulmonary cause mortality in association with long-acting beta-agonists 
compared with placebo.(Salpeter, Buckley et al. 2006) Overall, there remains insufficient 
evidence to choose between a combination of inhaled steroid and long-acting beta agonist 
and tiotropium in terms of their relative efficacy and safety.(Welsh, Cates et al. 2013) 
Inhaled therapies are most likely to benefit patients who have FEV1<60% predicted and 
symptoms, above this level there is little to no improvement in exacerbations, health related 
quality of life, COPD hospitalisations or mortality. In all patients, combination therapies do 
not consistently demonstrate benefits over monotherapy although they may be useful in 
some patient subgroups. However, adverse events may be more common.(Qaseem, Wilt et 
al. 2011) 
2.9.3 Pulmonary rehabilitation 
In people who have symptoms and FEV1<50% predicted pulmonary rehabilitation has been 
shown to improve symptoms, quality of life and the distance on the six minute walk test. 
There is also some moderate quality evidence that pulmonary rehabilitation is an effective 
intervention to reduce hospital readmission after exac rbations.(Puhan, Scharplatz et al. 
2009; Puhan, Gimeno-Santos et al. 2011) Pulmonary rehabilitation also reduces mortality 
after exacerbations (Odds Ratio 0.28; 95% CI 0.10 to 0.84).(Puhan, Gimeno-Santos et al. 
2011) 
2.9.4 Oxygen therapy 
There is widespread consensus that supplemental oxygen used for 15 or more hours daily in 
order to maintain partial pressure of oxygen above 60mmHg in patients with severe resting 
hypoxaeimia <55mmHg reduces mortality. Physiological indications for oxygen therapy 
include cor pulmonale or polycythaemia with PaO2 55-59mmHg.(Qaseem, Wilt et al. 2011) 
2.10 Management of COPD exacerbations 
COPD exacerbations are significant events in the natural history of COPD. They are 
upsetting for patients and account for much of the costs associated with caring for COPD 
patients. Commonly, symptoms include worsening breathl ssness, cough, increased sputum 
production and change in sputum colour. Bacteria and viruses are common causes of 
exacerbations. The value of antibiotics for less sever  exacerbations remains controversial, 
particularly in the context of increasing antibiotic resistance, and further research is needed 
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to identify those who will best respond to antibiotics.(Vollenweider, Jarrett et al. 2012) 
Therapy for exacerbations include inhaled and nebulised therapies, oral steroids, 
supplemental oxygen and, when required, non-invasive ventilation techniques as well as the 
full armoury of modern intensive care units when cosidered appropriate.(NICE 2010) 
2.10.1 Structure of care for people with COPD exace rbations 
In the UK, there has been a move to setting up anticipa ory care services for COPD.(NICE 
2010) This is with a view to preventing hospital admissions for exacerbations and managing 
a greater proportion of patients in primary care. However, the ethos of such services is very 
different from the rest of the NHS where a more tradi ionally “reactive” approach is the 
norm. There are consequently many challenges to making such services holistic, patient-
centred and able to ensure good communication between the relevant multidisciplinary 
professionals.(Cleland, Moffat et al. 2012) 
Other approaches to managing COPD in the community include increased use of 
telehealthcare, where the patient uses information technologies to communicate with the 
healthcare professional at a distance. A Cochrane syst matic review has found that 
telehealthcare can decrease hospital admissions for COPD.(McLean, Nurmatov et al. 2011; 
McLean, Nurmatov et al. 2012) 
2.11 Patient perspectives in COPD 
Of course patients do not measure their COPD in terms of the FEV1 and FVC, but in terms 
of how they are feeling “in themselves” and what they are able to do. The characteristic 
respiratory symptoms of COPD include dyspnoea (at rest and during exercise), chronic 
cough, sputum production, wheeze and chest tightness. Patients report dyspnoea to be the 
most bothersome symptom and it is often the primary reason for their seeking help.(van der 
Molen, Miravitlles et al. 2013) The onset of dyspnoea is gradual and patients often attribute 
it solely to aging or a lack of fitness. However, it is progressive and soon becomes an 
intrusive symptom, causing disability, especially as p tients limit their activity to avoid 
dyspnoea which results in deconditioning and worsening dyspnoea.(van der Molen, 
Miravitlles et al. 2013) Cough is another troublesome symptom in COPD and has notable 
effects on quality of life.(Calik-Kutukcu, Savci et al. 2014) The extra-pulmonary impact of 
COPD includes fatigue, muscle weakness, weight loss and sleep disturbance. Symptoms 
fluctuate for patients within the day with mornings often being particularly bad, but this may 
vary from day to day.(Giacomini, DeJean et al. 2012) 
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In contrast to other conditions, qualitative research has shown that patients with COPD view 
their condition as a “way of life” or “health problem” rather than an illness which disrupts 
life and from which they may expect to recover. Patients have great difficulty identifying the 
beginning of their illness and describe a “chaos narrative” of their illness: disjointed events 
associated with COPD in which they can see no clear purpose or direction.(Pinnock, Kendall 
et al. 2011) 
Disease progression in COPD is not smooth from the pati nt’s point of view. Gradual 
decline in the early years becomes more notable with exacerbations. There are steep 
deteriorations in function with exacerbations followed by recovery to impaired function (see 
Figure 2.5). Death is often unpredictable and relatives and doctors often express surprise 
when someone dies because they have rallied so manytimes before. (Lehman 2004; 
Giacomini, DeJean et al. 2012) This trajectory and the “chaos narrative” have challenged the 
traditional palliative care approach which was develop d for cancer patients and anticipates a 
clear transition to palliative care for a terminal decline. Instead it has been suggested that 
discussions about palliative care be entered into at milestones in the patient’s COPD 
narrative such as on discharge from hospital for an exacerbation or at installation of home 
oxygen therapy.(Murray, Kendall et al. 2005; Pinnock, Kendall et al. 2011) 
Figure 2.6 Typical end of life trajectory in COPD. Reproduced with permission from 
BJGP (Lehman 2004) 
 
2.12 Conclusion to Chapter 2 
In this chapter, I have discussed the major aspects of COPD in order to give an overview 
appropriate to this PhD. I began by discussing the definition of COPD and outlined how 
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COPD is diagnosed with the use of spirometry for FEV1 and FVC and the controversies that 
arise when using fixed spirometry thresholds for diagnosis. I then defined COPD for this 
thesis using a health services definition. I went on o explain the difference between 
epidemiology estimates from spirometry surveys and those from physician diagnosis. Then I 
presented various estimates for the prevalence of COPD globally, followed by estimates for 
England and Scotland and overall summaries. Then, I reviewed the burden of COPD in the 
UK in terms of morbidity, mortality and cost of COPD. Next, I reviewed the aetiology of 
COPD and the focus made upon smoking as the main cause of COPD in high income 
countries. I then discussed the pathophysiology of COPD and I summarised the clinical 
features of COPD, followed by the state of the art in terms of predicting COPD prognosis. I 
then considered the management of stable COPD and COPD exacerbations. Finally, I took a 
brief look at the experience of COPD from the patient’s perspective. It is hoped that this 







Chapter 3: Reusing healthcare data for research 
3.1 Introduction  
Chapter 2 introduced the condition of COPD on which this PhD concentrates. As the overall 
aim of the PhD was to model population projections f COPD, I review such models in 
Chapter 5. Such models need to be populated with healthcare data. Therefore, I want to 
introduce the ways in which healthcare data are captured by health systems in England and 
Scotland. In this chapter I will describe how healthcare data are captured in primary care and 
in hospital settings and then how they are captured in coded or narrative form. I describe 
how the validity of the data that are gathered may be assessed and improved. Then I discuss 
the validity of the data used in this PhD. I go on t  describe the ways in which healthcare 
data may be re-used for research. Healthcare data may be linked with other data for research, 
I describe some of the opportunities and challenges in carrying out such linked data studies. 
Healthcare data may be reused in the context of trials to speed recruitment and linked data 
may be used as a method of recording trial endpoints. I  addition, linked healthcare data can 
be used as a basis for pharmacovigilance. Next I describe the concerns with regards to 
privacy that such data reuse may pose and the process and regulatory responses in place to 
mitigate such concerns. I discuss the specific governance required for this PhD and conclude 
the chapter. 
3.2 Healthcare data capture 
3.2.1 Healthcare data capture in primary care 
Although UK general practices vary somewhat in their d gree of paperless processing, there 
have been incentives since the 2003 General Medical Services (GMS) Contract for them to 
computerise their healthcare records.(Thiru, De Lusignan et al. 2002; GMC 2003) UK NHS 
general practice now relies on these computer-based records. Extracts from the primary care 
computer records are used to inform eligibility for part of the remuneration package for 
general practices according to the Quality Outcomes Framework (QOF), where practices are 
rewarded for meeting certain standards of good medical care and organisation.(GMC 2003) 
There are four main computer systems for general practices in the UK: EMIS (EMIS 2015), 
Systmone (TPP-Systmone 2015) Torex (which was acquired by the company MICROS in 
2012) (MICROS 2015) and Vision (INPS4 2015). GPASS was a system used in Scotland 
which has now been superseded by other systems. 
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In order that these data can be used for research, these primary care systems are harvested for 
information by several large national primary care databases as summarised in Table 3.1. 
These databases may be accessed by researchers for r use of the data according to protocol, 




Table 3.1 Primary care databases covering England and Scotland. 
Database 
name 





















Extracts from Vision GP 
electronic health records. 
Contains patient 
registration information and 
all care events that GPs 
record including diagnoses, 
referrals to specialists and 
secondary care settings, 
prescriptions, 
immunisations, diagnostic 
testing and lifestyle 
information (smoking, 
alcohol etc.) 
680 General practices 
across the UK 
(England Scotland 
Wales and Northern 
Ireland), 8.5% of the 
UK population, Age 
and gender structure 
of the CPRD GOLD 
population is 
generally similar to 
the UK.(Campbell, 




























Data recorded in Vision 
software, the GP IT system, 
is recorded in the form of 
Read Codes concerning 
symptoms, diagnoses, 
referrals etc and also 
prescription information is 
available. In addition 
158,037 free text comments 
have been anonymised and 
added to the database this is 
35% of all comments in the 
records. 
562 general practices 
in the UK. Covers 
6.2% of UK 
population. Broadly 





















the UK  
Data recorded in the EMIS 
GP IT system. Patients’ 
data is pseudo-anonymised 
to prevent identification. 
Also available are linked 
data to cause of death, 
cancer registries and 
hospital data – however, 
such data must be analysed 
at the University of 
Nottingham. 
As well as medical 
data the system 
contains socio-


















Data recorded in GPASS 
GP IT system including 
details of patient 
encounters, Read Codes, 
prescriptions and 
measurements. Month and 
year of birth and gender.  
As PCCIU has 
postcode to sector 
level this can be 
linked to Scottish 



















collected by GPs, doctors in 
training and practice 
nurses. In March 2012, 19 
practices were using INPS 
Vision and 40 were using 
EMIS as their IT system. 
6% of Scotland’s 
population. The PTI 
population represents 
Scotland in terms of 
age, gender and 
deprivation. 






































et al. 2009) 
A wide variety of data 
sources connected with 
health and well-being 
including National 
Datasets, the NHS 
including primary care 
general practices that have 
signed up to SAIL, social 









services, primary care 
general practices, 
secondary care 
hospitals, and social 
care.  
 
3.2.2 Healthcare data capture in hospital settings 
Hospitals in the UK are approximately two decades behind general practices in adopting 
Electronic Health Records (EHRs).(Sheikh, Jha et al. 2014) This is despite, in 1998, the 
Department of Health making the commitment to adopting life-long EHRs for all NHS 
patients. The NHS National Programme for IT (NPfIT) Care Records Service (CRS) has 
faced many setbacks and much controversy in trying to implement electronic records in 
hospitals across the NHS.(Cresswell, Ali et al. 2011) (Robertson, Bates et al. 2011) Hospital 
staff still want EHRs for hospitals, however opinios differ as to the type of electronic record 
and scale of data sharing. Centrally negotiated contracts have proven inflexible and have 
contributed to the delay in the delivery of nationwide EHRs.(Robertson, Cresswell et al. 
2010) The main hospital EHR systems commissioned by the NPfIT CRS were Lorenzo 
Regional Care, RiO and Cerner Millennium.(Sheikh, Cornford et al. 2011) As well as the 
EHR systems, other computerisation in hospitals takes the form of the Patient Administration 
System (PAS) which manages appointments, admissions and discharges and the Picture 
Archiving and Communications Service (PACS) which is used to manage the radiology 
output of a hospital. Adoption of all of these systems by hospitals has been significantly 
scaled back since the 2010 spending review by the coalition government in 2010 which 
identified £0.7 billion savings from the NHS NPfIT (HMTreasury 2010) However, the think 
tank E-Health Insider (EHI) Intelligence estimates the total IT market for acute and mental 
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health trusts in England to still be around £1.3 billion per year, of which £560 million is 
locked up in NPfIT contracts until 2015. (EHIIntelligence 2012). 
The bulk of English hospital statistics used in research come from Hospital Episode Statistics 
(HES) which is derived from the hospital records of admissions and discharges, outpatient 
appointments and accident and emergency attendances. Data from all of these services are 
downloaded monthly by the Health and Social Care Information Centre (HSCIC) from the 
hospitals.(HSCIC 2014) Scottish hospital statistics are collected in the Scottish Morbidity 
Record (SMR01) by a special health board: The Information Services Division (ISD). The 
SMR01 has data on the admissions and discharges for all inpatient and day case episodes in 
Scotland. Both HES and SMR01 have identifier data for the patients, such as name, date of 
birth, postcode, NHS number (and Community Health Index (CHI) number in Scotland), the 
databases also contain International Classification of Disease version 10 (ICD-10) codes (see 
Table 3.2) for the illness, condition or procedure for which the person was admitted and 
some co-morbidities and specific geographical information, including measures of 
deprivation and responsible NHS board.(ISD 2014) The ICD-10 information is coded by a 
team of professional hospital coders who extract data from paper records or directly by 
clinicians where the hospital has an EHR system. 
3.2.3 Coded and narrative data 
The data that are collected in EHRs are either in the form of “narrative” or “coded” data. 
Narrative is the original way of recording information. (Morrison, Fernando et al. 2012; 
Morrison, Fernando et al. 2013) It is the most faithful because every aspect of the patient’s 
episode can be recorded. In paper records, the patint’s history and problems were recorded 
in the form of structured narrative text. The writer of the text had some discretion as to how 
best to indicate clinical importance of symptoms and signs and clinical context. (Williams 
and Morgan 1995) Narrative text relies on the semantics of the language to enable the reader 
to extract useful information.  
One review of the advantages of structuring a narrative text such as a patient history in the 
EHR found that more complete clinical histories are obtained. It also found that structuring 
improves the accuracy of patients’ self-documented histories and enables better associated 
decision-making by professionals. No studies were found examining the benefits of coding 
patient histories.(Fernando, Kalra et al. 2012) Another review examined the evidence of 
value for direct patient care of structuring and coing of clinical information within the EHR 
and found eight studies demonstrating improved clinical outcomes where a structured or 
coded EHR was combined with a prompting or alerting system in a targeted clinical domain. 
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Domains included the management of a long term conditi , a preventive intervention or 
appropriate choice of therapy. There were three studies demonstrating improvement in safety 
outcomes in the prescribing domain.(Kalra, Fernando et al. 2012)  
Computerisation of the sophisticated task of understanding narrative text is only relatively 
recently being realised. Computational linguistics is the field of computer science that seeks 
to understand and represent such narrative language as an interoperable set of semantics. 
(Elkin, Trusko et al. 2010) Natural language processing is the part of this field pertaining to 
task-based analysis of narrative text.(Jurafsky and Martin 2009) Natural language processing 
depends on a “language model”. Language models are dr wn from the areas of computer 
science, mathematics and linguistics and are familir to those who have trained in these 
areas. Models include sate machines, rule systems, logic models, probabilistic models and 
vector space models. Models underlie many of the tasks of language processing. For 
example: where the meaning of a phrase or sentence is ambiguous, language processing 
models choose the most probable meaning. Search engines such as “Google” and voice 
recognition software such as “Siri” use language models to decipher the meaning from the 
input words.(Jurafsky and Martin 2009) 
However, computers still have many short-comings when it comes to “reading” health 
records. In terms of being able to extract useful information from health records, the use of 
“coding” is therefore widespread. Coding is related to standardisation and 
structuring.(Morrison, Fernando et al. 2012) Words are chosen from a terminology system or 
controlled vocabulary. This is a system of labels for different diseases and conditions. There 
is a hierarchy in the labels in order to give more detailed information when required. Also 
more than one code can be selected to improve the specific meaning of the coding. Some 
coding systems go beyond diagnosis alone to include asp cts of patient management and 




Table 3.2 Clinical coding systems (de Lusignan and van Weel 2006; 
ConnectingForHealth 2013) 
Coding System History Use 
Read Codes Over 100000 codes which have 
gone through several rounds of 
updates. 
Version 2 and version 3 are 
used in UK General Practices. 
They allow more detail to be 
recorded than ICD-10 coding. 
Include codes for more precise 






The World Organisation of 
National Colleges and 
Academies of Family Practice 
developed these codes. They 
have been translated into over 20 
languages. 
These codes have also 
undergone updating and 
evolution. It is organised into 
body systems and components 
covering patient-orientated 
aspects of primary care. They 
are used in mainland Europe 





Distributed by the World Health 
Organization at very low cost 
thereby avoiding financial 
barriers to their use. 
Good for recording diagnoses. 
Used in the UK for Hospital 
Episode Statistics and various 
data outputs from the Office of 







This is a joint venture between 
the UK Department of Health 
and the American College of 
Pathologists. Created out of a 
merger of Read Code V3 and an 
American Coding Classification 
SNOMED-RT. 
A very extensive terminology, 
there are over 300000 medical 
concepts, multiple axes and 
over 7 million relationships. 
 
The main advantage of coding the health record is that i  then becomes amenable to 
computational analysis. Simple computer programmes can determine how many patients 
have each condition for audit purposes, patterns and tre ds within patient populations can be 
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identified during clinical practice, thus identifying problems e.g. epidemics and accelerating 
research.(Morrison, Fernando et al. 2013) In addition, computer programmes can look for 
combinations of codes, especially where the coding has been done from a rich terminology, 
in order to aid clinicians in diagnosis and other tasks. This is the basis of clinical decision 
support. Clinical decision support systems (CDSS) are defined as “systems that use two or 
more items of patient data to generate case specific advice”. CDSS becomes possible when 
the record is coded.(Wyatt and Spiegelhalter 1991) 
Disadvantages of coding include that the coding system may be limited and therefore unable 
to capture a specific situation or complex unstructured problem. In addition, coding is more 
time consuming than writing narrative text as it involves an interpretive process in firmly 
establishing the diagnosis and its subsequent implications. For example, in a qualitative 
study looking at the coding of depression, GPs were orried about the social stigma, 
inclusion on the mental health register and ramifications in terms of insurance reports and 
occupational health screening.(Cresswell, Morrison et al. 2012) There may be a preference 
for deliberately vague coding in order to reflect diagnostic uncertainty. (Morrison, Fernando 
et al. 2013) 
Problems also arise when accurate coding is a low priority for an organisation. Many 
clinicians do not see coding as important. In hospitals, clinical coding is a low status 
administrative job and there is little interaction with clinical staff. In general practice, there 
may be time constraints which limit the quality of the coded part of the clinical record and 
clinical users sometimes feel that coding distracts from good direct patient care. (Cresswell, 
Morrison et al. 2012; Morrison, Fernando et al. 2012) There is evidence that more complete 
coding can be achieved with targets and financial incentives – however, these can distort 
what is coded, especially when small numbers of additional coded patients will enable the 
achievement of targets. Addressing these problems rquires education of professionals, 
preferably with audit-type feedback from their own coded data.(de Lusignan 2005) 
In addition there can be problems with having rich coding vocabularies in terms of the 
reliability of the coding. Rates of agreement between different coders for the precise choice 
of code may be low when there are lots of options fr codes. Reliability is different from 
validity. Coders may pick equally valid codes but these are just not the same, hence lower 
reliability. This is important when selected codes are reported in audit and public quality 
reports from hospitals including performance statistics.(Coory, Youlden et al. 2002; 
Stausberg, Lehmann et al.) 
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3.3 Validity of healthcare data for research 
The quality of routine data is encapsulated in the concept of validity. Validity refers to the 
agreement of the routine data with a Gold Standard.(Stausberg, Lehmann et al.) Historically, 
there have been many problems with the validity of routine data (Williams, Cheung et al. 
2003). A Health Technology Assessment (HTA) review of routine data  in 2003 concluded 
that “the validity of routinely collected data is suspect, particularly in systems that are not 
under clinical and professional control.”(Williams, Cheung et al. 2003) The report also found 
difficulties with identifying accessing and extracting data and problems as a result of a lack 
of uniformity in data structuring and coding and definitions. A need for further research into 
several key areas was identified, including the need to define standards to ensure the 
uniformity and validity of data collected by different local and national systems. A 
subsequent HTA report in 2005 found over 1000 routinely collected databases and datasets 
potentially available for research in the UK.(Raftery, Roderick et al. 2005) They also found 
that, although internal consistency checks were comm n within databases, there was little 
regular external audit. 
How may the validity of routine data be improved? In order to be useful to research it may 
be necessary to “clean” data. This involves making checks on the data’s internal and external 
validity. In order to check the internal validity – measures of consistency may be developed 
and tested – for example, the consistent use of the same codes in specific situations. In order 
to check external validity it may be necessary to triangulate the routine data source with 
other sources. For example, in one study by Sinha et al they checked the validity of stroke 
diagnoses in a cohort database by reviewing the case notes of patients (Sinha, Myint et al. 
2008). There were 520 incident strokes identified by death certification and hospital record 
linkage. This increased to 726 when they included self-reported strokes. However, the 
authors were only able to validate 250 cases of true stroke because only 250 sets of paper 
case notes were retrieved. This was due to logistical reasons, the case notes that could not be 
retrieved were not in the health records department at the time they were requested – they 
were in other hospital departments. Out of the 250 clinically validated cases only 185 had 
had a CT scan and were therefore considered to be radiologically validated. This study 
illustrates that validation of routine data is time consuming and logistically challenging.  
Many of the problems that occur when trying to adapt routine data to research stem from the 
fact that the data are collected for one purpose – either administrative or clinical – but used 
in research as a proxy indicator for another. For example, tiotropium inhaler prescriptions are 
recorded as part of the clinical record, but may be us d as a proxy measure for COPD 
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diagnosis. Another example would be where a survey of mental health patients may include 
questions about their alcohol consumption; however, it would be stretching the validity of 
the routine data to draw conclusions about their physical health from this alone. The validity 
of routine data therefore varies depending on the original purpose of why it was collected. A 
study by Soo et al. used routine hospital administrative data, SMR01, and linked it to a 
cohort database for chronic kidney disease.(Soo, Robertson et al. 2014) The SMR01 data 
were screened for selected comorbidities and risk factors and the validity of this approach 
checked by case note review. Kappa agreement between th  SMR01 data and the case notes 
was substantial for ischaemic heart disease (K=0.80) and cerebrovascular disease (K=0.63) 
and moderate for six other comorbidities, but only fair for hypertension (K=0.28) and poor 
for smoking. This is because hypertension and smoking, as risk factors, are not often coded 
in acute admission records. Had the database been additionally linked to a primary care 
dataset then recording of risk factor variables would be expected to improve significantly, 
therefore the underlying purpose for the data colletion substantially affects the 
completeness and validity of the data. 
Another problem in the context of using routine data is what to do when data are missing. 
Statistical power is reduced and bias may be introduce  if cases with missing data are 
dropped from the dataset. It may, therefore, be necssary to use data imputation – a family of 
statistical techniques which build a probable total dataset from the base of the data that are 
present.(Sterne, White et al. 2009) 
3.3.1 Validity of routine data used in this thesis 
In terms of this thesis, the validity of COPD data in routine datasets requires discussion. In 
2003, Hansell et al. compared mortality data for Engla d 1991-1995 with HES data 1990/91-
1994/95 with General Practice Research Database (GPRD – now CPRD) data and Health 
Survey for England 1995 data and found broadly consistent patterns across all data 
sources.(Hansell, Hollowell et al. 2003) Incidence rat s for hospital admissions and 
mortality, and diagnosis and inhaler prescriptions in GPRD all increased with age and were 
generally higher in males than females. Mortality and hospital admissions for COPD shared 
similar seasonal patterns with higher levels in autumn and winter and peaks at the end of the 
year. Hansell et al.’s study therefore established t  external validity of these data sources 
and indicated that they are likely to be valid input sources for modelling. A similar exercise 
could be undertaken again today with cross-validation between prevalence data in one data 
source (i.e. CPRD) and another (e.g. HES) for a single condition such as COPD. However, I 
have not found further examples of this. I discussed some of the potential pitfalls of using 
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COPD mortality data in Chapter 2. Many patients die “with COPD” rather than “of COPD” 
and so do not have COPD on the death certificate. This means that the prevalence of COPD 
is underestimated where codes from the death certifi ate are used to guide estimates of 
prevalence, because many death certificates do not have COPD listed as one of the causes of 
death even though the patient had COPD. It is possible that this feature of mortality data has 
implications for the UK part of the Global Burden of Disease modelling study 2010, that I 
will discuss in Chapter 8. 
There has also been some more recent validation work on the CPRD GOLD database (the 
GOLD database is the higher quality CPRD primary cae database, see Table 3.1) from 
which the COPD cohort for this study was taken. Presented in 2013, Campbell et al. 
compared the number of patients actively registered on 27th March 2011 (census day) to the 
UK census data, overall and by age, sex and region.(Campbell, Dedman et al. 2013) (They 
compared overall numbers, including all CPRD patients, ot just those with COPD.) Age-
specific mortality rates were calculated in five year intervals for the CPRD data. Age-
standardised mortality rates were then calculated using the European Standard Population, 
by sex, overall and by UK country. Their results showed that, on census day, 7.3% of the UK 
population were registered in GOLD with little variation by sex, but a lower representation 
of younger age patients compared to the census data. Crude death rates were nearly the same 
as national rates 8.7 per 1,000 versus 8.69 in GOLD.(Campbell, Dedman et al. 2013) Age-
standardised mortality rates were lower in GOLD than n tional rates and age-specific 
mortality rates among the GOLD population were also below those reported for the UK 
population.(Campbell, Dedman et al. 2013) This may h ve implications for the results of the 
modelling in this thesis. If the CPRD GOLD population is generally older than the UK 
population then the CPRD prevalence of COPD may be higher with greater costs associated. 
This may lead to overestimates of the prevalence and costs when extrapolating from the 
GOLD database to the total English and Scottish populations by modelling. If mortality is 
lower in GOLD than nationally then there may be an underestimate following modelling.  
3.4 Data reuse for research 
As growing volumes of routine data are recorded in atabases and in datasets there is 
anticipated to be a huge expansion in the data potentially available for research analysis. 
(Bobrow 2013) The usefulness of these data is tempered somewhat by their validity as 
previously discussed, however, several potential avenues for medical researchers have 
opened up for reuse of data in linked studies, for data mining, trials and for 
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pharmacovigilance in addition to generation of estima es of disease burden as described in 
this thesis. 
3.4.1 Data reuse in linked data studies 
Linking data from different sources is a very fertil  ground for both medical research and 
collaborative interdisciplinary research. Primary care datasets may be linked with secondary 
care data including hospital admissions, and accident and emergency records. Other datasets 
may also be linked including the Office of National Statistics (ONS) registers of births and 
deaths, educational datasets, social care datasets and judicial datasets. 
One example of this is the Scottish Care Information – Diabetes Collaboration (SCI-DC), a 
web-based diabetes record used across Scotland, which has been linked to national morbidity 
(hospital admission and cancer) and mortality records for use in a wide range of research 
studies.(Cunningham, McAlpine et al. 2011; Kennon, Leese et al. 2012) 
The advantages of using unselected population-based healthcare databases for research 
include that the results reflect true clinical practice, additional variables can be collected for 
hypothesis-generation and they are an efficient and cost-effective means to undertake 
research. (Thuesen, Jensen et al. 2013) 
There are challenges in linking databases. Linking the correct individual’s records across the 
database may be done in healthcare records in Scotland by use of the Community Health 
Index number or CHI. As this is a unique identifier p r person, then records may be linked 
by a deterministic matching process. In datasets which do not have a CHI or equivalent 
identifier the records may be matched using probabilistic algorithms and a combination of 
different data fields including name, date of birth and information from the address or other 
fields used together to construct an identifier. This type of probabilistic matching is more 
often used for English records which do not always have a unique identifier. This process is 
somewhat controversial, as some people feel strongly that they do not want their records to 
be identifiable, especially without their consent. I shall explore the issue of privacy in routine 
data studies in Section 3.5.  
There are also technical challenges in linking datab ses. For example, EHRs may be stored 
on different IT systems or written with different standards of software code. Attempts have 
been made to introduce standardisation among NHS EHRs so that even where record 
software is produced by different IT providers, it w ll be able to function alongside each 
other in the clinical environment. The standard for this is Health Level 7 (HL7), a set of 
system-independent data interchange specifications and messaging standards supporting 
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clinical applications. These standards also aim to facilitate linkage in a pragmatic fashion.(de 
Lusignan, Pearce et al. 2011) This helps to open up the ossibility of using the EHRs for 
research. These standards are evolving rapidly there is HL7 version 2 and version 3 and the 
new specification FHIR (Fast Healthcare Interoperability Resource) which enables App 
development to be linked to EHRs amongst other featur s.(HL7 2015)  
Another technical challenge is that many EHRs have limited predefined sets of query-
options for patient retrieval e.g. unable to specify time-oriented retrieval of clinical datasets. 
Until sophisticated ad-hoc querying tools are develop d to provide research support to 
clinical records, the usefulness of clinical records for research will remain 
constrained.(Prokosch and Ganslandt 2009) 
3.4.2 Data mining 
Where a linked dataset exists, there is potential for data mining. Data mining is the practice 
of searching through large amounts of computerised data to find useful patterns or 
trends.(Merriam and Webster 2014) This type of searching uses sophisticated statistical 
analyses and may use artificial intelligence approaches such as machine learning. The aim is 
to find previously unrecognised clinical or other rlationships. This type of database analysis 
is practised widely by corporations in order to target their advertising and sell more of their 
products, so-called “business intelligence”. However, an analogous approach has potential in 
clinical informatics, but to date has not been widely employed.(Prokosch and Ganslandt 
2009) 
Data mining could help identify and explain patterns i  the variation of services. Clinicians 
and managers may then be able to adapt where services are underused or overused. For 
example, identifying where and why some children are not receiving their full complement 
of vaccinations or why there is a high rate of caesar an section in an institution and what 
may be done to address this.(Elkin, Trusko et al. 2010) 
3.4.3 Data reuse for trials 
The reuse of routine data has several potential empoy ents during the course of clinical 
trials. Firstly, routine data can significantly improve recruitment rates for prospective trials. 
Many randomised controlled trials fail to recruit their target number of patients, such that the 
ability to undertake clinical research in the UK is threatened.(Treweek, Lockhart et al. 2013) 
A national research register has been suggested as a potential solution to this. The register 
would hold the registration and contact preference of volunteer patients.(Grant, Ure et al. 
2013) The volunteers give permission for these datato be linked to primary and secondary 
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care EHRs and for their EHRs to be securely searched in the NHS to assess whether they 
meet the eligibility criteria for studies which have NHS ethical and governance approval. 
This enables automatic identification of potential subjects and streamlines patient 
recruitment. Thus also enhancing the speed of recruitment and enabling greater accuracy of 
consideration of eligibility.(Prokosch and Ganslandt 2009; Dugas, Lange et al. 2010) 
Secondly, the reuse of routine data can mean that some endpoints may be recorded from 
routine data, rather than in a time-consuming and expensive separate trial data recording 
exercise. The validity of this approach is still being explored. For example, the West of 
Scotland Coronary Prevention Study compared the cardiovascular event rates recorded by 
the trial with those from linked routine data. They concluded that the researchers would have 
drawn very similar conclusions using linked routine data alone compared with trial recorded 
outcomes.(Barry, Dinnett et al. 2013)  
3.4.4 Data reuse for pharmacovigilance 
Drug adverse events were traditionally passively monitored via systems such as the Yellow 
Card Scheme or databases of reported adverse events. However, active surveillance is 
increasingly being used to identify potential safety problems. Active surveillance systems 
include drug-based or condition-based registries which actively collect safety information on 
a defined population.(Wise, Parkinson et al. 2009)  
Alternatively, databases from routine clinical records or from community pharmacies can 
provide a basis for pharmacovigilance. Such databases contain information on the drug 
exposure and also on outcomes. In some cases databases m y be linked to provide these two 
pieces of information from a variety of sources including primary and secondary care and 
pharmacies as well as drug registries. The next step i  to use the data for follow-up studies of 
pharmacoepidemiological outcomes. For example, an association was discovered between 
the thiazolidineodiones, rosiglitazone and pioglitazone, and hip fractures using the SCI-DC 
database linked to hospital admissions data.(Colhoun, Livingstone et al. 2012) 
In the USA, the Food and Drug Administration (FDA) have developed a post-marketing 
surveillance system which includes a component called “Mini-Sentinel”, started in 2009. 
Mini-Sentinel is a data foundation which uses data from eighteen private health plans 
supplemented by other sources of data including clinical sources, insurer data, full-text 
medical records and electronic laboratory result data when needed. In 2014, it covered more 
than 380 million person-years of data. The network is used by the FDA to answer its new 
queries every week.(Curtis, Brown et al. 2014)  
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Also in the USA, there is a programme of research and capacity building named informatics 
for integrating biology and the bedside (i2b2) which began in 2002.(Kohane, Churchill et al. 
2012) It sought to provide the instrumentation for using the information and biological 
materials accumulated during healthcare delivery. The aim was to create standard shared 
tools to allow the conduct of research over millions of patients including measurements of 
their biological material. The i2b2 tools include core and optional software components 
which are web compatible and build up databases. Shared health research informatics 
network SHRINE is a clinical querying protocol whic an query multiple diverse i2b2 
databases. SHRINE can select patient records with defined inclusion/exclusion criteria for 
laboratories, diagnoses, demographics and medications.(Kohane, Churchill et al. 2012) In 
terms of pharmacovigilance, i2b2 tools were able to re rospectively identify a large spike in 
cardiovascular mortality which was associated with the cyclooxygenase 2 inhibitor 
treatments rofecoxib and celecoxib. This then returned to baseline with the withdrawal of the 
drugs. The authors suggest that a population monitori g strategy might enhance traditional 
pharmacovigilance.(Brownstein, Sordo et al. 2007) In addition, a study examining 
rosiglitazone identified high relative risk for myocardial infarction with this drug in 
comparison to other drugs including pioglitazone.(Brownstein, Murphy et al. 2010) This 
latter study was cited by the US FDA in their decision to impose further prescribing controls 
on rosiglitazone. These studies (Brownstein, Sordo et al. 2007; Brownstein, Murphy et al. 
2010) are proof of concept studies in modern pharmacovigilance. 
3.5 Professional and public concerns regarding data  privacy 
There has been much recent media focus on professional and public concerns regarding the 
privacy of data that is to be reused for research. NHS England has launched a plan called 
Care.data to upgrade the potential for use of routinely collected primary care data and there 
are similar plans for Scotland.(NHS_England 2014) However, many GPs remain very 
concerned as to how the data would be used and the confidentiality arrangements for their 
patients. There was much controversy in the press as to whether the data might be sold to 
pharmaceutical companies for financial gain or sold t  insurance companies who would then 
use it to hike premiums.(Borland 2014) There is controversy too over the opt-out model of 
consent and whether patients had sufficient awareness of how their data were being used and 
the lack of opportunity to exercise their choices. This has resulted in a delay in the 
implementation of the Care.data programme to collect additional data from GP practices 
while a public education campaign is ongoing. 
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In general, focus groups have found that the public appears supportive of the use of their 
routine data for medical research. However, they ar much more suspicious of research by 
insurance companies or pharmaceutical companies where t  outcomes of research might 
lead to financial gain for a company.(Haddow, Bruce et al. 2011; Hill, Turner et al. 2013) In 
the specific arena of a national genetic database, Generation Scotland, findings included that 
people who had an illness or cared for someone with an illness were more supportive of the 
involvement of pharmaceutical companies as a “necessary evil” than those with little or no 
personal experience of illness(Haddow, Laurie et al. 2007). The authors recommended that 
developing the genetic database should include obligations for private companies to share 
the profits from any output in order to help to restore public confidence in for-profit research 
and thereby encourage participation.(Haddow, Laurie et al. 2007) 
3.5.1 Governance for eHealth data linkages and reus e 
The governance for eHealth data linkages and reuse ha  been criticised for being unwieldy 
and overly complex. In 2008 the Department of Health identified 43 pieces of relevant 
legislation, 12 sets of relevant standards and eight professional codes of conduct, altogether 
fuelling “a culture of caution, confusion, uncertainty and inconsistency.” 
(Science_and_Technology_Committee 2009) Often data custodians and researchers are 
afraid of misunderstanding the law and risking sanctio s and so are over-cautious in their 
interpretations of what can be done with data. There as also been a tendency to view 
consent as a panacea that alone addresses the concerns around using data for research.(Sethi 
and Laurie 2013) This has resulted in governance solutions being shaped around the 
“consent moment” and, where this is not possible, anonymisation of data is the approach 
preferred. However, although anonymisation makes idnt fication of research subjects from 
their data less likely it does not make it impossible especially as other data may be released 
in the future that make identification more possible for a malignant analyst who is 
determined enough. (Information_Commissioner's_Office 2012; Lewis 2014) In addition to 
the above solutions, the European Data Protection Drective is under review and may result 
in an even more complex regulatory framework. 
A model of proportionate governance has been proposed by Sethi and Laurie following their 
governance work on the Scottish Health Informatics Programme (SHIP)(Sethi and Laurie 
2013). They propose balancing the two principles of (1) promotion of the public interest and 
(2) protection of the privacy and other interests of citizens as the central goal of governance. 
Consent and anonymisation are the starting points to consider within a proportionate 
governance approach. Decision makers can then depart from these two mechanisms and use 
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other routes where it can be shown that consent and anonymisation would be 
disproportionate. For example where there is only ver  low risk of harm following 
identification. This is a risk-based approach and risk assessment is a key role of authorising 
bodies such as the Caldicott Guardians whose functions are outlined in the Data Protection 
Act 1998 (OPSI 1998) and Caldicott report and review. (Dept_of_Health 1997; 
Dept_of_Health 2013) Other authorising bodies include the Confidentiality Advisory Group 
(CAG) in England which considers data access applications submitted to the HRA, and the 
Privacy Advisory Committee (PAC) which performs a similar function in Scotland. Such 
bodies provide oversight to the linking and sharing of data, assess the risks to privacy and 
determine the role of consent and anonymisation in healthcare data research. These bodies 
also oversee how the rules regarding how long datasets may be kept, how they may be kept, 
who has access to them and when they are destroyed, are interpreted. In providing the 
mechanism for balancing privacy and public interest CAG and PAC are ideally placed to 
ensure that research is not stifled by burdensome gov rnance yet proceeds with due respect 
for privacy.(Sethi and Laurie 2013) 
3.5.2 Governance relevant to this PhD 
I had to satisfy the CPRD data curators that I would take reasonable care of the COPD data 
and treat it responsibly, and that the risk of identification was minimised. I discuss this 
further in Chapter 6 when I discuss the process for obtaining these data, see also Appendices 
1.1 to 1.6. In addition, I required ethical approval for the PhD (see Appendix 2.1). For the 
Lothian COPD Cohort data there was a need to satisfy the Privacy Advisory Committee 
(PAC) of NHS National Services Scotland (See Appendices 3.2 and 3.3). 
3.6 Conclusion to Chapter 3 
This chapter has outlined the main ways in which data are captured in UK healthcare in both 
primary care and secondary care. It introduced several primary care databases which are 
used as a basis for research. There then followed an introduction to the differences between 
narrative and coded data and emphasis that the majority of data captured in the health service 
which may be reused in research, is of the coded form. There was then a discussion of the 
ways in which both the internal and external validity of routine data could be tested and 
improved, including by triangulation with other data, followed by a discussion of sources of 
triangulation for the CPRD data used for modelling ater in this thesis and the implications of 
this for the validity of these data. I then went on t  outline the ways in which routine data 
can be reused for research, namely: in linked data studies, for data mining, in trials and for 
pharmacovigilance. Finally, I discussed the issues regarding privacy in routine data research, 
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including the controversy around the NHS Care.data programme, and the regulatory 
responses to these concerns and how these have been applied to the data in my thesis. I will 
expand on the precise approvals which were required for each dataset in Chapter 6.  
In summary, I hope that this chapter has made clearth  origins of healthcare routine data and 
outlined how such data may be employed in research and the issues that need to be 
considered when reusing routine data in healthcare res arch.   
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Chapter 4: Concepts in modelling 
4.1 Introduction 
The previous chapter served to introduce how routine healthcare data are being reused for 
research. In the next chapter, Chapter 5, I will systematically review models for projecting 
the population with COPD, therefore, the purpose of this chapter is to introduce some of the 
concepts used in chronic disease modelling. The field of quantitative chronic disease 
modelling is growing rapidly as a new scientific discipline. Many chronic disease models are 
based on health economic models. The most common underlying structure of these health 
economic models is the Markov model. I will introduce the Markov model below, from the 
health economics perspective, followed by the two main ways it can be used in model 
simulations, namely cohort simulation and individual simulation. I then discuss alternative 
model formats namely demographic models, risk factor m dels, time trend and other models.  
Next I will discuss one of the main concepts of modelling termed quality adjusted life years 
(QALYs). Finally, I discuss an alternative modelling concept: disability adjusted life years 
(DALYs). (See also glossary). 
4.2 Introduction to Markov modelling 
Markov models are suited to modelling the progression of chronic disease. They are used to 
model stochastic processes, or random processes that evolve with time.(Briggs and Sculpher 
1998) The chronic disease is divided into a set of mutually exclusive disease states. 
Transition probabilities for movement between these states are assigned per time period that 
the Markov model is run, i.e. each “Markov cycle”. In health economics, resources and 
health outcomes are attached to each state. Running the model over a large number of cycles 
then allows estimation of the long-term costs and outc mes associated with that particular 
disease.  
An example of a Markov model for a chronic disease is shown in Figure 4.1. This disease 
has three states: asymptomatic, progressive and dead. A patient can only be in one disease 
state at any one time. The arrows between the ovalsrepresent the transitions between the 
states. A patient in the asymptomatic state can move t  the dead state (with transition 
probability equal to all-cause mortality excluding the disease in question) or to the 
progressive disease state. The progressive disease tate represents more unpleasant aspects of 
the disease and the patient experiences symptoms and has an increased risk of death over-
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and-above the all-cause mortality risk. The state of death is impossible to leave from and so 
is known as an “absorbing state”. There are also circular arrows returning to the state that 
they left, which represent patients remaining in the same state as they were in for the 
previous cycle. It is not illustrated here, but it is possible to represent clinical improvement 
by having a patient with progressive disease move back to an asymptomatic state. 
Figure 4.1 Example of a Markov Model. Reproduced with permission (Briggs and 
Sculpher 1998) 
 
Mathematically, in a model of k states, a k * k transition matrix would give all the transition 
probabilities of each cycle. However, many of these probabilities are set to 0. In this model 
there are three states, thus nine probabilities to be estimated, but patients here cannot 
recover, so there are no transitions from dead to progressive, progressive to asymptomatic 
and dead to asymptomatic. The probability of moving to states in each cycle must sum to 1, 
as patients must be only in 1 state at a time, thus t e probability of staying in the same state 
in a given cycle is one minus the probability of leaving that state. This model, therefore, 
requires the estimation of only three probabilities: tpProg the probability of moving from 
asymptomatic to progressive; tpDn the probability of dying when in the asymptomatic state 
from a condition other than the index disease (natural death); the probability of dying when 




In Markov models the probability of moving out of a st te is not dependent on the patient’s 
previous states. This is the “memoryless” feature of Markov models or the “Markovian 
assumption” and is sometimes a limiting factor when co structing models. 
In “Markov chain models” the transition probabilities are assumed to be constant over time. 
However, this may not be very realistic when trying to represent chronic diseases as it is 
likely that risk of death will increase with time in a disease state. This last may be 
represented with so-called “time-dependent Markov pr cesses” which assume that transition 
probabilities are a function of the number of cycles the model has run and use a run of 
temporary states which must be visited in a fixed squence as “tunnel states” to reflect the 
time dependency of the transition probabilities.(Briggs and Sculpher 1998) 
In terms of health economics, Markov models are oftn used to compare a model of disease 
progression without drug therapy to one including drug therapy, which is assumed to reduce 
the transition probabilities to disease and death. The model is run in both situations and the 
results of the treatment arm are compared with the results of the control arm. In economic 
analysis the key parameter is the incremental cost-effectiveness ratio (ICER).(McCabe, 
Claxton et al. 2008) This is calculated by the following formula where Ct and Et are the costs 
and effects associated with the treatment arm and Cc and Ec are associated with the control 
arm. The ICER is the difference in the costs divided by the difference in effects. 
ICER =  Ct-Cc 
 Et-Ec 
 
4.2.1 Cohort simulation 
In Markov model cohort simulation, a cohort of for example, 1000 patients will illustrate the 
experience of patients in the model.(Briggs and Sculpher 1998) The whole cohort begins the 
model at time 0 in the asymptomatic state, then at each cycle the appropriate transition 
probabilities are applied and the numbers of patients in each Markov state is altered. Each 
patient must be in one and only one disease state at ny one time. This cohort’s progression 




Table 4.1 Cohort simulation of Markov Model, Figure 4.1, with no drug therapy 
Cycle Asymptomatic state Progressive state Dead  Total 
0 1000 0 0 1000 
1 976 10 14 1000 
2 943 28 29 1000 
3 902 52 46 1000 
4 854 79 67 1000 
5 799 109 92 1000 
 
For health economic purposes, the progression of the co ort with no drug therapy is 
represented and compared with the progression of the co ort with drug therapy 
4.2.2 Individual simulation 
The alternative complementary method for Markov modelling is individual (or Monte Carlo) 
simulation.(Briggs and Sculpher 1998) This is where a large number of patients are followed 
through the model individually. In this case, the individual patients are subject to the same 
transition probabilities, but can only be in one state at a given time and may or may not move 
along states during any given cycle. Therefore the paths followed by each individual patient 
will have random differences. A profile of costs for each patient’s path through the model 
will be built up. Averaging these costs and effects over a large number of patients will give 
an estimate of the average costs and effects for both drug therapy and no drug therapy arms 
of a model.(Briggs and Sculpher 1998) 
4.2.3 Comparing cohort and individual simulation 
In contrast to the exact result obtained from the cohort method, the individual simulation 
method will not give the same results on any two occasions because the simulations vary 
randomly. However, as long as a large number of individual simulations are performed and 
averaged the differences between the two methods are likely to be small and insignificant. 
The individual simulation method gives an estimate of the likely variance associated with the 
parameters estimated by the model. This uncertainty is due to the intrinsic probabilistic 
uncertainty of the model and is often termed “first order” Monte Carlo simulation. (Second 
order Monte Carlo simulation also allows the parameters of the model to vary over a range 
with a specific distribution and are sometimes usefl).(Briggs and Sculpher 1998) 
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4.3 Alternative model formats 
4.3.1 Demographic models 
Demographic models are one of the most straightforward models that can be constructed to 
represent chronic disease. The national population is taken and each age and sex stratum is 
multiplied by the age and sex specific prevalence data. It is the reverse of a prevalence 
calculation. It is useful when prevalence is only known for a sample of the national 
population and where the sample needs to be multiplied up to represent the full population. 
This is done using age and sex strata so that the resulting disease prevalence represents the 
age and sex distribution within the national population.  
4.3.2 Risk factor models 
One example of a model of this type features in the tables in the systematic review in 
Chapter 5.(Peabody, Schau et al. 2005) An algorithm is formed by the accumulation of risk 
factors for COPD such as smoking, outdoor air polluti n, indoor air pollution, age and sex. 
Evidence is gathered to quantify these risks as contributing to COPD and the algorithm is 
multiplied out according to the age and sex profile of the population. In the end an estimate 
of the prevalence of COPD is obtained.  
4.3.3 Time trend models 
These models use historical data to graph the trend of COPD prevalence for a country then 
use computer software and mathematical techniques to project the trend into the future. 
There is an example of this type of model included in the systematic review in Chapter 
5.(Erbas, Ullah et al. 2012) 
4.3.4 Other models 
The Markov model is a flexible type of model. Many models in Chapter 5 are similar in their 
structure are not necessarily identified as “Markov”. Some state that they are “Markov-type” 
or “Markovian”. In general, the studies identified in Chapter 5 state that they are running 
cohorts, or micro-simulation, or a combination of the wo approaches; which are 
complementary rather than mutually exclusive.  
4.4 Outputs of health economics modelling 
The results of Markov and other models may be calcul ted and expressed in terms of either 
QALYs or DALYs. 
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4.4.1 Quality adjusted life years (QALYs)  
Quality adjusted life years (QALYs) and disability adjusted life years (DALYs) are similar 
terms for concepts which health economists and epidemiologists use in slightly differing 
situations to give an idea of the impact of an illness on people’s and a population’s health. 
They are both used as outputs from modelling. Both begin with the time period of a year and 
reduce it to allow comparisons to be made between different functional states due to illness, 
as explained below. 
Seminal work by Klarman et al. quantified the quality of experience of kidney patients who 
received a transplant as compared with those who continued on dialysis in the context of cost 
effectiveness analysis, and helped develop the QALY(Klarman, Francis et al. 1968). 
However, the term “QALY”, for a life year which had been modified to reflect illness, was 
not coined until 1976.(Zeckhauser and Shepard 1976) 
QALYs rely on a generic quantification of health status. The health status is a functional 
level or “utility”. This health status is quantified by assuming that the person without illness 
is unimpaired or has 1.0 utility and that a person in state 0 is dead. The original presumption 
by Klarman was a time-trade off where the participant traded length of life for quality of life. 
Other techniques currently in use allow participant use of visual analogue scales or of the 
standard gamble. The standard gamble is an assessment involving probabilities e.g. what 
proportion of people choose 100% chance of half “ful” health over a 50% chance of “full” 
health and vice versa. 
Currently, a variety of questionnaires are used to quantify health status. The EQ-5D (Brooks, 
Rabin et al. 2003) or Short Form 36 (SF36) (Ware and Sherbourne 1992) are examples of 
these. Completion of these forms varies depending on who fills them in. Members of the 
public, caregivers and health professionals rate illn ss states differently to people actually 
suffering these illnesses. The consensus is that the conditions be calibrated by lay people 
who are “healthy”. (Matza, Boye et al. 2014) 
QALYs are calculated from the utility or reduced utility as a result of a health condition, 
multiplied by the time spent at this utility, the life years. Then, by incorporating costs, health 
economic analysis may be performed. Cost-effectiveness is the concept that a finite amount 
of money may be spent on a treatment that improves utility for a number of years (measured 
in QALYs in one way or another), and the “cost per QALY” is calculated to enable 
comparison of treatments, or other interventions. (Gold, Stevenson et al. 2002) These cost-
effectiveness calculations are often used in developed nations to decide which drugs should 
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be paid for on behalf of the population in the face of budgetary constraints.(McCabe, 
Claxton et al. 2008)  
4.4.2 Disability adjusted life years (DALYs) 
QALYs are aspirational in that they measure health expectancy and the aim is to maximise 
the QALY score to 1.0, or as close to 1.0 or full health as possible. DALYs are the opposite: 
a measure of health gap. On the DALY scale, 1.0 is total disability and 0 is the target of zero 
disability.(Gold, Stevenson et al. 2002) 
DALYs were described in the 1990s in a World Health Organization (WHO) publication that 
proposed how the global burden of disease and injury could be quantified and reduced in 
developing nations.(Murray and Lopez 1994) DALYs measure the gap between a 
population’s health and a hypothetical ideal for health achievement. DALYs place different 
value weights on populations that are very young or very old as these are supposedly less 
economically productive than mid-age populations.(Murray 1994) DALYs rely on secondary 
data and expert opinion to identify and describe dis ases and different conditions are placed 
according to their level of disability. The WHO is the most prolific source of DALY 
estimates, the Global Burden of Disease Study update in 2012 quantified disease burden 
across the world’s countries in terms of DALYs.(GlobalBurdenofDisease 2012) 
4.4.3 Advantages and disadvantages of QALYs and DAL Ys 
Advantages of QALYs and DALYs include that they combine an estimate of the extra length 
of life gained from an intervention and of the quality of the extra life thus enabling 
quantification of health gains associated with interventions. This means that one intervention 
may be compared with another for effectiveness in relation to the same problem. 
Comparison of health burdens from different diseases or across different countries is also 
possible – this enables priority setting by policymakers.(Olsen 2009) 
Disadvantages of QALYs and DALYs are that patients who are actively receiving the 
intervention may have different views on the values as igned to quality of life from the 
sample of the general population who were questioned i  order to assign the values. This 
generates controversy as to whose values should be used. There are also some who argue 
that QALYs and DALYs oversimplify complex resource allocation decisions.(Malek 2001) 
4.5 Conclusion to Chapter 4 
This short chapter has introduced some of the concepts in modelling that come from the field 
of health economics. To begin with the Markov model was explored in some detail. This was 
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followed by a brief discussion of other types of model. Then, there followed an introduction 
to the key concepts of QALYs and DALYs.  These concepts should be helpful when making 
sense of the results from the systematic review to look for models in Chapter 5.   
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Chapter 5: Systematic review of the literature for 
models that calculate the prevalence and burden of 
chronic obstructive pulmonary disease (COPD) 
5.1 Introduction 
The aim of this thesis was to project the prevalence and burden of COPD in England and 
Scotland. This will require a model to use with routine data to make projections. Thus, this 
chapter describes a systematic search for models for calculating the prevalence and burden of 
COPD.  
I begin this chapter by summarising the methods that were used in order to conduct a 
systematic review of the literature. Then I outline th  quality of reporting framework that I 
developed in order to assess the quality of reports of the included models. I decided to assess 
the quality of reporting as a first step in assessing model quality on the basis that if a model 
is poorly reported there may not be enough information available on which to critique the 
model itself. Summary tables of the characteristics, and specific data inputs and outputs of 
the models are presented. This is followed by a table detailing the scores of each model on 
the quality of reporting appraisal framework. Then a table containing the specific findings by 
each model in its own context is given. I then present a narrative summary of the seven 
models which achieved the highest relative scores on the quality of reporting framework. I 
describe the features of each model and its functioing. These descriptions include an 
assessment of the quality of each model’s development in terms of sensitivity analyses and 
validation. Finally, I make a selection of one of the models for further study within the PhD 
and justify its selection. 
5.2 Methods 
5.2.1 Protocol 
In keeping with best practice recommendations in conducting systematic reviews, I 
developed and published a detailed protocol for  this work.(Appendix 6)(McLean, Wild et al. 
2013) I also registered the protocol in the PROSPERO database with number 
CRD42012002623. (PROSPERO 2013) 
5.2.2 Eligibility criteria 
Any modelling study which used demographic and epidmiological data to estimate the 
prevalence and disease burden was eligible for inclusion. The outcomes of interest were 
92 
 
incidence, prevalence, disease burden and mortality. For the purposes of this review, 
“disease burden” was considered from the perspective of the health system. The “disease 
burden” can also potentially be considered from the perspective of the individual or from the 
perspective of society (e.g. in terms of lost productivity). Such perspectives were considered 
to be outwith the scope of this PhD. 
The types of “models” of interest included demographic models, risk factor models and 
models which have evolved from health economic models including Markov-type models 
(see Chapter 4 for an overview). Models were excluded if they described animal cell lines, 
clinical series or estimates of individual risk (such as individual prognostic models). 
Decision analytical models or decision support models were excluded where they referred to 
clinical decision-making for individuals. Models comparing one intervention with another 
intervention were also excluded as the aim was to etimate the prevalence, disease burden 
and mortality rather than to investigate the effectiv ness of interventions. Regression models 
which were quantifying the effect of risk factors on COPD rather than projecting prevalence 
and/or disease burden were also excluded. 
5.2.3 Information sources and study selection 
A search strategy was developed using search terms o include the three concepts of 
“modelling”, “disease burden” and “chronic obstructive pulmonary disease”. The full search 
strategy is published in the protocol which is included in Appendix 6.(McLean, Wild et al. 
2013) Searches were conducted in Medline, Embase, CAB Abstracts, World Health 
Organization (WHO) Library and Information Services (WHOLIS – library catalogue of 
books and reports), WHO Regional Indexes (AIM (AFRO, LILACS, (AMR/PAHO), 
IMEMR (EMRO), IMSEAR(SEARO), (WPRIM (WPRO). A modified search strategy was 
used to identify reports from the WHO home website and Google. Searches were for both 
published and unpublished modelling studies from January 1980 (when modelling methods 
first began to be widely used) to November 2013. All studies were independently reviewed 
against the stated inclusion criteria by me and by an associate researcher, Dr Victoria 
Barbour (VB), and all disagreements were resolved by iscussion between reviewers, with 
arbitration by a third reviewer if a decision could not be reached. 
5.2.4 Data extraction 
A piloted data extraction form for each study was used by me and checked by VB. The 
following data were extracted from each study: author and email address, year, institution 
and funding source, the purpose of the model, model title, model type, model setting, time 
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period and population. Model inputs and source of input data details of processing of the 
model, were also extracted, along with COPD outcomes (i. . incidence, prevalence, 
mortality, primary care visits, emergency department visits, hospitalisations, treatment 
costs), model output/ results, details of the model’s availability, any comparisons with other 
studies, social and economic policy implications of m del’s output and future research 
recommendations. 
5.2.5 Quality appraisal framework 
A standard procedure in systematic reviewing is to assess the quality of studies included in 
the review. However, there are not yet any quality ppraisal frameworks for modelling 
studies. I therefore decided to first assess the quality of reporting of the modelling studies. I 
did this by designing a quality of reporting framework in discussion with Professor Simon 
Capewell from Liverpool University. The quality of reporting framework was designed 
following review of key guidelines as to good practice in modelling.(Weinstein 1989; 
Weinstein, Toy et al. 2001; Weinstein, O'Brien et al. 2003; Philips, Bojke et al. 2006) A 
scoring mechanism was devised to weight the different elements required in reporting the 
production of a relevant and high quality model.(Unal, Capewell et al. 2006) This scoring 
framework was described in the published protocol for this systematic review and is included 
in Appendix 6.(McLean, Wild et al. 2013) The quality appraisal framework’s elements are 
described as follows: 
5.2.5.1 Purpose and aim 
• There should be a clear statement of the question which the model is trying to 
answer and its scope, its limits or boundaries. 
• The structure of the model should be relevant to the decision making perspective. 
That is whether decisions are considered from the pati nt’s perspective, the 
healthcare system’s perspective or the perspective of broader society, and the 
appropriate implications should be included.  
• The time horizon of the model should be long enough to engender the differences 
between strategies – even if there is a lack of long term follow up input data – as 
long as this absence is made explicit in the model assumptions. 
5.2.5.2 Transparency 
• This is a key detail – if the model is publicly available it will be possible to use it for 
modelling COPD. Public availability is also importan  for peer review of the quality 
of the model before it was published. However, someti es there are intellectual 
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property concerns and models are not made available as they may be profitable for 
their authors. 
5.2.5.3 Data input 
• It is important to consider the quality of data used to develop the model and to 
consider if the source, variables and range are justified. 
• Even where data are weak, models can be helpful in aid g decision-making as they 
represent a logical framework of assumptions. 
• Inclusion or exclusion of data sources should always be justified.  
• The conclusions of the model should be framed as conditi nal upon the range of 
inputs, and special attention should be paid to attaining accurate inputs for those data 
to which the results of the model are particularly sensitive. 
• Where data are absent, expert opinion may be used to stimate parameters, for 
example, following a Delphi exercise. 
5.2.5.4 Data modelling 
• There should be a transparent method for how the raw data are transformed into data 
inputs.  
• There should be discussion of the model’s derivation and methods of update to 
reflect fresh evidence. 
• The assumptions on which a model is based should be documented and justified. 
• Any model should be consistent with accepted techniques of statistics and 
epidemiology. 
5.2.5.5 Data incorporation 
• Data may be incorporated as point estimates or as distributions. It should be clear 
which method has been used. 
• It should be clear whether a deterministic or probabilistic modelling approach has 
been taken and the resulting impact on the uncertainty of the outputs from the 
modelling. Where the data are incorporated as distribution for probabilistic analysis 
the choice of distribution and how the distribution has been defined should be 
described. The advantage of a probabilistic analysis is that it allows statistical 
statements to be made regarding the importance of input uncertainties. 
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5.2.5.6 Sensitivity analysis 
• Structural uncertainties should be evaluated using ensitivity analysis: multi-way 
sensitivity analysis is preferred over one-way sensitivity analysis as it is more 
rigorous. 
• Parameter uncertainty of point estimate inputs should be investigated by sensitivity 
analysis with explicitly stated and justified inputs. Probabilistic sensitivity analysis 
can assess the joint effect of uncertainty over all p rameters. 
5.2.5.7 Internal validation and calibration 
• Verification of internal consistency (debugging) should be undertaken by testing 
with extreme values of inputs and checking that outputs are logical. Sensitivity 
analysis with extreme or null values is a part of this. 
• External consistency (calibration) should be tested by using retrospective data from 
an independent source (not used in model derivation, e.g. from national health 
statistics) to see that the model works to give logically consistent outputs. Where 
discrepancies cannot be explained the model may need to be recalibrated. 
5.2.5.8 Predictive validity 
• Predictive validity is testing the accuracy of the model’s prediction and can only be 
done with time and long term follow up data. Often hese do not exist and so 
predictive validity cannot be confirmed. This does not mean that the model is not 
useful it must simply be recorded as a caveat. 
• Models should be flexible enough to evolve with the science of the subject they 
capture. As new research is undertaken they should incorporate new information. 
However, it should be recognised that the circumstances in which the model was 
derived may change significantly over time and the conditions in which the model 
was designed may no longer apply. In such circumstances predictive validity is 
impossible. 
• Models which cannot evolve or be recalibrated and remain inconsistent with new 
empirical evidence should be abandoned or replaced.  
5.2.5.9 Potential limitations 
• The authors should show an awareness of the potential lim tations of their model and 
discussion of the following in this context is desirable: assumptions, confounding, 
lag times and competing causes. 
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5.2.5.10 Involvement of policymakers, planners and decision makers 
• Were policymakers, planners and decision makers involved at all? 
• How were they involved: commissioning, influencing approach or methodology? 
• Will policymakers, planners and decision makers have n opportunity to act on the 
findings of the model? 
5.2.6 Scoring on the quality of reporting framework  
Following discussion with Professor Simon Capewell, it was decided to allocate scores to give 
a relative importance weighting to the domains. If one domain of the model is flawed or absent 
it is possible that it may not invalidate the whole model if the other domains are fully present 
and accurately reported. 
The most important consideration was the purpose of the model and whether it aligned with 
the aim of projecting burden of COPD. This is reflected by the four points available for this 
domain. Next follows model transparency, and so on. The domains of this framework and 
associated scores were as follows:  
1. Model purpose and aim (4) 
2. Transparency (3) 
3. Data input (1) 
4. Data modelling (3) 
5. Sensitivity analysis (2) 
6. Internal validation (1) 
7. Calibration (1) 
8. Predictive validity (3) 
9. Potential limitations (1) 
10. Involvement of policy makers, planners and decision makers in model. (1) 
Thus these 10 domains contributed to a total score out of 20 points. 
5.2.7 Synthesis of results 
As the models had different purposes and were context specific and based in different 
settings with different input data, I present results tables to summarise the features, inputs 
and outputs, and reported outcomes of all of the models. This is followed by a narrative 
synthesis of the seven highest scoring models on the quality of reporting scoring framework 




1743 studies were title-screened. 158 titles and abstr cts were selected for full text review. In 
the event that a paper used a model published previously to make a new projection, update a 
projection or make a projection in different setting or geography, I included only the original 
explanation of the model unless the model itself was substantially altered or updated in any 
of the newer papers. In the end, 22 models were selected for inclusion, as described in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram in Figure 5.1.  
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5.3.1 Introduction to tables of results 
This section begins with summary tables of the characte istics (Table 5.1), and specific data 
inputs and outputs of all 22 models (Table 5.2) (Bronnum-Hansen and Juel 2000; Stang, 
Lydick et al. 2000; Feenstra, van Genugten et al. 2001; Shibuya, Mathers et al. 2001; van 
Genugten, Hoogenveen et al. 2003; Hoogendoorn, Rutten-van Molken et al. 2005; Peabody, 
Schau et al. 2005; Chapmann, Mannino et al. 2006; Lopez, Shibuya et al. 2006; Hurley and 
Matthews 2007; Nacul, Soljak et al. 2007; IHME 2010; Atsou, Chouaid et al. 2011; Holt, 
Zhang et al. 2011; Hoogendoorn, Rutten-van Molken et al. 2011; Pichon-Riviere, 
Augustovski et al. 2011; Erbas, Ullah et al. 2012; Lhachimi, Nusselder et al. 2012; 
Najafzadeh, Marra et al. 2012; Perera, Armstrong et al. 2012; Pham, Ozasa et al. 2012; 
Stanciole, Ortegon et al. 2012). These are followed by Table 5.3 detailing the scores of each 
model on the quality of reporting appraisal framework. One model is missing from this table 
as it was not possible to quality appraise it because an appropriate report on which to base 
the quality appraisal was not found.(IHME 2010)Then there follows Table 5.4, which 





Table 5.1 Characteristics of modelling studies. Studies are in order of quality of reporting (Table 5.3) 
Author Model Title Model 
Type 
















To describe the development 
and validation of a health 
economic model to address 
the tobacco disease burden 
and the cost–effectiveness of 
smoking cessation 
interventions in seven Latin 
American countries. 
This model considers all tobacco-related diseases (i.e. heart, 
cerebrovascular, COPD, pneumonia/influenza, lung cacer and 
nine other neoplasms). COPD was a special case in terms of 
data because as national statistics are known to significantly 
underestimate COPD-related mortality, its incidence and 
prognosis were estimated based on the Stang model an  a
Mannino epidemiological study. A first order Monte Carlo 
probabilistic microsimulation of individual subjects was built, 
incorporating the prognosis, costs and quality of life of the 











To single out the impact of 
changes in demography and 
smoking behaviour on COPD 
morbidity, mortality and 
healthcare costs. 
Shows the impact of changing patterns in aging and smoking on 
the incidence and prevalence of COPD. COPD is modelled in a 
dynamic multistate life table model with other smoking related 
diseases: lung cancer, stroke, CHD and asthma. Multiple birth 
cohorts are followed year on year through the model. Two 
scenarios are modelled for 2015, the first assumes that the 
incidence of COPD remains constant, the second models 























To project the future burden 
of COPD in the Netherlands 
by disease severity and to 
evaluate the impact of 
different smoking cessation 
interventions on the national 
burden of COPD 
Part of the Dutch Chronic Disease Model. This model projects 
the incidence, prevalence, mortality, progression and healthcare 
costs of COPD per GOLD severity stage as well as chnge in 
the healthy population. A new birth cohort is followed each year 
and within each cohort patients smoke or stop smoking, 
transition along COPD severity and die all according to 
transition probabilities based on research conducte in the 
Dutch population including the Dutch Foundation for Smoking 
and Health and three Dutch cohort studies. 
(Peabody, 











To model COPD prevalence 
from demographic data and 
smoking prevalence and risk 
factors. 
Data were taken from a literature review to quantify the 
relationships between COPD and its risk factors and prevalence. 
There were five input risk factors: Age, gender, (by inclusion of 
gender specific smoking rates) percentage of smokers, COPD 
severity and percentage of population exposed to non-smoking 








et al. 2003) 
DISMOD 2 Burden 
estimation 
model 
Worldwide To estimate internally 
consistent values for 
incidence, prevalence and 
mortality due to COPD in 
developing world countries. 
Disease occurrence is inferred from mortality figures with the 
help of the mathematical consistency required by the following 
epidemiological relationships: prevalence, incidence, remission 









England To estimate the specific 
burden of continuous 
smoking as well as the 
effectiveness and cost 
effectiveness of smoking 
cessation. 
Follows a cohort aged 40-89. Two parallel cohorts ae modelled. 
All have COPD but one cohort stop smoking at cohort 
initialisation and remain sustained quitters. Patients are 
simulated individually. The severity stages of COPD are 
modelled and the patients transition along severity to death 












EU-wide To be a standard tool which 
is publicly available allowing 
researchers and policy 
makers to quantify the 
impact of policies using 
epidemiological evidence. 
Multiple smoking related diseases modelled. A closed real-life 
population is modelled according to the explicit risk factor states 
of each simulated individual. Incidence and prevalence of a 
disease are required as inputs at the population level and the 
module back-calculates the risk factor specific values using the 
relative risk from each risk factors state. Multiple risk factors 
states are modelled as a partial micro-simulation, his is 
combined with a deterministic macro approach for the disease 
life table. 
(Najafzadeh, 






Canada To project the total burden of 
COPD (epidemiology, cost, 
morbidity and mortality) 
over the next 25 years using 
the population of Canada as a 
case study and test three 
hypothetical intervention 
strategies. 
A dynamic population simulation model was built based on 
population growth projections from Statistics Canada nd 
parameters from the literature. Demographic data for Canadians 
of 40 years or older with information on rates of birth, 
immigration, emigration and mortality plus information on 
smoking status, presence of respiratory symptoms and 
prevalence of mild, moderate and severe COPD. The prevalence 
data came from the BOLD spirometry survey of the population 
and so included both diagnosed and undiagnosed COPD 
patients. Progression rates across mild to moderate and severe 
were calculated based on changes in lung function related to age 
and smoking status. Minor and major exacerbation rates were 
modelled. The impact of smoking status, age and disease 
severity on COPD-related mortality was captured indirectly by 













To determine the direct 
inpatient burden of COPD in 
2006, to characterize 
hospitalizations and 
determine the top ten 
diagnoses for COPD 
exacerbation cases and 
determine the association of 
comorbidities with 
exacerbations and their 
impact on costs. 
Two generalised linear models were fitted independently. One 
had outcome hospitalisation costs and the other: hospital 
mortality. The variables fitted included patient demographics, 
co-morbidity index, hospital region, ventilation type, primary 
payer, admission month and length of stay. The optimal model 
for each outcome was selected based upon the evaluation of 
residual analyses and goodness of fit statistics. 
(Hoogendoor
n, Rutten-van 














To include exacerbations and 
probabilistic sensitivity 
analysis into a stochastic 
dynamic population model of 
COPD. 
This model differs from the earlier model in that it is able to 
include the effects of COPD exacerbations and also al ows for 
probabilistic sensitivity analysis. Changes in the COPD 
population are the result of incidence, smoking statu  changes 
disease progression along severity according to an algorithm for 
lung function decline and mortality. In each severity stage 
COPD patients have an annual probability of experiencing 
exacerbations. It is a high quality model as many of the input 
parameters have come from systematic reviews and meta-
analyses of the literature and it was not industry ponsored and 














Australia To assess the consequences 
of quitting smoking in terms 
of cases avoided in four of 
the most common smoking-
associated diseases. 
Initially all subjects are considered to be in the health state 
“well”, including both smokers and quitters. Then every 1 year 
cycle a proportion of the simulated population will transition to 
illness states. The illnesses modelled for these purposes are 
stroke, lung cancer, acute MI and COPD. Smokers and quitters 
are analysed separately and there are 14 five-year age group 
categories up to 80-84 years. In this model no subjects are 
followed beyond the age of 85 years. 
(Erbas, Ullah 








Australia To project the age related 
forecasts for men and women 
separately for COPD 
mortality in Australia 2006-
2025 
The annual COPD mortality rates were calculated as a function 
of age. The age and mortality for each year were plotted and 
defined as mortality-age curves. The log of COPD mortality was 
taken and functional data analysis techniques were used to 
model the curves collectively as a functional time series. Each 
curve was expressed as a linear function of non-parametric basis 
functions, defined using a principal component decomp sition. 
The age effects were separated from time effects and this 
enabled the age-specific mortality rates to be forecast into the 
future while taking the correlations between ages and across 











To examine the population 
level costs, effects and cost 
effectiveness of individual 
interventions to combat 
COPD in low and middle 
income countries. 
This is the precursor to DISMOD. Regional populations were 
categorised into two live health states: those withthe disease 
and those susceptible but without disease; and dead. Cohort 
members are born into the population and move along by age. 
They develop disease and die according to incidence a d 
mortality rates respectively. The population is modelled as 
males and females separately with one year age groups up to age 
100. Values for incidence prevalence, case fatality nd 
background mortality were obtained from the Global Burden of 
















To describe the impact of 
increasing smoking 
prevalence over time in terms 
of future burden and costs of 
smoking related diseases. 
This is a multistate model with four diseases: lung cancer, 
coronary heart disease, stroke and COPD. If you follow one 
subject through their health states on a one year cycle, in each 
year they may start smoking and may have one or more 
diseases. Transition probabilities govern these changes and the 
incidence of the smoking related diseases depends on age, 
gender and smoking behaviour. Life years lost and quality of 














To extrapolate from past 
trends. (Best suited to short 
term projections.) 
Period and cohort effects were represented in a Bayesi n 
software programme. Period effects represented factors 
affecting people of all ages at a particular point in time (e.g. 
treatment advances or influenza epidemics) while cohort effects 
represent factors more common in people born at particular time 
points (e.g. smoking habits). The model combines the effects 
with a constant rate plus some other covariates. Different prior 
beliefs about the age period and cohort parameters could be 






Denmark To estimate the mortality due 
to cigarette smoking with the 
PREVENT model and 
compare it with an estimate 
from a 1992 Peto model 
(Lancet 339:1268-1278) 
The PREVENT model used data from the Danish National 
Bureau of Statistics, survey data on the prevalence of smoking 
and estimates on relative risks for different diseases from the 
CPS-II American study (with over a million patients) to estimate 
the mortality due to cigarette smoking in Denmark in 1993. 
Calculations were based on the “potential impact fraction” 
which indicates the proportion of new cases of disease in the 
population after changes resulting from the intervention. 
Alongside this was modelled the “trend impact fraction” to 





















To evaluate the costs of 
COPD disease and the value 
of new interventions 
This model incorporated elements from Feenstra and 
Hoogendoorn’s models to develop a health policy tool that can 
be used to calculate estimates of current and future impact of 
COPD. There were nine health states in this model and the 
transition probabilities amongst different stages of everity of 
COPD are informed by the Framingham cohort study. 
Exacerbations are also modelled. 
(Pham, 






Japan To examine secular trends in 
COPD mortality, 
emphasising the 
contributions of age at death, 
time period and birth cohort 
to COPD mortality trends 
between 1950 and 2004 in 
Japan 
Sex and age specific COPD mortality data were extracted from 
the Vital Statistics of Japan 1950-2004 for deaths  age 40 or 
older. The data were grouped into 10 five year age groups, 11 
five year time periods (from 1950-1954 interval to 2000-2004 
interval) and 20 five year birth cohorts (from 1865-1869 year 
interval to 1960-1964 year interval), The effects of age, time 
period and birth cohort on COPD mortality was analysed using 
and age-period-cohort model by means of Poisson Regression. 
(Nacul, 










England To estimate the population 
prevalence of COPD in 
England. 
Explanatory variables from the Health Survey for Engla d 
which were included in the final model were: sex, age, smoking 
status, ethnicity, area of residence and area based ind x of 
deprivation. A logistic regression model was used to erive the 
odds ratios for subjects with different combinations of risk 
factors in relation to baseline (baseline prevalence is the 
prevalence in non-smokers under 35 i.e. 0) and usedto calculate 



















To develop and validate a 
model based on smoking 
rates that will provide 
reliable estimates of the true 
prevalence of COPD 
including both clinically 
detected and undetected 
disease.  
The model estimated the true COPD prevalence based on 
smoking rates. Studies included are those that report rates of 
COPD based on systematic spirometric examination of the 
population.  
The proportion of individuals in each smoking category (never, 
current or former) within specific age groups was multiplied by 
the proportion of individuals with COPD as estimated by 
regression lines. Among current smokers many studies report 
10-15% have COPD, however, this varies with age from 17-
43%.The two prevalences were compared. 
(Holt, Zhang 









USA To compare geographic 
variations in COPD 
hospitalizations across the 
USA in order to highlight 
explanatory environmental 
and social factors. 
This model used Bayesian spatial mapping to analyse 
geographical variations in COPD hospitalisation risks for the 
medicare population in the USA. Regional characteristics and 
local characteristics were included in the analysis and indicators 
or spatial association were then computed to examine the local 
spatial dependence and discontinuities. The spatial model was 
implemented using Markov Chain Monte Carlo methods. 
(IHME 
2010) 





To provide comparable 
estimates of the impact of 
diseases and injuries in all 
countries to inform priorities 
for policies, funding, and 
further research. 
Models over 200 diseases in 22 world regions from regionally 
collected data in collaboration with the WHO. The model is 
fully Bayesian and internet based. COPD mortality was 
modelled using cause of death ensemble modelling (CODEm). 





Table 5.2 Data inputs and model outputs from all 22 modelling studies 
Author Model Title Model 
Type 











• Country-specific data for incidence and mortality. 
The model structure and parameter’s calculation 
approach were validated and calibrated using a 
selected country dataset (Argentinean national 
Health Statistics year 2005). 
• COPD incidence was modelled as dependant of 
sex, age and smoking status, its progression as 
dependant of sex, years in current stage and 
smoking status. COPD deaths were modelled as 
dependant of sex and stage. 
• Where this was not available a common 
methodology was used to derive baseline incidence 
data in non-smokers from mortality data using 
assumptions from DISMOD II. 
• Results can be presented according to 
age, sex and previous cardiovascular 
history. 
• Benefit measures reported to compare 
the costs effectiveness of different 
smoking cessation strategies included: 
cost per quitter, cost per year of life 
gained, cost per event averted and cost 
per QALY. 
• A graphical depiction of decision 
uncertainty was made showing the 
cost effectiveness rate dispersion as 










 • Demographic data. 
• Age and sex specific COPD incidence, prevalence 
and excess mortality rates. (Including COPD all-
cause mortality which was calculated including 
other smoking attributable cause). 
• Smoking data, start and stop rates, relative risks for 
smokers and former smokers, smoking prevalence 
rates. 
• Quality of life data. 
• Unit costs and trends per category of healthcare 
(GP, hospital, nursing home, medication). 
• Prevalence of COPD projected into 
the future for men women and total 
population. 
• DALYs lost owing to premature death 
among patients with COPD. 


















• As for Feenstra model plus: 
• Severity distribution of the prevalence. 
• Distribution of the incidence over the severity 
stages. 
• Decline in lung function by severity stage to model 
disease progression. 
• Mortality by COPD severity as per a model from 
meta-analysis. 
• COPD-related healthcare costs by severity. 
• Prevalence, mortality and costs 
specified by sex, age, smoking status, 
COPD severity and year. 
(Peabody, 







• Six key risk factors as data inputs for the model: 
smoking percentage, age and gender, indoor air 
pollution, outdoor air pollution and occupational 
exposure to airborne particles. And a prevalence 
(age and sex specific) and relative risk for each of 
the key risk factors. E.g. percentage of population 
which are urban and rural for exposure to outdoor 
air pollution. 








et al. 2003) 
DISMOD 2 Burden 
estimation 
model 
• Sex and age-specific mortality data on COPD and 
total mortality in a population. 
• Remission is zero for COPD. 
• Case-fatality/relative risk of death from comparing 
survival curves between groups of COPD patients 
and healthy population in the United States.  
• Risk factor variables by region: cigarette smoking 
and indoor air pollution from WHO’s Comparative 
Risk Assessment database. 
• Years lived with a disability due to COPD by 
region calculated from prevalence and disability 
weights. 
• Estimation of incidence used to 
calculate years lived with disability 
and combined with years of life lost 
from the mortality estimates enabled 
disability adjusted life years due to 










• Prevalence of COPD data for five year age classes 
(Shahab). 
• Office of National Statistics English population 
details. 
• Transition probabilities from the Framingham 
cohort (Nielsen). 
• Transition probabilities according to smoking status 
(Hoogendoorn). 
• Probability of experiencing one or more 
exacerbations depending on severity stage (Soler-
Cataluna). 
• Mortality for the UK general population in 2007, 
data from Mannino and data from Ekberg-Aronsson 
for smoking status of COPD patients. 
• Relapse rates from smoking status from 
Hoogendoorn. 
• Costs from Jansson, both direct and indirect costs.  
• Health utilities based of estimates reported by Borg 
and Cataluna. 
• Mean remaining lifespan of smokers 
versus quitters. 
• Additional disease-related cost of 
continuous smoking versus sustained 
abstinence. 
• Health gains associated with sustained 
abstinence. 
• Specific burden of continuous 
smoking during a 10 year period. 
• The above parameters for different 
scenarios of quitting during different 












• Incidence and prevalence at the population level by 
age and sex of each disease. 
• Relative risks for each risk factor state for disease. 
• Exact configuration of disease life tables, e.g. the 
numbers and types of diseases, can be specified by 
the user. 
• Cohort disease life table for every 
simulated cohort or the period data for 
every simulated year. 
• Population pyramids or survival rates 
• Summary outcome measures e.g. 
cohort life expectancy, period life 














• Prevalence of mild, moderate and severe COPD, 
according to age and smoking status. 
• Model of the likelihood of exacerbations according 
to disease severity to give annual rates of minor ad 
major exacerbations. 
• Mortality rate for Canada and mortality rate 
according to disease severity and age and smoking 
status. 
• Prevalence of respiratory symptoms. 
• Progression rates to next COPD severity stage. 
• Quality of life proportional to disease severity. 
• Annual direct cost of COPD maintenance treatment 
and exacerbations according to disease severity. 
• Annual discount rate of 3%. 
• Number of COPD patients. 
• Annual societal cost of COPD. 
• Burden of COPD in terms of 









• Inpatient discharge records from the Agency for 
Healthcare Research and Quality Healthcare cost 
and Utilization Project Nationwide Inpatient 
Sample for 2006, United States. These records 
contain information on patient demographics, 
diagnoses, procedures, admission and discharge 
characteristics, payer, total charges, length of stay
and hospital characteristics.  
• Hospitalisation costs. 
• In hospital mortality . 
• Factors associated with higher 
hospitalisation costs and higher rates 



















• As for Hoogendoorn 2005 plus: 
• Exacerbation frequency by COPD severity. 
• Case-fatality of exacerbations. 
• Relation between exacerbations and lung function 
decline. 
• QALYs lost for exacerbations. 
• Costs of exacerbations. 
• Total annual number of life years, 
quality adjusted life years, moderate 
and severe COPD exacerbations, total 











• Incidence and hospitalisation counts for four 
diseases: acute myocardial infarction, stroke, lung
cancer and COPD, transformed into probabilities 
for disease specific incidence death and other 
events. These probabilities were initially obtained 
for smokers, ex-smokers and never smokers 
combined. Then probabilities for smokers were 
estimated by adjusting the population probabilities 
on the basis of smoking prevalence data and disease 
relative risks. Probabilities for quitters were 
estimated according to functions that describe the 
decreasing risk with time. 
• Probabilities for death for people with smoking 
related diseases and other causes. 
•  Healthcare costs for smoking related diseases. 
• Utilities for smoking related diseases. 
• Incidence of four diseases: acute 
myocardial infarction, stroke, lung 
cancer and COPD.  
• Total deaths, including deaths 
attributable to all smoking related 
diseases and deaths due to the above 
four diseases. 
• Life expectancy. 
• Quality adjusted life expectancy. 
• Direct health costs from the above 
four diseases. 
(Erbas, Ullah 








• Annual COPD (ICD10  J41-J44) death rates 2922 
to 2005 for 5 year age groups from 50-54 to 85+ 
obtained from the General Record of Incidence of 
Mortality, Australia. 
• Forecasts of COPD mortality rates in 




POPMOD   Multistate 
population 
model 
• Mortality data. 
• Modelled demographic population data from 
Popmod. 
• Estimated disease rates prevalence and severity 
• DALYs averted, costs, cost 
effectiveness ratios for all 
interventions in both sub-Saharan 














• Demographic data on migration, birth and total 
mortality by gender and age from Statistics 
Netherlands.  
• Incidence rates for lung cancer, coronary heart 
disease, stroke and COPD, 1994 prevalence rates 
from several general practitioner registrations were 
combined. 
• Disease specific mortality rates, estimated as the 
difference between mortality in the general 
population and mortality among patients. 
• Gender and age-specific start and stop rates for 
smoking were estimated from observed trends 
1987-1994 using age-period-cohort analysis. 
• Relative risks of smokers and former smokers for 
incidence of smoking-related diseases. 
• Dutch disease specific quality of life weights. 
• Cost of illness estimates per person from the Cost 
of Illness in the Netherlands study. 
• Prevalence of smoking among men 
and women for each of three tobacco 
control scenarios. 
• DALYs lost each year to smoking-
related diseases. 
• Costs avoided by each of the tobacco 













• COPD and population data for England and Wales 
1945-1999 by five year age bands. 
• Population projections for 2000-2009 from the 
Government Actuarial Dept, London UK. 
• Age specific conversion factors for COPD ICD 
coding of mortality over time. 
• Graphs of trends in males and females 
of deaths from COPD in England and 











• Based on data for the period up to 1993: the size of 
the Danish population and total mortality rates form 
the Danish National Bureau of Statistics. 
• Cause specific death rates from the Danish National 
Institute of Public Health for ischaemic heart 
disease, stroke, lung cancer and chronic bronchitis 
and emphysema. 
• Data on the prevalence of cigarette smoking by sex 
and age based on personal interviews carried out on 
9,000-20,000 Danes annually by Gallup Market 
Analysis. 
• Relative risk estimates from Michael Thun, 
American Cancer Society. 
• Data from CPS-II: The American Cancer Society 
Prospective Studies. 
• Comparison between the numbers of 
death attributable to smoking as 
calculated using two different 
modelling methods from these data, 
for different diseases. 
• Life expectancy gains if there were no 















• Aggregate estimates from the BOLD prevalence 
survey. 
• Local cost and population estimates. 
• Estimates of prevalence, smoking rates and 
healthcare utilisation rates. 
• Cost estimates based on local unit costs estimates 
for hospitalisations, physician (or other healthcare 
provider visits) and medications. 
• Incidence rates for COPD, mortality rates and 
smoking prevalence in younger populations. 
• Estimates on the costs related to the 
treatment of COPD. 
• The types of healthcare resources 
consumed. 
• Estimates of current and future costs 
of overall and per capita spending. 
• Costs stratified by severity. 
• Number of events in terms of 
hospitalisations, emergency dept visits 
and outpatient visits. 











• Sex and age-specific mortality data on COPD from 
the vital statistics of Japan 1950-2004 restricted to 
deaths at age 40 or older. 
• Graphs of the age-specific rate of 
COPD mortality per 100,000 persons 
by birth cohort. 
• Graph of effects of age, time periods 
and birth cohort on COPD population. 
(Nacul, 










• Health Survey England data 2001 findings for lung 
function parameters and their association with 
relevant risk factors. These data refer to 5269 men
and 6133 women over age 15 with valid lung 
function measures. 
• Age group, smoking status, ethnicity and degree of 
urbanisation and deprivation score for the above 
sample. 
• Map of prevalence of COPD by age 
and gender in England. 
(Stang, 






 • Estimates of healthcare utilization rates for COPD 
from outpatient and inpatient data then divided by 
the mean number of visits per diagnosed COPD 
subject reported in the Third National Health and 
Nutrition Examination Survey to derive an estimate 
of diagnosed COPD prevalence. 
• Estimates from a literature review of population 
based surveys presenting information on smoking 
status and spirometry to estimate the true rate of 
COPD by age, sex and smoking status (smoothed 
by regression.)  
• Available information from government surveys on 
smoking rates in Germany, the UK, Spain and Italy 
and France. 
• Prevalence of diagnosed COPD from 
outpatient visits in the United States. 
• Prevalence of diagnosed COPD from 
hospital discharges in the United 
States. 
• Proportion of total COPD cases that 
are currently diagnosed in the United 
States. 
• Estimates of total COPD prevalence 














• COPD hospitalisation data from Medicare claims 
for 1995-2006 for each Health Service Area in the 
United States. 
• Map detailing COPD hospitalisation 
rates per 1000 enrollees among 
Medicare beneficiaries by state and by 
Health Service Area in the United 
States. 
• Map of COPD hospitalisation relative 
risk exceeding 1 attributable to 




DISMOD 3 Burden 
estimation 
model 
• Many inputs from international data. 
• COPD mortality was modelled using cause of death 
ensemble modelling (CODEm) for those countries 
that did not have enough mortality data to use as 
input data.  
• DALYs were modelled separately in a multi-
national collaboration. 
• Global ranking of diseases according 
to disability adjusted life years. 
• Global mortality from COPD for men 
and women in 2010. 
• Years of life lost globally due to 




































4 2 1 3 1 1 1 1 3 0.5 17.5 
 
(Feenstra, van 
Genugten et al. 
2001) 




Molken et al. 
2005) 
4 2 1 3 2 0 1 1 2 1 17 
(Peabody, 
Schau et al. 
2005) 
4 3 1 3 2 0 0 0 3 0 16 
(Shibuya, 










Chouaid et al. 
2011) 







4 3 1 3 1 1 0 1 0 1 15 
(Najafzadeh, 
Marra et al. 
2012) 




3 2 1 3 2 0 0 0 2 1 14 
(Hoogendoorn, 
Rutten-van 
Molken et al. 
2011) 




4 3 1 3 2 0 0 0 0 1 14 
(Erbas, Ullah 
et al. 2012) 




Ortegon et al. 
2012) 





4 2 1 3 1 0 0 1 0 0.5 12.5 
(Lopez, 
Shibuya et al. 
2006) 




2 3 1 3 0 0 0 1 2 0 12 
(Chapmann, 
Mannino et al. 
2006) 
4 2 1 3 2 0 0 0 0 0 12 
(Pham, Ozasa 
et al. 2012) 
3 2 1 3 0 0 0 0 0 0.5 9.5 
(Nacul, Soljak 
et al. 2007) 
2 3 1 3 0 0 0 0 0 0 9 
(Stang, Lydick 
et al. 2000) 
3 1 1 2 0 0 0 0 2 0 9 
(Holt, Zhang 
et al. 2011) 





Table 5.4 Reported outcome of each modelling study 











The International Society for Pharmacoeconomics and Outcomes 
Research criteria for model development and reporting were 
followed. Internal validation was performed by inputting null and 
extreme values to detect inconsistencies and programming errors. 
Calibration was performed using Argentinian data for all data 
excluding COPD data (as national statistics were thoug t to 
underestimate mortality due to COPD and so this would have been 
counter-productive). External validation was performed using the 
statistics from the PLATINO Burden of Obstructive Lung Disease 
survey of five South American cities which were found to have a 
good fit to the modelled statistics. 














The result from the model showed that there would be an increase in 
COPD disease burden between 1994 and 2015, in particul  n 
women. By 2015, changes in the population alone would lead to an 
expected rise in prevalence to 33 per 1000 (men) and 25 per 1000 
(women), 27 per 1000 total. This was largely as a result of past 
smoking behaviour and aging of the population. All efforts to 
decrease smoking prevalence by smoking cessation campaigns would 
only show an effect on disease burden in the long term. In the 
medium term in order to impact the disease burden, public health 
associations were recommended to focus on the burden from 
exacerbations. 
For a projection that assumed changes in 
smoking behaviour, it was found that the total 
costs increased approximately 90% over the 
period 1994 to 2015. Healthcare costs 
increased more for women than for men in line 















A projection between 2000 and 2025 demonstrated an increase in 
prevalence from 24 to 33 per 1000 for men and from 15 to 27 per 
1000 inhabitants for women. Absolute number of deaths from COPD 
increased from 15000 to 23000 in 2025 in men and from 8000 to 
16000 in women.  
Total related healthcare costs in 2000 were 
estimated to be 280 million Euros. In 2025 this 
is estimated to grow to £495 million Euros. An 












Model projections were calculated for Spain (6.2%), Norway (6.3%), 
Nepal (11.1%) and Poland (6.7%) and were validated by comparison 
with survey obtained prevalence data. Model projections were not 
statistically different from collected survey prevalence data for any 
of the four comparison countries. This model was then used to 
project prevalence in 12 Asia-Pacific countries.  








en et al. 
2003) 
DISMOD II Worldwide Estimates of incidence, prevalenc  and mortality of COPD for 
different WHO regions of the world are derived from available data 
on mortality and compared with estimates from other national burden 
of disease studies and other published data. Regions including China 
and India accounted for 52 and 11 per cent respectively of the global 
total in 2000 despite a smaller prevalence than in other regions where 
risk factors were more prevalent – this is because of these regions’ 
large populations. In Africa where female smoking prevalence is low 
the male to female ratios of years lost to disability were higher than 
in other regions. The COPD global total disease burden from 
disabling states accounted for 2.7% of global total disease burden 
using 1990 weights. Other comparisons of the regional proportions 
of the global COPD burden were made. 











England COPD patients remaining continuous smokers till death had a mean 
remaining lifespan of 15.6 lifeyears worth 8.47 QALY. However, if 
they became sustained quitters then they would gain 2.73 lifeyears 
and 1.225 QALY.  
Considering the patients’ lifespans the 
additional disease-related costs of continuous 
smoking versus sustained abstinence was 
£1661 per patient. During a ten year period, 
the 1.4 million COPD smokers in England 














UK An example of the total elimination of smoking in the UK projected 
25 years into the future with the whole population c sisting of never 
smokers and no uptake of smoking: the prevalence of COPD halved 
from 1.7% to 0.5%. Prevalence of ischaemic heart disease and stroke 
fall, prevalence of lung cancer, oesophageal cancer and oral cancer 
all decrease. Prevalence of diabetes, breast cancer d colorectal 
cancer all increase due to larger number of surviving individuals at 
risk of such chronic diseases. 








Canada In terms of demographics alone, the population over the age of 40 in 
Canada will increase from 17 million to 24 million by 2035. In terms 
of COPD, the model projects that the number of COPD patients will 
increase from 3.45 million in 2011 to 5.83 million in 2035. In terms 
of strategies for managing this increase, the most effective strategy 
was to improve prevention of exacerbations in order to reduce costs 
and burden. 
The annual societal cost of COPD in Canada 
was $4.52 billion in 2011 and will be $3.61 
billion ($7.33 billion undiscounted) per year in 
2035. Over the 25 years from 2011 to 2035 
COPD will cost Canadian society $101.4 
billion ($147.5 billion undiscounted) and 12.9 












USA 1,254,703 hospitalisations in the USA in 2006. Average length of 
stay was 5.9 days. Inpatient mortality was 4.3%. After controlling for 
variables in the models several co-morbidities were associated with 
both higher costs  and higher mortality including acute MI, 
congestive heart failure, cerebrovascular disease, lung cancer, 
cardiac arrhythmias, pulmonary circulation disorders and weight 
loss. 
Acute exacerbations of COPD overall 
aggregate cost $ 11.98 billion in 2006, adjusted 
to $14.05 billion in 2010. Costs were higher 
for non-invasive ventilation cases by a factor 














The cost effectiveness of three different COPD intervention 
strategies was modelled. These were a pharmacologic intervention, a 
smoking cessation intervention and a pulmonary rehabilitation 
intervention. Total exacerbations avoided were 77,700 for the 
pharmacologic intervention, 90 for increased smoking cessation and 
0 for community rehabilitation. 
Savings in COPD-related healthcare costs were 
37.9 million Euros for the pharmacotherapy, -
0.9 million Euros for the smoking cessation 












Australia Overall 40 per every 1000 who quit smoking i dividuals will be 
spared a diagnosis of acute MI/COPD/lung cancer or str ke in the 
first ten years following quitting with an estimated saving of 47 life 
years and 75 QALYs. 
For every 1000 males chosen at random from 
the reference population who quit smoking 
there is an average saving of $408,000 in 
healthcare costs associated with the four 
diseases (MI, COPD, lung cancer or stroke) 







Australia Trends in COPD mortality rates among men in Australia have been 
declining since 1970 and the rates are expected to continue to decline 
for the next 20 years. Likewise the trends in COPD mortality rates 
among women are expected to decline but at a lower rat  than that of 
men. 













The model considered both asthma and COPD. Inhaled 
bronchodilators averted 58 DALYs per million population in Africa 
and 370 DALYs in SE Asia. This was based on the use of long term 
anticholinergic bronchodilator reducing COPD associated disability 
by up to 97% as measured by St George’s Respiratory Questionnaire. 
(This would seem to be very optimistic). 
For COPD the most cost-effective intervention 
was influenza vaccination – incremental cost 
$4,590 per DALY averted. COPD had higher 
costs in SE Asia than in Africa because of the 
high number of patients who could benefit 












Several scenarios of antismoking measures were considered. The 
reference scenario, with future smoking prevalence based on trend 
extrapolation resulted in the prevalence of smoking men declining 
from 35% in 1995 to 29% in 2020 and 28% in 2050. For w men 
there is a decrease form 27% in 1995 to 23% in 2050. Other 
scenarios included stopping young people from starting and 
alternatively increased quit rates amongst established mokers. 
Taxing tobacco also reduced smoking prevalence. 
If the Netherlands were able to increase the 
rate of smokers quitting, this model estimates 
that up to 80 million Euros for males and 100 
million Euros for females, could be saved. 
Avoided costs were even greater if people 
could be prevented from starting but there was 
a long time lag before benefits were seen. The 











COPD death rates in males aged over 45 will continue the decline of 
recent decades falling by 24% by 2009 from a 1999 baseline. In 
females projections suggested fluctuations in COPD death rates and 
wide credible intervals with 2% higher rates in 2009. A fall in rates 
was strongly suggested for males in their 60s and 70s and females in 
their 60s. However, for other age groups 90% credibl  intervals 
encompassed both a fall and rise in rates. 









PREVENT Denmark The PREVENT model estimated that 1052 men and 864 women died 
a smoking-attributable death in 1993. Overall 33% of deaths in men 
and 23% in women were attributable to smoking. The authors 
validated their model with comparison to the Peto model. 
















The model was used to project the prevalence of COPD among males 
and females over the age 40 over 10 years, i.e. from 2005 to 2015. 
After 10 years the prevalence of COPD stage I + will be 22% in 
Iceland and 24% in Norway. 
The current overall annual cost in Euros for 
COPD patients (2005) in Iceland was 12 
million rising to 13 million in 10 years’ time. 
For Norway the annual cost was 141 million 







Japan From 1950 to 2004 COPD mortality substantially decreased, from 
71.3 per 100 000 to 19.7 in men and from 41.7 to 4.3 in women. The 
greatest decreases were observed from 1959 to 1956 when the age 
standardised rate decrease by half, the downward tren s then slowed. 
The effects of age, time period and birth cohort were expressed in 
terms of relative risk The age effects increase with age in both sexes. 
The period effects initially rapidly decline then start increasing in the 
1960s. In men period effects tended to increase in r cent years, 
whereas they continue to decrease in women. Birth cohort effects 
initially increase up to the 1880-1889 cohort then d crease 
continuously until the 1960-1964 cohort. 















England The average prevalence in over 45s varies fourfold with the highest 
values in men in deprived urban areas and lowest in women in 
wealthy rural areas. 
Comparison of model prevalence estimates gives an indication of 
undiagnosed subjects and unmet need. The prevalence of COPD in 
2004 according to General Practice Quality and Outcomes 
Framework figures was only 1.4%, translating as 600 0  cases of 
COPD (nearly half) remaining undiagnosed. 










This study’s main outcome is that only a small proportion of people 
with COPD have a spirometric diagnosis and therefore an effort to 
increase case-finding is desirable. Estimates were a population of 3.0 
million people with COPD in the UK, 2.7 million in Germany, 2.6 
million in Italy and 2.63 million in France and 1.5 million in Spain.  











USA The Bayesian spatial mixture model showed that 73% of the 
variability of the COPD hospitalisation relative risk was attributable 
to the spatially structured effects. Thus regionalised influences on the 
social and physical environment had more impact on COPD 
hospitalisation rates than local social and physical environmental 
factors. The specific factors were not identified in the report. 
No cost estimates. 
(Murray, 
Vos et al. 
2012) 
DISMOD 3 Worldwide The global DALY rank for COPD has fallen from 6th to 9th. This is as 
a result of a decrease in indoor air pollution in India and China 
despite an increase in cumulative cigarette smoking worldwide. 
Global mortality from COPD for men and women, all ages was 
estimated as 2,899,900 in 2010. Years of life lost globally due to 
COPD in 2010 for both sexes all ages was estimated as 47,359,000 
years down from 58,186,000 in 1990. 






5.3.2 Narrative results 
This section reports a narrative version of the results, namely by summarising the results of 
the studies in a form as follows: the seven models reported in the following nine papers 
(Feenstra, van Genugten et al. 2001; Shibuya, Mathers et al. 2001; Barendregt, Van 
Oortmarssen et al. 2003; Hoogendoorn, Rutten-van Molken et al. 2005; Peabody, Schau et 
al. 2005; Atsou, Chouaid et al. 2011; Pichon-Riviere, Augustovski et al. 2011; Kulik, 
Nusselder et al. 2012; Lhachimi, Nusselder et al. 2012) that have been awarded the most 
points in the quality of reporting assessment were ranked in that order and are presented 
here. Each modelling procedure is described, then, as these models were reported in a high 
quality fashion, a comment may be made on the underlying quality of the model; as enough 
details have been included to draw conclusions as to how well structured and designed the 
model was. The main focus of quality was whether sensitivity analysis had been reported and 
what were the results of this. I also considered whether other features of quality assurance 
were present, such as debugging and external validation of results. 
5.3.2.1 Pichon-Riviere smoking burden model (Pichon -Riviere, Augustovski et 
al. 2011) 
This model was designed to meet the needs of 68 decision makers who had been surveyed 
across seven countries in Latin America (i.e. Argentina, Bolivia, Brazil, Chile, Colombia, 
Mexico and Peru). It considered heart disease, cerebrovascular disease, COPD, 
pneumonia/influenza, lung cancer and nine other neoplasms. The model used country 
specific data sources where possible. However, as a re ult of the lack of local data, estimates 
of incidence were often derived from mortality data using the WHO DISMOD II 
methodology.(Shibuya, Mathers et al. 2001) The baseline risk in non-smokers was then 
calculated based on the age-, sex- and country-specific smoking prevalence as well as 
disease specific smoking relative risk. The parameters for smokers and former smokers were 
then calculated from this baseline risk. The model was a first order Monte Carlo 
(probabilistic) micro-simulation of individual subjects incorporating the natural history, costs 
and quality of life of the above diseases. A functioning version of the model was constructed, 
validated and calibrated using data from Argentina.   
The Argentinian version of this model underwent extensive internal validation with 
debugging by the inputting of null and extreme values and checks for inconsistencies. The 
model was then calibrated by comparing general mortality and all age- and sex-specific 
death rates predicted by the model with local healt statistics. COPD was an exception from 
this process as COPD mortality was agreed to be undrestimated in national statistics. 
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Equations were modified to improve fit to the refernce values. Lethality and survival rates 
were estimated from local and international studies and also used to calibrate the model by 
visual exploration of observed and expected curves to confirm a good fit. After calibration, 
as had been expected, correlation between predicted and observed results was better among 
high incidence events. 
External validation for age- and sex-specific COPD predicted prevalence was performed by 
comparison with the results from the Latin American Project for the Investigation of 
Obstructive Lung Disease, a population-based survey carried out in five Latin American 
cities.(Menezes, Lopez et al. 2009) The model underestimated the level of COPD in 
comparison to the survey, however, the results were ithin 5% for each age group. This 
model’s report followed the International Society Pharmacoeconomics and Outcomes 
Research guidelines for model development and reporting (Weinstein, O'Brien et al. 2003) 
and therefore included extensive description of preliminary consultation with policy and 
decision makers and detail regarding debugging, internal validation, calibration and external 
validation procedures.  
5.3.2.2 Feenstra chronic disease model (Feenstra, v an Genugten et al. 2001) 
This model was designed to describe the population w th COPD in the Netherlands. A 
dynamic multistate life table model combined information on the demography of the Dutch 
population and their smoking behaviour. The number of new cases of COPD each year were 
calculated from the incidence rates of COPD for smokers and former smokers in 
combination with COPD prevalence data. Independently modelled modules exist for 
mortality from lung cancer, stroke, coronary heart disease and asthma. The model is dynamic 
in that each year’s total incorporated calculations for birth, migration and mortality. 
One way sensitivity analysis was performed to determine the effect of changes in inputs of 
incidence and excess mortality rates on the output prevalence rates. It was found that a 20% 
change in incidence input rates resulted in a 17% change in prevalence rates and a 20% 
change in excess mortality input resulted in a 4% change in estimated prevalence. Therefore 
the model was more sensitive to changes in incidence rates than changes in excess mortality 
rates. However, overall it was felt that the model was relatively stable when challenged with 
changes in input rates. 
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5.3.2.3 Hoogendoorn COPD model 2005 (Hoogendoorn, R utten-van Molken et 
al. 2005) 
This model was developed from the Feenstra chronic disease model(Feenstra, van Genugten 
et al. 2001) by the addition of the four Global initiat ve for Obstructive Lung Disease 
(GOLD) severity stages for COPD into the model to pr vide estimates for the Dutch 
population. The COPD population is divided into mild, moderate, severe and very severe 
COPD subpopulations and also by smoking status: never-smoker, smoker or former smoker. 
Annual incidence and mortality rates are applied to each age, sex and smoking 
subpopulation. The model exhibits the Markov property, in that the model has no memory 
for the previous years’ conditions of each patient at the individual level. Costs are calculated 
by multiplying annual cost data for each severity stage by the number of patients in each 
stage. 
Sensitivity analyses for this model were conducted by changing the input severity 
distribution of the COPD prevalence so that it was as umed firstly that COPD patients began 
with less severe COPD ( i.e. mild and moderate cases) next it was assumed that the 
distribution changed to include a higher proportion of severe and very severe cases.  The 
next sensitivity analysis to be conducted changed th  severity distribution of the incident 
COPD cases to first less severe and then more severe. Further sensitivity analyses were 
conducted varying the rate of lung function decline a d changing the impact on lung 
function decline of stopping smoking from an improvement to a null impact. The results of 
the sensitivity analyses were that all prevalence results were within a range of 5% of the 
projections of the base case. The results were most sen itive to the distribution of the 
severity of COPD at incidence. Cost projections were more sensitive than prevalence 
projections due to the difference in costs for different COPD severity stages. 
5.3.2.4 Peabody prevalence estimation model (Peabod y, Schau et al. 2005) 
This model used six key risk factors for COPD identified and quantified from the literature: 
smoking, age, gender, indoor air pollution, outdoor air pollution and occupational exposure 
to airborne particles. They assumed no cases under the age of 30 years, and a smoking 
prevalence of 15%. Based on the literature it was assumed that there was an exposure of non-
smoking population to occupational airborne particles of 1.9% and a prevalence of COPD in 
urban populations of 1.4%. In the model, population was distributed between urban and rural 
populations and geographical distribution was linked to environmental exposure. There was 
also an input for national socio-economic development based on World Bank figures. COPD 
prevalence was then estimated for four countries and compared with survey data for external 
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validation. Then COPD prevalences were estimated for an additional 12 countries 
(Bangladesh, Brazil, China, Denmark, Korea, Mexico, Philippines, Russia, Thailand, 
Turkey, UK and the US). 
Sensitivity analysis was performed on hypothetical populations with differences in their 
rural/urban population distribution and high/low income split. The model was externally 
validated by comparing its results to survey results for Nepal, Norway, Poland and Spain. 
The predictions were not statistically different from the survey results for any of the 
countries suggesting that the model is a useful prediction tool.(Peabody, Schau et al. 2005) 
The authors concluded that the model appeared robust and capable of providing reliable 
projections although further validation is desirable, especially in developing countries where 
data may be scarcer.  
5.3.2.5 WHO burden of disease model DISMOD II 2001 (Shibuya, Mathers et al. 
2001; Barendregt, Van Oortmarssen et al. 2003) 
DISMOD (Disease Model) II used the WHO world regions to calculate the global burden of 
COPD in terms of years lived with disability and mortality in terms of years of life lost. The 
model was based on a regression model including a measure of smoking impact and an air 
pollution variable to take into account proportions of households in each region that use 
indoor biofuels and age and sex dummy variables which reflected variability in the exposure 
data for different regions. The input data to the model was COPD related mortality rates and 
total mortality rates per WHO region. These data were used to generate an equation which 
could be solved for the prevalence and incidence of COPD.  
No sensitivity analysis using DISMOD II was undertaken. However, the predictive validity 
of the model was checked by comparing the estimated relative risks for death from COPD 
for the America and Pacific regions with recent burden of disease analyses from the USA 
and Australia. Published prevalence data based on spirometry in the WHO regions were also 
compared to the DISMOD II outputs and found to be consistent with the exception of 
estimates from the Global Burden of Disease 1990 estimates due to improved methodology 
since then.(Murray 1994) 
5.3.2.6 Atsou smoking burden model (Atsou, Chouaid et al. 2011) 
This modelled the severity stages of COPD: mild, moderate, severe and very severe. 
Transition probabilities could be altered for modelled patients moving up these severity 
stages as their disease progressed. The model aimedto r port the impact of smoking 
cessation on a COPD patient’s life expectancy in terms of individual health gains. The model 
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then performs a health economic assessment of the impact of various cost-effectiveness of 
smoking cessation programmes in England. This was a Markov-type model, but used 
individual simulation in place of the more usual Markov cohort simulation to assess both 
expected values and variability. 
The sensitivity analyses that were conducted involved changing the transition rates from one 
disease severity stage to the next, the mortality and exacerbation rates and the costs of COPD 
management, different discounting rates and different smoking cessation rates. For the 
scenarios investigating the costs, QALYs and cost-effectiveness of the smoking cessation 
programmes, the effects of different input costs for the programme and different quit rates, 
were investigated. The results were sensitive to transition rates from one disease stage to the 
next and to an increase in mortality rates; however, th y were not very sensitive to an 
exacerbation-free rate of 15% greater than in the reference case. But then when it was 
suggested that ex-smokers experience fewer exacerbations than smokers (probability of an 
exacerbation-free year 30% higher in ex-smokers than current smokers) there were monetary 
and healthcare gains. The model was not very sensitive to changes in disease management 
costs. Overall, extensive sensitivity analysis was undertaken so that the model could be used 
for a wide variety of smoking cessation scenarios. 
5.3.2.7 DYNAMO-HIA model (Kulik, Nusselder et al. 2 012; Lhachimi, Nusselder 
et al. 2012) 
This was a multi-state Markov-type and partial micro-simulation model designed for 
European Union-wide use. Data from most European Union countries were collected for 
nine diseases: COPD, diabetes, ischaemic heart disease, stroke, lung cancer, oral cancer, 
oesophageal cancer, colorectal cancer and breast cancer. The model was designed so that 
member government policy makers could firstly quantify the development of risk factor 
exposure over time and secondly quantify the impact of health interventions on the 
population, such as smoking cessation initiatives. This would be represented in the model as 
a risk factor reduction resulting in lower prevalenc  and hence mortality. The risk factors 
considered in the model were body mass index, alcoho  and tobacco consumption. The 
model is publicly available online at www.dynamo-hia.eu. The output of the model is in 
terms of the modelled cohort, most often the input country or region, giving population 
pyramids and survival rates and life table data including life expectancy. As the inputs can 
be updated, the model can be modified. 
The model can be set for sensitivity analysis as requi d, either one way or multi-way. The 
authors argued that gathering data for predictive validity assessment is embedded with 
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uncertainty and therefore projecting future disease patterns is always compromised. They 
argue that their strength is in comparing alternative scenarios for the future as the same 
baseline data can be used in each scenario. They chose to incorporate trend-free data into the 
model as past trends are not always indicative of future trends, so, in this way, the model is 
also a compromise (Lhachimi, Nusselder et al. 2012) 
5.4 Selection of model for further study 
In conducting the systematic review, it became apparent that three of the 22 models were 
very closely related: (Feenstra, van Genugten et al. 2001; Hoogendoorn, Rutten-van Molken 
et al. 2005; Hoogendoorn, Rutten-van Molken et al. 2011). On further enquiry I discovered 
that the Dutch Model in the Feenstra et al study (Feenstra, van Genugten et al. 2001) was the 
original model and was updated firstly to the (Hoogendoorn, Rutten-van Molken et al. 2005) 
model then to the (Hoogendoorn, Rutten-van Molken et al. 2011) model. The team which 
had produced these three models work closely together in the Netherlands. The three models 
had scored 17, 17 and 14 respectively on the quality of reporting scale. The reason for the 
slightly lower score of the 2011 model was that some of the quality elements had been 
reported more fully in the 2001 and 2005 manuscripts and so the 2011 manuscript did not 
receive the points for these elements. On reviewing the models I noted the extensive 
sensitivity analysis which had been undertaken and the high quality of the models. This 
Dutch team clearly held a dominant position in the modelling of COPD and had the longest 
history of experience in this area. 
I therefore decided to contact the Dutch team with a view to collaboration. They offered that 
I could use their latest model along with English and Scottish routine data. In addition, the 
model could be run in Mathematica (Wolfram 2013) which was a readily available computer 
programme. Another advantage of this choice was that, unlike other models, the outputs 
were not only limited to current estimates but also could be used to project estimates of the 
prevalence and burden of COPD in England and Scotland in the future. 
5.5 Conclusion to Chapter 5 
Models which aim to predict the prevalence and burden of COPD have widely differing 
structures and include Markov models, demographic models and risk factor models. In this 
chapter I have described an extensive and systematic search for models and the process I 
undertook in order to appraise their quality of reporting. I then listed the features of all 22 
models in tables including their main characteristics and the inputs and outputs required for 
the models. Then I presented a grid with quality of reporting scores. This was followed by a 
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summary table of the outcomes of each model in context. The seven models which scored 
most highly among the quality of reporting were then assessed for their underlying quality, 
with a focus on sensitivity analysis. A narrative summary of these seven models was given.  
Finally, I observed that three of the models were closely related and were produced by the 
same team in the Netherlands. These three models had all obtained reasonably high scores on 
the quality of reporting scale. It became clear that e Dutch team had much experience in 
developing and running COPD population models. An approach for collaboration with the 
team in the Netherlands was successful and so their most recent model was chosen to 
produce projections of the prevalence and burden of COPD in England and Scotland in the 




Chapter 6: Model description and data requirements 
6.1 Introduction 
The previous chapter reported a systematic review to find models for calculating the 
prevalence and burden of COPD. Chapter 5 concluded with the selection of related models 
for further study. (Feenstra, van Genugten et al. 2001; Hoogendoorn, Rutten-van Molken et 
al. 2005; Hoogendoorn, Rutten-van Molken et al. 2011). The Dutch team who had produced 
these models in Rotterdam agreed to collaborate and to share their most up to date model (as 
of October 2013) with me for calculating projections of prevalence and burden of COPD for 
England and Scotland from 2011 to 2030. 
This chapter has two main parts: firstly, a description of the Dutch Model; this is then 
followed by an overview of the data required to runthe model. The data section continues 
with an explanation of the origins of the data for each component of the Dutch Model. The 
governance processes which were gone through to obtain the data permissions are also 
described alongside each type of data.  
In Chapter 7, the results of the Dutch Model are presented for prevalence, healthcare costs 
and mortality, and finally the sensitivity analyses are presented. These results represent 
original estimates for the prevalence, costs and mortality of COPD in England and Scotland 
as estimated for 2011 to 2030. 
6.2 Dutch Model description 
The Dutch model, as discovered through the systematic review of Chapter 5, had evolved 
over the years from a dynamic epidemiological projection model (Feenstra, van Genugten et 
al. 2001) to a model which incorporated the distribution of severity within the COPD 
population and also estimates of numbers and costs of exacerbations. The 2011 incarnation 
of the model also could use stochastic techniques (i.e. mathematical techniques involving 
running the model through a certain high number of repetitions thus giving an overview of 
the most likely outcomes) to provide uncertainty analysis for the model (Hoogendoorn, 
Rutten-van Molken et al. 2011). Uncertainty was modelle  for selected parameters (see 
Chapter 7 and Appendix 5 for a fuller discussion of uncertainty in the model). Subsequently 
the most up to date version of this model (supplied in October 2013) is referred to as “The 
Dutch Model.” 
The Dutch Model is a Markov type multi-state cohort model where members of the 
population are first characterised as either having COPD or not having COPD. The 
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prevalence of COPD included four COPD severity stages based on the 2011 GOLD 
classification as illustrated in Figure 6.1. The prvalence was distributed over the three 
smoking classes (i.e. smoker, non-smoker and former s okers) using the numbers of 
smokers in each smoking class and the relative risks of smokers and former smokers of 
having COPD.  
COPD cohorts were modelled progressing through the stages of severity: mild, moderate, 
severe and very severe according to transition probabilities that were related primarily to 
lung function decline. The lung function decline was modelled as the annual decline in 
FEV1% predicted depending on age, sex, smoking status and FEV1% predicted. 
Exacerbations accelerate this decline slightly. Outcomes were death from COPD or other 
causes or survival to 2030. This annual decline was modelled using a random effects model 
based on 5,000 patients with longitudinal spirometry information in the Lung Health 
Study.(Scanlon, Connett et al. 2000) Transitions betwe n smoking status categories, based 
on proportions of people starting, stopping and resta ting smoking, were also modelled. 
Difference equations described the change of state variables over time, as a result of 
transitions from one state to the other. The cycle length was one year. The two most 
important state variables in the model were: 1) probability values per COPD severity stage 
(including not having COPD as a special stage), per smoking class, per age class and sex; 
and 2) coefficients describing the distribution of FEV1% predicted within each COPD 
severity stage per smoking class. This latter distribution was interpreted as the mean 
distribution over both sexes and all ages. The severity distribution of COPD prevalence at 
the start of the modelling process was based on Dutch GP data.(Van Weel, Smith et al. 2000; 
Wijnhoven, Kriegsman et al. 2001). The distribution of COPD severity stages among the 
incident cases was calculated to preserve this severity distribution of COPD prevalence in 
the first year of the model. 
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Figure 6.1 The Dutch Model. Reproduced with permission (Hoogendoorn, Rutten-
van Molken et al. 2011) 
 
The number of COPD exacerbations at each stage of severity is also important for 
calculating the transition probabilities between severity categories.(Hoogendoorn, Feenstra 
et al. 2010; Hoogendoorn, Hoogenveen et al. 2011) A severe exacerbation was defined as an 
exacerbation necessitating a hospital admission. A moderate exacerbation was defined as a 
an acute exacerbation of COPD necessitating a visit to a GP for an increase in 
symptoms.(Hoogendoorn, Rutten-van Molken et al. 2010) 
The costs of COPD were calculated from the costs of maintenance in each severity stage plus 
the costs of exacerbations. In the original model, th se costs were distinct for age and sex 
groups with costs of maintenance therapy increasing w th age and costs for women being 
higher than for men.(Hoogendoorn, Rutten-van Molken et al. 2005) However, the data 
available for the UK adaptations of the model did not i clude such detail – only giving 
differential costs for different COPD severity stages. This will be explained further in the 
section on data sources later in this chapter. 
6.3 Modelling data input overview 
There was a long process of ensuring that the data with which the model would be run were 
suitable. The plan was to re-run the Dutch Model with English and Scottish data, to produce 
respective estimates for each country. The final data sources that were used for each of the 
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model inputs are summarised in Table 6.1. The base year for the model was selected to be 
2011 so, whenever possible, estimates for that year w re obtained. 
Table 6.1 Model inputs and respective data sources for England and Scotland 
Data Input English Source Scottish Source 
1 year age and sex 
distribution of the general 
population in 2011 
Officefor National 
Statistics(ONS 2011) 
General Register Office for 
Scotland(GROS 2012) 
Incidence of COPD Clinical Practice Research 
Datalink(CPRD 2011) 
Lothian COPD Cohort (see 
below) 
Prevalence of COPD 
 
Clinical Practice Research 
Datalink(CPRD 2011) 
Scottish Practice Team 
Information Database (see 
below) 
Smoking prevalence The General Lifestyle Survey 
for England 2011(ONS 2011) 
and Health Survey for 
England 2010(ESRC 2011) 
Scottish Health Survey 
2011(Bradshaw, Bromley 
et al. 2011) and Scottish 
Schools Adolescent 
Lifestyle and Substance 
Use Survey 2010(Black, 
Eunson et al. 2010) 




Avon Longitudinal Study 
of Parents and 
Children(BristolUniversity 
1991) 
Stop smoking rates Smoking Toolkit 
Survey(West and Brown 
2013) 
Smoking Toolkit 
Survey(West and Brown 
2013) 
Restart smoking rates Original Netherlands 
data(Hoogendoorn, Rutten-
van Molken et al. 2005) 
Original Netherlands 
data(Hoogendoorn, Rutten-
van Molken et al. 2005) 
Age and sex specific 
relative risks of smokers 
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Original Netherlands 
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van Molken et al. 2005) 
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6.4 Model data inputs and sources 
6.4.1 General population data 
6.4.1.1 England 
Demographic details of the English population in 2011 were obtained from the Office for 
National Statistics (ONS). These included the number of males and females at each age in 
one year age bands to age 100. 
6.4.1.2 Scotland 
Demographic details of the Scottish population in 2011 were obtained from the General 
Register Office for Scotland (GROS) mid-year population estimates. These included the 
number of males and females at each age in one year ag  bands to age 100. 
6.4.2 Incidence of COPD from general practice data 
6.4.2.1 England 
The Clinical Practice Research Datalink CPRD is the English NHS observational data and 
interventional research service, jointly funded by the NHS National Institute for Health 
Research (NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA). 
CPRD extracts data from electronic health records in primary care (see Chapter 3, Table 
3.1). My colleague, Dr Daniel Kotz, and two of my supervisors, Dr Colin Simpson, and Prof 
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Aziz Sheikh, had formerly approached CPRD to extract a COPD patient dataset based on 
general practice data and linked to mortality data (see CPRD protocol Appendix 1.1). They 
had used these data to develop an individual prognostic model for COPD based on GP 
data.(Kotz, Simpson et al. 2014) With permission from CPRD, I was able to extend the 
analysis of these data to include provision of incidence and prevalence estimates for COPD 
in primary care (see Appendix 1.2 for amendment to protocol). The data were drawn from a 
broad and representative sample of general practices throughout England, Scotland and 
Wales, however they were coded for geographical region and so incidence and prevalence of 
COPD could be estimated for England. These were requested in one year age and sex 
groups. The risk of identification and the likelihood of uneven data in such narrow age 
categories was lower than in Scotland because of the larger population size. 
The incidence of COPD in English patients was calcul ted using the CPRD resource as 
above. As this COPD cohort were derived from data which had linked mortality data, only 
those patients could be used as source whose practices had provided data to participate in the 
linkage. This limited the source population to 4,780,8 7 patients. 
The source population for the cohort was further limited to those that have at least five years 
of “up to standard” follow-up on the CPRD GOLD data extract (see Table 3.1 which 
describes the sources of this GP database, the CPRD GOLD database is the highest quality 
CPRD database, there is also a CPRD Silver database which contains less high quality data). 
This gave a total of 2,655,917 patients. “Up to standard” data essentially involves ensuring 
that the data can be used for research purposes by xamining for gaps as a result of problems 
in coding when patients move practices or die. 
The numerator and denominator for the incidence were provided, as documented in 
Appendix 1.3. 
6.4.2.1.1 Permissions required for use of the CPRD data 
The following permissions were required to use CPRD data in the modelling. 
1. University of Edinburgh, local level 1 ethical approval, this was covered by my 
supervisor who confirmed that the data would not be distributed or identifiable. (See 
Appendix 2.1) 
2. Permission to use the data as in the protocol amendt was applied to from the 
(Independent Scientific Advisory Committee) ISAC committee of CPRD, who 




There were several options for measuring the incidee of COPD in Scotland. As incidence 
is number of new cases of a condition presenting in a population, it was decided to take 
advantage of the Lothian COPD Cohort database. One of my supervisors (Professor Wild) 
was a co-applicant on a project to bring together primary care data on COPD for Lothian. 
Following review of the Chief Scientist’s Office (CSO) application for this grant, we 
approached the Principal Investigator, Dr Rachel Hardie, with a plan to use the cohort data to 
fill the incidence data field. Dr Leonie Hunter was my liaison researcher at Lothian Health 
Board. 
The Lothian COPD Cohort database brought together a list of all (approximately 7000) 
COPD patients in the primary care records of the Lothian region of Scotland. Data extraction 
had been undertaken from the 72 general practices in Lothian that had agreed to data sharing 
for the original project (overall there are 126 general practices in Lothian). Of these, all 
practices agreed that their data could be used for my further work.  
The following Read Codes (version 2) were extracted from the records to form the COPD 
Lothian cohort. These Read Codes were selected as those specified in the Quality and 
Outcomes Framework Business Rules.(HSCIC 2013) Originally the research team for the 
above project extracted data for spirometry, smoking a d co-morbidities; but I only used the 
data to estimate the incidence of COPD. 
Table 6.2 COPD Read Codes used to identify the Lothian COPD Cohort  
Read 
Code 
Read Code description 
H3... Chronic obstructive pulmonary disease 
H31.. Chronic bronchitis 
H310. Simple chronic bronchitis 
H3100 Chronic catarrhal bronchitis 
H310z Simple chronic bronchitis NOS 
H311. Mucopurulent chronic bronchitis 
H3110 Purulent chronic bronchitis 
H3111 Fetid chronic bronchitis 
H311z Mucopurulent chronic bronchitis NOS 
H312. Obstructive chronic bronchitis 
H3120 Chronic asthmatic bronchitis 
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H3121 Emphysematous bronchitis 
H3123 Bronchiolitis obliterans 
H312z Obstructive chronic bronchitis NOS 
H313. Mixed simple and mucopurulent chronic bronchitis 
H31y. Other chronic bronchitis 
H31y1 Chronic tracheobronchitis 
H31yz Other chronic bronchitis NOS 
H31z. Chronic bronchitis NOS 
H32.. Emphysema 
H320. Chronic bullous emphysema 
H3200 Segmental bullous emphysema 
H3201 Zonal bullous emphysema 
H3202 Giant bullous emphysema 
H3203 Bullous emphysema with collapse 
H320z Chronic bullous emphysema NOS 
H321. Panlobular emphysema 
H322. Centrilobular emphysema 
H32y. Other emphysema 
H32y0 Acute vesicular emphysema 
H32y1 Atrophic (senile) emphysema 
H32y2 MacLeod's unilateral emphysema 
H32yz Other emphysema NOS 
H32z. Emphysema NOS 
H36.. Mild chronic obstructive pulmonary disease 
H37.. Moderate chronic obstructive pulmonary disease 
H38.. Severe chronic obstructive pulmonary disease 
H39.. Very severe chronic obstructive pulmonary disease 
H3y.. Other specified chronic obstructive airways disease 
H3y0. Chronic obstructive pulmonary disease with acute lower 
respiratory infection 
H3y1. Chronic obstructive pulmonary disease with acute 
exacerbation, unspecified 




The Lothian Cohort database fulfilled the requirement for estimating incidence because it 
was made up of new diagnoses of COPD with the Read Codes as shown in Table 6.2. The 
incidence in the Lothian Cohort Database was calculted as follows:  
1. Numerator=all new diagnoses of COPD identified using specified Read Codes 
between 2000 and 2008 grouped by sex, five year age b nds and Scottish Index of 
Multiple Deprivation (SIMD) quintile (based on the 2009 SIMD code);  
2. Denominator=practice population at 2010 multiplied by 8 to reflect the 8 years in the 
cohort, and grouped by sex, 5 year age band and SIMD quintile (again based on the 
2009 SIMD code). Inclusion of SIMD allows rates in each deprivation quintile to be 
considered separately. 
3. Incidence rate was calculated by dividing numerator by denominator to give 
incidence per 100,000 population per year. This was the incidence rate in the 
Lothian COPD Cohort only. 
 
In order to calculate the incidence rate in Scotland s a whole it was necessary to adjust 
the estimates because the practices in the original cohort hailed from Lothian and as such 
were not representative of Scotland as a whole. The Lothian population was, on average, 
more affluent than the Scottish population and has a different age and sex structure. This 
correction was done as follows.  
1. The first step was to obtain Scottish population numbers for each deprivation 
quintile. This was done by accessing SIMD online (GovernmentStatistics 2009) 
which gave the population per 2009 decile and summing every two deciles together 
to obtain numbers of patients per SIMD quintile for the Scottish population by five 
year age category and sex.  
2. Then incidence by age, sex and SIMD quintile for the Lothian COPD cohort was 
applied to Scottish population estimates to give estimates of number of COPD 
patients in each stratum. These were summed over SIMD quintiles to give the total 
number with COPD in each five year age and sex group.(A) 
3. The total Scottish population in each age and sex group was calculated by summing 
the data over the five SIMD quintiles.(B) 
4. Finally, the overall Scottish incidence of COPD (now weighted for national 




6.4.2.2.1 Permissions required for use of the Lothi an COPD Cohort Data 
The following permissions/waivers had to be obtained b fore it would be possible to use the 
Lothian COPD Cohort Data in the modelling: 
1. National Health Service Ethical approval waiver, on the understanding that the data 
were anonymised without risk of identification of participants and so did not require 
NHS ethical approval. See Appendix 3.1. 
2. University of Edinburgh, local level 1 ethical approval, was submitted to the local 
committee confirming that the data would not be distributed or identifiable. See 
Appendix 2.1. 
3. Privacy Advisory Committee (PAC) at Information Services Division (ISD) 
approval waiver. This special health board has a dat  collection and analysis 
function for the NHS. However, where data are going outside the NHS they approve 
the transfer and review the risks of identification. In my case, permission had already 
been obtained for the original research project regarding the Lothian COPD Cohort it 
was just a matter of obtaining additional approval for additional analysis. See email 
from Janet Murray, Appendix 3.2 and PAC Application, Appendix 3.3. 
4. Caldicott Guardian review, this is a review under the terms of the data protection act. 
The Caldicott guardian for Lothian Health Board was Dr Allison McCallum and to 
start with she was very conservative in her advice – however, this was due to a lack 
of clarity on my part as to the precise use and whereabouts of the data at all times. I 
wrote again to the Caldicott Guardian to confirm that the only data requested from 
the Lothian COPD Cohort would be the incidence and that the only data taken to 
Rotterdam would be the calculated, aggregated Scottish level estimates. See 
Appendices 4.1 to 4.5. Finally, permission was forthcoming as long as the data were 
transported on an encrypted laptop. 
6.4.3 Prevalence of COPD 
6.4.3.1 England 
Prevalence of COPD was calculated from the same COPD C RD GOLD database extract as 
incidence, see Section 6.3.2.1. Appendix 1.3 contains details of the calculation undertaken 
by CPRD to provide prevalence. The results of this calculation are shown in table 6.3. 
Table 6.3 Prevalence of COPD in England from Clinical Practice Research Datalink 
2011. 
Prevalence rate per 100,000 cases (95% CI) 
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Age males females 
35 92.0 (47.6 , 160.7) 152.7 (93.3 , 235.8) 
36 124.7 (72.7 , 199.7) 66.9 (30.6 , 126.9) 
37 139.4 (85.2 , 215.3) 163.9 (103.9 , 245.9) 
38 246.3 (173.4 , 339.4) 183.2 (120.8 , 266.6) 
39 244.2 (173.7 , 333.8) 160.7 (104.0 , 237.2) 
40 190.9 (130.6 , 269.5) 236.4 (168.1 , 323.2) 
41 239.9 (171.4 , 326.7) 361.6 (275.3 , 466.4) 
42 312.6 (234.2 , 408.9) 345.9 (262.0 , 448.1) 
43 457.9 (362.5 , 570.6) 298.2 (221.3 , 393.1) 
44 396.3 (308.4 , 501.6) 488.3 (389.5 , 604.5) 
45 412.1 (322.4 , 518.9) 428.7 (337.2 , 537.4) 
46 484.1 (387.7 , 597.1) 599.8 (490.6 , 726.1) 
47 624.2 (514.4 , 750.4) 618.2 (507.6 , 745.8) 
48 597.9 (489.1 , 723.9) 731.5 (609.4 , 870.9) 
49 849.7 (717.9 , 998.7) 969.1 (825.6 , 1130.3) 
50 787.4 (658.8 , 933.8) 1061.6 (909.3 , 1232.1) 
51 985.8 (839.8 , 1149.8) 1075.2 (920.9 , 1247.9) 
52 1206.2 (1041.2 , 1389.9) 1408.9 (1227.7 , 1609.4) 
53 1502.0 (1316.1 , 1706.8) 1393.4 (1212.6 , 1593.7) 
54 1470.1 (1283.9 , 1675.8) 1669.6 (1468.2 , 1890.8) 
55 1689.8 (1483.2 , 1917.2) 1751.2 (1541.7 , 1981.3) 
56 2019.8 (1791.3 , 2269.4) 2366.7 (2116.4 , 2638.5) 
57 2278.0 (2033.7 , 2543.5) 2396.8 (2145.9 , 2669.0) 
58 2451.5 (2197.8 , 2726.4) 2681.2 (2415.3 , 2968.4) 
59 3040.2 (2756.0 , 3345.7) 2760.1 (2487.5 , 3054.6) 
60 2959.3 (2674.3 , 3266.4) 3418.8 (3112.2 , 3747.5) 
61 3702.1 (3384.0 , 4041.9) 3472.9 (3168.2 , 3799.0) 
62 3947.1 (3622.0 , 4293.5) 3702.7 (3392.1 , 4034.0) 
63 4109.5 (3785.3 , 4454.0) 3858.7 (3547.8 , 4189.5) 
64 4732.4 (4400.8 , 5082.3) 4274.2 (3963.2 , 4603.1) 
65 5121.9 (4760.9 , 5503.0) 4547.6 (4211.9 , 4902.9) 
66 6037.8 (5600.6 , 6500.1) 4925.2 (4535.4 , 5339.5) 
67 6286.9 (5858.5 , 6738.4) 5673.2 (5272.3 , 6096.5) 
68 7180.7 (6695.8 , 7691.4) 5646.0 (5227.4 , 6089.1) 
69 7589.7 (7075.3 , 8131.6) 5839.5 (5401.4 , 6303.6) 
70 7473.9 (6925.4 , 8054.3) 6810.5 (6301.9 , 7349.2) 
71 8378.5 (7792.2 , 8997.3) 6519.3 (6022.8 , 7045.8) 
72 8704.3 (8108.5 , 9332.2) 7241.5 (6728.8 , 7783.0) 
73 9778.5 (9144.1 , 10445.4) 7168.4 (6647.5 , 7719.3) 
74 9398.4 (8759.5 , 10071.6) 7579.6 (7037.4 , 8152.4) 
75 9158.3 (8510.7 , 9842.2) 7440.4 (6893.2 , 8019.6) 
76 10352.1 (9640.5 , 11102.3) 7706.0 (7143.2 , 8301.3) 
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77 10050.6 (9337.0 , 10804.2) 8147.5 (7557.1 , 8771.7) 
78 10517.6 (9751.2 , 11328.2) 7821.2 (7215.7 , 8464.0) 
79 10317.8 (9552.4 , 11128.3) 7706.6 (7113.7 , 8335.7) 
80 10994.9 (10173.1 , 11865.3) 8286.5 (7661.2 , 8949.3) 
81 11872.4 (10997.3 , 12798.6) 8541.3 (7900.6 , 9220.2) 
82 11408.1 (10505.3 , 12367.8) 8156.7 (7509.0 , 8845.3) 
83 12755.2 (11739.0 , 13835.9) 8489.7 (7807.0 , 9216.2) 
84 12132.6 (11074.6 , 13264.5) 7477.9 (6807.2 , 8196.8) 
85 11844.6 (10769.5 , 12997.9) 8149.2 (7422.2 , 8928.2) 
 
6.4.3.1 Scotland 
It was decided to use data from the Information Servic s Division’s (ISD) Practice Team 
Information (PTI) database to estimate COPD prevalence for Scotland. The source of this 
database is described in Chapter 3 Table 3.1. The COPD Read Code Group is a standard 
grouping used by ISD Scotland for producing statistics about COPD. It contains the 
following codes for COPD and related conditions. Unfortunately, although these codes 
substantially overlap, they are not identical to thse used for the Lothian COPD Cohort 
Database. 
Table 6.4 COPD Read Code Grouping for Practice Team Information Database 
Read 
Code 
Read Code description 
66YB. Chronic obstructive pulmonary disease monitoring 
66YB0 Chronic obstructive pulmonary disease 3 monthly review 
66YB1 Chronic obstructive pulmonary disease 6 monthly review 
66Yd. COPD accident and emergency attendance since last visit 
66YD. Chronic obstructive pulmonary disease monitoring due 
66Ye. Emergency COPD admission since last appointment 
66Yf. Number of COPD exacerbations in past year 
66Yg. Chronic obstructive pulmonary disease disturbs sleep 
66Yh. Chronic obstructive pulmonary disease does not disturb 
sleep 
66Yi. Multiple COPD emergency hospital admissions 
66YI. COPD self-management plan given 
66YL. Chronic obstructive pulmonary disease follow-up 
66YM. Chronic obstructive pulmonary disease annual review 
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66YS. Chronic obstructive pulmonary disease monitori g by nurse 
66YT. Chronic obstructive pulmonary disease monitoring by doctor 
8BMa0 Chronic obstructive pulmonary disease medication 
optimisation 
8CeD. Preferred place of care for next exacerbation of COPD 
8CMV. Has chronic obstructive pulmonary disease car plan 
8CR1. Chronic obstructive pulmonary disease clinical m nagement 
plan 
H0614 Obliterating fibrous bronchiolitis 
H3... Chronic obstructive pulmonary disease 
H30.. Bronchitis unspecified 
H300. Tracheobronchitis NOS 
H301. Laryngotracheobronchitis 
H302. Wheezy bronchitis 
H30z. Bronchitis NOS 
H31.. Chronic bronchitis 
H310. Simple chronic bronchitis 
H3100 Chronic catarrhal bronchitis 
H3101 Smokers' cough 
H310z Simple chronic bronchitis NOS 
H311. Mucopurulent chronic bronchitis 
H3110 Purulent chronic bronchitis 
H3111 Fetid chronic bronchitis 
H311z Mucopurulent chronic bronchitis NOS 
H312. Obstructive chronic bronchitis 
H3120 Chronic asthmatic bronchitis 
H3121 Emphysematous bronchitis 
H3122 Acute exacerbation of chronic obstructive airw ys disease 
H3123 Bronchiolitis obliterans 
H312z Obstructive chronic bronchitis NOS 
H313. Mixed simple and mucopurulent chronic bronchitis 
H31y. Other chronic bronchitis 
H31y0 Chronic tracheitis 
H31y1 Chronic tracheobronchitis 
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H31yz Other chronic bronchitis NOS 
H31z. Chronic bronchitis NOS 
H32.. Emphysema 
H320. Chronic bullous emphysema 
H3200 Segmental bullous emphysema 
H3201 Zonal bullous emphysema 
H3202 Giant bullous emphysema 
H3203 Bullous emphysema with collapse 
H320z Chronic bullous emphysema NOS 
H321. Panlobular emphysema 
H322. Centrilobular emphysema 
H32y. Other emphysema 
H32y0 Acute vesicular emphysema 
H32y1 Atrophic (senile) emphysema 
H32y2 MacLeod's unilateral emphysema 
H32yz Other emphysema NOS 
H32z. Emphysema NOS 
H36.. Mild chronic obstructive pulmonary disease 
H37.. Moderate chronic obstructive pulmonary disease 
H38.. Severe chronic obstructive pulmonary disease 
H39.. Very severe chronic obstructive pulmonary disease 
H3A.. End stage chronic obstructive airways disease 
H3y.. Other specified chronic obstructive airways disease 
H3y0. Chronic obstructive pulmonary disease with acute lower 
respiratory infection 
H3y1. Chronic obstructive pulmonary disease with acute 
exacerbation, unspecified 
H3z.. Chronic obstructive airways disease NOS 
Hyu3. [X]Chronic lower respiratory diseases 
Hyu30 [X]Other emphysema 
Hyu31 [X]Other specified chronic obstructive pulmonary disease 
The numbers of people consulting a GP or practice nurse at least once for a COPD Read 
Code in the time period 1 January 2011 to 31 March 2012 were extracted from the database. 
This number of visits was thought to be a reasonable proxy for prevalence because, as a 
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result of the Quality and Outcomes Framework (QOF) in the General Practice General 
Medical Services Contract 2003: people with COPD were put on a register by their General 
Practitioner and invited to attend at least once a y ar for a review.(GMC 2003) Not all the 
visits occur within a year period, however, and so a 15 month period was used. The number 
of visits was stratified by SIMD deprivation for the PTI population then mapped onto the 
Scottish population according to SIMD. This was to enable a correction for the different 
level of deprivation among the 6% of the Scottish population that fall within the PTI and the 
level of deprivation in the total Scottish population. Finally, the populations were aggregated 
into sex and five year age groupings. This was done by summing the numbers of cases across 
each five year age grouping for each sex and then dividing this by the sex specific population 
for each 5 year age grouping to produce prevalence for ach five year age group. The 
original intention had been to use sex and one year age categories, however, the numbers of 
people varied widely from year to year and could have resulted in unwarranted and 
unrepresentative fluctuations when modelled and so it was decided to use five year intervals. 
Table 6.5 COPD prevalence for Scotland 
Age group (years) Male Female 
0-4 0.002 0.002 
5-9 0.000 0.001 
10-14 0.001 0.000 
15-19 0.000 0.001 
20-24 0.000 0.000 
25-29 0.001 0.001 
30-34 0.001 0.002 
35-39 0.002 0.002 
40-44 0.003 0.004 
45-49 0.008 0.010 
50-54 0.016 0.021 
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55-59 0.028 0.030 
60-64 0.049 0.053 
65-69 0.057 0.070 
70-74 0.094 0.090 
75-79 0.097 0.084 
80-84 0.094 0.080 
85+ 0.073 0.046 
6.4.4 Proportions of the population who smoke 
6.4.4.1 England 
The General Lifestyle Survey for England 2011(ONS 2011) describes the proportion of 
smokers in fairly broad age categories. However, when compared with the data for Scotland 
and the original Dutch Model data it appears that te smoking prevalence in each age group 
were comparable and therefore I accepted that the General Lifestyle Survey for England 
estimates were valid. I had initially looked at using more granular, one year age group data 
from the Smoking Toolkit Study (West and Brown 2013), however, in older age brackets it 
appeared that too few people had completed questionnaires and there were some unusual 
patterns in the data (e.g. 50% or greater rates at very age over 75) therefore, I could not 
accept that the data were valid and decided not to use this source. 
Table 6.6 England smoking proportions from General Lifestyle Survey Data 2011 
From General Lifestyle Survey  
Smoking prevalence in England in 2011 % 










16-19 18 2 19 4 
20-24 30 10 28 7 
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25-35 26 15 21 18 
35-49 25 22 23 22 
50-59 20 27 18 24 
60 and over 14 45 12 30 
Never smoker proportions were calculated as 100%- (current smoker + former smoker). 
For younger smokers, the Health Survey for England 2010(HSE 2010) was the most recently 
published source of prevalence estimates and this was retrieved via the Economic and Social 
Data Service online portal.(ESRC 2011) Only one estimate for the age group for which data 
had been missing was available, for children age 8-15 years, but sex specific estimates were 
not available. These were used to estimate the percentage of never, current and former 
smokers for the age group 10-14 years. 
Table 6.7 Health Survey for England smoking prevalence among 8-15 year olds 
Health Survey for England 2010 from Economic 
and Social Data Service (ESRC 2011) 
Male and female combined 
Never Current Occasional 
0.974 0.017 0.002 
 
6.4.4.2 Scotland  
The data for Scotland in terms of the proportion of the population by sex and age who were 
smokers, former smokers and who have never smoked was another important input to the 
model. These data were published in the Scottish Health Survey 2011 online report, page 
119.(Bradshaw, Bromley et al. 2011) As the age groups were different to the age groupings 
in the model I contacted the Scottish Health Survey and Rosalia Munoz-Arroyo responded 




Table 6.8 Scottish Health Survey 2011, proportion of smokers by age and sex 
Scottish Health Survey 2011(Bradshaw, Bromley et al. 2011) 
 Males  Females 














0-4 1 0 0 1 0 0 
5-9 1 0 0 1 0 0 
10-14 0.9 0.03 0.07 0.79 0.03 0.07 
15-19 0.8 0.19 0.02 0.81 0.15 0.04 
20-24 0.65 0.32 0.03 0.57 0.35 0.08 
25-29 0.55 0.37 0.07 0.63 0.26 0.1 
30-34 0.53 0.31 0.16 0.59 0.24 0.17 
35-39 0.55 0.31 0.14 0.56 0.28 0.16 
40-44 0.52 0.26 0.21 0.6 0.22 0.18 
45-49 0.54 0.23 0.23 0.6 0.25 0.15 
50-54 0.45 0.27 0.28 0.54 0.25 0.21 
55-59 0.52 0.19 0.29 0.46 0.3 0.25 
60-64 0.46 0.25 0.28 0.48 0.24 0.28 
65-69 0.35 0.17 0.48 0.5 0.18 0.31 
70-74 0.43 0.12 0.45 0.55 0.11 0.34 
75-79 0.41 0.07 0.52 0.56 0.09 0.35 
80-84 0.39 0.11 0.5 0.62 0.07 0.31 




For the 10-14 age group, data came from the Scottish Schools Adolescent Lifestyle and 
Substance Use Survey (SALSUS) which was accessed online, these data were available  for 
13 year olds by sex in 2010 when the most recent survey was undertaken.(Black, Eunson et 
al. 2010) 
6.4.5 Start smoking proportions 
It was desirable to find a dataset with age and sex related proportions of people starting 
smoking in England and Scotland in any one year. Unfortunately, I was unable to find a 
current dataset. However, the Avon Longitudinal Cohort Study in 1991/2 collected this 
information on their cohort in Bristol and so I decided I would have to extrapolate these 
proportions to both the English and Scottish populations (BristolUniversity 1991). I did not 
standardise for deprivation as it was unclear which measure could be taken as representative 
for the cohort to standardise to the total populations. In addition, as the cohort was small 
relative to the total populations, any errors during standardisation would be amplified to the 
total population.  
6.4.6 Stop smoking proportions 
These were calculated from smoking quit proportions as collected by the Smoking Toolkit 
Survey, University College London.(West and Brown 2013) Dr Jamie Brown and Professor 
Robert West kindly shared their data from the questionnaires. The numbers quitting were 
stratified by one year age intervals and sex. Then t se data were converted into a proportion 
using the denominator of number of people in each age/sex strata that had been surveyed. 
Such a proportion can effectively be used as a probability of stopping smoking at that age. 
Although these data were collected in England, I decided that because they were current data 
from a large sample and so likely to have high validity, they would be representative enough 
for Scotland as well.  
6.4.7 Restart smoking proportions 
No source was found of current restart proportions f r moking quitters in Scotland or 
England. Therefore, the original data used in the Dutch Model which came from a survey 
conducted annually in the Netherlands(STIVORO 2003), were used in the English and 
Scottish projections. It was thought that this would be reasonably valid as overall smoking 
prevalences for the three countries are comparable. 37% of males and 31% of females aged 
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25-64 smoked in 2012 in the Netherlands, compared with 33% of UK males and 29% of UK 
females in this age group).(Zatonski, Przewozniak et al. 2012) 
6.4.8 Relative risks of smokers and non-smokers 
The relative risks for smokers to receive a diagnosis f COPD were the same risks as were 
used in the original model. These came from a report by the US Surgeon 
General(SurgeonGeneral 2004) and a Dutch report(Van Oers 2002). I thought that such rates 
could reasonably be transferred from the Dutch and American contexts because the risk of 
getting COPD is intrinsic to the biological mechanisms of the development of COPD from 
cigarette smoking and therefore does not change with geography. (There may be underlying 
genetic susceptibility issues in different populations in emerging research – however, as yet, 
there is insufficient data available to vary this input on this basis.) 
6.4.9 Lung function decline rate 
The Dutch Model included a lung function decline rate which had been calculated from a 
random effects model using data from 5000 Dutch COPD patients. The lung function decline 
rate was set at the same rate as had been calculated for a previous incarnation of the Dutch 
Model.(Hoogendoorn, Rutten-van Molken et al. 2005) The lung function decline rate was 
then varied in the sensitivity analyses to see how sensitive the model is to changes in this 
parameter. 
6.4.10 COPD-related maintenance costs 
The Dutch Model included a table of costs from a previous Dutch study.(Hoogendoorn, 
Feenstra et al. 2006) However, the numbers in this table show some unusual patterns. 
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Table 6.9 Original COPD direct cost input data for modelling (Euros) from Dutch 
Model report (Hoogendoorn, Rutten-van Molken et al. 2010) 
 
These are the costs for maintenance care of COPD in the community, so this includes GP 
and nurse visits and drugs. The costs of exacerbations including hospital admissions were 
modelled separately. 
Firstly, it is not clear why the costs for women were so much greater than the costs for men. 
It is also not clear why the costs varied four-fold for women and over ten-fold for men for 
the different age groups when one compares caring for the youngest age group compared 
with the oldest age group. 
The Rotterdam team encouraged me to find equivalent data by age and sex for the 
maintenance costs of COPD in Scotland and England. The “best estimate” scenario for 
generating these costs would be to undertake a micro-costing exercise. This is a skilled 
undertaking involving first the identification of typical costs for each age and sex band 
within the population. For example, the costs of drugs and GP visits and nurse visits would 
155 
 
need to be identified. Then the typical drug doses/ prescription numbers and the typical 
numbers of visits per time period would need to be counted. This often involves the use of 
detailed cohort study data. Indeed, one of the Lothian COPD Cohort’s future aims is to 
pursue a grant for a micro-costing exercise of this nature. The results of this exercise were 
not to be available until beyond the submission date for this PhD, and so it would not be 
feasible to undertake a micro-costing exercise to generate COPD maintenance cost data as 
part of the PhD. 
There remained several alternatives for generating these cost data. One option was to update 
the costs from the Dutch study using the retail price index. However, as a result of the 
problems discussed above it seemed unlikely that the distribution of these Dutch data could 
be transferred to an equivalent Scottish or English population.  
Another option was to use the available costs from an Audit Scotland report to provide 
Scottish data from 2004/5 without the correction for age and sex and to use the upper and 
lower estimates for the different regions in Scotland s a guide for setting boundaries for 
sensitivity analysis.(Matthew 2007) However, the Audit Scotland costs were not divided by 
age or by severity and so did not provide useful variability for the modelling process. 
I reviewed NICE technology appraisal cost-effectiveness analysis for the new drug 
Roflumilast.(NICE 2012) However, this only modelled severe and very severe COPD and so 
the costs for more moderate disease states are not included. 
Finally, I consulted a source of micro-costing evidnce from the cost utility analysis of 
Indacaterol.(Price, Asukai et al. 2013) This is very detailed evidence giving median and 
uncertainty range per item. However, I required the total costs per average patient and so I 
contacted the authors of the paper to see if they could share their breakdown of total 
maintenance costs per severity grouping and possibly by age. Unfortunately they had no 
information on costs by age; however, the cost dataper item was published along with 
average annual usage statistics per severity level of COPD that came either from analysis of 
a large COPD patient database or from expert opinion via a Delphi-like process. This 
allowed me to multiply cost by usage per average pati nt of each severity level and total up a 
cost per severity level, as shown in Table 6.9.
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Table 6.10 Unit costing from indacaterol study data converted to total cost per severity level (Price, Asukai et al. 2013) 


















flu vaccine 14.2 0.73 10.366 0.73 10.366 0.73 10.366 0.73 10.366 
pneumovacc  46.75 0.69 32.2575 0.69 32.2575 0.69 32.2575 0.69 32.2575 
Theophylline (no. of scripts) 3.43 0.26 0.8918 0.32 1.0976 0.73 2.5039 1.63 5.5909 
Mucolytics 21.85 0.35 7.6475 0.4 8.74 0.8 17.48 2.05 44.7925 
oral corticosteroids 8.79 0.88 7.7352 0.96 8.4384 1.7 14.943 2.7 23.733 
short acting beta agonists 5.98 3.74 22.3652 4.65 27.807 6.87 41.0826 9.78 58.4844 
Inhaled corticosteroids 12.12 0.89 10.7868 0.81 9.8172 0.71 8.6052 0.62 7.5144 
short acting antimuscarinics 10.24 0.59 6.0416 0.65 6.656 0.91 9.3184 1.19 12.1856 
leukotriene receptor antagonists 31.77 0 0 0 0 0.37 11.7549 0 0 
Pulmonary rehabilitation 1017.27 0.02 20.3454 0.03 30.5181 0.06 61.0362 0.09 91.5543 
GP visits 36 15.05 541.8 15.76 567.36 16.2 583.2 16.16 581.76 
Outpatient respiratory specialist visit 134.61 0 0 0 0 2 269.22 4 538.44 
Spirometry  51.38 1 51.38 2 102.76 2 102.76 4 205.52 
          
Total   711.617  805.8178  1164.528  1612.199 
   
157 
 
These costs did not include costs of tiotropium as th t drug was also investigated in the study 
or of home oxygen, as the study had found such costs hard to source.(Price, Asukai et al. 
2013)  
In order to validate these costs I could triangulate with the Audit Scotland costs mentioned 
above. This report put the range of costs for providing services to patients with COPD at 
£988 in NHS Tayside and £1222 in NHS Grampian. However, these Audit Scotland costs 
were largely made up from inpatient costs which were not investigated in the indacaterol 
study except for exacerbations. The exacerbations cst  are considered later in this section. 
Another source of costing evidence that came to my attention was a cost-utility analysis 
conducted for tiotropium.(Hettle, Wouters et al. 201 ) Here, costs for each disease severity 
state had been estimated by a Delphi panel consisting of four general practitioners and four 
secondary care consultants. Unit costs were obtained from the Personal Social Services 
Research Unit and NHS National Tariff 2009/2010 (as are standard to be used for micro-
costing) and usage was estimated by the Delphi panel. Th  problem arose that there were no 
costs for the mild COPD category.  
Table 6.11 Costs of managing COPD in the UK 2011 from tiotropium study.(Hettle, 
Wouters et al. 2012) 
GOLD Stage Monthly cost of managing 
COPD in the UK 2011 (£) 
Annual cost of managing 
COPD in the UK 2011(£) 
Moderate COPD 39.50 474.00 
Severe COPD 82.88 994.56 
Very Severe COPD 136.87 1642.44 
 
This costing also did not include the costs of exacrbations. This costing can therefore be 
used to validate the indacaterol costing for very svere COPD because the cost estimates 
from the two studies are similar. However, the indacaterol costings for mild, moderate and 
severe COPD are not so comparable. It seems most likely that the tiotropium study costs are 
an underestimate because they were produced by expert opinion and the indacaterol study 
used database evidence. 
In the end, I decided to use the indacaterol calculted costs per year for each severity level of 
COPD for the maintenance costs of COPD because this was the only source with an estimate 
for all four severity stages of COPD and was also the most transparent formulation of costs. 
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In terms of costs pertaining to exacerbations I used th  tiotropium study’s Delphi panel’s 
estimates for exacerbations in Scotland and England.(Hettle, Wouters et al. 2012) They 
calculated that the cost of a moderate exacerbation would be £118 and the cost of a severe 
exacerbation, i.e. one requiring hospital admission, was £3726 in England per event and 
£3329 in Scotland per event. 
6.4.11 Mean utility scores by COPD severity stage 
Utility scores are a way of estimating the reduced quality of life as a result of having COPD 
as described in Chapter 4. A person with a utility score of 1.0 has perfect health. Where 
utility scores decrease, this reflects worsening healt . Utility scores are used to calculate the 
numbers of QALYs lost as a result of people having COPD and thus the burden of this 
disease. The utility scores for COPD in the original Dutch Model were used for these 
calculations in the English and Scottish versions as no published UK-based utility 
weightings could be found. (Hoogendoorn, Rutten-van Molken et al. 2010)  
Table 6.12 Utility scores for Dutch Model (Hoogendoorn, Rutten-van Molken et al. 
2010) 
GOLD Stage Mean Utility Score (SD) 
Mild COPD 0.8971(0.1117) 
Moderate COPD 0.7551(0.2747) 
Severe COPD 0.7481(0.2991) 
Very severe COPD 0.5493(0.3129) 
 
6.4.12 Excess mortality  
The Dutch Model used a slightly complicated manipulation to calculate the excess mortality. 
In the model all-cause mortality among COPD patients was divided into “excess mortality” 
and “mortality from other causes”, where “excess mortality” was defined as the difference in 
mortality between COPD patients and the general population which includes the increased 
risk of dying from other smoking-related diseases. 
Definitions: 
M1= All cause mortality of COPD patients  
M0= All cause mortality in those without COPD 
R= relative risk of death from COPD 
p=Prevalence 




R=M1/M0 therefore M1= M0R 
 
Total population mortality= mortality in those with COPD + mortality without COPD 
       = M1p+M0(1-p) 
Substituting for M1     =M0Rp+M0(1-p) 
Factorising for M0      =M0{Rp+(1-p)} 
Rearranging  M0=total population mortality/{Rp+(1-p)} 
 
Then “Excess mortality” =(R-1)*M0 where M0 is defined as above. 
In the 2005 Dutch Model, in order to calculate thisexcess mortality, data from the original 
GPRD (UK data) were used with Poisson regression to model age and sex related relative-
risks for COPD. These were then substituted into the formulae with the Dutch total mortality 
from National Registers to obtain Dutch excess mortality. 
A similar calculation had been undertaken in 2007 to obtain UK COPD excess mortality for 
the DYNAMO-HIA project.(Lhachimi, Nusselder et al. 2012) These excess mortality figures 
were obtained to be used as a sensitivity analysis. 
However, I also decided to generate de novo estimates of the relative risks of death from 
COPD by age and sex using the available CPRD case-control database. This was because the 
original relative risks of death in the original model were over 10 years old and I believed 
that an update would more closely reflect the current isk of death from COPD given current 
treatments. A time to event analysis was undertaken using Cox-regression to generate these 
relative risks then the excess mortality by age and sex was calculated by substitution again 
into the above formulae with the prevalence data from CPRD (England) and PTI (Scotland), 
respectively. 
The CPRD case-control database was derived from CPRD data which included “up to 
standard follow up” for at least five years for inclusion in the cohort. COPD patients had 
been identified using relevant Read Codes (see Appendix 1.1 original protocol for CPRD 
COPD case-control database for a list of the relevant Read Codes). Then this file had been 
linked by a unique patient identifier number to a mortality file which included the date of 
death. The person-time each individual contributed to the cohort was calculated and an 
analysis conducted from time of inclusion to time of either event or censoring (when data 
ceased to be submitted to CPRD for that specific pra tice). 
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The results for the coefficients in the modelling equation are shown in Table 6.12. The 
parameters were age (AGEA), sex (GENDERA) and a marker as to whether the patient had 
COPD or not and interaction terms (AGEGENDER, AGECOPD, GENDERCOPD, 
GENDERCOPDAGE). The outcome was death over the total time for which data were 
available. The coefficient with the most influence on whether or not a patient died was 
whether the patient had a diagnosis of COPD (odds ratio 9.4). 
Table 6.13 Parameters for Cox Regression Model of COPD patient survival 
 B SE Wald Df Sig. Exp(B) 
GENDERA -.894 .228 15.352 1 .000 .409 
AGEA .054 .002 835.708 1 .000 1.055 
AGEGENDER .008 .003 8.946 1 .003 1.008 
AGECOPD -.018 .002 62.812 1 .000 .982 
GENDERCOPD .458 .277 2.739 1 .098 1.581 
GENDERCOPDAGE -.005 .003 2.231 1 .135 .995 
Marker 2.245 .185 146.713 1 .000 9.441 
These coefficients were then used to calculate relativ  risks for patients in the middle of each 
five year age bracket by multiplying out the model for every x. Where x was a patient of a 
specific age and gender (gender=1 for females and ge er =0 for males) and COPD marker 
(1=COPD, 0=no COPD). 
Hazard at age and sex x= e(BMarkerx * BGENDERAx * BAGEAx *BAGEGENDERx * BAGECOPDx * BGENDERCOPDx * 
BGENCERCOPDAGE) 
Relative risk was calculated by finding the risk (or hazard) at age and sex x with COPD then 
dividing this by the risk at age and sex x without COPD. 
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Table 6.14 Age specific relative risk of dying per year if patient has COPD compared 







40-44 4.39 5.62 
45-49 4.01 5.01 
50-54 3.67 4.46 
55-59 3.35 3.98 
60-64 3.06 3.54 
65-69 2.80 3.16 
70-74 2.56 2.82 
75-79 2.34 2.51 
80-84 2.14 2.24 
85+ 1.95 1.99 
 
Then these relative risks were combined with the total mortality (all-cause mortality) from 
the ONS(England) for 2011 and the GROS(Scotland) for 2011 according to the above 
formulae and each 1 year age and sex interval in order to generate the excess mortality. I 
used the modelled excess mortality from these smoothed relative risks for England and 
Scotland base cases (i.e. run of the model without sensitivity analysis). Then the UK 
modelled excess mortality as used in the DYNAMO-HIA study as a sensitivity analysis.  
6.5 Strengths and limitations of datasets 
Table 6.15 Strengths and limitations of datasets 






dataset from primary 
care in England 
Routine data so quite “messy” 
(some miscodes, some terms 
included in free text so not 
captured by codes) Also see 
Chapter 3 section on validity for 
the representativeness of this 
dataset compared to the national 
population. Charged for work 
done to produce estimates. 





COPD specific dataset, 
only available 
incidence data, not 
charged for use.  
Also routine data. Only derived 
from Lothian, so needed SIMD 
corrections to produce estimates 




Able to give COPD 
estimates specific to 
Scotland, cheaper than 
CPRD. 
Also routine data. Uses 
consultation rates as proxies for 
prevalence. Does not include 
whole Scottish population (only 
6% representative sample). 





2011(ONS 2011)  




Research quality data, therefore 
high quality, 15,000 interviews, 
therefore small sample compared 
to population. 
Avon Longitudinal 




Only source of start 
smoking rates 
available in UK for 
males and females 
(parents of the children 
who were born). 
Research grade data. Based on 
14,541 pregnancies, so relatively 





Only source of up to 
date quit smoking rates 
in UK.  
Large sample size (139000 
smokers and non smokers) is still 
a relatively small section of the 




Bromley et al. 
2011)  
Largest survey 
available in Scotland, 
data easier to interpret 
than Primary Care 
Record data. 
Research grade data. 7245 Adult 
interviews is a small sample 
compared with the whole 
population of Scotland. 
 
6.6 Conclusion to Chapter 6 
This chapter has described the selected Dutch Model. It is a Markov multi-state model and 
models a population cohort progressing through their lif times with and without COPD. This 
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description was followed by an initial overview and then a detailed description of the data 
inputs to the Dutch Model required for English and Scottish versions of the model. The 
governance and permissions required for specific datasets were described.  
The next chapter contains the results of the modelling process and the sensitivity analyses. 
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Chapter 7: Modelling process and results 
7.1 Introduction 
The previous chapter introduced the Dutch Model and gave details of the data inputs 
required to run this model for England and Scotland. This chapter will describe the 
modelling process then detail the results in terms of population, costs and mortality for the 
deterministically modelled base case scenario and the sensitivity analyses. Then the 
uncertainty intervals for the results will be discused and presented. 
7.2 Modelling process 
The Dutch Model was set to run in Wolfram Mathematica version 9 (Wolfram 2013) on a 
Windows 7 laptop. This is a mathematical programme that enables computational analysis 
and modelling with large datasets. The code for the Dutch Model was loaded from the 
Rotterdam team’s source onto the laptop. Then the programme was instructed to seek the 
relevant input data files from the laptop’s directories.  
The base case model was run using a deterministic process with the data inputs as detailed in 
Chapter 6. The model was run once with English datafor the English base case and once 
with Scottish data for the Scottish base case. 
Sensitivity analyses were then performed. These enabl d me to see the impact of making 
changes to the input of the model on the output of the model. It is important to do this in 
order to understand the sensitivity of the outputs to changes in the inputs as this sensitivity is 
an effect of the Model’s intrinsic structure. The 10 sensitivity analyses shown in Table 7.1 
were run for both England and Scotland. 
These analyses were all run as one way sensitivity analyses where one input parameter was 
changed in one direction (i.e. either increase or dec ease) at a time. 
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Table 7.1 One way sensitivity analyses for Dutch Model projections from 2011 to 




1 Prevalence Increased by 10% 
2 Prevalence Decreased by 10% 
3 Incidence Increased by 10% 
4 Incidence Decreased by 10% 
5 Mean annual decline in lung function Increased by 10% 
6 Mean annual decline in lung function Decreased by 10% 
7 Severity distribution of baseline prevalence More severe cases 
8 Severity distribution of baseline prevalence Less severe cases 
9 Use DYNAMO-HIA data for excess mortality N/A 
10 Smoking quit rate increased to 10% at each age N/A 
 
7.3 Results of modelling base case scenario 
7.3.1 England: COPD population results 
The population with COPD was calculated in life-years. The number of life-years in any one 
year can be taken as the mid-year (June) number of people with COPD for that year. The 
populations for England and Scotland were given to the nearest thousand. 
Using the Dutch Model, I estimated that in 2011 there were a total of 952,000 people with 
diagnosed COPD in England (480,000 males and 473000 females, 274,000 of whom were 
current smokers). The first year calculation (2011) was a straightforward demographic 
calculation where the prevalences for COPD were mapped onto the population in each one 
year age group for males and females. The modelling e ement only becomes functional in 
years beyond the first year where increases in COPD population are dictated by smoking risk 
and COPD incidence year on year. The COPD population increased to 1.35 million people 
by 2030 of whom there were 616,000 males and 734,000 females (419,000 smokers), see 
Figure 7.1 for the modelled population over this period. 
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Figure 7.1 Modelled population of males and females with COPD in England 
 
7.3.2 England: overall prevalence results  
The model projected that the overall prevalence of diagnosed COPD among over 40 year 
olds would rise from 3.6% in 2011 to 4.5% in 2030. This involved an increase from 3.8% in 
2011 among males over 40 to 4.3% in 2030. The change in COPD prevalence among 
females over 40 years of age was from 3.4% in 2011 to 4.6% in 2030. This represented a 
0.5% increase among males and a 1.2% increase among females in the over 40 years age 
group. 
7.3.3 England: age-related prevalence 
Figures 7.2 and 7.3 show the age-specific prevalence, as modelled by the Dutch Model, of 
males and females in England and how it is anticipated to change between 2011 and 2030. 
Note that the y-axis is comparable across both figures and that the units are percentage of 
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Figure 7.2 Age-specific prevalence of males with COPD in England 
 
It can be seen that in most age categories in males the age-specific prevalence was relatively 
stable. In fact, in the oldest age category there may be a reduction in prevalence of COPD 
between 2011 and 2030. 
Figure 7.3 Age-specific prevalence of females with COPD in England 
 
In England in 2011, the age specific prevalences were mostly lower among females than 
among males (see Figure 7.2). However, the prevalences were projected to be comparable 
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7.3.4 England: direct healthcare costs from COPD  
The total annual costs of COPD in England were projected to increase from £1.489 billion in 
2011 to £2.275 billion in 2030. These costs are in t rms of 2011 costs without the application 
of any economic trends (no annual increase applied for inflation). 
These costs were made up of maintenance costs: that increased from £818 million in 2011 to 
£1.241 billion in 2030, and costs of caring for moderate and severe COPD exacerbations, as 
shown in Figure 7.4. A moderate exacerbation involved contact with the doctor for 
deterioration in symptoms, a severe exacerbation involved a hospital admission by 
definition. 
Figure 7.4 Modelled costs for COPD in England 
 
 
7.3.5 England: number of deaths  
The number of deaths among people with COPD was modelled to be 96,000 in 2011, then to 
fall slightly over the next few years as the model stabilised, then gradually increase again to 
134,000 people with COPD in 2030, see Figure 7.5. These reflect estimates of all-cause 
mortality among people with COPD and therefore these figures cannot be equated with 
COPD recorded on the death certificate. These estimates come from the increased relative 
risk of dying with COPD due to COPD or other diseases which was extracted by Cox 
regression from the CPRD database and used to calculate the excess mortality. The excess 
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deaths of COPD patients from all causes. This process was more fully explained in Section 
6.4.12.  
Figure 7.5 Number of deaths among people with COPD in England from all causes 
 
 
7.3.6 Scotland: COPD population 
In Scotland, in 2011, there were estimated to be a total of 108,000 people with COPD 
(49,000 males and 60,000 females, 33,000 of whom were smokers). This was projected to 
increase to 128,000 people by 2030, of whom there wr  55,000 males and 73,000 females 
(39,000 smokers), see Figure 7.6. 
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7.3.7 Scotland: overall prevalence results  
The prediction for Scotland was that the prevalence among the over 40 year olds was 4.0% 
in 2011 and that this would rise to 4.5% by 2030. This involved an increase from 4.1% to 
4.8% among females over 40; however, among males ovr 40, the prevalence was more 
stable at 3.9% increasing to 4.1%. 
7.3.8 Scotland: age-specific prevalence 
Figures 7.7 and 7.8 show the age-specific prevalence, as modelled by the Dutch Model, of 
males and females in Scotland and how it changes between 2011 and 2030. Note that the y-
axis is comparable across both figures and that the units are percentage of population with 
COPD in that age group. 
Figure 7.7 Age-specific prevalence of males with COPD in Scotland 
 
 
Figure 7.7 demonstrates that the prevalence of COPD in every age group in males is 
projected to remain roughly stable in Scotland with some decrease in the oldest age group. 
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Figure 7.8 Age-specific prevalence of females with COPD in Scotland 
 
 
Figure 7.8 shows that the prevalence of COPD among female younger age groups is 
estimated to fall between 2011 and 2030 in Scotland. However, among the older female age 
groups, the prevalence was projected to increase, even above the level of prevalence seen for 
males in those age groups. 
7.3.9 Scotland: direct healthcare costs from COPD 
The total annual direct healthcare costs of COPD in Scotland were estimated to increase 
from £163 million in 2011 to £207 million in 2030. These costs are, again, in terms of 2011 
costs without the application of any economic trends.  
In 2011, COPD maintenance costs in Scotland were estimated to be £93 million and this was 
projected to rise to £117 million in 2030. 
The composition of total costs in terms of maintenance costs and costs of caring for 
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Figure 7.9 Modelled costs for COPD in Scotland 
 
 
7.3.10 Scotland: number of deaths results 
Deaths among COPD patients for Scotland were projected to be stable over the next 3-4 
years from 2011 then rise steadily. In 2030 there were projected to be 14,000 deaths among 
people with COPD from all causes, having risen from 10,000 in 2011. 
Figure 7.10 Number of deaths among people with COPD in Scotland from all causes 
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7.4.1 Sensitivity analyses for England 
The following Tornado diagram (Figure 7.11) shows the results of the modelling multiple 
one-way sensitivity analyses on the projected number of people diagnosed with COPD in 
2030, in England. 
Figure 7.11 Sensitivity analyses for England, vertical line represents base case 
 
This Tornado diagram (Figure 7.11) shows the results of he sensitivity analyses. Increasing 
and decreasing prevalence by 10% had only a limited effect on the number of people with 
COPD in England in 2030. However, increasing and decreasing incidence by 10% had much 
more impact on the number of people with COPD in Engla d in 2030. The model was, 
therefore, much more sensitive to changes in incidee than prevalence. The sensitivity of 
the model to changes in the mean annual decline in lung function and to changes in the 
distribution of severity of COPD at baseline was much less than the sensitivity of the model 
to changes in incidence and slightly less than the sensitivity of the model to changes in 
prevalence.  
Using the DYNAMO-HIA estimates for excess mortality greatly increased the mortality of 
people with COPD resulting in many fewer people with COPD in 2030. This is not 
surprising as the excess mortality estimates for COPD from DYNAMO-HIA were much 
higher than the excess mortality estimates that I derived from the CPRD data. The reasons 
for this difference are not clear but may be because these estimates are considerably older 
(from DYNAMO-HIA data gathered in the 1990s) when prognosis with COPD was worse 
due to lack of treatment. The prognosis also appeared to be worse because fewer milder 
cases were diagnosed as COPD than in the current figures. Milder cases live longer affecting 
the excess mortality figures from the current figures.  
1100000 1200000 1300000 1400000 1500000
Quit rate increased to 10%
DYNAMO-HIA for excess mortality
Distribution of severity at baseline
prevalence more severe/milder
Mean annual decline in lung function +/-
10%
Incidence decrease or increase by 10%
Prevalence decrease or increase by
10%
Prevalence
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Increasing the quit rate of smokers to 10% within each one year age category resulted in a 
slight decrease in the numbers with COPD due to fewer smokers, therefore fewer people 
developing COPD. However, the model demonstrated that overall numbers of COPD are not 
very sensitive to an increase in quit rate to 10% at all ages. This is because in some age and 
sex groups (e.g. females of reproductive age) quit rates are almost 10% already, so it is not a 
great increase in quit rate for all age groups. 
7.4.2 Sensitivity analyses for Scotland 
Figure 7.12 shows the results of the modelling multiple one-way sensitivity analyses on the 
projected number of people diagnosed with COPD in 2030, in Scotland. 
Figure 7.12 Sensitivity analyses for Scotland, vertical line represents base case 
 
The sensitivity analyses for Scotland show a similar pattern to those for England, with the 
model being more sensitive to changes in incidence than prevalence and not very sensitive to 
changes in the mean annual rate of decline in lung f ction or changes in the distribution of 
severity of the baseline prevalence of COPD. 
Again, the DYNAMO-HIA estimates for excess mortality resulted in many more people 
estimated to be dying with COPD than the estimates from the CPRD dataset (see Chapter 6). 
This resulted in a much reduced population with COPD in 2030. 
There was only a very small effect of increasing the quit rate for smoking to 10% in each one 
year age category. This is because smoking quit rates are approaching 10% in many age 
categories already according to the data collected by the Smoking Toolkit Study (see Chapter 
6). However, the model did demonstrate that increasing the smoking quit rate would have the 
110000 120000 130000 140000 150000
Quit rate increased to 10%
DYNAMO-HIA for excess mortality
Distribution of severity at baseline
prevalence more severe/milder
Mean annual decline in lung function +/-
10%
Incidence decrease or increase by 10%
Prevalence decrease or increase by 10%
Number of people with COPD 
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desired public health effect of reducing the overall number of people with COPD. The fact 
that the results are consistent with this effect helps to validate the model. 
7.5 Uncertainty limits for results 
Uncertainty limits for the results were calculated by my colleagues in Rotterdam. I helped in 
an intermediate step by preparing data. The method of doing this was the same as the method 
that they had used to produce uncertainty estimates in their 2011 paper.(Hoogendoorn, 
Rutten-van Molken et al. 2011) 
The first part of calculating uncertainty limits involved using the raw data for incidence, 
prevalence, and excess mortality to generate 200 smoothed curves for each of incidence, 
prevalence and excess mortality for both England and Scotland which were consistent with 
the probability distributions of the original data. This minimises the impact of the 
“messiness” of raw gathered data on the uncertainty estimates. That is: some chance findings 
may not fit the underlying pattern and would have a disproportionate effect when the next 
step in developing uncertainty intervals is taken. This method helps to clarify the research 
data’s underlying pattern. The method for doing this is explained in Appendix 5 by Dr 
Rudolf Hoogenveen, the mathematician who did this work.  
This generated 200 potential input files for each parameter of incidence, prevalence and 
excess mortality. The model was then set to run 1000 times picking randomly from these 
input files. The 1000 results from the Model’s runs were then arranged in order, and the 
values at 2.5% and 97.5% were recorded because these values contain 95% of the predicted 
values of the results from the Model. These “uncertainty intervals” are shown in the table 
below: 
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Table 7.2 Uncertainty intervals for outputs from the Dutch Model for England 

































Costs  £1.18 billion £2.50 billion £1.85 billion £3.08billion 
Number of 
deaths 
92,504 128,511 126,350 133,431 
 
Table 7.3 Uncertainty intervals for outputs from the Dutch Model for Scotland 
































Costs  £128 million £268 million £165 million £274 million 
Number of 
deaths 
9,000 12,281 13,418 14,548 
 
These uncertainty intervals are all quite broad, in particular for costs, where the upper limit 
for costs in 2011 overlaps with the lower limit forcosts in 2030, thus giving the theoretical 
possibility that costs could decrease, although this seems unlikely given the direction of all 
other parameters. 
7.5.1 Point estimates and overall prevalence 
Up until now, I have been reporting point estimates from the deterministic base case and 
sensitivity analyses which were modelled initially by me in Rotterdam. However, with the 
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benefit of the smoothed base case and uncertainty estimates it is possible to give a better 
point estimate, taking this information into account. Therefore, in Table 7.4, I report the 
mean of the 1000 runs for the uncertainty calculation as the point estimate along with the 2.5 
and 97.5 percentile estimates. Table 7.4 also shows the prevalence results from the 
modelling study with the overall projected prevalenc  of COPD in England and Scotland 
calculated from the ONS population projections (ONS 2012).  
Table 7.4 Overall numbers of people with COPD, the population size and 
prevalence of COPD in 2011 and 2030 in England and Scotland (uncertainty 
intervals from Tables 7.2 and 7.3, with probabilistic mean) 
 England Scotland 
Males with COPD in 2011 (all 
ages) 
479,423 47,891 
Total male population in 2011 
(Census 2011) 
26,133,162 2,548,200 
Prevalence (%) 1.8(1.8-1.9) 1.9(1.8-1.9) 
Males with COPD in 2030 (all 
ages) 
595,274 53,370 
Total male population in 2030 
(from ONS 2012 
projections(ONS 2012)) 
30,076,000 2,789,000 
Prevalence (%) 2.0(1.7-2.1) 1.9(1.7-2.1) 
Females with COPD in 2011 (all 
ages) 
472,812 58,843 
Total female population in 2011 
(Census 2011) 
26,974,007 2,706,600 
Prevalence (%) 1.8(1.7-1.8) 2.2(2.1-2.3) 
Females with COPD in 2030 (all 
ages) 
728,465 71,834 
Total female population in 
2030(ONS 2012) 
30,334,000 2,901,000 
Prevalence(%) 2.4(2.0-2.6) 2.5(2.1-2.7) 
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7.6 Conclusion to Chapter 7 
This chapter has described the modelling and sensitivity analyses undertaken for this PhD. 
The results of the modelling were given separately for England and Scotland. The dynamic 
population projection results were presented, followed by the prevalence, the costs and the 
number of deaths. The results of the sensitivity analyses for England and Scotland are 
detailed in Tornado diagrams. Finally, the uncertainty limits for the major results are 
presented. The strengths and limitations of this work, the interpretation of the results, and 
their implications for policy, practice and further r search will be discussed in the 
concluding chapter of this thesis. 
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Chapter 8: Discussion 
8.1 Introduction 
In this final chapter I draw together and interpret the findings from this PhD. Firstly, I 
summarise the principal findings of the systematic review and modelling studies, then I 
discuss their strengths and weaknesses. I next consider the findings of the PhD in relation to 
other published work. I explore the interpretation of the PhD followed by a discussion of its 
implications for clinicians and policymakers. Finally, I consider the implications of the PhD 
in terms of what future relevant research needs to be done. 
8.2 Statement of principal findings  
8.2.1 Principal findings from the systematic review  
This is the first work to systematically review models for calculating the prevalence and 
burden of COPD. I identified 22 relevant models(Bronnum-Hansen and Juel 2000; Stang, 
Lydick et al. 2000; Feenstra, van Genugten et al. 2001; Shibuya, Mathers et al. 2001; van 
Genugten, Hoogenveen et al. 2003; Hoogendoorn, Rutten-van Molken et al. 2005; Peabody, 
Schau et al. 2005; Chapmann, Mannino et al. 2006; Lopez, Shibuya et al. 2006; Hurley and 
Matthews 2007; Nacul, Soljak et al. 2007; IHME 2010; Atsou, Chouaid et al. 2011; Holt, 
Zhang et al. 2011; Hoogendoorn, Rutten-van Molken et al. 2011; Pichon-Riviere, 
Augustovski et al. 2011; Erbas, Ullah et al. 2012; Lhachimi, Nusselder et al. 2012; 
Najafzadeh, Marra et al. 2012; Perera, Armstrong et al. 2012; Pham, Ozasa et al. 2012; 
Stanciole, Ortegon et al. 2012). These models were very varied and context specific w th 
some specifying the burden of COPD in DALYs and QALYs and others using population 
and cost measures. The models were scored for their quality of reporting. Seven models, 
described in the following nine papers (Feenstra, van Genugten et al. 2001; Shibuya, 
Mathers et al. 2001; Barendregt, Van Oortmarssen et al. 2003; Hoogendoorn, Rutten-van 
Molken et al. 2005; Peabody, Schau et al. 2005; Atsou, Chouaid et al. 2011; Pichon-Riviere, 
Augustovski et al. 2011; Kulik, Nusselder et al. 201 ; Lhachimi, Nusselder et al. 2012) 
scored highly on the quality of reporting framework.(McLean, Wild et al. 2013) Their high 
quality of reporting enabled an assessment to be made of the actual quality of modelling 
within these seven models. 
Three studies (Feenstra, van Genugten et al. 2001; Hoogendoorn, Rutten-van Molken et al. 
2005; Hoogendoorn, Rutten-van Molken et al. 2011) were closely related as versions of the 
same model and I had the opportunity to collaborate with the Dutch team who had produced 
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these studies and use their most up to date model fr projecting the prevalence and burden of 
COPD in England and Scotland. The model used routine data from primary care health 
records including incidence and prevalence rates of COPD as described in Chapter 6; 
estimates are therefore based on diagnosed COPD. 
8.2.2 Principal findings of modelling study 
The Dutch Model demonstrated an increase in the population with COPD in England and 
Scotland between 2011 and 2030. In England, the model projected that the overall 
prevalence of diagnosed COPD among the over 40 year olds would rise from 3.6% in 2011 
to 4.5% in 2030. In Scotland, the estimated prevalence among the over 40 year olds was 
4.0% in 2011 and this was projected to rise to 4.5% by 2030. This increase in prevalence was 
chiefly due to an increase in the numbers of older people with COPD, in particular females 
over 65 years of age.  
Using the probabilistic means and uncertainty intervals, the total annual direct healthcare 
costs of COPD in England were projected to increase from £1.60 billion (95% uncertainty 
interval 1.18-2.5) in 2011 to £2.35 billion (1.85-3.08) in 2030. And in Scotland, costs were 
projected to increase from £170 million (128-268) in 2011 to £210 million (165-274) in 
2030. These costs are in terms of 2011 costs without e application of any economic trends 
(i.e. no annual increase applied for inflation).  
Again using probabilistic means and uncertainty intervals, the number of deaths among 
people with COPD in England was modelled as 99,181 (92,504-128,511) in 2011, increasing 
to 129,428 (126,350-133,431) in 2030. In Scotland there were modelled to be 9,734 (9,000-
12,281) deaths in 2011, increasing to 13,896 (13,418-14,548) in 2030. 
The Dutch Model suggested a 39% increase in the number of people with COPD in England 
and a 17% increase in Scotland between 2011 and 2030. It modelled a 30% increase in 
deaths among people with COPD in England and a 43% increase in Scotland. Overall, there 
was an estimated 46% increase in the direct healthcare costs required to care for people with 
COPD in England and a 23% increase in Scotland between 2011 and 2030.  
8.3 Comparison of modelling results from England wi th 
results from Scotland 
There are interesting differences between the results of the modelling for England and 
Scotland. Both England and Scotland prevalence results reveal that there will be a 
predominance of females with COPD by 2030. However, in comparing figures 7.1 and 7.6, it 
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can be seen that the predominance of females with COPD appears to be established in 
Scotland, however, it is still emerging in England. There is some evidence that this may be a 
real difference from the smoking patterns in the two countries, however, it must also be 
explored whether the difference is artefactual, due to differences in the input data for the two 
countries. 
8.3.1 Female COPD predominance, differences between  England and 
Scotland, evidence from smoking habits 
Comparing the smoking habits of males and females in England and Scotland by graphing 
the prevalence of smokers from tables 6.5,6.6 and 6.7, a pattern emerges. In figure 8.1, it can 
be seen that males from the two countries have an approximately similar prevalence of 
smoking at different ages, with the overall prevalence slightly higher in Scotland, especially 
at younger ages. 
Figure 8.1 Age related prevalence of smoking in England and Scotland in males 
 
 
This is different to figure 8.2, which shows the prvalence of smoking in England and 
Scotland in females. This demonstrates a markedly greater prevalence among females in 
Scotland compared with females in England in the key age group for the development of 
COPD of 45 to 75 year olds. As this age group will be composed of established smokers, this 
suggests that the COPD female predominance is already established in Scotland and is partly 
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Figure 8.2 Age related prevalence of smoking in England and Scotland in females 
 
8.3.2 Female COPD predominance, differences between  England and 
Scotland, differences in baseline input prevalence 
Before it can be concluded that the early predominance of females in Scotland compared 
with England is a real difference, it is important to review any evidence that it may in fact be 
an artefactual difference. Due to the differences in data used in the modelling process. 
Whereas the above smoking data for both countries came from broadly equivalent survey 
sources, the General Lifestyle Survey in England and the Scottish Health Survey in Scotland, 
the data used for the prevalence at the baseline of the model was quite different between 
England and Scotland. CPRD data was used for England and PTI consultation data was used 
for Scotland. The fact that the Scottish PTI dataset was based on consultation rates may bias 
this data. The reason for this is that there is a body of evidence which shows that females are 
heavier users of healthcare services than men.(Hunt, Ford et al. 1999; Bertakis, Azari et al. 
2000; Wang, Hunt et al. 2013) This may result in the calculation of a higher prevalence for 
COPD among females in Scotland compared with the CPRD England data. 
The reason for using PTI data rather than CPRD data for the prevalence in Scotland was 
down to cost restrictions. It should also be noted that there were some slight differences in 
the Read codes used to extract data from PTI and from CPRD, (see table 6.3 and Appendix 
1.1). In addition, the definition used from CPRD was lifetime point prevalence, whereas in 
PTI it was a 15 month consultation prevalence. In order to see the impact using these 
different data may have had, the following graph compares the baseline prevalence rates 
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Figure 8.3 Age related prevalence at baseline in England and Scotland 
 
It can be seen that in England the CPRD data clearly shows a higher prevalence of COPD 
among males at baseline, than among English females. Whereas in Scotland, up until the age 
of 70 the prevalence is higher among females than mles. This could clearly be artefactual 
due to the data being based on consultation rates. Therefore one of the limitations of this 
modelling study is that the baseline 2011 results for Scotland may be biased due to the 
source of the prevalence data. However, as the model c ntinues to run the impact of this bias 
will be attenuated as a result of the effects of the input data for incidence having greater 
impact as shown in the sensitivity analysis. See 7.4.1 and 7.4.2. 
8.3.3 Differences between England and Scotland, dif ferences in relative 
increases over 20 years 
The above section compared the differences in prevalence at baseline, however, over the 
course of running the model comparisons can be made in th  absolute increases of males and 
females with COPD. There appears to be something strange happening when you consider 
these absolute and relative increases over the time to 2030. The relative increase for English 
males and females is 24% and 54% respectively. The relative increase for males and females 
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Table 8.1 Absolute and relative differences in increases in the COPD population 
 2011 2030 Absolute 
increase 
Increase as % 
of 2011 value 
England males 479423 595274 115851 24 
England females 472812 728465 255653 54 
Scotland males 47891 53370 5479 11 
Scotland females 58843 71834 12991 22 
 
Initially I thought that these differences could be caused by higher smoking rates among 
English females, however, the opposite is true, English females have the lowest smoking 
rates and Scottish males have the highest rates. Se figure 8.4. The effects of these smoking 
rates are that females in England experience lung fction decline and COPD related 
mortality later on in their life than males in Scotland. Males in Scotland, in contrast die 
younger as a result of their heavy smoking and so are not prevalent with COPD for as long. 
It should also be noted that among the age groups over 70 there are fewer people within each 
demographic category and so the effect on the COPD absolute numbers comes from the 
largest demographic categories age 30-65. 
Figure 8.4 Age related smoking prevalence in England and Scotland (a combination 
of figures 8.1 and 8.2) 
 
The impact of this pattern of smoking is enhanced in the model’s projections by the impact 
of the COPD related excess mortality. English females have the lowest rate of excess 
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excess mortality (due to their high rate of smoking). The different levels of excess mortality 
are compared in figure 8.5. 
Figure 8.5 Age related COPD excess mortality per 1000 population. 
 
 
As the sensitivity analyses showed that the model was most sensitive to the input of excess 
mortality in terms of the output of absolute numbers of population, it is, therefore, not 
surprising that the pattern of high excess mortality mong males in Scotland and low excess 
mortality among females in England results in the above respective increases in absolute 
numbers of population. (i.e. 54% for females in Engla d and 11% for males in Scotland). 
Note that although the pattern of excess mortality for those over 90 changes in the above 
graph this has little effect on the absolute number with COPD because there are few people 
alive in this age group. 
8.4 Strengths and limitations 
8.4.1 Strengths and limitations of the systematic r eview 
The strengths of the systematic review include that a protocol was developed and registered 
in advance and that I used a highly sensitive search st ategy. I searched Medline, Embase, 
CAB Abstracts, World Health Organization (WHO) Library and Information Services 
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LILACS), (AMR/PAHO), IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO)) and 
used a modified search strategy to identify reports from the WHO home website and Google. 
I updated the searches in November 2013. There were no language restrictions employed 
when undertaking searches. The selection of studies and data extraction was checked by a 
second person as per established systematic review methods. Furthermore, a formal approach 
to assessing reporting quality was used.(McLean, Wild et al. 2013) 
The limitations of the systematic review include that by preliminary assessment of the 
quality of reporting of studies I may have excluded a study that was of high quality, but not 
appropriately reported. There is some potential for this to have happened as I could not find a 
suitable report of the WHO Burden model DISMOD 3 (IHME 2010) to assess its quality.  
In addition, I did not undertake an in-depth critical review of the 22 models identified. This 
limitation is in part due to modellers not fully disclosing their modelling techniques in the 
reporting papers. Also, I did not have the mathematical skill set to fully evaluate the 
mathematical properties of the models. 
I would also like to comment on the limitations of using a quality of reporting scoring 
checklist. This type of scoring checklist which assign  a numerical score to different 
elements of the study was previously often used by systematic reviewers including those 
who worked for the Cochrane collaboration. However, more recently raw numerical scores 
have fallen out of Cochrane’s favour due to their prception that it is not logical to “sum up” 
technically diverse elements of a study in this way and also that such summing allows high 
performance in one area to have the potential to disguise fatal deficiencies in another. 
Cochrane replaced numerical sum scores with a system of scoring separate categories for 
potential risk of bias and then giving an overall summary impression for the study as to 
whether it was at high, moderate or low risk of bias. This system involves a loss of 
granularity of information when the categories are summarised. As the purpose of using a 
scoring system in this thesis was to identify the “b st” study, I would argue that maintaining 
a numerical aspect to the categorisation was helpful in enabling me to discriminate between 
studies. However, I do concede that the logic of summing scores for separate technically 
diverse elements is, at best, somewhat fuzzy. Therefor  the use of the quality scoring system 
in this thesis should be seen as a compromise methodology. However, I would argue that 
Cochrane’s current risk of bias scores have not negated completely the need to summarise 
across diverse technical elements and still maintain a degree of fuzziness in the process, and 
so I am in good company in having to choose a comprise. 
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8.4.2 Strengths and limitations of modelling study  
The strengths of the modelling study include the car ful selection of the Dutch Model. 
Having the opportunity to work alongside the team that developed the model enabled me to 
acquire a deep understanding of the model. The high validity of the data sources used to 
enter into the model is an additional strength. (See Chapter 6 discussion of the strengths and 
weaknesses of the original data sources). The model was also thoroughly tested using 
sensitivity analyses, which can also be regarded as a strength. 
In addition, another strength is the fact that both modelled COPD prevalence for England 
and Scotland in 2030 among the over 40 year olds were anticipated to be 4.5% despite 
slightly different starting points. These similar results can be taken as cross-validation of the 
modelling process because in these two countries with similar prevalences of smoking and 
demographic distributions, the model, run on these two separate but similar sets of data, 
produces similar results.  
Limitations of the modelling study include that no further predictive validation was possible 
for the population or mortality data. Ideally, comparisons would be made with another 
source of projections. However, projections for Engla d (ERPHO, Walford et al. 2011) 
which might have provided a comparison are for rates of diagnosed and undiagnosed COPD, 
as described in Chapter 2. The alternative is to compare the projections with true count data 
as they are gathered, year upon year, as time goes on. 
It is also important to consider the validity of the data that were employed in the modelling 
study. In Chapter 6, I described each of the data sources and the efforts that were made to 
select data sources of high validity. In Section 3.3.1, I detailed the relevant validation work 
done on the CPRD database by Campbell et al. (Campbell, Dedman et al. 2013) which 
indicated that overall the CPRD database may contain a group that is older than the general 
UK population. The implications of this difference for the modelling study is that prevalence 
of COPD may be higher among the older CPRD database cohort than among the general UK 
population, leading to an over-estimate of the English prevalence of COPD by the model. In 
addition, there are implications for the mortality f gures. If mortality is lower among the 
CPRD cohort including among COPD patients in the CPRD cohort than among the whole 
population then the modelling of the excess mortality w ll result in a lower estimate of the 
excess mortality due to COPD and a consequently higher prevalence of COPD from the 
model. However, the differences in the ages of the CPRD GOLD database compared to the 
whole population found by Campbell et al. were relatively minor in proportion. 
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Another limitation to be highlighted is the inevitable compromises that occur when 
expressing real-world populations as models. Represnting the COPD population of one or 
more countries in the form of a Markov model results in an inevitable compromise on 
information The model represents a caricature of disease progression and although the Dutch 
model is complex and even includes parameters for some patients to recover some lung 
function if they quit smoking it cannot fully repres nt the real-world situation. One of the 
areas where most information is compromised in this model is the characterisation of COPD 
severity on the basis of airflow limitation alone. As mentioned in chapter 2, the 2013 GOLD 
rubric for classification of severity of COPD has been amended to include a consideration of 
symptoms and exacerbations in addition to airflow limitation.(GOLD 2013) These GOLD 
guidelines have also highlighted the need to consider co-morbidities when classifying the 
severity of people with COPD. However, such updating can result in simply shifting the 
compromises to different areas, for example, it has been shown that although the 2013 
GOLD classification is better than the 2007 classification for predicting exacerbations, it is 
worse at predicting mortality and lung function decline.(Goossens, Leimer et al. 2014)It is 
inevitable that all models are compromises, however, when carefully used, with the 
appropriate caveats they remain useful tools.  
8.5 Interpretation of the results of this study in the context of 
previous research 
8.5.1 The shape of the smoking epidemic 
A schematic diagram describing the smoking epidemic in developed countries was originally 
suggested in 1994.(Lopez, Collishaw et al. 1994) This diagram was updated in 2012 (Figure 
8.1) and shows the epidemic’s shape (Thun, Peto et al. 2012). Stage 1 is the beginning of the 
epidemic when smoking prevalence is rising among males, but smoking has, as yet, caused 
relatively few deaths. Stage 2 shows a rapid rise in smoking prevalence among men to a peak 
of 40-80%. Also during Stage 2 is the start of the increase in smoking among women and the 
start of the increase in smoking attributable mortality which still only accounts for 10% of 
male deaths at the end of this stage. Stage 3 sees a flattening in smoking prevalence among 
men and a convergence of male and female smoking prevalence. Mortality due to cigarette 
smoking rises from 10% to approximately 30% of all deaths, mostly in men. In Stage 4, 
although paradoxically the prevalence of smoking is decreasing in both sexes, the mortality 
attributable to smoking continues to rise for some ti e. This mortality peaks at about a third 
of all male deaths (more among middle-aged men) and a smaller percentage of all female 
deaths before beginning to decline. 
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Figure 8.6 Smoking epidemic diagram for high-income countries. Reproduced with 
permission (Thun, Peto et al. 2012) 
 
The methods used to develop this diagram used estimates of smoking attributed mortality in 
economically-developed countries in an indirect approach, where the lung cancer death rates 
were used as a guide to the smoking attributed fractions of the deaths from various other 
diseases. If in an economically-developed country, lung cancer rates are high then smoking 
is probably responsible – not only for these deaths but also for many other deaths. The 
updated diagram (see Figure 8.2) emphasised the age group of 35-69 years because the 
proportion of all deaths attributable to smoking is higher in that age group than at older ages 
and death in this age group is considered premature.  
The patterns of smoking attributable deaths in fourhigh income countries are shown below: 
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Figure 8.7 Smoking-attributable deaths at ages 35-69 estimated indirectly from lung 
cancer rates and expressed as a percentage of all deaths. Reproduced with 
permission (Thun, Peto et al. 2012)  
 
In the UK, smoking attributable mortality among men in 1970 was 47% at the peak of the 
epidemic curve. It then fell to 22% in 2009 and continues to fall. The epidemic among 
women is significantly later than among men in all four countries. Smoking prevalence has 
decreased among women, but more slowly than among me . Therefore, smoking attributable 
deaths have not decreased substantially among women in any country yet, and are still 
increasing rapidly in the Netherlands as shown. This figure also shows that the male and 
female smoking attributed proportions of all deaths at ages 35-69 have converged. This is in 
line with the earlier convergence of the male and female prevalences of smoking. In the 
Netherlands the male and female smoking attributed proportions of deaths at ages 35-69 
years will cross over in the early 2010s. The smoking epidemic among females lagged 
behind males by 20-30 years in the UK and the USA. Cultural norms changed with World 
War II and women became freer to smoke.(Centers_for_disease_control_and_prevention 
2001)  
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This description illustrates how there is a long delay between a large increase in smoking in 
a particular generation of young adults and the full increase in smoking attributable mortality 
when that generation becomes middle aged and elderly. The updated schematic diagram 
separates out the epidemic for males and females with the following stages. Stage1: the 
prevalence of cigarette smoking begins to rise in the gender of interest. Stage 2: the 
prevalence of smoking increases rapidly but until it levels off and cigarette smoking only 
accounts for a limited proportion of premature deaths. Stage 3: the paradoxical stage in 
which the smoking prevalence is stable or decreasing, however the smoking attributable 
mortality is increasing rapidly. Stage 3 ends when this mortality peaks. Then, in Stage 4, 
prevalence and then, many years later, smoking attributed mortality are expected to both fall 
- this has not yet been experienced by any population.  
This schematic diagram can be used to put the future projections from the Dutch Model of 
COPD prevalence and mortality for England and Scotland in context. 
The predictions from the Dutch Model fit broadly into this characterisation of the smoking 
epidemic. The model projects that over the next 20 years there will be an increase in the 
numbers of older people with COPD, in particular the numbers of older women (see age-
specific prevalence diagrams for England and Scotland in Chapter 7). This is as a result of 
the time lag from the peak in the prevalence of smoking (and also a high prevalence of ex-
smokers) to getting COPD. In addition, people are living longer with COPD and increasing 
survival also contributes to higher prevalence figures. 
8.5.2 Comparison with UK data from the Global Burde n of Disease 
Study 2010 
The main measure used to quantify burden of disease in th  Global Burden of Disease 
(GBD) Study is the Disability Adjusted Life Year (DALY).(Murray, Richards et al. 2013) 
(Page 1009) The absolute numbers of DALYs for all ages in the UK, contributed by COPD 
in 1990 was 714,000 (95% uncertainty interval 594,000-866,000) and in 2010 was 707,000 
(573,000-875,000), a fall of 1.0% (Page 1009 of GBD Lancet report). When this decrease is 
standardised by population, a decrease of 8.5% change in DALYs becomes apparent, from 
1,249,000 (1,038,000-1,513,000) per 100,000 in 1990 to 1,142,000 (942,000-1,413,000) in 
2010. The GBD authors concluded that this representd falling rates of tobacco attributable 
burden for both men and women as the UK has a more advanced tobacco epidemic than 
most high-income nations.(Murray, Richards et al. 2013) 
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The apparent inconsistency is that the GBD study state  that the burden of COPD fell (by 
8.5% in standardised rates) between 1990 and 2010 in DALYs in the UK (Murray, Richards 
et al. 2013), whereas, my work suggests that the prevalence, costs and deaths will increase 
from 2011 to 2030. 
There is one area where the findings of the GBD and my study are comparable. The major 
decrease of the GBD is among Years of Life Lost (YLL) due to COPD in the age group 20-
54 (Murray, Richards et al. 2013). My findings of falling age specific prevalence among the 
younger age groups as reported in Chapter 7 are consiste t with this finding from the GBD. 
It should, however, be remembered that prevalence is not the same as YLL. 
The main thing to realise is that the GBD and the Dutch Model represent very different 
approaches and time periods and so cannot easily be compared. In addition, the GBD used a 
spirometric definition of COPD as its input data for prevalence including data from the 
Health Survey for England whereas the Dutch Model us s a definition of physician 
diagnosed COPD.(Gupta 2014) 
One explanation to be considered is that the GBD and my work are not actually inconsistent. 
The GBD represents findings from 1990 to 2010, therefore, it may be that during this period 
there were high levels of undiagnosed COPD and low levels of diagnosed COPD with the 
COPD that was diagnosed being among the more severe cases. Therefore this would be 
calculated to represent a high burden in terms of DALYs (this would be the case if the work 
done to inform the DALY allocation was done in diagnosed COPD rather than in 
spirometrically defined COPD). This burden would fall with falling smoking prevalence. In 
contrast, my work which focuses on diagnosed COPD show  a rising prevalence of COPD 
because, from 2011 to 2030, more mild cases of COPD are being diagnosed and people are 
living longer with their COPD, therefore being prevalent for longer. However, the burden in 
terms of DALYs for this period would not actually be so high because the cases represent the 
milder end of the COPD spectrum. 
8.5.3 The lag effect of smoking: ex-smokers develop ing COPD 
The paradox that needs addressing in these results is why the prevalence of COPD is still 
modelled to be increasing despite the widely observed fall in smoking prevalence in Scotland 
and England. A similar paradox was seen in the Netherlands (Pride 2006). This is because 
people who have given up smoking still are at risk of developing COPD (see Table 8.1). 
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Table 8.2 Relative risks for ex-smokers of developing COPD compared to non-
smokers (Van Oers 2002; SurgeonGeneral 2004) 
Age Male ex-smoker relative risk of 
developing COPD* 
Female ex-smoker relative 
risk of developing COPD* 
55-59 9.6 7.7 
60-64 10.3 8.3 
65-69 9.5 8.2 
70-74 8.5 6.5 
*No confidence intervals were available. 
Many of these ex-smokers become part of the older ag  classes where incidence of COPD is 
high. The relative risk of developing COPD after smoking cessation does not decline as fast 
as it does for lung cancer. The rate of FEV1 declin is faster in smokers than ex-smokers, 
however, there is evidence from the Lung Health Study hat the rate of decline in FEV1 in 
ex-smokers reverts to values similar to those in healt y never-smokers within a year of 
stopping smoking.(Scanlon, Connett et al. 2000) However, note that this is still a decline, 
there is little recovery in lung function ( i.e. there is no increase in FEV1 with stopping 
smoking.) The effect of this decline at normal “healthy” rates in ex-smokers who quit 
smoking with some established impairment is to delay rather than prevent death from or with 
COPD.(Pride 2001) This delay in death thereby increases the population with established 
COPD.  
8.5.4 Comparison with results from the Netherlands 
The Dutch Model was used to calculate projections of COPD prevalence from 2000 to 2025 
in the Netherlands. It projected that COPD patients increased from 188,000 to 270,000 for 
males and from 117,000 to 224,000 for females (Hoogendoorn, Rutten-van Molken et al. 
2005). The prevalence estimates are shown in the following Table 8.2. 
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Table 8.3 Overall projected prevalence of COPD in 2025 in three countries 
 England Scotland Netherlands 





Total male population in 2025 
(from ONS 2012 
projections(ONS 2012) 
29,144,000 2,728,000 - 
Prevalence(%) 2.0(1.7-2.1) 2.0(1.8-2.2) 3.3 





Total female population in 
2025(ONS 2012) 
29,463,000 2,857,000 - 
Prevalence(%) 2.3(1.9-2.4) 2.4(2.1-2.6) 2.7 
 
Table 8.2 shows that in 2025 the overall prevalence of COPD among males (all ages) is 
projected to be 2.0% in both England and Scotland, whereas in the Netherlands it is 
projected to be 3.3%. The overall prevalence among females (all ages) is projected to be 
England 2.3% and Scotland 2.4%; but not as high as for females in the Netherlands 2.7%. 
In this context, estimates for Scotland and England ppear very similar but estimates for the 
Netherlands are different. It may be an artefactual difference due to the inputs to the 
Netherlands model being sourced before 2000 and therefor  reflecting higher smoking 
prevalences. The later data sourcing for England and Scotland may result in lower smoking 
prevalences - as in European Union countries smoking prevalences have been falling. 
However, there is some evidence that the smoking prevalence in the Netherlands is higher 
than in the UK (37% of males and 31% of females aged 25-64 smoked in 2012 in the 
Netherlands, compared with 33% of UK males and 29% of UK females in this age group). 
(Zatonski, Przewozniak et al. 2012) In this case, th se findings may represent a real 
difference.  
An alternative explanation is that perhaps patterns of diagnosis are different in the 
Netherlands from England and Scotland. It may, therefore, be the case that although 
undiagnosed prevalence rates might be similar across the three countries, the Netherlands are 
more efficient at diagnosing COPD. Therefore these figures would show a greater prevalence 
of diagnosed COPD in the Netherlands than in England and Scotland. 
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8.6 Interpreting this research: implications for cl inicians and 
policymakers  
8.6.1 Five, 10 and 20 year projections  
Table 8.3 summarises the results from Chapter 7 (this time using the deterministically 
modelled results rather than the probabilistic results with uncertainty intervals as it was not 
possible to calculate probabilistic results for each year). In England, the COPD population 
was modelled to increase by 13% from 2014 to 2019 and by 24% from 2014 to 2024. In 
Scotland the increases were modelled to be 7% and 11% respectively. Deaths among people 
with COPD occur among about 10% of the COPD population each year and this is not 
projected to change greatly over the 20 year period; except for Scotland in 2030 when deaths 
are expected to affect 11% of the population with COPD. The UK government is already 
aware that there is likely to be an increase in the number of COPD patients dying in the 
future and so is planning evidence-based action to help try and prevent this as far as 
possible.(Dept_of_Health 2014) This forms part of the aims of the UK as a signatory to the 
World Health Organization’s Framework Convention on Tobacco Control.(FCA 2015) This 
WHO public health treaty encourages signatories to intr duce smoke free legislation, stop 
the promotion of tobacco, make tobacco less affordable through tax, regulate tobacco 
products effectively and help tobacco users to quit. 
Table 8.4 Predictions from the Dutch Model 
England 2011 2014 2019 2024 2030 
COPD population 952,000 1,026,000 1,163,000 1,273,000 1,350,000 
COPD deaths 96,000 93,000 106,000 120,000 134,000 
COPD cost 
(billions) 1.49 1.64 1.91 2.13 2.28 
Scotland      
COPD population 108,000 114,000 122,000 127,000 128,000 
COPD deaths 10,000 11,000 12,000 13,000 14,000 
COPD cost 
(billions) 0.18 0.19 0.21 0.22 0.21 
 
8.6.2 Implications of the age of the COPD populatio n 
The results presented in Figures 7.2 and 7.3 show te age-specific prevalence of COPD in 
England by sex, comparing predictions for 2011 with 2030. These show that the majority of 
increase in overall prevalence of COPD is as a result of an increase in females age 65 to 85. 
A similar pattern is seen for Scotland in Figures 7.7 and 7.8. These women will suffer 
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disabilities in proportion to their COPD and this will have important implications for the 
shape of the health and social care services that they require. Both my work and the GBD 
imply that disability is not so much prevented as po t oned, which means that there will be a 
demographic bulge of frail elderly people with COPD requiring health and social care. In 
addition, these people with COPD are likely to have co-morbid conditions resulting in very 
complex needs. There is already evidence of a trend among elderly patients towards multi-
morbidity and highly complex medical needs.(Barnett, Mercer et al. 2012) Traditional health 
and social services are already stretched beyond capacity dealing with such frail elderly 
people. There is policy interest in the role of technology to provide care services that were 
once provided by staff, this being driven by a shortage of skilled staff and a drive to keep 
costs down. Technological solutions to providing care services are already being trialled in 
some settings (e.g. to deliver intelligent context-specific medication reminders so that an 
elderly person is prompted to take medication when patients are at home.)(Hayes, Cobbinah 
et al. 2009) Other developments include “smart homes” for elderly people to enable 
independent living as long as possible, with a particular focus on falls prevention.(Haux, 
Hein et al. 2014) The role of telehealth in caring for people with COPD is also being 
clarified, a key problem is how best to predict COPD exacerbations from the data gathered 
from telehealth monitoring and further work is ongoing in this area.(Pinnock, Hanley et al. 
2013) 
8.6.3 Implications in terms of NHS spending for Eng land 
According to the ONS (ONS 2011) the NHS spent £142 billion in 2011. The 
deterministically modelled costs for COPD in England £1.490 billion in 2011 would be 1% 
of UK NHS spending for that year. 
Some predictive validation is possible for the cost data. Table 8.4 shows the direct costs 
predicted for COPD from the model for the years 2011-2013 and the actual costs estimated 
from Primary Care Trust (PCT) returns for the financi l years 2010/11, 2011/12 and 
2012/13.(Dept_of_Health 2012; Dept_of_Health 2013) 
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Table 8.5 Comparison of English cost data from the Dutch Model with PCT returns 
Year 2010 2011 2012 2013 
Modelled cost 
(£billions) 
Not modelled 1.49 (95% UI 
1.17 to 2.46) 
1.53 1.58 
Financial year 2010/11 2011/12 2012/13 2013/14 
Estimated cost 




0.70 0.75 0.80 Not yet 
available 
 
These PCT returns are the best data available to guide how much NHS England is spending 
on different conditions, however, there are some issue  with the quality of the returns data. 
In the PCT returns, costs are categorised firstly by speciality ( i.e. “Respiratory”) and include 
all primary care, hospital inpatient and outpatient costs. They do not include Department of 
Health and Strategic Health Authority expenditure. Therefore, they are an estimate of direct 
costs similar to the direct costs calculated in this PhD and so can be used for validation. 
However, the PCT returns data encountered problems clas ifying “Respiratory” spending 
into subcategories: it was not always possible for subcategories to be assigned. In 2011/12, 
“Respiratory” expenditure was £4.41 billion, this was sub-categorised as £0.75 billion 
“Obstructive Airways Disease”, £1.01 billion “Asthma” and £2.65 billion “Other”. This 
£2.65 billion “Other” is not exclusive, therefore, it is likely to include unclassified spending 
on COPD. (Lung cancer is considered under “Cancer” rather than “Respiratory”). “Other” 
expenditure in 2010/11 was £2.58 billion and in 2012/2013 was £2.85 billion so these are not 
insignificant funds and may well account for the difference between the subcategory and the 
cost estimates from this PhD. In other words, my belief is that my PhD has not 
underestimated the direct healthcare costs of COPD, simply the remaining COPD costs have 
been classified as “Other” in the PCT Returns and so I think the official NHS England PCT 
returns vastly underestimate true COPD related costs. 
8.6.4 Implications in terms of NHS spending for Sco tland 
Table 8.5 shows data from a costing exercise at Information Services Division (ISD) to try to 
establish how much was spent on COPD by the NHS in Scotland in each of the three years 
shown. The estimated costs represent hospital inpatient and day-case costs for COPD. 
Therefore the equivalent subgroup of costs which were modelled would be the severe 
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exacerbation costs, which were defined as those COPD exacerbations that required hospital 
management. 
Table 8.6 Comparison of Scottish cost data from the Dutch Model for severe 
exacerbations with ISD cost data for hospital admissions 
Year 2010 2011 2012 2013 
Modelled cost  
of exacerbations 
(£millions) 
Not modelled 56.8 58.3 59.8 




50.0 55.3 57.9 Not yet 
available 
 
These estimates show that in the financial year 2011/12, Scotland was estimated to have 
£55.3 million on COPD inpatient and day-case care by ISD. The Dutch Model estimated 
expenditure on severe exacerbations to be £56.8 million in 2011. Relevant estimates for 
2012/13 were £57.9 million and £58.3 million respectively. Therefore, it can be seen that 
these ISD figures closely validate the Dutch Model’s predictions for severe exacerbations.  
8.6.5 Implications in terms of COPD inpatient care 
The Dutch Model provided projections in terms of exacerbations, both moderate and severe 
exacerbations (with a severe exacerbation requiring an admission to hospital by definition.)  
Table 8.7 Estimated numbers of exacerbations as predicted by modelling for 
England and Scotland for selected years 
England 2011 2014 2019 2024 2030 
Severe exacerbations 150166 166027 193980 215725 230532 
Multiplier for severe 
exacerbations 1 1.11 1.29 1.44 1.54 
Moderate 
exacerbations 957334 1060303 1241200 1381835 1477448 
Scotland      
Severe exacerbations 17069 18425 20327 21452 21804 
Multiplier for severe 
exacerbations 1 1.08 1.19 1.26 1.28 
Moderate 
exacerbations 108816 117658 130047 137380 139686 
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Table 8.6 shows that the model projects an 11% increase in severe exacerbations in England 
by 2014, becoming a 29% increase by 2019 and a 54% increase by 2030. The equivalent 
values for Scotland are 8% by 2014, 19% by 2019 and 28% by 2030. The annual 
exacerbation rates were dependent on the GOLD severity class of the patients. 
These figures mean that additional hospital beds an hospital staffing will have to be found 
to manage this increased number of severe COPD exacerbations. Alternatives to managing 
COPD exacerbations in hospital will also have to be found, such as hospital at home 
programmes. In addition, improved detection and treatm nt of moderate exacerbations 
should help prevent severe exacerbations. The programme of influenza and pneumococcal 
vaccination for the COPD population also has a role in preventing exacerbations.(Menon, 
Gurnani et al. 2008; Cimen, Unlu et al. 2014) Maximis ng such initiatives will hopefully 
prevent the predicted growth in COPD patients requiring care for exacerbations. 
8.6.6 Policy developments in COPD 
The model helps to validate the recent emphasis that policymakers have put on smoking 
cessation.(Dept_of_Health 2014) The sensitivity analysis that considered how COPD 
prevalence would be affected if there were a 10% smoking quit rate achieved among current 
smokers at all ages, predicted a decrease in the COPD population from 1,350,000 to 
1,340,000 in 2030, that is 10,000 fewer people having COPD. In Scotland the decrease was 
500 fewer people with COPD than if smoking prevalence remained constant. This 
demonstrates that the increase in COPD can be limited if the government increases 
investment in effective stop-smoking services. 
Other possible areas which may address the increasing clinical and economic burdens of 
COPD were identified by the British Thoracic Society and the Primary Care Respiratory 
Society in their document “Improving and Integrating Respiratory Services” IMPRESS 
(Williams, Baxter et al. 2012), these include the following: 
1. Under use of smoking cessation. 
2. Rationalising oxygen prescribing. 
3. Reducing inhaler waste. 
4. Overuse of high dose inhaled corticosteroids and/or combination products, such as 
seretide. 
5. Overuse of enteric-coated prednisolone tablets for patients with COPD instead of 
uncoated prednisolone tablets – there is a difference i  the drug tariff. 
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6. Overuse of hospital beds (COPD length of stay) and underuse of hospital respiratory 
specialist care. 
7. Underuse of referral to pulmonary rehabilitation. 
8. Under use of psychological support. 
9. Overuse of outpatients for common conditions. 
10. Under-coordination with social care. 
The Managed Clinical Network (MCN) for COPD in Lothian has made some progress in 
addressing these policy areas.(Hewitt 2014) Their strategy has included the following 
elements: 
1. Promotion of pulmonary rehabilitation. 
2. Creation of a community respiratory team. 
3. Specific investment identified for COPD. 
4. Targeting training of GP practices on therapy. 
5. Creation of self-management plans for COPD. 
6. Updating of website resources for all professionals who care for patients with 
COPD. 
The results to autumn 2014 in Lothian include the following: 
1. Admissions for COPD exacerbations have reduced. 
2. Length of stay for COPD exacerbations have reduced. 
3. The total bed days for COPD have reduced. 
4. 300 frequent admission patients have been identified. 
5. A multi-disciplinary team has been created and meets w ekly. 
6. A psychologist has assessed 90 patients. 
7. Repeat admissions have reduced, but not yet by the targ t amount. 
8. The admitting unit now advises GPs to contact the community respiratory team 
where appropriate rather than admit. 
9. The community respiratory team is now available seven days a week including early 
evenings. 
10. Use of seretide has stabilised and costs have been contained.  
11. Self-management plans are widely used by GPs and practice nurses.(Hewitt 2014) 
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8.7 Unanswered questions and future research  
8.7.1 The COPD population and socio-economic status  
It would be interesting to know how the COPD population is distributed across the socio-
economic groups of the populations in England and Scotland. This is of interest with regard 
to health inequalities as smoking prevalence is higher among lower socio-economic groups 
than among higher socio-economic groups (West 2012) and premature all-cause mortality is 
higher among lower socio-economic groups.(ScottishGovernment 2012) Further research 
would help unpick the role of COPD in premature mortality. 
8.7.2 Alternative modelling strategies 
It may be interesting to use trends as inputs to the Dutch Model. It would be possible to use 
regression models to project the trend for incidence or prevalence or start and stop smoking 
rates over the years and have different inputs for each year. Although this is theoretically 
possible it would add significantly to the Model’s complexity and may produce outputs 
which are not very different from those demonstrated in this version, especially, as the 
sensitivity analysis demonstrated that the level of sensitivity of the model to changes in input 
prevalence and smoking quit rate was not very sensitive. However, the changes would be 
more dramatic if trends in incidence were used, instead of point incidence as inputs, because 
the model is much more sensitive to changes in the input of incidence than to other inputs. 
This is another potential avenue for further research. 
Additionally, it may be possible to use some or all of the inputs I used in this model with 
alternative high quality models from the systematic review, e.g. the Dynamo-HIA 
model(Lhachimi, Nusselder et al. 2012). As long as the inputs were for the same time frame 
and population, comparison of the outputs would then allow cross-validation of these 
models. Alternatively, some of the models from the systematic review may require subtly 
different inputs to enable their models to run and llow an output comparison. 
8.7.3 Further work that may require new models  
COPD often prevents its sufferers from working and therefore results in lost economic 
output.(HealthcareCommission 2006; NICE 2010) This is an indirect cost of COPD. New 
health economic models are required in order to quantify the lost productivity for which this 
accounts. 
Similarly, COPD patients will require social care in addition to healthcare, in particular as 
they become older and frailer and suffer with co-morbidities. New models will help to 
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quantify the additional costs of this social care. Such costs are likely to be substantial given 
the projected age profile of the COPD population (See ection 8.5.2). 
The Dutch Model does not take into account many of the factors that research is uncovering 
as being related to the development of COPD. The importance of prematurity, childhood 
respiratory infection, asthma and occupational lung disease in influencing risk of COPD all 
provide possible avenues for future research into alternative models for projecting the future 
patterns of COPD.(Barker, Godfrey et al. 1991; Galob rdes, McCarron et al. 2008; Baines, 
Hsu et al. 2013; Toren and Jarvholm 2014) 
8.7.4 Validation of projections with real data 
As time goes on, it would be useful to validate these projections with real data. The 
increasing scope of routine data that is collected may eventually allow closer validation of 
the projection for the number of people with COPD. It may prove more difficult to validate 
the number of deaths from all causes among people with COPD – however this could still be 
possible with some large primary care routine datasets for example that from CPRD, THIN 
QResearch or SAIL (as described in Chapter 3). 
In terms of validating the costs of COPD (see Section 8.5.2), the Dutch Model’s projections 
appeared to be perhaps overestimates for NHS England; however, it is more likely that the 
NHS England PCT returns data underestimates the costs of COPD. Where available, costs 
for Scotland have been shown to closely validate the expenditure on severe exacerbations. 
8.7.5 Re-working the Dutch Model 
The Dutch Model is based on the progression of COPD through the mild, moderate, severe 
and very severe disease stages as related to FEV1 decline. However, the more we learn about 
COPD as a disease, it is increasingly suggested that having a linear basis for decline in lung 
function is an oversimplification. The ECLIPSE study, as described in Chapter 2, found that 
lung function decline in COPD is far more variable than previously thought and that 
exacerbations play an important role in non-linear decline in lung function.(Vestbo, Edwards 
et al. 2011; Vestbo, Agusti et al. 2014) There is a future need to rework the Dutch Model to 
enable modelling of more complex, non-linear scenarios. 
In addition, with increased computing power it may be possible in the future to model 
individual patient trajectories rather than modelling n cohorts. This would blur the lines 
between population models and individual prognostic models. 
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8.7.6 The definition of COPD 
The Dutch Model considered only those patients who have a recorded diagnosis of COPD. 
Future work could usefully consider the current preval nce estimates from Nacul et al 
(Nacul, Soljak et al. 2007) based on COPD as identifi d from spirometry that includes both 
diagnosed and undiagnosed COPD. These prevalence estimat  could then be fed into the 
Dutch Model to project the future total population f COPD regardless of the proportion of 
the COPD that is diagnosed. However, using such a technique has implications for 
calculating cost estimates – as it may be difficult to establish a cost of treating 
“undiagnosed” COPD. 
8.8 Conclusion to thesis 
I have contributed carefully undertaken projections f the increase in the COPD population 
and the number of deaths among people with diagnosed COPD for England and Scotland 
from 2011 to 2030. I also include estimates of the dir ct healthcare costs for caring for this 
group of patients. I used a high quality modelling tool, the Dutch Model, and worked in close 
association with its original developers. 
I believe these to be the best estimates of future COPD prevalence and costs available to 
guide English and Scottish policymakers. Sensitivity analyses have shown how the Model 
responds to changes in inputs, in that it is robust to changes in prevalence estimates but 
sensitive to changes in incidence estimates and mortality estimates. Some of the cost 
projections may be over-estimates; however, some information is missing from the NHS 
England PCT returns costs that were used for comparative validation.  
In contrast to the highly cited GBD Study (Murray, Richards et al. 2013), my estimates 
project that there will be an increase in the number of people with COPD from 2011 to 2030 
as opposed to the decrease in the number of COPD related DALYs from 1990 to 2010 that 
they showed. This difference is more due to the different measures used and the different 
ways of modelling burden employed in the two studies than to the different time period. I 
believe that my modelling is more transparent in comparison to the Global Burden of 
Disease and that my projections are, thus, likely to prove more helpful to policymakers. 
My results suggest that governments should do more to support effective quit smoking 
services, especially among women, to reduce future b den of COPD. In addition, there is a 
need to plan to address higher prevalence of COPD among age groups over 65 years of age 
as part of the wider approach to managing increasing prevalence of multi-morbidity. 
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In order to validate and update this model there is a need to monitor the incidence, 
prevalence, mortality and healthcare costs of COPD in England and Scotland. Routine data 
from primary care needs to be collected as it has a valuable role in this process. There are 
sources of high quality data in England and Scotland which may be exploited in the future 
for similar projects. 
  
   
205 
 
Appendix 1.1 CPRD Original protocol 
GPRD data protocol 
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Lay summary of research  
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic disease and 
death and results in an economic and social burden that is both substantial and increasing. 
Cigarette smoking is the most important risk factor of COPD. Other factors play a role in the 
development and progression of the disease as well, but our knowledge about these risk 
factors is limited.  
 
We therefore wish to use the General Practice Research Database (GPRD) to identify all 
possible risk factors that are related to COPD. We will do this by undertaking a study in 
which we compare a random selection of 50,000 regist red patients who have a clinician-
recorded diagnosis of COPD with a random selection of 50,000 patients who are not 
recorded with such a diagnosis.  
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We will assess which factors from the patient's electronic health record are associated with 
the development of COPD. In the group of patients wi h COPD, we will also assess which 
factors are associated with death within 10 years of diagnosis. 
 
Results from this study would enable the identification of potentially modifiable risk factors 
at an early stage thereby possibly preventing progression of disease and premature death.  
 
Objectives, specific aims, and rationale 
Objectives:  
 The primary objective is to utilise the GPRD for developing a model that integrates 
smoking and other risk factors from the patient's electronic health record to predict the 
risk of developing COPD.  
 The secondary objective is to utilise the GPRD for assessing smoking and other risk 
factors in patients with a recorded diagnosis of COPD to predict the 10-year-risk of 
death from all causes and from circulatory or respiratory disease. 
 
Specific aims: 
 The primary aim is to assess which factors, in addition to smoking, predict a first 
recorded diagnosis of COPD in patients aged 35 years or older. 
 The secondary aim is to assess which factors, in addition to smoking, predict the 10-
year-risk of death from all causes, from circulatory disease and from respiratory disease 
in patients with a recorded diagnosis of COPD. 
 
Rationale:  
 The efficiency of early treatment of modifiable risk factors could be enhanced if 
individuals at high risk of COPD could be identified at an earlier stage.  
 Furthermore, the identification of risk factors of premature death in patients with a 
recorded diagnosis of COPD could help to identify improved treatment strategies in this 
group of patients.  
 
Background 
Chronic obstructive pulmonary disease (COPD) is a respi atory disease which is 
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characterised by progressive airflow limitation that is not fully reversible.(Global Initiative 
for Chronic Obstructive Lung Disease 2008) COPD is a major cause of chronic morbidity 
and mortality throughout the world and results in an economic and social burden that is both 
substantial and increasing.(Global Initiative for Chronic Obstructive Lung Disease 2008) 
The current worldwide prevalence of COPD is estimated to be 10%.(Buist, McBurnie et al. 
2007) Projections indicate that COPD will become the third largest cause of death worldwide 
by the year 2020.(Murray and Lopez 1997) COPD patients not only die prematurely, they 
also have a decreased quality of life due to impaired physical, mental, and social 
functioning.(Heijmans, Spreeuwenberg et al. 2005)  
 
COPD is a largely preventable disease.(Global Initiative for Chronic Obstructive Lung 
Disease 2008) The most important risk factor for its development and progression is 
cigarette smoking.(Global Initiative for Chronic Obstructive Lung Disease 2008) Smokers 
with COPD experience an accelerated decline in lungf ction, which cannot be fully 
reversed.(Fletcher and Peto 1977) Notably, almost all patients with COPD have a history of 
cigarette smoking, but only a minority of smokers will develop COPD; the estimated overall 
percentage varies between 15-50% of smokers.(Lundback, Lindberg et al. 2003) This large 
variability indicates the role of other risk factors in the aetiology and pathogenesis of the 
disease. Our appreciation of these risk factors is however as yet limited as much of the 
current knowledge is based on cross-sectional association studies rather than analytical 
studies that would allow causal relationships to be more reliably ascertained.(Global 
Initiative for Chronic Obstructive Lung Disease 2008) These other risk factors regarded to be 
associated with COPD include respiratory infections, age, sex, nutrition, and socioeconomic 
factors.(Mannino and Buist 2007; Global Initiative for Chronic Obstructive Lung Disease 
2008)  
 
Given the characteristics of COPD, it is reasonable to assume that the morbidity and 
mortality from COPD could be reduced in the future if individuals at high risk of developing 
the disease could be identified, and if a subsequent intervention could reduce modifiable risk 
factors. Concerning the first requirement, no tool currently exists to identify individuals at 
high risk of developing COPD. Available tools are aimed at case-finding individuals with 
established COPD (see for example (van Schayck, Halbert et al. 2005; Price, Tinkelman et 
al. 2006)).  




In the GPRD, patient information (including diagnostic and disease-related data and smoking 
status) are well recorded. The database offers the possibility for an assessment of the 
association between established and novel risk factors and COPD diagnosis. Integrating 
these risk factors into one model would allow a valid nd accurate prediction of COPD risk 
in individual patients screened in primary care. 
 
Study type 
The study will be hypothesis generating. The associati n between cigarette smoking and the 
development of COPD is well established. However, knowledge about other risk factors in 
the aetiology of the disease is limited.  
 
Study design 
We will use a nested case-control design. A random sa ple of 50,000 patients older than 35 
years who have a recorded diagnosis of COPD will be sel cted as cases. For each case, one 
control patient with the same year of birth will be randomly selected from the same general 
practice (i.e., a total of 50,000 controls). Potential risk factors from the electronic health 
records will be compared between cases and controls.  
 
The analysis of risk factors of mortality will be rstricted to the group of 50,000 patients with 
a recorded diagnosis of COPD. These patients will be inked to Office for National Statistics 
(ONS) mortality data to assess risk factors of 10-year mortality from all causes and from 
circulatory disease (ICD-10 I00-I99) and respiratory diseases (ICD-10 J00-J99).  
 
Study population 
A random sample of 50,000 cases of COPD will be drawn from the GPRD. 
Inclusion criteria:  
 a recorded diagnosis of COPD 
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 age ≥35 years (this lower limit has been chosen because risk prediction of COPD at 
earlier age is unlikely to be feasible) 
 
Exclusion criteria: 
 less than one year of complete data in the medical re ord. 
 
Selection of comparison group(s) or controls 
For each case, one control patient will be randomly se ected matched by year of birth and 
general practice (i.e., a total of 50,000 controls). 
 
Inclusion criteria:  
 no recorded diagnosis of COPD 
 age ≥35 years 
 
Exclusion criteria: 
 less than one year of complete data in the medical re ord 
 
Sample size/power calculation 
In order to achieve a sufficient sample size for the statistical analyses of all potential risk 
factors, the calculation of the sample size should be based on a potential risk factor that is 
less frequent in the population of patients registered in GPRD. One of the potential risk 
factors of COPD morbidity we want to assess is a history of acute respiratory infection 
(ARI). In order to provide an estimate of the percentage of patients over 35 years that have 
been exposed to a clinician-recorded episode of ARI we interrogated the  primary care 
database of the Primary Care Clinical Informatics Unit (PCCIU) of the University of 
Aberdeen. This database includes the electronic health records of patients from more than 
300 Scottish primary care practices. The lifetime pr valence of a recorded diagnosis of ARI 
in patients over 35 years of age that had was 5%.  
 
We based our sample size calculation on the following parameters: 
 minimum odds ratio to detect = 1.1 
 percentage exposed with ARI among controls = 5% 
 α = 0.05 
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 power = 0.9 
 number of controls per case = 1 (1:1 matched study design) 
This resulted in a total required sample size of 93,2 0 patients. Thus, the 100,000 patient 
records that we request from the GPRD database would be sufficient to statistically detect 
even a small effect of a rather infrequent risk factor of COPD.  
 
Exposure, outcomes, and covariates 
The GPRD will be used as the main source of data for this study. We will use the complete 
time period of the database as our observational period (1990 to current). 
 
Exposure variables for COPD: 
 sex  
 socioeconomic status / deprivation score (Carstairs deprivation categories) 
 ethnic category (Read Codes (9i and below, 9S and below) 
 tobacco consumption (Read Codes 137 and below) 
 smoking status (Read Codes 13p and below) 
 smoking cessation (Read Codes 6791, 67A3, 67H1, 8CAL, 8h7i, 8HTK, 9N2k, 9OO and 
below) 
 body mass index (Read Codes 229, 22A, 22K and below) 
 acute respiratory infections (Read Codes H0 and below) 
 respiratory symptoms: 
o cough (Read Codes 171, R06z, A33z) 
o wheezing and difficulty breathing (Read Codes 173 and below) 
 occupational exposure to risk factor (Read Codes 0 (i.e., occupation), ZV4C) 
 family history of COPD (Read Codes 12D1 and 12DZ) 
 pulmonary tuberculosis (Read Codes A11, A1z, 65P2) 
 physical activity (Read Codes 138 and below) 
 genes: alpha-1 antitrypsin deficiency  
 
Exposure variables for mortality (in addition to the above 
mentioned variables): 
Prescription of COPD pharmacotherapy listed in the National Institute for Health and 
Clinical Excellence (NICE) guideline(NICE 2010): 
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o short- and long-acting bronchodilators 
o short-acting beta2-agonists 
o short-acting anticholinergics  
o theophylline  
o inhaled and oral corticosteroids  
Common pathway, complicating, and coexisting morbidities(Global Initiative for Chronic 
Obstructive Lung Disease 2008): 
o asthma (Read Codes H33 and below) 
o ischaemic heart disease (Read Codes G3 and below) 
o hypertension (Read Codes G2 and below) 
o heart failure (Read Codes G58 and below) 
o anxiety and depression (Read Codes E200 and below, E204, E2B) 
 
Outcome variables for COPD: 
Diagnosis of COPD based on one or more of the following Read Codes (case definition): 
o H3: COPD 
o H31 and below: chronic bronchitis  
o H32 and below: emphysema 
o H36: mild COPD 
o H37: moderate COPD 
o H38: severe COPD 
o H3y and below: other specified COPD 
o H3z: COPD not otherwise specified  
Emergency admission due to COPD (Read Code 8H2R) 
Lung function measurements:  
o pre- and post-bronchodilator Forced Expiratory Volume in one second 
(FEV1) 
o pre- and post-bronchodilator Forced Vital Capacity (FVC) 
Oxygen treatment (Read Code 6639) 
 
Outcome variables for mortality: 
 all cause mortality 
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 mortality from circulatory diseases (ICD-10 I00-I99) 
 mortality from respiratory diseases (ICD-10 J00-J99) 
 
Data/statistical analysis 
For the primary analysis, a "baseline date" will be assigned to all cases and controls, i.e. the 
latest of the following dates: 35th birthday or the date of registration with the practice. For 
each potential risk factor of COPD diagnosis, we will use the entry of the risk factor in the 
electronic health record at the date which is closest to the baseline date. The association 
between potential risk factors and COPD will be analysed using a multiple logistic 
regression model in which COPD diagnosis (case vs. control) will be regressed on all 
potential risk factors. Risk factors that are not associated with COPD diagnosis (based on a 
p-value of >0.05) will be removed from the model one by one (i.e., backward stepwise 
logistic regression).  
 
For the secondary analysis, a "COPD diagnosis date" will be assigned to all cases, i.e. the 
date of the first recorded diagnosis of COPD confirmed by spirometry including reversibility 
testing (where available). For each potential risk factor of mortality, we will use the entry 
which is closest to the COPD diagnosis date. The association between potential risk factors 
and mortality will be analysed using three separate multiple logistic regression models in 
which the 10-year-risk of: (1) all cause mortality, (2) mortality from circulatory diseases 
(ICD-10 I00-I99), and (3) mortality from respiratory diseases (ICD-10 J00-J99) will be 
regressed on all potential risk factors. Risk factors hat are not associated with mortality 
(based on a p-value of >0.05) will be removed from the model one by one (i.e., backward 
stepwise logistic regression). 
 
In both analyses, we will assess the level of missing data and will use multiple imputation 
(MI) techniques to replace missing values where necessary. MI is a statistical technique that 
allows patients with incomplete data to still be included in analyses, thereby making full use 
of all available data. This will increase the power of the analyses and may produce models 
that are more statistically reliable and applicable within clinical practice.(Clark and Altman 
2003) 




All analyses will be carried out by Prof. Aziz Sheikh in collaboration with Dr. Daniel Kotz 
and Dr. Colin Simpson.  
 
Patient or user group involvement 
The Edinburgh Allergy & Respiratory Research Group has its own Consumer Involvement 
Group, which will advise on this project. Results of the study will be fed back to the British 
Lung Foundation.  
 
Limitations of the study design, data sources, and analytic methods  
Our case definition is dependent on a clinician-reco ded diagnosis. Thus, we have to assume 
that the absence of a recorded diagnosis of COPD is equivalent to the person not having the 
disease, which is not always the case and may lead to some degree of misclassification. This 
problem is amplified by the fact that COPD is not easily diagnosed; a proper diagnosis can 
only be made by spirometry with reversibility testing. Furthermore, the quality of recording 
of disease has probably varied over time and has improved in the last years which may bias 
the association between risk factors and COPD.  
 
This study is based on routinely collected primary care data. An important disadvantage of 
this approach is that no all potential risk factors as ociated with the development of COPD 
are recorded in GPRD. Furthermore, the level of exposure to some of the risk factors (i.e., 
the dose-response relationship) is insufficiently recorded. This will result in a reduction of 
variation in COPD morbidity and mortality that can be explained by the model. On the other 
hand, using routinely recorded data for the development of the model maximises the 
usability for primary care clinicians who want to identify patients at high risk of developing 
COPD.   
 
Other potential limitations are inherent in the study design; a case-control study is commonly 
more vulnerable to bias (in particular confounding) than a prospective design. 
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Plans for disseminating and communicating study results 
We plan to disseminate our results via publication in an international peer reviewed journal 
in the field of respiratory research (e.g., European Respiratory Journal). We also plan to 
submit an abstract to the annual congress of the European Respiratory Society. Any 




The GPRD Group has obtained ethical approval from a Multi-centre Research Ethics 
Committee (MREC) for all purely observational research using GPRD data. 
 
National Research Register (NRR) 
This study has not yet been registered at the NRR, but will be once the study is approved.  
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Appendix 1.2 CPRD Amendment protocol 
 
 
Predicting the risk of chronic obstructive pulmonary 
disease:  
a nested case-control study 
 
Protocol Amendment: predicting the future disease 
burden of chronic obstructive pulmonary disease 
 
Aziz Sheikh1*, Daniel Kotz1,2, Colin R. Simpson1, Susannah McLean1, Sarah Wild1, Maureen 
Rutten-van Mölken3, Martine Hoogendoorn3. 
 
1University of Edinburgh, Centre for Population Health Sciences 
2Maastricht University, Department of General Practice 
3Erasmus University, Rotterdam, Institute for Medical Technology Assessment 
 
*Principal Investigator. Correspondence: Prof. Aziz Sheikh, Allergy and Respiratory Research 
Group, Centre for Population Health Sciences, University of Edinburgh,  
Edinburgh EH8 9AG, phone: 0131 6514151, e-mail: Aziz.sheikh@ed.ac.uk   
 
Data was made available under MRC licence agreement no additional funding available for 
amendment to protocol, no additional data required, just additional analysis of dataset. 
 
Lay summary of research  
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Chronic obstructive pulmonary disease (COPD) is a major cause of chronic disease and 
death and results in an economic and social burden that is both substantial and increasing. 
Cigarette smoking is the most important risk factor of COPD. Other factors play a role in the 
development and progression of the disease as well, but our knowledge about these risk 
factors is limited.  
 
We plan to use the General Practice Research Database (GPRD) to identify all possible risk 
factors that are related to COPD. We will do this by undertaking a study in which we 
compare a random selection of 50,000 registered patients who have a clinician-recorded 
diagnosis of COPD with a random selection of 50,000 patients who are not recorded with 
such a diagnosis. We will assess which factors from the patient's electronic health record are 
associated with the development of COPD. In the group of patients with COPD, we will also 
assess which factors are associated with death within 10 years of diagnosis. Results from this 
study would enable the identification of potentially modifiable risk factors at an early stage 
thereby possibly preventing progression of disease and premature death.  
 
In addition 
We would use specific measures of the disease burden of COPD derived from this database 
to feed into a Markov type model(Hoogendoorn, Rutten-van Molken et al. 2005; 
Hoogendoorn, Rutten-van Molken et al. 2011) developed by Erasmus University in order to 
predict the costs and burden of COPD patients 5 and 10 years in the future. Such predictions 
would help healthcare planners ensure that there weadequate resources made available for 
caring for people with COPD. 
Amendment objective, aims and rationale 
 
Objective 
The amendment objective is to quantify disease burden derived from this UK cohort and 
then to compare with similar disease burdens computed from Dutch and Scottish cohorts. 
 
Specific aims: 
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The amendment aim is to predict disease burden from COPD in 5 and 10 years time using a 
pre-existing model(Hoogendoorn, Rutten-van Molken et al. 2011) developed by Erasmus 
University, Rotterdam, using parameters derived from this database.  
These predictions can then be compared with predictions made by other means or in other 
countries. 
Sensitivity analysis to the parameters derived from the database will also be undertaken 
 
Rationale:  
Quantification and prediction of the disease burden in the future will better enable planning 
of healthcare resources. 
 
Background 
Chronic obstructive pulmonary disease (COPD) is a respi atory disease which is 
characterised by progressive airflow limitation that is not fully reversible.(GOLD 2010) 
COPD is a major cause of chronic morbidity and mortality throughout the world and results 
with a large economic and social burden. The 2010 World Health Organization Global 
Burden of Disease study lists COPD as the third largest cause of death worldwide.(Lozzano, 
Naghavi et al. 2012) COPD patients not only die prematurely, they also have a decreased 
quality of life due to impaired physical, mental, and social functioning.(Murray, Vos et al. 
2012)  
 
The most important risk factor for COPD development and progression is cigarette 
smoking.(GOLD 2010) Smokers with COPD experience an accelerated decline in lung 
function.(Peto, Speizer et al. 1983)  
 
As populations are ageing, the prevalence of long term conditions such as COPD is 
increasing. This means that more resources are required to provide healthcare for the COPD 
population.(DoH 2010) To help plan these resources a dynamic COPD population model has 
been developed by Erasmus University.(Hoogendoorn, Rutten-van Molken et al. 2005; 
Hoogendoorn, Rutten-Van Molken et al. 2011) This model includes provision for calculating 
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how many people will develop COPD and at what severity if they continue to smoke or stop 
smoking later in life. It also includes provision for modelling the healthcare needs of these 
people from data on the rate of exacerbations and costs of healthcare.(Hoogendoorn, Rutten-
Van Molken et al. 2011) 
 
In order to plan healthcare for people with COPD in the future, these calculations as to the 
size of the disease burden are useful. In addition, he effects of interventions such as smoking 
cessation campaigns may be computed. 
 
The CPRD will allow calculation of UK-specific parameters for, lung function decline, 
mortality and exacerbations which can be fed into the model. Then predictions can be made 
on this basis. The sensitivity of the predictions to these inputs will also be tested. 
 
Study type 
Providing parameters for an existing model. Hypothesis generating in this context. 
 
Study design Methodology 
A cohort of 50,000 cases in the case-control database who have COPD will be used to 
generate parameters to feed into an established Markov Model, by Erasmus University.  
 
Study population 
A random sample of 50,000 cases of COPD has been drawn f om the CPRD. 
Inclusion criteria:  
a recorded diagnosis of COPD 
age ≥35 years (this lower limit has been chosen because risk prediction of COPD at earlier 
age is unlikely to be feasible) 
Exclusion criteria: 
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less than one year of complete data in the medical re ord. 
 
Sample Size 
The original Erasmus study used a cohort of only 5887 patients (the lung health study 2000) 
to model the annual decline of FEV1%  in the following model: 
 
Annual decline FEV1% predicted~ intercept +year+smoking status+sex+age+   baseline 
FEV1 + interaction effects 
 
With this much larger cohort of 50,000 patients the annual decline of FEV1 would be ten 
times more powerfully modelled. 
 
Exposures, Outcomes and covariates: 
 
This following table demonstrates the inputs to the Erasmus model and  a * indicates the 
items which will be calculated using this CPRD data. 
 
Ref Data title Scottish Run UK wide run 
A1 General Population Data National Records 
Scotland 
Office National Statistics 
(England and Wales) 
A2 Proportions of population 
that smoke, former smoker 
and never smoker by age and 
gender 
Scottish Health 
Survey, over 16. 
Under 16 SSALSUS 
Age over 16, Smoking toolkit 
study; (England) 
Under 16 General Lifestyle 
Survey,  (England) 
A3a GP prevalence of COPD, age 
and gender specific 
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A3b GP incidence of COPD age 
and gender specific 






A4 Relative risks of smokers and 
nonsmokers 
Use Rotterdam data,  Use Rotterdam data,  
A5 Age and sec specific start 
stop and restart probabilities 
for smoking 
Use Rotterdam data,  Use Rotterdam data,  
A6 Random effects model to 
predict lung function decline 
Recalculate model 
using COPD Lothian 
data 
*3 
A7 COPD related maintenance 
costs 
Use Rotterdam data Use Rotterdam data 
 
A8  
Mean utility scores by COPD 
severity stage 
Use Rotterdam data Use Rotterdam data 
A9 All cause mortality, mortality 
attributable to COPD 
mortality and mortality from 
other causes, by age and sex 
( per 1000 COPD patients) 
(i.e. what do COPD patients 
die of?) 
Lothian cohort data 
will allow to form a 
case fatality profile. 
*4 
 
*1 In order to calculate the prevalence of COPD from the cohort of 50000 patients, a 
denominator of the total population of the practices from which the 50000 were drawn 
ideally, per year or at a fixed point in time. 
 
*2 In order to calculate the incidence rate of COPD, it would have to be established whether 
the 50,000 cases were incident cases and over what time period they were discovered. This 
may be possible using the second half of the database with the first half as a “look-back 
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period” to eliminate previous diagnoses. The denomiator would then be the total person 
time for the practice populations which contributed hese cases. 
 
*3 see above 
 
*4 As these 50,000 patients with a recorded diagnosis of COPD are linked to Office for 
National Statistics (ONS) mortality, it will be possible to develop an age stratified case 
fatality profile of the population. A profile of age at death, sex and whether death was due to 




The parameters below would also be modelled/calculated using the COPD cohort. 
 
A Rate of Exacerbation by 
COPD stage 
Individual patient data calculation, potentially a fresh 
model, as the CPRD is linked to HSE for exacerbations the 
rate of exacerbations at different times of year, by sex and 
smoking status can be modelled.  
B Case fatality rate Develop age stratified case fatality profile of either 
Lothian Cohort or CPRD from linked death certificate data 
rather than modelling  
C Decline in FEV1 due to 
exacerbation 
Calculate using CPRD or Lothian cohort (Average lung 
function decline per year/no. of exacerbations per year)= 
average lung function decline per exacerbation  
 
All analyses will be carried out by a collaboration f Prof. Aziz Sheikh, Dr Susannah 
Mclean, Dr. Daniel Kotz, Dr. Colin Simpson, Prof Sarah Wild, Dr Martine Hoogendoorn and 
Prof Maureen Rutten-van Mölken.  
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Patient or user group involvement 
The Edinburgh Allergy & Respiratory Research Group has its own Consumer Involvement 
Group, which will advise on this project.  
 
Limitations of the study design, data sources, and analytic methods  
The case definition is dependent on a clinician-reco ded diagnosis. Thus, we have to assume 
that the absence of a recorded diagnosis of COPD is equivalent to the person not having the 
disease, which is not always the case and may lead to some degree of misclassification. This 
problem is amplified by the fact that COPD is not easily diagnosed; a proper diagnosis can 
only be made by spirometry with reversibility testing.(Holleman and Simel 1995) There is 
also debate regarding the precise spirometry threshold to use.(Celli, Halbert et al. 2003; 
Roberts, Farber et al. 2006; Garcia-Rio, Soriano et al. 2011)  
 
This study is based on routinely collected primary care data.(Jones, Dickson-Spillmann et al. 
2008) These vary in their accuracy and completeness and techniques may have to be used to 
account for missing data, for example, data imputation – a standard statistical technique 
where missing data re estimated from the statistical d stributions and other features of the 
available data for the same parameter.  
 
Another limitation is the complexity of the Markov model. As these models often build up 
layers of assumptions, they become vulnerable to criticism due to accumulation of errors. 
However, using this dataset would be a breakthrough in terms of validating the Erasmus 
model as it has not so far been trialled with the data of a country other than the Netherlands. 
Also as the Netherlands and the UK have similar provisi n of healthcare, interesting 
comparisons will, therefore, be made and critiqued. 
 
Plans for disseminating and communicating study results 
We plan to disseminate our results via publication in an international peer reviewed journal 
in the field of respiratory research (e.g., European Respiratory Journal). We also plan to 
submit an abstract to the annual congress of the European Respiratory Society. Any 
publication will be in accordance with ICMJE guidelin s.  





The GPRD Group has obtained ethical approval from a Multi-centre Research Ethics 
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Appendix 1.3 CPRD agreement for provision of 




Date: 11 September 2013 
 
Predicting the risk of chronic obstructive pulmonary 
disease: a nested case-control study 
Prepared by: Helen Strongman, CPRD 
Distribution: Susannah Maclean, University of Edinburgh 
 
Objective 
To estimate the incidence and point prevalence of COPD in the general population 
in 2011. 
 
Source Population  
The extraction population will comprise of all patients in CPRD GOLD from the 
CPRD build used in the original research; April 2012 (n=13,519,941).  
 
Practice Criteria 
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The study cohort will be drawn from of all up-to-standard English practices that 




The study population will consist of all patients in eligible practices who: 
• Are acceptable (n=6,112,231) 
• Are male or female (n=6,112,056) 
• Were alive and registered in an up-to-standard practice on and for at least 18 
months prior to 01/01/2011 (n=2,152,744) 
• Were aged at least 35 in 2011 (2011 – birthyear >=35) (n=1,346,902) 
• Have not been diagnosed with COPD at an unspecified date (nn=1,346,895) 
 
The age of the patient will be the calculated by subtracting the year of birth of the 
patient from 2011. 
 
The following criteria that were used to define the cases and controls in the original 
study will not be applied: 
• have a valid postcode/SOA (for socioeconomic status)  




Aggregated data based on cohort analysis 
 
Point prevalence of COPD 
 
Denominator 
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Denominator data will include all patients in the study population. 
 
Numerator 
The numerator will be all patients in the denominator population who have a first 
record of COPD at any time in their patient record prior to 01/01/2011. 
 
Point prevalence calculation 
The point prevalence of COPD will be calculated by dividing the number of patients 
in the numerator by the number of patients in the denominator.  Prevalence data 
will be presented per 100,000 patients with 95% CI calculated using the Poisson 
distribution.  Results will be stratified by gender and age.  The data tables will 
include the numerator and the denominator. 
 
Incidence of COPD 
Numerator 
The number of patients with a first mention of COPD in 2011 whilst registered at an 
up-to-standard practice.  
 
Denominator 
Denominator data will consist of the sum of the person years of up-to-standard 
follow-up in 2011 of all at risk patients in the study population. 
 
The start of observation will be the 01 January 2011.  The end of observation will be 
defined as the minimum of the practice last collection date, the patient transfer out 
date, the CPRD derived death date, the first record of COPD (index date)  or 31 
December 2011. 




Incidence rate calculation 
The incidence rate of COPD in 2011 will be calculated by dividing the number of 
incident cases by total person time between 01/1/2011 and 31/12/2011 in the 
denominator population.  Incidence data will be presented per 100,000 patient years 
with 95% CI calculated using the Poisson distribution.  Incidence rate data will be 
stratified by gender and age.  The data tables will include the numerator and the 
denominator. 
 
Note on small cell counts 
Due to the possibility of deductive disclosure, CPRD policy is that no cell should 
contain < 5 events when data is reported. 
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Appendix 1.4 Covering letter to CPRD ISAC for 
approval 
 
Centre for Population Health 
Studies 












Re: Amendment to CPRD protocol “Predicting the riskof COPD a nested case-control 
study” 
 
Our research group led by Prof Aziz Shiekh, previously submitted a protocol for data for the 
above study under the MRC funding scheme. We receivd the data and Daniel Kotz has 
recently commenced analysis of it. 
 
We would now like to submit an amendment to this protocol to enable further analysis of 
this dataset by a wider team in order to calculate some parameters for a COPD health 
economics model. 
 
This is a linked project because it covers a different aspect of projection in COPD. The 
primary aspect was a plan to use a nested case control study to predict outcomes in COPD. 
This secondary aspect is to consider the health economics needs of a simulated population 
with COPD. The model is a well established health economics model developed by Erasmus 
University, the Netherlands. Data from the “cases” will be used as a cohort in order to 
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populate certain parameters of the model including the rate of decline of FEV1 with time and 
with exacerbations. Please see protocol for further details.  
 
The protocol also includes a proposal to include in this analysis an estimation of both the 
prevalence and incidence of COPD in the UK dataset, for which some additional data will be 
required. Whether or not we finalise this request for additional data will depend on the 
costing as some of the data may have already been extracted as part of the preliminary work-
up to the data that we previously received. 
 
With the above exception, this protocol amendment is essentially an application for 
permission to extend and publish further related analysis on the same data which we already 
possess and will not require further work by CPRD, as such we anticipate that no further 
costs will be incurred. 
 





On behalf of the research team at University of Edinburgh, Centre for Population health 
studies. 
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Appendix 1.5 ISAC Application form 
 
 
ISAC APPLICATION FORM:   
PROTOCOLS FOR RESEARCH USING THE GPRD DATA 
AMENDMENT TO PROTOCOL 
 







If you have any queries, please contact ISAC Secretariat: 
ISAC@gprd.com 
 
1. Study Title  
 Predicting the risk of chronic obstructive pulmonary disease: a nested case-control study, amendment.  
 
2. Does this protocol describe a purely observational study using GPRD data (this may include the review of 
anonymised free text)? 
 
 Yes                         No                          
 
 
3. Does this protocol also seek access to data held under the GPRD Data Linkage Scheme? 
 
              Yes    No      
 
 
4. If you are seeking access to data held under the GPRD Data Linkage Scheme, please select the 
source/s of linked data being requested. 
 
         Hospital Episode Statistic†       Cancer Registry Data *         MINAP*                                                    
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         Townsend Score                       ONS Mortality Data             Other: (please specify)  
        
* Please note that access to these data sources are not covered under the GPRD-MRC Scheme. 




5. If you are seeking access to data held under the GPRD Data Linkage Scheme, have you discussed 
your request 
        with a member of the Research team?  
              Yes                                                 No                       




6. Does this protocol involve requesting any additional i formation from GPs?  
 
       Yes                     No                       
 
 If yes, please indicate what will be required:  
   
 Completion of questionnaires by the GP*     Yes     No   
 Provision of anonymised records (e.g.  hospital discharge summaries)  Yes     No   
 Other (please describe)          
 
*any questionnaire for completion by GPs needs to be approved by ISAC before being sent out for completion.   
 
GUIDANCE ON ANSWERING QUESTIONS 4-6: 
These questions must be completed by all applicants.  You should note the following:   
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(i) If you have answered NO to question 2, may need to seek separate ethics approval from an 
NHS Research Ethics Committee for this study. The ISAC will provide advice on whether 
this may be needed. 
 
 (ii) If you have answered YES answered to question 2 above and you will be using data obtained 
from the GPRD Group at the MHRA, this study does not require separate ethics approval 
from an NHS Research Ethics Committee.  
 
If you will be using data obtained from EPIC, you will need to consult the data provider 
regarding their arrangements for obtaining ethics approval for the study.  
 
NB: Answering YES to question 2 means that the answers to questions 7-9 should all be NO. If 
any of the answers below are YES please review youranswer to question 2 as it should be NO. 
 
7. Has this protocol been peer reviewed by another Committee?                                  Yes      No  
 
 
       If yes, please state in your protocol the name of the reviewing Committee/s and provide an 
outline of the 
       review process and outcome on final review. 
 
 
8. Does the study involve linking to patient identifiable data from other sources?    Yes       No   
 
9. Does this study require contact with patients in order for them to  
 complete a questionnaire?       Yes       No   
 
10. Does this study require contact with patients in order to collect a sample?  Yes      No   
 If yes, please state what will be collected           
 
 
11. Type of Study (please tick one box below) 




Adverse Drug Reaction  Drug Use               Disease Epidemiology                   
Pharmacoeconomic           Drug Effectiveness                          Other    
 
12. Data source  (please tick one box below) 
 
GPRD Division at MHRA     Other         
       (please specify)                                            
Full Feature on-line access             
Ad hoc dataset      
MRC dataset      
Other commissioned study     
 
 
13. Financial Sponsor of study 
 
MRC*                      Pharmaceutical Industry (please specify)         
Government / NHS (please specify)         Other (please specify)          
None        
 
* Tick this box if you wish to access GPRD data under the MRC licence with GPRD.  It is expected that if you use the 
MRC licence, no other direct commercial/public sector funding for this study will be sought/has been applied for or is 
in place. If funding is in place, but does not cover the use or extraction of GPRD data, please tick the boxes for 




14. Is the study intended for 
Publication in peer reviewed journals                         Presentation at scientific conference              
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Presentation at company/institutional meetings           Other               
 
15. Principal Investigator (full name, job title, organisation & e-mail address for correspondence regarding this 
protocol) 
Prof. Aziz Sheikh, Professor of Primary Care Research & Development, University of Edinburgh,  
phone: 0131 6514151, e-mail: Aziz.sheikh@ed.ac.uk 
 
 
16. Affiliation (full address) 
Allergy and Respiratory Research Group, Allergy andRespiratory Research Group, Centre for Population Health 
Sciences - General Practice Section, University of Edinburgh, Doorway 3, Teviot Place , Edinburgh EH8 9AG 
 
17. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider                   Pharmaceutical Industry    
NHS            Government Departments       Others     
 
 
18. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of researchers 
actively involved in the proposed research, including  analysis of data and interpretation of results 
                                   Previous GPRD                                                   Publications                   
                                         Studies                                                     using GPRD data 
 
None                                                                                           
1-3                                                                                           
> 3                                                                                           
                                                                                                                   Yes                             No 
Is statistical expertise available within the research team?                                                                
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 If yes, please outline level of experience                           
 Expertise in applied statistics is available from the research group of Epidemiology and Statistics 
which is part of the Centre for Population Health Sciences  
 
Is experience of handling large data sets (>1 million records)                                                          
 available within the research team?                            
 If yes, please outline level of experience                          
 Prof. Aziz Sheikh and Dr. Colin Simpson have long standing experience from working with large 
data sets. They have published several papers usingdata from GPRD, QRESEARCH, and the 
Primary Care Clinical Informatics Unit of the University of Aberdeen. 
 
Is UK primary care experience available within the research team?                                                 
 If yes, please outline level of experience                            
 Prof. Aziz Sheikh and Dr. Colin Simpson are experienced researchers in the field of UK primary 
care. 
 
19. Other collaborators (if applicable: please list names and affiliations of all collaborators) 
Dr. Daniel Kotz, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centr 
Dr. Colin Simpson, Centre for Population Health Scien es, University of Edinburgh 
Prof.  Sarah Wild, Centre for Population Health Scien es, University of Edinburgh 
Dr Susannah McLean, Centre for Population health Sciences University of Edinburgh 
Prof Rutten van Molken, Erasmus University, Rotterdam 
Dr Martine Hoogendoorn, Erasmus University, Rotterdam 
 
20. Protocol’s Author (if different from PI) 
Susannah Mclean for amendment to protocol 
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Protocol content checklist 
 
In order to help ensure that protocols submitted for review contain adequate information for 
protocol evaluation, ISAC have produced instructions  the content of protocols for research 
using GPRD data. These instructions are available on the GPRD website 
(www.gprd.com/ISAC). All protocols using GPRD data which are submitted for review by 
ISAC must contain information on the areas detailed in the instructions.  IF you do not feel 
that a specific area required by ISAC is relevant for your protocol, you will need to justify this 
decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted 
includes all the areas required by ISAC, or to provide justification where a required area is not 
considered to be relevant for a specific protocol.  Protocols will not be circulated to ISAC for 
review until the checklist has been completed by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, 
or if you answer ‘no’ and fail to include justification for the omission of any required 
area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for omission 
Lay Summary (max.200 words)         
Objective, specific aims and rationale         
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Hypothesis Testing         
Study Design Methodology              
Study population, including estimate of 







      
 





      




No controls required for this 
analysis 




      










      
      
Patient/ user group involvement †  
 
         
Limitations of the study design, data 
sources and analytic methods 
        
Plans for disseminating and 
communicating study results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups in their planning 
and refinement, and/or in the interpretation of the r sults and plans for further work. This is particularly, but 
not exclusively true of studies with interests in the impact on quality of life.   Please indicate whethr or not 
you intend to engage patients in any of the ways mentioned above. 
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ISAC strongly recommends that researchers using GPRD consider registering as a NRR data provider in order 
that others engaged in research within the UK can be made aware of current works. The National Research 
Register (NRR) is a register of ongoing and recently completed research projects funded by, or of interest to, the 
United Kingdom's National Health Service. Information on the NRR is available on www.nrr.nhs.uk . 
Please Note: Registration with the NRR is entirely voluntary and will not replace information on ISAC 
approved protocols that are published in summary minutes or in the ISAC annual report.   
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Appendix 1.6 ISAC Protocol approval 
ISAC EVALUATION OF PROTOCOLS FOR RESEARCH 
INVOLVING CPRD DATA 
 
FEED-BACK TO APPLICANTS 
CONFIDENTIAL                                                                       by 
e-mail 
PROTOCOL NO:  10_084RA 
PROTOCOL TITLE:   Predicting the risk of chronic obstructive pulmonary disease: a 
nested case-control study 
APPLICANT:   Prof. Aziz Sheikh, Professor of Primary Care Research & 
Development, Allergy and Respiratory Research Group, Allergy 
and Respiratory Research Group, Centre for Population Health 
Sciences - General Practice Section, University of Edinburgh 
APPROVED  
  
APPROVED SUBJECT TO 
MINOR AMENDMENT  










Please include your response/s to the Reviewer’s feedback below only if you are required to 
Revise/ Resubmit your protocol.  
Protocols with an outcome of ‘Approved’ or ‘Approved subject to minor amendments’ do not 
require resubmission to the ISAC 
REVIEWER  COMMENTS: 
The proposed amendment to Protocol 10-084RA is approved. 
 
DATE OF ISAC FEEDBACK: 05 April 2013  
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DATE OF APPLICANT FEEDBACK:  
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Appendix 2.1 Level 1 Ethics approval from UoE 
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Appendix 3.2 Email approval for use of the Lothian 
COPD Cohort database from Privacy Advisory 




Thank you for this information regarding the modell ing for which you 
will use the Lothian data. I am sorry that I overlo oked your 
response. I have not had a reminder since then. 
 
I do not think that there is a risk of identifying individuals from 
the aggregate data you will produce and agree that it is acceptable 
for you to analyse the Lothian linked dataset. 
 




Dr Janet Murray 
Consultant CPHM 
Information Services Division 
Gyle Square 
1 South Gyle Crescent 
Edinburgh EH12 9EB 
 
0131 275 6954 




PA Sian Bennett 
 




From: Susannah McLean [ mailto:Susannah.McLean@ed.ac.uk ] 
Sent: 16 April 2013 11:14 
To: Murray Janet (NATIONAL SERVICES SCOTLAND) 
Cc: Campbell Fiona (NATIONAL SERVICES SCOTLAND); PA C (NATIONAL 
SERVICES SCOTLAND) 
Subject: Re: Amendment to pac Application 49/10 
 
Dear Janet, 
Thank you for your reply, with regards the first po int, that is good 
news. 
With regards the second I have attached a more deta iled working 
document 
which outlines the origin of every parameter we hop e to include in 
the 
model. the parameters that will originate from the Lothian cohort 
can be 
seen in the summary tables in pages 2 and 3 are des cribed in detail 
later in the document. they are 
A3b. incidence of COPD in Lothian/Scotland 
A6. a random effects model to predict lung function  decline. 
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A9. a case fatality profile by age and sex 
A A rate of exacerbation model 
B case fatality profile, very similar to A9 
C decline in FEV1 due to exacerbation, calculated u sing results from 
previous models. 
 
I hope this helps, the document has further details  on the models 
but I 
plan to have done the detailed work on the model be fore I go to 
Rotterdam. Then simply travel with the aggregated d ata. 




On 11/04/2013 15:16, Murray Janet (NATIONAL SERVICE S SCOTLAND) 
wrote: 
> Dear Susannah and Fiona 
> 
> Thank you for your updated application Susannah. I have read it 
with the original PAC application and note the two changes to the 
original application which you list in your email b elow. I do not 
think that this application requires full assessmen t by the 
committee. I think I may be able to make a decision  alone, depending 
on the extent of data to be sent to Rotterdam. 
> 
> 1 The additional use of the data is epidemiologic al research into 
COPD. Although the focus is different from the aim of the original 
application, I am content that the purpose is in li ne wit that for 
   
249 
 
which the database was created. I note that Dr Rach el Hardie who as 
responsible for its creation is involved with this work. 
> 
> 2 The application indicates that aggregate data w ill be supplied 
to the University of Rotterdam and will be stored o n a laptop there. 
Depending on the level of detail required there may  be a risk of 
identifying individuals even from an aggregated dat abase. So that I 
can consider the level of risk, and whether particu lar sensitive 
information would be revealed, please would you let  me know all of 
the variables which will be used to create the aggr egate data? 
Depending on the level of risk, I may have to discu ss with our 
privacy and security advisors. 
> 




> Dr Janet Murray 
> Consultant CPHM 
> Information Services Division 
> Gyle Square 
> 1 South Gyle Crescent 
> Edinburgh EH12 9EB 
> 
> 0131 275 6954 
> 
> PA Sian Bennett 
> 
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> T: 0131 275 6293 E: sian.bennett@nhs.net  
> 
> 
> -----Original Message----- 
> From: Susannah McLean [ mailto:Susannah.McLean@ed.ac.uk ] 
> Sent: 10 April 2013 10:24 
> To: Campbell Fiona (NATIONAL SERVICES SCOTLAND) 
> Subject: Re: Amendment to pac Application 49/10 
> 
> Dear Fiona, 
> The original application created the Lothian COPD  Cohort which is 
> currently undergoing the approved analysis. This application is to 
> approve an extension to this analysis which invol ves an economic 
model 
> from Erasmus University and therefore involves ta king aggregated 
data to 
> Rotterdam for use in the model. Data from the Lot hian COPD Cohort 
on 
> lung function decline, mortality and exacerbation s will be used to 
adapt 
> the model for use in Lothian/Scotland to predict the size of the 
future 
> local and national COPD disease burden. 
> The fact that we extend analysis and take data to  the Netherlands, 
we 
> thought we'd need a new PAC application. 
> Thank you 





> On 10/04/2013 09:26, Campbell Fiona (NATIONAL SER VICES SCOTLAND) 
wrote: 
>> Hi Susannah, 
>> 
>> Thanks for the amendment to your original PAC fo rm. 
>> 
>> To make it easier for us, could you explain in a  couple of 
paragraphs what is additional to your previous PAC application? It's 
not that clear from the form you have submitted. 
>> 
>> Also, given the time that has lapsed since your original 
application can you justify why it's an amendment a nd not a new 
application. 
>> 
>> Thanks for this. It will help us to deal with yo ur application as 




>> ------------------------------------------------ ---- 
>> Fiona Campbell 
>> Information Consultant 
>> ISD Scotland 
>> Gyle Square 
>> 1 South Gyle Crescent 
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>> Edinburgh, EH12 9EB 
>> Tel: 0131 275 6923 
>> Email: Fiona.Campbell2@nhs.net  
>> 
>> -----Original Message----- 
>> From: Susannah McLean [ mailto:Susannah.McLean@ed.ac.uk ] 
>> Sent: 08 April 2013 15:40 
>> To: PAC (NATIONAL SERVICES SCOTLAND) 
>> Subject: Amendment to pac Application 49/10 
>> 
>> Dear PAC, 
>> Please find attached a PAC application for a stu dy which has 
already been approved and an amendment request on t he pilot form 
dated 8th April 2013. 
>> Please could you consider this request for an am endment to the 
already approved study protocol. 
>> Please contact me if you require further informa tion. 
>> Thank you very much 
>> Susannah 
>> -- 
>> Dr Susannah McLean 
>> Doorway 1 
>> Medical Quad 
>> Teviot Place 
>> Edinburgh 
>> EH8 9AG 




>> Tel: 0131-650-9242 
>> 
>> The University of Edinburgh is a charitable body , registered in 







>> This message may contain confidential informatio n. If you are not 
the intended recipient please inform the 
>> sender that you have received the message in err or before 
deleting it. 
>> Please do not disclose, copy or distribute infor mation in this e-
mail or take any action in reliance on its contents : 
>> to do so is strictly prohibited and may be unlaw ful. 
>> 
>> Thank you for your co-operation. 
>> 
>> NHSmail is the secure email and directory servic e available for 
all NHS staff in England and Scotland 
>> NHSmail is approved for exchanging patient data and other 
sensitive information with NHSmail and GSi recipien ts 
>> NHSmail provides an email address for your caree r in the NHS and 
can be accessed anywhere 
>> 









> Dr Susannah McLean 
> Doorway 1 
> Medical Quad 
> Teviot Place 
> Edinburgh 
> EH8 9AG 
> 
> Tel: 0131-650-9242 
> 
> The University of Edinburgh is a charitable body,  registered in 







> This message may contain confidential information . If you are not 
the intended recipient please inform the 
> sender that you have received the message in erro r before deleting 
it. 
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> Please do not disclose, copy or distribute inform ation in this e-
mail or take any action in reliance on its contents : 
> to do so is strictly prohibited and may be unlawf ul. 
> 
> Thank you for your co-operation. 
> 
> NHSmail is the secure email and directory service  available for 
all NHS staff in England and Scotland 
> NHSmail is approved for exchanging patient data a nd other 
sensitive information with NHSmail and GSi recipien ts 
> NHSmail provides an email address for your career  in the NHS and 




















The University of Edinburgh is a charitable body, r egistered in 






This message may contain confidential information. If you are not 
the intended recipient please inform the 
sender that you have received the message in error before deleting 
it. 
Please do not disclose, copy or distribute informat ion in this e-
mail or take any action in reliance on its contents : 
to do so is strictly prohibited and may be unlawful . 
 
Thank you for your co-operation. 
 
NHSmail is the secure email and directory service a vailable for all 
NHS staff in England and Scotland 
NHSmail is approved for exchanging patient data and  other sensitive 
information with NHSmail and GSi recipients 
NHSmail provides an email address for your career i n the NHS and can 
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Appendix 3.3 Privacy Advisory Committee (PAC) 
Application for Lothian COPD Cohort Database 
 
NHS National Services Scotland Privacy Advisory 
Committee 
 
Application for Privacy Advisory Committee Approval  
 
THE PRIVACY ADVISORY COMMITTEE (PAC) is an advisory committee to NHS 
National Services Scotland (NSS) and the Registrar General.  
 
The PAC advises on the correct balance between protecting personal data and making data 
available for research, audit and other important uses and ensures that any information 
releases are carefully controlled. 
 
PAC views are sought in relation to any request for access to information that would involve 
the release of data under the control of NSS or Nation l Records of Scotland (NRS) that are, 
or have the potential to be, person-identifiable, and in respect of any new record linkages.  
 
Where the data you wish to access is not in the control of NSS or NRS you may need to 
consider applying to another advisory body - see ‘Appendix One: Advisory Bodies within 
NHSScotland’.  
 
Assistance with PAC 
 
NSS Research Coordinators are a specialist team of principal and senior information analysts 
based within the Information Services Division (ISD) who will help you to define 
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requirements for linked datasets and any analyses required. The NSS Research Coordinator 
will explain what information is available and assist you deciding what variables would be 
useful for your study. They will also advise when you may require to approach another 
advisory body. 
 
When to Complete a Privacy Advisory Application Form 
The PAC Application Form must be completed for data requests that involve: 
 
(a) access to identifiable or potentially identifiable information; 
(b) circumstances where NSS or National Records of Sc tland (NRS) have indicated their 
intention to  
  seek guidance from PAC; and/or  
(c) record linkage of previously unlinked datasets involving data from more than one Health 
Board. 
 
Our aim is to make data for research available through the ScottisH Informatics Programme 
(SHIP) infrastructure. All applicants to PAC will be expected to use the SHIP National Safe 
Haven as a means of accessing data except in very exceptional circumstances.  
 
 
ScottisH Informatics Programme (SHIP) 
SHIP is a Scotland-wide research platform for the collation, management, dissemination and 
analysis of Electronic Patient Records (EPRs). The programme brings together the 
Universities of Dundee, Edinburgh, Glasgow and St Andrews with the Information Services 
Division (ISD) of NSS. 
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The SHIP programme will provide a platform for Scottish record linkage that will drive EPR 
research throughout the UK and abroad. The SHIP National Safe Haven is the analytical 
platform for this. This includes the following. 
 
 Provision of a record linkage service where personal identifiers are kept separate from 
the payload/content data. 
 Provision of a secure environment for researchers to analyse anonymised patient level 
or summarised records. 
 Provision of a Secure File Transfer service to support the transmission of data between 
data providers and researchers. 
 
Anyone wishing to access data through the SHIP Nation l Safe Haven requires to be 
registered as a SHIP Approved Researcher or to have recently completed an Information 
Governance training course. 
 
Further Advice on National Records Service and NHS Central 
Registry 
 






For All Other Requests 
 
For all other requests or advice please contact the Research 
Coordinators at nss.ISDMedicalRecordLinkage@nhs.net





Before you submit your application, you should include the following items and ensure that 
the application has been signed by the appropriate individuals and then save the final 
document as a PDF to be e-mailed to the PAC mailbox at: 
nss.pac@nhs.net. 
 
Your application should be typed, not handwritten. 
 
Items to support application  
Where applicable, you should include the following. 
 
 Study protocol 
 Information provided to study participants and/or the wider public 
 Participant consent forms 
 Draft correspondence (if the data generated through your study will be used to contact 
any individuals) 
 Evidence of ethical approval 
 Evidence of approval from other Data Controllers e.g. CHIAG 
 Local Information Governance / security policies and procedures  
 The list of variables you require in the file for analysis 
 Details of each individual accessing the data (where there are more than five allowed on 
this form). 
 
Please ensure that your application has been signed by the: 
 
 main study contact; 
 study information custodian (for studies requesting he release of data outside the SHIP 
National Safe Haven). 
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You must also ensure that individuals named on the form have read and approved this 
submission. 
You must save this form as a PDF and only send the PDF version.  
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NSS Information Request 
Number  
(Your NSS Research 









 The information contained in this application form will be regarded as confidential 
as it goes through the scrutiny process but it is the duty of applicants to point out 
any information within the application that they consider to be particularly 
sensitive, confidential or commercially sensitive.  
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 As NHS National Services Scotland is a public authority, it is subject to Freedom 
of Information (Scotland) Act. 
 
 PAC applications are kept by NHS National Services Scotland for a minimum 
period of 15 years from date of application or date of the last linkage undertaken 
in relation to the application. 
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Application Part One: People Involved  
 
The names of all the individuals involved in and responsible for the design and analysis of 
the study should be included here. It is expected that those who have access to the data 
supplied by NSS have adequate and regular updated knowledge and skills in the secure and 
confidential handling of health data.  
 
 You must ensure that anyone required to access the data provided should be a SHIP 
Approved Researcher or should be able to demonstrate skills and knowledge of/having 
successfully recently completed approved training in Information Governance.  
 You must ensure that all staff taking part in this study must have appropriate contracts 
in place containing clauses that clearly identify their duties and responsibilities for 
confidentiality, data protection and data security. 
 You do not need to include clerical and secretarial support staff.  
 
Head of Department responsible for project/study or the Principal Investigator 
This should be the name of the person with overall responsibility for the study and who 




Position  Professor of Research and Development in 
Primary Care 
Qualifications MBChB, MD, MRCPCH, FRCGP 
Professional Registration Number (if 
applicable) e.g. General Medical Council 
(GMC) 
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Organisation Name University of Edinburgh 
Address Doorway 3, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode EH8 9AG 
Telephone number 0131-650-8101 
Email Aziz.sheikh@ed.ac.uk 
Please complete following questions if you will access the individual level data requested 
in this application 
Are you a SHIP Approved Researcher  Yes  
What was the date when SHIP Approved 
Researcher status was conferred 
 
 
If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
Name of Course: Graham Laurie’s online 
SHIP ethics  course 
Institution University of Edinburgh 
Date attended 
 
Main Contact    Researcher responsible for day to day running of prject (to whom all 
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Position  PhD Student 
Qualifications MBBS, MSc, MRCGP 
Professional Registration Number (if 
applicable) e.g. GMC  
6052508 
Organisation Name University of Edinburgh 
Address Doorway 1, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode EH8 9AG 
Telephone number 0131-650-9242 
Email Susannah.mclean@ed.ac.uk 
Are you a SHIP Approved Researcher  Yes  
What was the date when SHIP Approved 
Researcher status was conferred 
 
If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
Name of Course “ ADLS Safe researcher 
Course” 
Institution ADLS (Administrative Data and 
linked service) 
Date attended May 2011 
 
Information Custodian   The Information Custodian is the person taking respon ibility 
for safeguarding the confidentiality of the data.  This is likely to be the Head of 
Department responsible for the project. An Information Custodian is required if the SHIP 
National Safe Haven will not be used e.g. where data is requested from NRS 
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Title Prof  
Forename Aziz 
Surname Sheikh 
Position  Professor of primary care research and 
development 
Qualifications MBChB, MD, MRCPCH, FRCGP 
Professional Registration Number (if 
applicable) e.g. GMC  
4016942 
Organisation Name University of Edinburgh 
Address Doorway 3, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode EH8 9AG 
Telephone number 0131-650-8101 
Email Aziz.sheikh@ed.ac.uk 
Are you a SHIP Approved Researcher  Yes  
What was the date when SHIP Approved 
Researcher status was conferred 
20.3.2012 
 
If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
Name of Course  Graham Laurie’s online 
SHIP Ethics course 
Organisation SHIP 
Date attended  20.3.2012 
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Please list the name(s) of each person who will access the individual level data requested in 
this application. There is space here to provide details for three names. If there are more than 
three names, please append the additional information w th your application. 
 




Position  PhD Student 
Qualifications MBBS, MSc, MRCGP 
Professional Registration Number (if 
applicable) e.g. GMC  
6052508 
Organisation Name University of Edinburgh 
Address Doorway 1, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode EH8 9AG 
Telephone number 0131-650-9242 
 
Email Susannah.mclean@ed.ac.uk 
Are you a SHIP Approved Researcher  Yes  
What was the date when SHIP Approved 
Researcher status was conferred 
May 2011 
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If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
Name of Course ADLS safe researcher 
Organisation ADLS 
Date attended May 2011 
 




Position  PhD Supervisor, Professor of Epidemiology 
Qualifications MB BChir FRCP FFPH 
Professional Registration Number (if 
applicable) e.g. GMC  
3133196 
Organisation Name University of Edinburgh 
Address Doorway 1, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode EH8 9AG 
Telephone number 0131-651-1630 
Email Sarah.Wild@ed.ac.uk 
Are you a SHIP Approved Researcher  Yes   
What was the date when SHIP Approved 
Researcher status was conferred 
May 2011 
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If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
Name of Course ADLS safe researcher 
Organisation ADLS 
Date attended May 2011 
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Access Individual Level Data – 3 
Title Dr  
Forename Colin  
Surname Simpson 
Position  PhD Supervisor, Reader in Epidemiology 
Qualifications BSc PhD 
Professional Registration Number (if 
applicable) e.g. GMC  
NA 
Organisation Name University of Edinburgh 
Address Doorway 3, Medical Quad, Centre for 
Population Health Sciences, Teviot Place, 
Edinburgh 
Postcode Eh8 9AG 
Telephone number 0131 651 4151 
Email c.simpson@ed.ac.uk 
Are you a SHIP Approved Researcher   No 
What was the date when SHIP Approved 
Researcher status was conferred 
 
If not a SHIP Approved Researcher, please 
provide details of most recent Information 
Governance training undertaken. 
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Please list the names of any people not listed above that have had significant input into the 
design and content of this study, or will be involved in the study hereafter 
 
Other People Involved 
Name (Forename/Surname) Organisation 
Aziz Sheikh University of Edinburgh 
Leonie Hunter Lothian Health Board 






Please list up to three publications which you have produced or been involved in that 
demonstrate experience in the use of administrative data for research. 
 
Journal Name Title of publication Date of publication Author(s) and 
Organisation 
NA    
    
    
    
    






Please confirm that the data supplied by NSS will not be passed to anyone other than 
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Application Part Two: Study Overview 
In order to help the PAC assess your application, yu are required to provide an overview of 
your study. The following section should be completed with information accessible and 
comprehensible to a lay reader, expressing any acronyms in full.  
You should include your study protocol with your application. 
 
What is the background to the study?   
Chronic obstructive pulmonary disease (COPD) is a respi atory disease which is 
characterised by progressive airflow limitation that is not fully reversible. COPD is a 
major cause of chronic morbidity and mortality throughout the world and results in an 
economic and social burden that is both substantial and increasing. The 2010 World 
Health Organization Global Burden of Disease study lists COPD as the third largest cause 
of death worldwide. COPD patients not only die prematurely, they also have a decreased 
quality of life due to impaired physical, mental, and social functioning.  
 
The most important risk factor for COPD development and progression is cigarette 
smoking. Smokers with COPD experience an accelerated decline in lung function.  
 
As populations are ageing, the prevalence of long term conditions such as COPD is 
increasing. This means that more resources are required to provide healthcare for the 
COPD population. In order to accurately plan these r ources a dynamic COPD 
population model has been developed by Erasmus University, Rotterdam, the Netherlands. 
This model includes provision for calculating how many people will develop COPD and 
at what severity if they continue to smoke or stop smoking later in life. It also includes 
provision for modelling the healthcare needs of these people from data on the rate of 
exacerbations and costs of healthcare. No equivalent model exists for Scotland. 
 
In order to plan healthcare for people with COPD in the future, these calculations as to the 
size of the disease burden are useful. In addition, he effects of interventions such as 
smoking cessation campaigns may be computed. 
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Why is the study needed? 
In order to better plan the care costs and provisions of people with COPD in Scotland in 
the future. 
What are the aims and objectives of the study?  
Objective 
 
 The objective is to quantify COPD burden derived in Scotland and then to compare 
with similar disease burdens computed from Dutch and other UK cohorts. 
 
Specific aims: 
 The aim is to predict disease burden from COPD in 5 a d 10 years time using a pre-
existing model developed by Erasmus University, Rotterdam, using parameters 
derived from this database.  
 These predictions can then be compared with predictions made by other means or in 
Give a brief outline of the study design and data sources involved. 
Study Design 
A modelling study involving generating specific parameters based on the Lothian COPD 
Cohort database and inputing them into model from Erasmus University to better estimate 
the disease burden from COPD in the future in Lothian and Scotland. Comparisons will be 




Lothian COPD Cohort Database 
Please describe your study sample (inclusion/exclusion criteria e.g. involvement in 
trial/survey, health event, relevant date range, requi ment for a matched control cohort, 
etc). 
The Lothian COPD Cohort is an existing incidence cohort database of patients with a 
COPD code in participating Lothian primary care practices. 
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Please indicate whether this study has any implications for sensitive groups of vulnerable 
populations (see Appendix Two for details). 
NA 
 
Please describe envisaged benefits of your study either to patients or the wider public. 
Better planning of COPD healthcare resources. 
 
 
Does this study have any of the following commercial a ms? 
To be used by your organisation as part of a product or 
service to be sold by you to your customers 
 No 
To be used as part of a commercially funded research 
project 
 No 
To be used by your organisation as part of a product or 
service given freely by you to your customers 
 No 
To be incorporated into a publication which will be 
subsequently distributed free of charge 
Yes  




Does this application relate to previous PAC applications?
  
Yes  
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If yes, please provide the PAC reference number(s) This is an amendment to 
49/11 
Do you have funding in place for your study?  Yes  
If yes, please provide the name of the funding body Susannah Mclean is funded 
by a University Scholarship 
Do you intend to use the SHIP National Safe Haven? 
Scottish-based researchers will be expected to use the 
National SHIP safe haven.  By using SHIP safe haven th  
applicant doesn’t need to complete the IG section  





If no, please explain your reason why below.  
This project is an extension to an existing project and data are already available on a 
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Application Part Three: Data Requests 
This section of the form requests further detail rega ding the use of data to meet the 
objectives of the study. 
 
3.1 NRS Data 
Does your study involve NRS data?  If no, go to section NSS 
Data? 
Yes  
Does your study require use of NHS Central Registry (NHSCR) as 
a sampling frame for study controls?  
 No 
Does your study involve flagging of individuals on the NHSCR? If 
yes, please answer the following questions.  
 No 
Is the flagging of individuals: 
 To help trace and contact individuals throughout the UK? Yes No 
 To be informed of fact and cause of death? Yes No 
 To be informed of cancer registrations? Yes No 
 To be informed of emigrations prospectively and 
retrospectively? 
Yes No 
 To be provided with safe haven analysis? Yes No 
 For population analysis? Yes No 
 For household analysis?  Yes  No  
Does your study require the provision of any other service from 
NRS? If so detail below. 
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3.2 NSS Data 
Does your study involve NSS data?  Yes    
If yes, please identify the dataset(s) involved below. 
 SMR00 - Outpatients  
 SMR01 - Inpatients and Daycases Yes 
 SMR02 - Maternity  
 SMR04 - Mental Health  
 SMR06 - Cancer Registration  
 SMR11/SBR - Neonatal/Scottish Birth Record  
 CHSP-PS/CHSP-S/SIRS - Child Health Surveillance     
 A&E - Accident and Emergency  
 PIS - Prescribing Information  
 National Audits and Disease Registries e.g. Surgical 
Mortality, Renal Registry 
 
 Birth, Stillbirth or Death Records (NRS) Death records 
 Other (please list below)  
 
These dataset have been already linked into the Lothian COPD Cohort database 
 
 
Indicate by ticking all the box (es) that apply whether the information provided by NSS 
Scotland will be used to make direct contact with the following. 
 Make  
Contact 









 Hospital consultants     
 Other hospital staff     
 General 
Practitioners 
    
 Study members or 
patients 
    
 Relatives of study 
members or patients 
- please specify 
    
 Some other party - 
please specify 
    
Does your application request NSS to facilitate 
communication with individuals in the study sample?  
 No  
Does your study involve use of NSS Data as a sampling 
frame? 
 No 
Will all analysis be done in NSS by NSS staff e.g. you
only require aggregate output.  
 No 
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3.3 Non-NRS/NSS Datasets 
Does your study involve linkage to non-NRS/NSS data? If yes, 




Please complete for each of the non-NSS datasets that you will provide to ISD e.g. 
 
 Data held by GPs 
This linkage has already been performed 
 
There is space here to provide details for three non-NRS/NSS datasets. If there are more than 
three names, please append the additional information w th your application.  
 
Non NRS / NSS Dataset - 1 
What is the name of the dataset? Lothian COPD Cohort Database is 
already in existence, please see PAC 
application 49/11 
The purpose for which it was collected    
Describe the content of the dataset  
The time period to which it pertains  
The identifying variables which will be 
provided to enable linkage (please tick all 
that apply) 
 
Forename   
Middle name  
Surname  
CHI Number  




Date of Birth  
Gender  
UK NHS Birth 
Registration Number 
 




Non NRS/NSS Dataset - 2 
What is the name of the dataset?  
The purpose for which it was collected.  
Describe the content of the dataset.  
The time period to which it pertains.  
The identifying variables which will be 




Forename   
Middle name  
Surname  
CHI Number  
Postcode  
Date of Birth  
Gender  
UK NHS Birth 
Registration Number 
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Non NRS/NSS Dataset - 3 
What is the name of the dataset?  
The purpose for which it was collected.    
Describe the content of the dataset.  
The time period to which it pertains.  
The identifying variables which will be 
provided to enable linkage (please tick all 
that apply) 
Forename   
Middle name  
Surname  
CHI Number  
Postcode  
Date of Birth  
Gender  
UK NHS Birth 
Registration Number 
 









3.4 Output File for Analysis 
 
The risk of disclosure of individuals increases with increased level of detail contained in the 
dataset.  Only variables required to meet study objectives should be requested.   
 
Identifiable data includes variables such as name and d te of birth. In general, access to 
personal identifiers will not be provided.  Exceptional requests for access may be considered 
taking account of Information Governance principles. 
 
Do you require any patient identifiers in the output file for analysis? Yes  
 
If yes, please identify which patient identifiers you require in the output file for analysis 
Forename   
Surname  
CHI Number  
NHS Number  
Postcode (full or part)  
Date of Birth Yes 
Gender Yes 
Other (please list  
Please provide justification on why you need these patient identifiers. This information 
can only be provided where a clear need is shown.  




Male and female and age to give the profile of people with COPD 
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Data without identifiable variables may retain the potential to identify an individual. This 
increases with the level of detail included, particularly where the denominator population is 
small as when rare conditions or low level geographies are involved.  
 
Our Research Co-ordinators will be able to advise wh ther ‘derived variables’ may be 
provided e.g. length of stay with month of admission rather than dates of admission and 
discharge. Output files may include a study index number where recognition of individual 
records is necessary. 
 
Please identify which, if any, of the following vari bles are required. 
Dates: 
 Full dates  
 Year and Month Yes 
Geographical variables: 
 NHS Board area  
 Local Authority area  
 Datazone  
 Postcode district  
 Information regarding rare 
conditions (please list the 
conditions)   
 
Please provide justification on why you need these variables. Variables can only be 
provided where a clear need is shown.  
 
To derive age and time with COPD 
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3.5 Other Variables 
Please list all the other variables (not already listed) which will be required, identifying 
which variables come from which data source. 
 
Variable Data Source 
Lothian COPD Cohort Database is 











3.6 Duration of the Study 
What is the expected duration of the study? 
18 months 
 
3.7 Updates and Retention  
Does your study require access to a regular update of data?  No 
If yes, please explain the reason for this. 




Please specify the frequency of updates your study will require. 
 
How long will you be keeping the data (including the updates) after the study is complete?  
5 years in the Edinburgh University Data Archive 
Please provide justification on why you need to retain he data for that length of time.  
To complete publications from the study 
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Application Part Four: Permissions to Use Data 
For each dataset not under the control of NRS or NSS, you must seek authority to access 
those data. 
 
 An application to the CHI Advisory Group (CHIAG) is necessary where the study 
requires access to information from the CHI dataset. 
 An application to the NHSScotland Caldicott Guardian Forum is necessary where the 
study requires access to information datasets held by multiple NHS Boards. 
 Approval from the National Research Ethics Service should be sought in the following 
situations:  
 
 Where the study involves linkage of a research dataset to another dataset. 
 Where the study involves use of identifiable data. 
 Where study involves use of highly disclosive data e.g. information regarding rare 
conditions or at the level of small geography.   
 
Evidence that use is authorised by the Data Controller(s). This may include authorisation 
from CHIAG, NHS Caldicott Guardians Forum or other. This can be attached to your 
application. 
Permission will be sought from the NHS Caldicott Guardian, We have a waiver from NHS 
ethics and we will apply to the University Internal ethics procedure.  
Please describe the methods used to inform study partici nts and/or the wider public 
regarding the use of their data in this way.   
GP practices that gather patient data have information in the practice waiting room 
regarding data use. 
Please provide copies of the information provided to study participants and/or the wider 
public regarding the use of their data in this way.  This can be attached to your 
application. 
NA 
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Please provide the consent form for research studies or surveys.  This can be attached to 
your application. 
NA 
Where no consent for proposed use has been obtained from data subjects, please provide 
justification below explaining why there is use without consent e.g. please explain why 
consent has not been obtained and explain how this proposed use relates to the original 
purpose of data collection.   
It is believed that this study is in the wider public interest. Namely to improve the 
prediction of the burden from COPD in a country andtherefore patients will benefit from 
the study output. In addition, all data required for this study are non-identifiable, thereby 
protecting the participants and only aggregate datawill be required for the model. 
Have any members of the public/lay people been involved in the study design? Please 
provide information.  
No 
 
Application Part Five: Information Governance  
 
NSS must ensure that any data approved for release to th applicant will be adequately 
protected against inappropriate access and use during the term of the study and on 
completion of the study the data will be securely disposed of.  
 
 This section does not require to be completed for studies in which data will be accessed 
only through the SHIP National Safe Haven.  Please complete this section for all other 
applications i.e. studies requiring release of datato he applicant.  
 
 Researchers from Scottish institutions will be expected to access NSS data using the 
SHIP National Safe Haven.  Any alternative to this w ll require justification.  
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 You may need to consult your organisation’s Information Governance Lead and IT 
service supplier when completing this part of the form. 
 
5.1 Local Information Governance Policies and Procedures 
Your organisation(s) should have Information Governance policies and procedures for each 
location and that these are accessible and used by all staff on this study.  Please attach copies 
of local Information Governance policy/policies foreach location to this application or 





5.2 Information Governance Incident Reporting 
Your organisation(s) should have Information Governance incident reporting procedures for 
each location and that these are accessible and used by all staff on this study.  
 
NSS should be notified immediately of any information governance breaches that 
have occurred involving NSS supplied data during this study. Please confirm you will 
notify nss.pac@nhs.net of any such incidents X  
 
URL(s) if policies are available online: 
http://www.ed.ac.uk/schools-departments/records-management-section/data-
protection/guidance-policies/research/research 
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5.3 Data Protection Registration 
Please provide the Data Protection Registration Number of each of the organisation (s) 
where data will be held. 
Organisation(s) Name/Data Storage 
location 
Data Protection Registration Number 
 















5.4 IS0 27001 
If your organisation(s) have adopted IS027001 - Information Security - Security Techniques 
- Information Security Management Systems, please provide your certification number. 
 
Organisation Name / Data Storage location ISO 27001 Certification Number 
University of Edinburgh We do not have this certificate 
  
  






5.5 NSS Data Transfer and Storage Policies 
 
 NSS requires that all sensitive and person identifiable data is encrypted during transfer and 
whilst stored on mobile data storage devices and desktop and laptop computers.  
 
 NSS prefers that any data provided is stored on secure networked drives as part of a 
secure managed server.  If mobile data storage devices have to be used, you must 
implement adequate protection against device loss or theft, unauthorised interception 
and access . 
 
 Where NSS supplied data is being stored on mobile data storage devices (for example 
but not limited to: USB ‘sticks’ and USB data storage drives, desktop or laptop 
computer) these devices must be fully encrypted to FIPS 140-2/CESG CAPS certified 
level of security protection.  
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 Where devices cannot be encrypted (for example: CDs, DVDs) then the data must be 
encrypted to FIPS 140-2/CESG CAPS certified level of security prior to storage on the 
mobile data storage device.  
 
 NSS uses NHSmail email services for regular communications and the transfer of person 
identifiable data however cannot send or receive password encrypted attachments using these 
email services. NSS can only send sensitive and person identifiable data to other users using 
NHSmail services (either NHSmail accounts or the secure file transfer service).  Please discuss 
methods with the Research Coordinator. 
 
 There are risks associated with using any email services for the transfer of data 
including sending the communication to the wrong email address. Please ensure that the 
NHSmail email address you provide is the correct address to be used. NSS will only 
send data to individual user (e.g. named) email addresses and not to generic email 
addresses. 
 
Please confirm that you have read and understood the details regarding NSS Data 
Transfer and Storage Policies by ticking here  X 
 
5.6 Data Storage 
Please provide details on how and where you will store he data supplied by NSS. If data is 
being stored in more than one location then this section needs to be clearly completed for 
each location. 
 
At what location(s) will data be stored?   
Please list. 
Information services , University of  
Edinburgh. 
Will any data be stored outside of Scotland?  Yes  
If yes, please state the location outside Scotland 
where data will be stored.   
Aggregated summary data will be used 
in Rotterdam to facilitate the running of 
the modelling. 
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Specific considerations will apply where data is 
stored outside of the European Union. 
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5.7 Storing of Data 
This section relates to where data supplied by NSS will be stored.  
Storage Device  
 
Please tick all that apply and specify for each, the 
location at which the data will be stored. *delete as 
appropriate. 
 Confirm Location 
Networked server disk drive      X University of Edinburgh 
Networked desktop PC*/ 
laptop*       
X (laptop) Aggregated data at University 
of Rotterdam 
Standalone desktop PC*/ 
laptop* 
  
Mobile device   
 
Storage Format  Please tick all that apply and specify for each, the 
location at which the data will be stored. 
 Confirm Location 
Database   
Oracle database   
Microsoft Access database   
Microsoft SQL server   
IBM DB2   
MySQL   
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Flat file e.g Excel spreadsheet, 
comma delimited file. 
X University of Edinburgh and 









Please confirm that your back up schedule is subject to the same security as the data 
provided by NSS for each location(s) that the data will be stored. 
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5.9 Other Encryption or Anonymisation Procedures 
 
NSS Data Transfer and Storage Policies require that all sensitive and person identifiable data 
is encrypted during transfer and whilst stored on mobile data storage devices and desktop 
and laptop computers to the standards outlined earlier. Please provide details of any other 
encryption or anonymisation procedures that may be used and at what stage.  
 
Any other encryption or anonymisation 
procedures used 
At what stage 
Password protected encryption and transfer 
in a tamper proof bag 
Transfer of data from Lothian Health 
Board to Edinburgh University, further 
transfer of aggregated summary data from 






5.10 Data Transfer - In  
If you are providing NSS with a copy of data for linkage and/or analytical purposes please 
detail how this data will be transferred and what security, complying with NSS Policy, will 
be used to protect the data from interception and inappropriate access.  
 
 Please note that by sending sensitive or personal dat  you will be responsible for 
ensuring the data is adequately protected against inappropriate access and tampering 
during the transfer. Data must not be sent via fax services. 
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 NSS uses NHSmail services for regular communications and the transfer of person 
identifiable data. NSS cannot send or receive password encrypted attachments using 
email services. NSS can send sensitive and person identif able data to other users using 
NHS mail services (either NHSmail accounts or the secure file transfer service). 
 
 NSS may use the same mode of data transfer however still reserves the right to use 
alternative mechanisms and security measures for the protection of NSS data. This can 
be discussed with your NSS SHIP Research Coordinator. 
  




Mobile data storage device e.g. CD, USB, 
data stick. 
Encrypted hard drive 
FTP URL  
sFTP URL  
Email address from which data will be sent  
Other data transfer method  
 
The NSS Research coordinator dealing with your application will discuss requirement for ` 
and/or passwords for the data transfer and/or encryption process. You should not provide this 
information to PAC either via this form or to the PAC e-mail address. 
 
5.11 User Access  
Please provide details on user access and account management policies that you have in 
place to limit or prevent inappropriate access to the data supplied by NSS. 
 
Will those accessing data, access it through 
individual or shared accounts? 
Individual Shared 
Are ‘complex’ passwords (a mixture of 
alpha, numeric, upper/lower case, special 
characters) used on all accounts? 
Yes No 
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Other please specify  
Are procedures in place to regularly review 
user access to sensitive and potentially 
identifiable personal data? 
Yes  
Are procedures in place to revoke user 
access to sensitive and potentially 
identifiable personal data when the user no 
longer requires this access? 
Yes  
Will the data be accessed by staff working 
off site e.g. staff working from home? 
Yes  
If yes, please detail how this access will be securd 
Via University of Edinburgh’s Secure VPN service.  
Please provide any additional details of how data provided by NSS will be protected from 
unauthorised access. 
Data are stored on a Unix file system which is mounted on shared access systems. Full 
access control list support is available on the system and is configured to be restrictive by 
default b the system administrators . 
 
5.12 Hardware Security 
Please describe the physical security arrangements for the location where the data is 
to be stored e.g. this could be your computer department if the data is stored on a 
networked server, or may be where the PC/laptop holding the data is physically located. 
 
The university servers are stored in secure machine  
rooms. These are locked, and accessible only to authorised personnel  
using swipe card access. Backups are held in separat  machine rooms in  
different sites, subject to the same access restrictions. 




Please describe the physical security arrangements for the location where the data is to be 
processed e.g. this is where your PC/laptop is located or wherever you are accessing the 
data from. 
 
Office with Locked Doors and restricted access to building after work hours. 
 
 
Please detail any protection that is implemented against the introduction of malicious 
software (e.g. computer viruses) in the areas where t  data will be stored and processed. 
 
Anti Virus and malware scans. Firewall protection. Regular software patching. 






Do your hardware replacement agreement(s) address how 
data are handled when hardware under warranty fails? 
 No 
If yes, would the hardware be returned to the supplier if there 
was a fault(s)?  
 No 
Please explain below how your organisation(s) dispose of hardware that they no longer 
require, that are faulty or covered by warranty. 
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Data is always securely wiped and then disposed of in secure manner at the end of its 
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If the data is being held in long-term archive(s) please explain how this data will be 
secured against further unauthorised access. 
All Data archived on archive NAS boxes. Password restricted using AD and stored in 
Secure locked rooms and cabinet. 
Who will have data management responsibilities for the data whilst in archive(s)? 
Prof Aziz Sheikh 
 
What procedures are in place to retrieve the data from the archive(s)? 
 
Requests can be placed to the computing support team to retrieve any data. 
 
 
5.13 Data Retention and Disposal  
Data should not be kept any longer than is necessary. 
 
Please give details of your data retention policy for each of the organisations(s) holding 
the data, including any back-up copies. 
Data will be retained as long as required to complet  publications and PhD thesis. 
This is possibly up to 5 years. 
 
Please give details of how the data, and any back-up copies, will be securely disposed of 
at the appropriate time by each of the organisation(s) holding the data. 
Hard drives and USB sticks will be securely wiped using appropriate software. 
Information on Network drives will be deleted and written over 
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 Data are stored in such a way that it would be difficult to reconstruct it from an  
individual drive if that failed and was returned to the supplier for  
replacement (all data is striped over a large number of volumes, each of  
which is made up of several disks which are themselv s striped over  
several drives, thus splitting the data up into very small components  
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Application Part Six: Declaration 
 
I DECLARE THAT this application is accurate, and that any health data made accessible to 
me, should it be successful, will be used for no other purpose, and in no other way, than as 
described above.   
 
I UNDERSTAND THAT NHS National Services Scotland will refuse any future 
applications by me, or my employing or sponsoring organisation, should I use any health 
data made accessible to me for any other purpose or in any other way than that described 
above.   
 
I CERTIFY THAT all staff who have access to health data are aware of the requirements of 
confidentiality and understand that its breach (e.g. disclosure of confidential information to a 
person not authorised to receive it) constitutes grounds for disciplinary action, which might 
result in dismissal. 
 
I UNDERSTAND THAT NHS National Services Scotland will refuse any future 
applications by me, or my employing or sponsoring organisation, should I use any health 
data made accessible to me for any other purpose or in any other way than that described 
above.   
 
I CERTIFY THAT all staff who have access to health data are aware of the requirements of 
confidentiality and understand that its breach (e.g. disclosure of confidential information to a 
person not authorised to receive it) constitutes grounds for disciplinary action, which might 
result in dismissal. 
 
I GUARANTEE THAT no publication will appear in any form in which an individual may 
be identified unless the written permission of that individual has been obtained, and that I 
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will follow the ISD Statistical Disclosure Control  Protocol when planning publications 
involving the data requested. 
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To be signed by the Information Custodian named in Part One where the Information 
Custodian is not the applicant. 
 
I DECLARE THAT (the applicant named above) is a bona fide worker engaged in a 
reputable project and that the data he/she asks for can be entrusted to him/her in the 
knowledge that he/she will conscientiously discharge his/her obligations, including in regard 
to confidentiality of the data, as stated in the declaration above. 
 
Information Custodian Signature: 
 
Date:08.04.2013 
Name (in Capitals): AZIZ SHEIKH 
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Appendix 4.1 Request for Caldicott Guardian 








Re amendment to Caldicott application ref JMS/J1/10115 
 
We are seeking approval for an amendment to our original Caldicott application for project title: Chronic 
Obstructive Pulmonary Disease in Lothian: a cohort study to identify modifiable risk factors in primary 
care that are associated with COPD emergency admission.  Caldicott approval for this project was 
originally granted in August 2010 (ref: JMS/J1/10115). 
 
The amendment is to cover the transfer of linked pseudonymised COPD data from NHS Lothian to 
University of Edinburgh to allow statisticians based there to use advanced statistical tests to carry out 
further analysis.  This work is being funded by the CSO. The aims of the work are to identify modifiable 
risk factors and interventions that reduce the riskof hospital admission and repeat admission.  This 
project will extend the current work, taking account of time varying covariates and the interdependence 
of exacerbations occurring within the same patient tha were beyond the scope of the initial analyses.  
 
The data will be transferred to the University and secured at the University using a strict protocol that 
has been agreed with yourself as Caldicott Guardian. This is detailed below.  It should be noted that 
only copies of files are being transferred; the datab se will still remain in the control of NHS Lothian. 
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Approval is currently being sought from PAC for this data transfer. NHS Lothian R&D consider it to 
be a minor amendment to the original application and have requested that we inform MREC of this once 
Caldicott approval is obtained. 
 
Dr Chris Weir, Associate Director (Statistics), MRC Hub for Trials Methodology Research, Centre for 
Population Health Sciences, University of Edinburgh Medical School, and co-applicant for the CSO 
project, will be overseeing the analyses. A further named statistician will be working on the database. 
We will be able to forward you the details of this person once they are appointed.   Dr Sarah Wild, co-
applicant on the HSRU funded project, and collaborator on CSO project will be acting as data 
intermediary at University of Edinburgh.  We confirm that access to the data at the University will be 
restricted to these named individuals and that theyhave/will have received appropriate data governance 
training before being given access to the data. 
 
Protocol for file transfer from NHS Lothian to Univ ersity of Edinburgh: 
 
1. Appropriate approvals obtained for the transfer and ccess to data from PAC and NHS Lothian 
Caldicott guardian. 
2. A COPD research project specific folder from which all analyses will be performed has been 
set up at Edinburgh University on a secure university server.  Access will be  limited to data 
intermediary (Dr Sarah Wild) and named analysts (Dr Ch is Weir and statistician name tbc). 
The server is regularly backed-up. 
3. Data files will be transferred using NHS net email from Dr Leonie Hunter to Dr Sarah Wild, 
who will upload the files to the research project folder (it is not anticipated that file size will 
be a problem for this transfer but if necessary larger files will be transferred by FTP file 
transfer). 
4. University policies on records management, retention and disposal of records and data 
protection http://www.recordsmanagement.ed.ac.uk/ will be adhered to. 
 
For the record, the university servers are stored in secure machine rooms. These are locked, and 
accessible only to authorised personnel using swipe card access. Backups are held in separate machine 
rooms in different sites, subject to the same access r trictions. These machine rooms have fire 
suppressants, security alarms, air conditioning (including humidity control). Data are stored on a Unix 
file system which is mounted on shared access systems. Full access control list support is available on 
the system, and this is configured to be restrictive by default by the system administrators. Data are 
stored in such a way that it would be difficult to reconstruct it from an individual drive if that failed and 
was returned to the supplier for replacement (all dta is striped over a large number of volumes, eachof 
which is made up of several disks which are themselve  striped over several drives, thus splitting the 
data up into very small components and dispersing it over many drives).  




We would be grateful if you could confirm as Caldicott guardian that you allow transfer of and access 








Dr Rachel Hardie 
Principal Investigator 
Consultant in Public Health Medicine 
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Appendix 4.2 Request for Caldicott Guardian 
approval for PhD data use 
 
 
         20th March, 2012 
 
Dear Professor McCallum 
 
Re Further amendment to Caldicott application ref JMS/J1/10115 
 
I am seeking approval for a further amendment to an original Caldicott application for project title: 
Chronic Obstructive Pulmonary Disease in Lothian: a cohort study to identify modifiable risk factors in 
primary care that are associated with COPD emergency admission.  Caldicott approval for this project 
was originally granted in August 2010 (ref: JMS/J1/10115). A subsequent amendment was approved 
on 20th March 2012 allowing the data to be transferred and stored on a University of Edinburgh server. 
 
This further request for amendment of the project would enable further analysis to be conducted on the 
data by a PhD student at the University of Edinburgh, Susannah McLean, who is supervised by 
Professor Aziz Sheikh, Professor Sarah Wild and Dr Colin Simpson.  whose project involves adapting 
a Dutch model to predict the population burden and costs of COPD in Scotland and Lothian in 5 and 10 
years time. Following approval from you as Caldicott Guardian, PAC and the ethics committee I would 
use selected linked anonymised data on the server to enable me to: 
1. estimate incidence of COPD by age, sex and SIMD using population data for participating 
practices in order to provide estimates for Scotland s a whole. 
2. describe patterns of lung function over time and their relation to exacerbation 
3. Estimate annual age and sex specific mortality among a cohort of people with COPD  
4. Estimate costs and QALYs generated by COPD burden 
 
The project would involve me taking these aggregated data to Erasmus University, Rotterdam, the 
Netherlands to use the statistical program Mathematica to run the model with the support of the Dutch 
team. Aggregated data for other inputs to the model will be obtained from a variety of sources (please 
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see attached table for more details) and patient identifiable data will not be used in this modeling 
process. I propose taking the aggregated data to Rot erdam on an encrypted hard drive. 
 
Please let me know if you require any further information or have recommendations before you can 
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Data title Scottish/Lothian Run 
1 General Population Data National Records Scotland 
2 Proportions of population that smoke, former smoker and 
never smoker by age and gender 
Scottish Health Survey 
3a GP prevalence of COPD, age and gender specific Information services division 
prevalence data 
3b GP incidence of COPD age and gender specific Lothian cohort data and practice 
populations 
4 Relative risks of smokers and nonsmokers Use Rotterdam data 
5 Age and sec specific start stop and restart probabilities for 
smoking 
Use Rotterdam data 
6 Random effects model to predict lung function declin  Recalculate model using COPD 
Lothian data 
7 COPD related maintenance costs Use Rotterdam data 
8  Mean utility scores by COPD severity stage Use Rotterdam data 
9 All-cause mortality, mortality attributable to COPD 
mortality and mortality from other causes, by age and sex 
( per 1000 COPD patients) (i.e. what do COPD patients 
die of?) 
Lothian cohort data  
 
Calculated parameters table 
Parameter Name Alternative source 
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A Rate of Exacerbation 
by COPD stage 
Individual patient data calculation, potentially a fresh 
model using Lothian cohort data 
B Case fatality rate Develop age stratified case fatality profile of either 
Lothian Cohort from linked death certificate data 
rather than modelling  
C Decline in FEV1 due to 
exacerbation 
Calculate using Lothian cohort (Average lung 
function decline per year/no. of exacerbations per 
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Appendix 4.3 Initial reply from Caldicott Guardian 
May 2013 




Thank you for your letter of March 20, 2013. It came in when I was on leave so I am sorry 
about the delay in getting back to you. If these are de-identified tabulated data then they 
should still be transferred by secure file transfer protocol from Edinburgh to Rotterdam. 
  
Transferring data in person by encrypted hard drive in a locked case would be a last resort.  
  
Whichever approach is used, a data processing agreement with Erasmus will be required 
and will need to be checked by the lawyers for Erasmus and Central Legal Office. Erasmus 
will have a standard document in English.  
  
A full list of variables will also be required and all of the documentation will obviously have to 





Denise Foley  
Caldicott Administrator 
Tel 0131 465 (3)5452 
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Lothian NHS Board 
Waverley Gate 




Please note that I am not in the office on a Thursday or Friday 
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Dear Professor McCallum 
 
Re Revised application for amendment to Caldicott application ref JMS/J1/10115 
 
Thank you for considering my request to use data from the Lothian COPD cohort to estimate 
COPD burden in Scotland and the UK using a model developed in the Netherlands in my PhD 
project. Based on my initial request you recommended obtaining a legal agreement for data 
sharing between Erasmus and Edinburgh University.  
 
Since I submitted my request to you I have clarified the data I would like to use from the 
Lothian COPD cohort.  I would simply like to request timates of COPD incidence and 95% 
confidence intervals by sex, age in 5 year age groups from 35 -85+ years and Scottish SIMD 
quintile to allow me to generate estimates of COPD incidence for Scotland as a whole by 
applying the incidence estimates to Scottish population estimates. Leonie Hunter from Lothian 
is able to calculate Lothian incidence estimates using data from the cohort and participating 
practice population data provided to her by Bill Rams y. I will then take the Scottish estimates 
to the Netherlands to use in the model.  
 
Examples of the data formats are given below.  
 
Thank you for considering this revised application which, given the aggregated nature of the 
data that will be used, presumably will not require th  legal agreements necessary for use of 
individual level data.  Please contact me if you require any further information. 








Student of Sarah Wild, Aziz Sheikh and Colin Simpson 
 








95%CI Upper 95%CI 
F 35-39  1    
F 35-39  2    
F 35-39  3    
F 35-39  4    
F 35-39  5    
      
 
Scotland data format (to be used in Dutch model) 
sex Age band 
Incidence per 
1000 
population Lower 95%CI Upper 95%CI 
F 35-39    
F 40-44    
F 45-49    
F 50-54    
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F 55-59    
F 60-64    
F 65-69    
F 70-74    
F 75-79    
F 80-84    
F 85+    
M 35-39    
M 40-44    
M 45-49    
M 50-54    
M 55-59    
M 60-64    
M 65-69    
M 70-74    
M 75-79    
M 80-84    
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Appendix 4.5 Caldicott Guardian Approval August 
2014 
 
Dear Susannah  
  
I have heard back from Professor Alison McCallum with regards to the amendment to 
Caldicott application, ref 10115. This amendment has been approved with the following 
caveat. 
  
'If the tabulated data needs to be transferred using a mobile device then evidence of 
compliance with the relevant circular from 2012 is required. This means using an 
encrypted laptop and NHS encrypted memory stick.' 
 Best wishes 
Denise 
  
Denise Foley  
Caldicott Administrator 
Tel 0131 465 (3)5452 
  
Lothian NHS Board 
Waverley Gate 
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Appendix 5 Description of method of generating 
random incidence and prevalence curves for COPD  
Rudolf Hoogenveen,  




The research question was to generate age-curves of incidence and prevalence probability 
values for England and Scotland, based on age-specific data, and taking account of 
uncertainty. Uncertainty can be defined in different ways here. I have assessed the 




I have applied the same method for all data, i.e. initial prevalence probability values for 
England and Scotland, and incidence rates for England. All data available were specified by 
gender and age, the latter being different between England and Scotland data. I stuck to the 
age-specifications applied in the data. 
 
The calculation steps applied were: 
- I calculated a smooth curve through the age-specific data, using the R-routine 
smooth.spline (spline-based method, R Version 3.0.1). The smoothing parameter 
used was spar0, and the value was selected to optimize both fit and smoothness. For 
values, see below. I used the mid-points of the age-classes as the independent 
variable. 
- Next, I applied the same procedure for each generated random curve. That means, I 
randomly drew event (prevalence or incident) numbers for each age-class. In case of 
prevalence, I drew from binomial distributions with parameters sample size and 
observed prevalence probability numbers, i.e. for each age-class. In case of 
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incidence, I drew from Poisson distributions with parameter observed event number. 
Then again, I calculated a smooth curve through the randomly drawn age-specific 
data using the same smoothing parameter value. 
 
Smoothing parameter values used: Scotland: spar0 = .25, England: spar0 = .6. The number of 
randomly drawn curves was nMC = 200. 
 
For the highest ages I applied the following procedur . For Scotland, I assumed the mid-
point of the highest age-class (85+) being 87.5 years. For England, I aggregated all numbers 




For each parameter (incidence, prevalence, country) I present below graphical results 
without and with randomly drawn curves.  
  






























































































































































Conclusion & discussion 
 
This is a first solution to the research question stated above. There are some smaller issues to 
be taken care of, e.g. the smoothing procedure sometimes generates negative probability 
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values.  The results for excess mortality probability values are still to come. I have presented 
graphical results only here. Numerical values are of course available. 
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Appendix 6 Contribution to science 
Publications 
Published: McLean, S., S. H. Wild, C. R. Simpson, A. Sheikh. (2013). "Models for 
estimating projections for the prevalence and disease burden of chronic obstructive 
pulmonary disease (COPD): systematic review protocol." Prim Care Respir J 22(2): PS8-21. 
Accepted: McLean, S, V. Barbour, S. H Wild, C. R Simpson, A. Sheikh. Models for 
estimating projections for disease prevalence and bur en: a systematic review focusing on 
chronic obstructive pulmonary disease. The Journal of Health Services Research and Policy  
Policy  
My data were used in a series of briefings that Lothian Public Health supplied to the 






4th March 2014 Presentation to School of Population Health Sciences, University of 
Edinburgh, Teviot Place, Edinburgh “Chronic Obstructive Pulmonary Disease; Modelling 
prevalence in England and Scotland” 
31st March 2014 Continuing professional development in public health, presentation at the 
Scottish Government, St Andrew’s House, Edinburgh, “C ronic Obstructive Pulmonary 
Disease; Modelling prevalence in England and Scotland” 
25th April 2014 Presentation to NHS Lothian COPD Managed Care Network, Effectivity and 
Productivity Meeting, Little France, Edinburgh “Chronic Obstructive Pulmonary Disease; 
Modelling prevalence in England and Scotland” 
Poster 
9th September 2014 European Respiratory Society Confere c , Munich, “Burden of chronic 
obstructive pulmonary disease in Scotland and England” 
  




Birthrate  a summary rate based on the number of live births in a population over a given 
period, usually 1 year.(Porta 2014) 
Birthrate = Number of live births to residents in an area in a calendar year * 1000 
 Average or midyear population in the area in that year 
 
Difference equation an equation expressing a functional relationship of one or more 
independent variables, one or more functions dependent on these variables, and successive 
differences of these functions.(McGraw-Hill 2003) 
Disability adjusted life year (DALY) DALYs are the opposite of QALYs (see QALYs 
below) DALYs are a measure of health gap. On the DALY scale, 1.0 is total disability and 0 
is the target of zero disability. The DALYs are calculated from the measure of disability on 
the DALY scale multiplied by the number of life years at that level of disability.(Gold, 
Stevenson et al. 2002) 
Functional data analysis is a branch of statistics that analyses data providing information 
about curves, surfaces or anything else that varies ov r a continuum. The continuum is often 
time, but may also be spatial location, wavelength, probability, etc. 
Incidence the rate at which new events occurs in a population. The numerator is the number 
of new events that occur in a defined period. The denominator is the person-time at risk of 
the event during this period. 
Incidence =              Number of new events in specified period                     *10n 
 Average number of persons exposed to risk during this period 
 
Strictly, this ratio is neither a rate nor a proportion but is instead the rate multiplied by the 
length of the specified period. If the period is a ye r the ratio is called the annual incidence 
rate. The average size of the population is often the estimated population at the midpoint of 
the time period. If the number of new cases during a specified period is divided by the sum 
of the person time units at risk for all persons during the period the result is the p rson-time 
incidence rate.(Porta 2014) 
 
Model a system of postulates, data and inferences presented as a mathematical description of 
an entity or state of affairs.(Merriam-Webster 2013) 
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Prevalence A measure of occurrence of disease or risk factor. The total number of 
individuals who have the condition or risk factor at a particular time, divided by the 
population at risk of having the condition at that time, or midway through the period. It is a 
proportion not a rate. Point Prevalence is the proportion of individuals who have the 
condition at a specified point in time. (Porta 2014) 
Quality adjusted life year (QALY) QALYs rely on a generic quantification of health 
status. The health status is a functional level or “utility”. This health status is quantified by 
assuming that the person without illness is unimpaired or has 1.0 utility and that a person in 
state 0 is dead. QALYs are calculated from the utility or reduced utility as a result of a health 
condition, multiplied by the time spent at this utility, the life years.(Zeckhauser and Shepard 
1976) 
Spatial modelling refers to a particular form of disaggregation, in which an area is divided 
into a number (often a large number) of similar units: typically grid squares or polygons. The 
model may be linked to a geographical information system (GIS) for data input and display. 
(simulistics 2011) 
Statistical mediation study a type of statistical study in which the influence of one variable 
on the second variable is determined by the effects of a third intermediate variable. 
Stochastic process a process, which is usually a temporal sequence, which incorporates an 
some element of randomness. (Porta 2014) 
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Introduction 
Policymakers and governments must decide their healthcare
priorities on the basis of the best healthcare intelligence available to
them. Recent interest has increasingly focused on the global
implications of an increasing and elderly population with long-term
conditions.1-3 The most recent figures from the Global Burden of
Disease Study 2010 show that the third top global cause of death
was chronic obstructive pulmonary disease (COPD),4 rising from
fourth place in 1990.5 It is predominantly caused by cigarette
smoking and leads to lung airflow limitation, cough, excessive
sputum production, and breathlessness. People with COPD can
suffer from substantial disability as the condition progresses.6 A
pressing challenge for governments is how best to project the future
trend in the prevalence and burden of COPD in order to plan
adequate health and social care for those affected by this condition
within the scope of limited resources. Governments should ideally
be planning for COPD on two levels: (1) they should consider how
to manage resources to care and treat people who are already
affected by COPD; and (2) how to prevent a greater increase in the
burden from COPD by minimising the continuing smoking epidemic.   
In order to make such calculations, governments and other
healthcare providers need to draw on epidemiological models.
Merriam-Webster’s dictionary defines a ‘model’ as ‘a system of
postulates, data, and inferences presented as a mathematical
description of an entity or state of affairs’. This is a useful starting
point when considering the role of models in epidemiology. Most
models are explanatory in nature and describe the relationships
between different parameters. The focus of this study is on models
which help to project future epidemiological trends and patterns in
populations with COPD. Governments and policymakers have
access to many models, but a review is required to appraise the
published COPD models to aid selection between them.
Various features of COPD present a particular challenge to
mathematical and epidemiological modelling, including the many
different definitions of a COPD diagnosis and its overlap with a
diagnosis of asthma. Although COPD is most clearly attributable to
cigarette smoking, there is debate over how best to classify non-
smokers who develop COPD with the immunological and
pathological features of COPD as a result of exposure to
occupational dusts and gases or recurrent chest infections. In
addition, there is uncertainty as to the correct classification of older
non-smoking adults who have evidence of lung cell remodelling
including squamous metaplasia following chronic inflammation due
to long-term asthma. Such older adults have often lost the
reversibility in their airways obstruction and demonstrate spirometry
which is consistent with the thresholds for COPD.7-9
According to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD), the diagnosis of COPD is characterised by an
obstructive lung defect with forced expiratory volume in one second
to forced vital capacity (FEV1/FVC) ratio <0.7.10 Controversy
regarding this threshold also complicates decisions of precisely
which population to include in modelling. Lung function decreases
with age, so a proportion of elderly people (age 75+) who have
never smoked still fit these criteria for COPD. Some doctors
reasonably argue that such elderly people really have normal lung
function for their age and that medicalisation of the elderly should
be avoided.7 An alternative threshold of the lower limit of normal for
FEV1/FVC has been proposed with a decreasing threshold according
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to age by percentile. The bottom 5% of FEV1/FVC measurements for
whichever total population being measured would be considered
abnormal in the older age group.9 However, no up-to-date large
standardised population database currently exists to validate such a
measure. The nearest is the use of the European Coal and Steel
Workers Population to provide percent predicted FEV1 values;
however, this population was standardised over 20 years ago and is
based on a working white European population without ethnic
minorities.11-13 Similarly, younger people (age 30–40 years) with
larger FVC values and greater respiratory reserve may already have
sustained COPD-type damage to their lungs before they reach the
<0.7 ratio threshold, so at this end of the age range there is a risk
of under-diagnosis of COPD.13
The debate regarding the diagnosis of COPD is more than just a
debate over spirometry thresholds. As many developing countries
do not have access to spirometry or even to a reliable power supply,
the usefulness of such diagnostic thresholds is limited. It has been
proposed that COPD may also be diagnosed on history and clinical
features. However, studies have shown that using clinical indicators
of pulmonary function to diagnose COPD missed many participants
who had low lung function and airways obstruction, especially in
current smokers.14 Therefore, in many countries the current situation
has evolved where COPD is diagnosed from physician opinion
without corroborating evidence from spirometry, resulting in a
significant overlap between a diagnosis of COPD and a diagnosis of
asthma.
It seems likely that classifications in the future will evolve as the
role of host susceptibility is increasingly understood in terms of
genetic and epigenetic features. Several candidate genes related to
COPD have been identified.15 In addition, the science of epigenetics
helps to explain how DNA transcription has been activated or
suppressed by DNA methylation, acetylation, or other mechanisms
in response to predominantly prenatal and early life environmental
influences.16 The result of such switching on or off of DNA
transcription is to determine the host’s response to noxious stimuli
including cigarette smoke. Increased understanding of these factors
is helping to unravel the mysteries of why some life-long smokers
are virtually unaffected by their habit while others have severe
COPD. Estimates as to the prevalence of COPD among smokers
aged >45 years vary from 15% to 50% according to the criteria
used for diagnosis.17,18
Modelling COPD is also challenged by the key feature of
exacerbations. An exacerbation may be triggered by increased
bacterial or viral load in the lungs which induce an aggressive
immune response and associated clinical features.19-21 Associated
with a greater frequency of exacerbations is higher morbidity, due to
faster disease progression in terms of loss of lung function, and also
mortality.21
An additional challenge is the level of mathematical
sophistication within each model. Ideally, a researcher with
considerable statistical skill would be available to check the
algorithms that drive each model and so provide a full appraisal of
the quality of each model. In the absence of this ideal, it was decided
to appraise the quality of reporting of each model as a proxy for the
model’s mathematical quality. Taking these challenges into account,
it will be necessary to describe a degree of context with each model
in order that it can be applied in an appropriate setting. This will help
subsequent researchers to understand the necessary caveats to
include when describing the results from each model. 
Objectives   
To identify all available models for estimating projections of COPD
prevalence and burden, and to assess the quality of reporting of
each model in its key publication.
Methods 
A search strategy has been developed using search terms to cover
the three concepts of ‘modelling’, ‘disease burden’, and ‘chronic
obstructive pulmonary disease’ (see Appendix 1 for full details).
Searches will be conducted in the following electronic databases:
MEDLINE, EMBASE, CAB Abstracts, World Health Organization
(WHO) Library and Information Services (WHOLIS – library catalogue
of books and reports), WHO Regional Indexes (AIM (AFRO), LILACS
(AMRO/PAHO), IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO)),
and a modified search strategy will be used to identify reports from
the WHO home website and Google. Searches will be for both
published and unpublished modelling studies from 1980 (when
modelling methods first began to be widely used) to 2013. Two
authors will independently review the studies against the inclusion
criteria and make a decision as to whether the study is suitable.
Disagreements will be resolved by discussion and, if this is not
possible, a third reviewer will arbitrate. 
Inclusion criteria   
Any modelling study which uses demographic and epidemiological
data to project the prevalence and disease burden will be included.
The included projected outcomes which are of interest are one or
more of: incidence, prevalence and mortality, and disease burden.
With regard to ‘disease burden’, the outcomes of interest can be
considered from the individual’s point of view, from the point of
view of the healthcare system, and from the point of view of
broader society. For the purposes of this review, the focus is on the
perspective of the healthcare system. Other perspectives are valid;
however, different instruments are used to measure them and the
purpose of this study is to guide policymakers who will focus on the
healthcare system perspective. Quality-adjusted life years (QALYs)
and disability-adjusted life years (DALYs) are often used to measure
and quantify the burden to the individual of the morbidity they are
suffering. Treatments are assigned a cost per restored QALY, and this
is an important measure used in cost-effectiveness studies. However,
the scope of this study is more limited in order to avoid confusion of
perspectives. Some of the studies included may discuss QALYs and
DALYs, but they have not been chosen as primary disease burden
outcomes for this review. Instead, we will concentrate on primary
care visits, emergency department visits, hospital admissions, and
COPD treatment costs. 
Exclusion criteria    
There will be no exclusions on the basis of language of the report.
Studies which are population-based surveys of prevalence without
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modelling will be excluded as there has recently been a systematic
review of such studies.22 ‘Models’ will be excluded if they describe
animals, cell lines, clinical series, or estimates of individual risk (such
as individual prognostic models). Decision analytical models or
decision support models will be excluded where they refer to clinical
decision-making for individuals rather than populations. Models
that compare one intervention with another intervention will also be
excluded, as the aim is accurately to project the baseline outcomes
so it is premature to take into account the effect of interventions.
Also excluded will be regression models which start with a COPD
population and ‘back-calculate’ the prevalence or burden using
regression to quantify risk factors, as this follows a different logic
from that of projection modelling.
Participants     
The source population for the model may be from anywhere in the
world. The model will pertain to adult populations aged >40 years
as it is usually not appropriate to diagnose COPD in younger
people.10 COPD may be diagnosed by physician, spirometry, or by
questionnaire. Other assumptions regarding the diagnosis of COPD
will be evaluated in the context of the model. 
Data extraction          
The data will be extracted by one author and checked by a second.
Data will be extracted using a pre-piloted data extraction form. The
following identification details will be extracted for each model:
author and email address, year, institution, and funding source.
These data will be followed by: the purpose of the model, model
title, model type, model setting, time period, and population (age,
sex and country). Also extracted will be: inputs to the model, source
of input data, details of processing of the model, outcomes for
COPD (incidence, prevalence, mortality, GP visits, emergency
department visits, hospitalisations, treatment costs), model
output/results, details of the model’s availability, any comparisons
with other studies, social and economic policy implications of model
outcomes, and future research recommendations. In this way, the
data extraction form aims to encompass a comprehensive picture of
the model.
Quality appraisal framework           
Ideally, a quality appraisal of the actual modelling process would be
undertaken. However, this requires significant statistical technical
expertise. A pragmatic decision has therefore been made to quality
appraise the reporting of the models rather than the actual
modelling process for those that have full published reports. In order
to do this, a quality of reporting framework has been designed
following review of key guidelines as to good practice in
modelling.23-26 A scoring mechanism was devised in collaboration
with Simon Capewell of Liverpool University27 to weight the
importance of the different elements required to produce a relevant
high-quality model (see Appendix 2).
Strategy for data synthesis            
The study will be the unit of analysis. Models will be described and
classified. A detailed critical narrative synthesis of the highest scoring
models will be undertaken. Where the models are not available, we
will write to the model authors for further clarification. No subgroup
analysis is planned.
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Review Article
Models for estimating projections for
disease prevalence and burden: a
systematic review focusing on chronic
obstructive pulmonary disease
Susannah McLean1, Victoria Barbour2, Sarah Wild3,
Colin Simpson4 and Aziz Sheikh5
Abstract
Objective: Epidemiological models for estimating the prevalence and burden of disease inform health policy and service
planning decisions. Our aim was to describe the challenges in evaluating such models using the example of epidemio-
logical models for chronic obstructive pulmonary disease (COPD).
Methods: Two reviewers searched Medline, Embase, CAB Abstracts and World Health Organization (WHO) Databases
from 1980 to November 2013 for epidemiological models of COPD prevalence and burden. Two reviewers extracted
data and assessed the quality of the studies. We then undertook a descriptive and narrative synthesis of data.
Results: We identified 22 models employing a variety of techniques to calculate the prevalence and/or burden of COPD.
Models calculated prevalence and/or mortality or other facet of disease burden using demographics and risk factors or
trends, Markov-type modelling and microsimulation modelling. The six models which scored highly on the quality
framework were: the Peabody model, which generated estimates of COPD prevalence; the WHO DISMOD II model
which produced burden estimates in terms of disability adjusted life years with COPD and life years lost to COPD; the
Atsou model which gave the life expectancy gains of individual smokers who quit smoking and associated costs; two
Dutch COPD models which produced estimates of mortality and health care costs related to COPD; and the Pichon–
Riviere model which gave the costs and cost effectiveness of smoking quit programmes.
Conclusions: The field of chronic disease modelling is burgeoning. As a result, policy makers need to understand how
to interpret epidemiological models and their data sources.
Keywords
chronic obstructive pulmonary disease, epidemiology, systematic review
Introduction
Governments need accurate and timely information in
order to be able to plan for the health care needs of
their population. Over recent years, the challenges of
ageing populations with a high prevalence of chronic
diseases have been widely discussed.1 While epidemio-
logical modelling has traditionally been used to
describe patterns of infectious diseases, chronic disease
epidemiological modelling is relatively new. It combines
elements of mathematical and health economic disease
modelling with clinical data to estimate current and
future prevalence and disease burden. However, as
models proliferate, decision makers will need to
choose which will best suit their purposes.
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Key challenges in the evaluation of an epidemiologi-
cal model
First, it is pertinent to consider as precisely as possible
the definition of the disease that is being modelled.
Diseases may be defined according to the presence of
risk factors or according to diagnostic tests.
Second, data sources should be clearly documented
so that they can be consulted and assessed by other
researchers for their validity. This is sometimes poorly
done in modelling; however, it is important that other
researchers can decide for themselves whether the
sources of data used for the modelling are the most
representative available and substitute alternative
sources of data into the model where appropriate to
allow cross validation of the model.
Third, the method of modelling should be docu-
mented transparently so that future researchers can
understand what analysis has taken place. The 2010
global burden of disease2 did not make clear how
they had processed their data. The earlier version of
the global burden of disease had an online supplement
and additional publication3,4 detailing how they had
calculated prevalence from mortality figures; however,
this was lacking for the 2010 version.
Fourth, modelling is a relatively young science and
there are a variety of different techniques being used.
The Markov model is one of the most commonly used,
and many models in this systematic review describe
themselves as Markov models or Markov-type
models. Such models originate in the discipline of
health economics but also give estimates of prevalence
and burden. Essentially, Markov models describe a dis-
ease as a number of linked health states and a cohort
moves through these states from health to deteriorating
health to (eventually) death. Sometimes states can add-
itionally describe recovery from disease. Data from
clinical trials is used to inform the transition probabil-
ities between the states. For an excellent introduction to
Markov models please see Briggs and Sculpher.5
Fifth, the time frame for the model’s operation needs
to be considered. It should be considered whether the
model is set to use past data to produce an estimate for
current times and whether this done by projecting
trends or by another method, or does it use present
data and project into the future. The population for
which the projection is made should also be considered.
Populations as big as entire countries are often the
frame of reference; however, this often pools estimates
across urban and rural areas and other forms of geo-
graphical heterogeneity.
Sixth, sensitivity analysis should be carried out. This
is where the inputs of the model are altered by a thresh-
old amount, e.g. 10% and the model re-run to see the
effect on the output. This allows the reviewer to thereby
evaluate how sensitive the model is to each of its inputs.
Sensitivity analysis may be one-way where only one
input parameter is changed at a time or multi-way
where additional input parameters are changed simul-
taneously to evaluate the combined effect of these sim-
ultaneous changes on the output.
And finally, it would be possible to compare the
results from each model with results from large preva-
lence surveys. Comparisons with surveys have to ensure
that the model and the survey were aiming for the same
target population prevalence or burden. In the absence
of an appropriate survey with which to compare, more
than one model for the same population can be used for
cross validation.
Our aim was to review systematically the models
available for one specific long-term condition – chronic
obstructive pulmonary disease (COPD).
Methods
We developed and reported a detailed protocol for this
work.6 We also registered the protocol in the
PROSPERO database.7
Eligibility criteria
Any modelling study which used demographic and epi-
demiological data to estimate the prevalence and/or dis-
ease burden was eligible for inclusion. The outcomes of
interest were incidence, prevalence, disease burden and
mortality. For the purposes of this review, disease
burden was considered from the perspective of the
health system.
The types of models of interest included demo-
graphic models, microsimulation models and Markov-
type models. Models were excluded if they described
animal cell lines, clinical series or estimates of individ-
ual risk (such as individual prognostic models).
Decision analytical models or decision support models
were excluded where they referred to clinical decision-
making for individuals. Models comparing one inter-
vention with another intervention were also excluded as
the aim was to estimate the prevalence, disease burden
and mortality rather than to investigate the effective-
ness of interventions.
Information sources and study selection
A search strategy was developed using search terms to
include the concepts of ‘modelling’, ‘disease burden’
and ‘chronic obstructive pulmonary disease’ as has
been fully described elsewhere in McLean et al.6
Searches were conducted in Medline, Embase, CAB
Abstracts, World Health Organization (WHO)
Library and Information Services (WHOLIS – library
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catalogue of books and reports), WHO Regional
Indexes (AIM (AFRO, LILACS, (AMR/PAHO)),
IMEMR (EMRO), IMSEAR (SEARO), WPRIM
(WPRO)). A modified search strategy was used to iden-
tify reports from the WHO home website and Google.
Searches were for both published and unpublished
modelling studies from 1980 (when modelling first
began to be widely used8,9) to November 2013. All stu-
dies were independently reviewed against the stated
inclusion criteria by SM and VB and all disagreements
were resolved by discussion between reviewers.
Data extraction
A piloted data extraction form was used by SM and
checked by VB. The following data were extracted from
each study: author and email address, year, institution
and funding source, the purpose of the model, model
title, model type, model setting, time period and popu-
lation. Model inputs and source of input data details of
processing of the model, were also extracted, along with
COPD outcomes (incidence, prevalence, mortality, pri-
mary care visits, emergency department visits, hospital-
izations, treatment costs), model output/ results, details
of the model’s availability, any comparisons with other
studies, social and economic policy implications of
model’s output and future research recommendations.
Quality appraisal framework
We quality appraised the reporting of the models. A
quality of reporting framework was designed following
review of key guidelines as to good practice in model-
ling.10–13 A scoring mechanism was devised to weight
the different elements required to produce a relevant
and high quality model.14 This scoring framework
was described in the protocol for this systematic
review6 and considered the reporting of whether
model development and the elements of calibration,
internal and external validation and whether it was
reported that policy and decision makers had had
input into the development of the model. The quality
of reporting scoring was up to a maximum of 20 points.
Synthesis of results
As the models had different purposes and were based in
different settings we present a narrative synthesis of
results as heterogeneity precluded any meaningful
quantitative synthesis of results.
Results
Around 1726 studies were title-screened following
duplicate deletion. About 157 titles and abstracts were
selected for full text review. Excluded were regression
models which were quantifying the effect of risk factors
on COPD rather than projecting prevalence and/or dis-
ease burden. Twenty-one models3,4,15–35 and DISMOD
3 (unpublished) were selected, as described in the
PRISMA flow diagram in Figure 1.
Six models scored highly on the quality of reporting
framework out of a maximum 20 points: Peabody’s
prevalence model21 (16), Atsou’s smoking burden
model36 (16), WHO burden model as described by
Shibuya4 (16), two Dutch models: Feenstra 21 (17)
and Hoogendoorn et al.17 (17) and the Pichon–
Riviere smoking burden model34 (17.5). These models
are described below in detail; summaries of all models
are found in Tables 1 to 4, available online. High
reporting quality should ensure that adequate informa-
tion is included in the report in order to draw some
conclusions as to the underlying quality of the model.
The main focus of quality was whether sensitivity ana-
lysis had been reported and what were the results and
other features of quality assurance such as debugging
and external validation of results.
Peabody prevalence estimation model
This model used six key risk factors for COPD identified
and quantified from the literature: smoking, age, gender,
indoor air pollution, outdoor air pollution and occupa-
tional exposure to airborne particles. They assumed no
cases under the age of 30 and a smoking prevalence of
15%. Based on the literature it was assumed that there
was an exposure of non-smoking population to occupa-
tional airborne particles of 1.9% and a prevalence of
COPD in urban populations of 1.4%. In the model,
population was distributed by percentage between
urban and rural populations and linked to environmen-
tal exposure. There was also an input for national socio-
economic development based on World Bank figures.
COPD prevalence was then estimated for four countries
and compared with survey data for external validation.
Then COPD prevalences for an additional 12 countries
were estimated.
Sensitivity analysis was performed on hypothetical
populations with differences in their rural/urban popu-
lation distribution and high/low income split. The
model was externally validated by comparing its results
to survey results for Nepal, Norway, Poland and Spain.
The predictions were not statistically different from the
survey results for any of the countries suggesting that
the model is a useful prediction tool.
Atsou smoking burden model
This Markov-type model included the severity stages of
COPD: mild, moderate, severe and very severe.
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Transition probabilities could be altered for modelled
patients moving up these severity stages as their disease
progressed. The model aimed to report the impact of
smoking cessation on a COPD patient’s life expectancy
in terms of individual health gains. The model includes
a cost-effectiveness assessment of the impact of smok-
ing cessation programmes in England.
The sensitivity analyses that were conducted
involved changing the transition rates from one disease
severity stage to the next, the mortality and exacerba-
tion rates and the costs of COPD management, differ-
ent discounting rates and different smoking cessation
rates. For the scenarios investigating the costs,
Quality Adjusted Life Years and cost effectiveness of
the smoking cessation programmes; the effects of dif-
ferent input costs for the programme and different quit
rates, were investigated. The results were sensitive to
transition rates from one disease stage to the next and
to an increase in mortality rates. When it was suggested
that ex-smokers experience fewer exacerbations than
smokers, there were monetary and health care gains.
The model was not very sensitive to changes in disease
management costs.
WHO burden of disease model DISMOD II
DISMOD II used the WHO world regions to calculate
the burden of COPD in terms of years lived with dis-
ability and mortality in terms of years of life lost. The
model was based on a regression model including a
measure of smoking impact and an air pollution vari-
able to take into account proportions of households in
each region that use indoor biofuels and age and sex
dummy variables which reflected variability in the
exposure data for different regions. The input data to
the model was the COPD-related mortality rates and
total mortality rates per WHO region. These data were
used to generate an equation which could be solved for
the prevalence and incidence of COPD.
No sensitivity analysis using DISMOD II was under-
taken. However, the predictive validity of the model
was checked by comparing the estimated relative risks
for death from COPD for the America and Pacific
regions with recent burden of disease analyses from
the United States and Australia. Published prevalence
data based on spirometry in the WHO regions were
also compared to the DISMOD II outputs and found
Figure 1. PRISMA diagram.
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to be consistent with the exception of estimates from
the Global burden of disease 1990 estimates due to
improved methodology since then.37
Feenstra chronic disease model
This model concentrated on the population with COPD
in the Netherlands. A dynamic multistate life table
model combined information on the demography of
the Dutch population and smoking. The number of
new cases of COPD each year was calculated from
the incidence rates of COPD for smokers and former
smokers in combination with prevalence data.
Independently modelled modules exist for mortality
from lung cancer, stroke, coronary heart disease and
asthma. The model is dynamic in that each year’s
total incorporated calculations for birth, and mortality.
One way sensitivity analysis was performed to deter-
mine the effect of changes in inputs of incidence and
excess mortality rates on the output prevalence rates. It
was found that a 20% change in incidence input rates
resulted in a 17% change in prevalence rates and a 20%
change in excess mortality input resulted in a 4%
change in prevalence output. Therefore, the model
was more sensitive to changes in incidence rates.
Hoogendoorn COPD model
This Markov-type model was developed from the
Feenstra chronic disease model16 by the addition of the
four Global Initiative for Obstructive Lung Disease
(GOLD) severity stages for COPD into the model. The
COPD population is divided into mild, moderate, severe
and very severe COPD subpopulations and also by smok-
ing status: never-smoker, smoker or former smoker.
Annual incidence and mortality rates are applied to
each age, sex and smoking subpopulation. Costs are cal-
culated by multiplying annual cost data for each severity
stage by the number of patients in each stage.
Sensitivity analyses for this model were conducted
by changing the input severity distribution of the
COPD prevalence so that it was assumed firstly that
COPD patients began with less severe COPD: more
mild and moderate cases, then it was assumed that
COPD patients began with more severe COPD: more
severe and very severe cases. The next sensitivity ana-
lysis to be conducted was similarly changing the sever-
ity distribution of the incident COPD cases to first less
severe and then more severe. Further sensitivity ana-
lyses were conducted varying the rate of lung function
decline and changing the impact on lung function
decline of stopping smoking from an improvement to
a null impact. The results of the sensitivity analyses
were that all prevalence results were within a range of
5% of the projections of the base case. The results were
most sensitive to the input of the severity distribution of
the incidence. Cost projections were more sensitive than
prevalence projections due to the difference in costs for
different COPD severity stages.
Pichon–Riviere smoking burden model
This model met the needs of 68 decision makers who
had been surveyed across seven countries in Latin
America (i.e. Argentina, Bolivia, Brazil, Chile,
Colombia, Mexico and Peru). It considered heart dis-
ease, cerebrovascular disease, COPD, pneumonia/influ-
enza, lung cancer and nine other neoplasms. The model
used country-specific data sources where possible.
However, as a result of the lack of local data, estimates
of incidence were often derived from mortality data
using the WHO DISMOD II methodology.4 The base-
line risk in non-smokers was then calculated based on
the age-, sex- and country-specific smoking prevalence
as well as disease-specific smoking relative risk. The
parameters for smokers and former smokers were
then calculated from this baseline risk. The model
was a microsimulation of individual subjects incorpor-
ating the natural history, costs and quality of life of the
above diseases. A functioning version of the model was
constructed validated and calibrated using data from
Argentina.
The Argentinian version of this model underwent
extensive internal validation with debugging by the
inputting of null and extreme values and checks for
inconsistencies. The model was then calibrated by com-
paring general mortality and all age- and sex-specific
death rates predicted by the model with local health
statistics. COPD was excepted from this process as
COPD mortality was agreed to be underestimated in
national statistics. Equations were modified to improve
fit to the reference values. Lethality and survival rates
were estimated from local and international studies and
also used to calibrate the model by visual exploration of
observed and expected curves to confirm a good fit.
After calibration, as had been expected, correlation
between predicted and observed results was better
among high incidence events.
External validation for age- and sex-specific COPD
predicted prevalence was performed by comparison
with the results from the Latin American Project for
the Investigation of Obstructive Lung Disease, a popu-
lation-based survey carried out in five Latin American
cities.38 The model underestimated the level of COPD
in comparison to the survey; however, the results
were within 5% for each age group. This
model’s report followed the International Society
Pharmacoeconomics and Outcomes Research guide-
lines for model development11 and reporting and there-
fore included extensive description of preliminary
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consultation with policy and decision makers and detail
regarding debugging, internal validation, calibration
and external validation procedures.
Discussion
Main findings
We identified 22 models, of which six scored highly on
the quality of reporting framework. These six were: the
Peabody model21 generates credible estimates of COPD
prevalence in specific countries round the world. In
addition, the WHO DISMOD II model4 produces
burden estimates in terms of disability adjusted life
years with COPD and life years lost to COPD and
the Atsou model32 gives the life expectancy gains of
individual smokers who quit smoking and associated
costs. Feenstra et al.16 and Hoogendoorn et al.17
models produce estimates of mortality and health care
costs related to COPD. The Pichon–Riviere model34
gives the costs and cost effectiveness of smoking quit
programmes in the context of all tobacco-related
diseases.
Strengths and limitations
This study involved a very broad and comprehensive
search strategy including many world databases
included in the WHO’s library. A limitation of this
study is that we did not consider models that studied
the effects of interventions on COPD because it was
decided that our first priority should be to establish
the baseline burden of COPD and pharmacological
interventions have already been systematically
reviewed.39
COPD models are chiefly focused on smoking as the
main risk factor and any risk-reduction predictions
made by these models were from consideration of
smoking alone. As understanding of the pathogenesis
of COPD increases the role of other factors in the
development of COPD is better understood, the over-
whelming focus on smoking may be considered to be a
further limitation of these models.
A limitation of using the quality of reporting frame-
work is that a high quality of model may be ignored
because its reporting is not such high quality or lacks
clarity. No report on the development of the model and
its subsequent quality validation was found for COPD
for DISMOD 3, this is the model that was used to
calculate Global burden of Disease in the recent
Lancet series.2,40
Deep critical review of all the models in this paper
was not possible as we did not have full access to all the
models and their underlying mathematics. This is a
potential limitation when reviewing any kind of
model, there is a need for transparency in publication
and for a mathematical modelling skill-set to interpret
the findings.
Interpretation of findings in the light of previous
research
This is the first systematic review of modelling studies
for COPD prevalence and burden. A review of chronic
heart disease policy models14 commented that while
reporting criteria are available for many study types
this does not yet apply to modelling studies and this
affects the quality of model reporting and consequently
the underlying model quality as inferred by potential
model users. In addition, it was highlighted that
although models are heavily reliant on their data
inputs, few models critique the quality of their data
sources.
Implications for policy and research
Implications for COPD policy are not clear overall as
the models included have many different purposes and
were designed for different contexts, there is not yet a
consensus on the structure of the optimum COPD
model.
Implications for policymakers include that, as tech-
niques of chronic disease modelling are increasingly
being used and recognized, they need to be aware of
how to interpret them and how to critique the datasets
that are used as model inputs.
Implications for research on COPD models include
that sensitivity analyses should be conducted in order
to highlight the parameters that most affect the outputs
and so demonstrate the internal validity of each model.
Validation of the included COPD models is fertile
ground for further research, in particular as more
detailed and higher quality data become available. In
addition the design of future COPD models to include
other risk factors such as prematurity, low birthweight,
asthma, tuberculosis and childhood respiratory infec-
tions needs further research.
In terms of models in general, Markov-type models
cannot easily model differences between cohorts and so
future work could be directed towards how to best
represent such differences where they exist.
Conclusions
COPD epidemiological models have widely differing
structures and include Markov models and microsimu-
lation models. In general, the field of chronic disease
modelling is burgeoning. As a result, policy makers
need to understand how to interpret epidemiological
models and their data sources.
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